Investigating the mechanism of GABA neuron degeneration in a model of coenzyme Q deficiency by Hacker, Mallory Louise
	   	  
INVESTIGATING	  THE	  MECHANISM	  OF	  GABA	  NEURON	  DEGENERATION	  
IN	  A	  MODEL	  OF	  COENZYME	  Q	  DEFICIENCY	  
By	  
	  
Mallory	  Louise	  Hacker	  
	  
Dissertation	  
Submitted	  to	  the	  Faculty	  of	  the	  
Graduate	  School	  of	  Vanderbilt	  University	  
in	  partial	  fulfillment	  of	  the	  requirements	  for	  	  
the	  degree	  of	  
DOCTOR	  OF	  PHILOSOPHY	  
in	  







Aaron	  B.	  Bowman,	  Ph.D.	  
	  
Joshua	  T.	  Gamse,	  Ph.D.	  
	  
Kathleen	  L.	  Gould,	  Ph.D.	  
	  
Laura	  A.	  Lee,	  Ph.D.	  
	  
David	  M.	  Miller	  III,	  Ph.D.	  
	  
	   ii	  
To	  the	  memory	  of	  my	  father,	  Tim	  Hacker	  
	   iii	  
ACKNOWLEDGEMENTS	  
	  
I	   must	   first	   thank	   my	   mentor,	   David	   Miller.	   David’s	   research	   expertise	   is	   in	  
developmental	  neurobiology,	  but	   I	   am	  very	   thankful	   that	  he	  allowed	  me	   to	  work	  on	   the	   lab’s	  
only	  neurodegeneration	  project.	   I	  knew	  during	  my	  rotation	  that	  the	  environment	  of	  the	  Miller	  
lab	  was	  the	  perfect	  fit	  for	  me	  and	  David’s	  willingness	  to	  accommodate	  my	  desire	  to	  work	  on	  this	  
project	   solidified	  his	   lab	  as	   the	   ideal	  place	   to	  do	  my	  graduate	   research.	  David’s	   teaching	   style	  
struck	   the	   perfect	   balance	   of	   providing	   mentorship	   and	   yet	   also	   allowing	   me	   to	   work	   very	  
independently.	   This	   allowed	   me	   to	   learn	   from	   him	   while	   also	   growing	   tremendously	   as	   a	  
scientist.	   My	   communication	   skills	   (verbal	   and	   written)	   have	   also	   improved	   vastly	   thanks	   to	  
David.	  Finally,	  David	  understands	  the	  importance	  of	  having	  a	  work-­‐life	  balance,	  and	  I	  will	  forever	  
be	  grateful	  for	  his	  compassion	  that	  allowed	  me	  to	  be	  with	  my	  family	  when	  I	  needed	  to	  the	  most.	  
	   I	  thank	  the	  members	  of	  my	  thesis	  committee,	  Aaron	  Bowman,	  Josh	  Gamse,	  Kathy	  Gould,	  
and	  Laurie	  Lee,	  for	  their	  feedback	  and	  encouragement.	  I	  am	  especially	  grateful	  for	  the	  numerous	  
letters	   of	   recommendation	   they	   have	   written	   on	   my	   behalf.	   I	   give	   special	   thanks	   to	   my	  
committee	   chair,	   Kathy	   Gould.	   Since	  my	   first	   day	   at	   Vanderbilt	   (where	   she	   was	   assigned	  my	  
IMPACT	  mentor),	   Kathy	   has	   been	   someone	   I	   can	   go	   to	   for	   advice	   and	   I	   am	   thankful	   for	   her	  
support	  over	  the	  years.	  
I	  thank	  the	  Department	  of	  Cell	  &	  Developmental	  Biology,	  the	  Program	  in	  Developmental	  
Biology,	  and	  the	  Neurodegeneration	  Research	  Group	  for	  opportunities	  to	  present	  my	  work,	  give	  
journal	  club	  presentations,	  and	  discuss	  science	  collaboratively.	  	  
I	   would	   also	   like	   to	   thank	   my	   funding	   sources,	   which	   have	   included	   the	   Cellular,	  
Molecular,	   Biochemical	   Science	   (CBMS)	   training	   program	   (T32GM08554)	   and	   predoctoral	  
fellowships	  from	  the	  American	  Heart	  Association	  (AHA)	  (10PRE4230025)	  and	  (12PRE11650022).	  
	   iv	  
	   My	   chemistry	   research	   mentor	   at	   UT-­‐Chattanooga,	   Dr.	   Manuel	   Santiago,	   saw	   my	  
potential	  and	  encouraged	  me	  to	  apply	  for	  Vanderbilt’s	  IGP	  program.	  I	  am	  very	  thankful	  to	  have	  
had	  that	  support	  as	  an	  undergraduate,	  because	  I	  would	  not	  be	  where	  I	  am	  today	  without	  it.	  
	   I	   had	   the	   great	   fortune	   of	   working	   in	   a	   wonderful	   laboratory	   environment.	   My	  
coworkers	   happily	   embraced	   the	   many	   silly	   traditions	   that	   I	   started	   in	   the	   lab	   (such	   as	   Jack	  
Friday,	  “cake”	  timer,	  beer	  birthdays,	  and	  the	  lab	  trophy).	  Cody	  was	  my	  scientific	  sibling	  (he	  and	  I	  
joined	  the	  Miller	  lab	  at	  the	  same	  time).	  Both	  inside	  and	  outside	  of	  the	  lab,	  Cody	  has	  been	  a	  great	  
friend	  and	   I	  am	  thankful	   to	  have	  gone	   through	  graduate	  school	  with	  him.	  Rachel	  has	  not	  only	  
been	  a	  great	  bay	  mate	  but	  also	  a	  close	  friend.	  I’m	  fortunate	  to	  have	  spent	  most	  of	  my	  graduate	  
years	  working	  beside	  her.	  Tyne	  joined	  the	  lab	  a	  couple	  of	  years	  ago,	  and	  she	  perfectly	  fit	  in	  with	  
the	  lab	  dynamic.	   I	  am	  thankful	  to	  have	  had	  her	  here	  these	  past	  few	  years.	  Clay,	  Sarah	  and	  Jud	  
were	  the	  older	  graduate	  students	  whose	  advice	  and	  assistance	  made	  the	  first	  years	  in	  lab	  much	  
easier.	  Tim,	  Becky	  and	  Kathie	  were	  essential	  to	  keep	  the	  lab	  running	  smoothly.	  
I	  am	  very	  thankful	  for	  the	  many	  friendships	  I	  have	  made	  with	  fellow	  graduate	  students	  
at	  Vanderbilt.	   It	  has	  been	   invaluable	   to	  have	  peers	   that	  understand	  the	  trials,	   tribulations	  and	  
triumphs	  that	  accompany	  this	  journey.	  
	   Finally,	   I	   lovingly	   acknowledge	   my	   family	   for	   their	   support.	   Henry	   has	   been	   my	   rock	  
throughout	   graduate	   school,	   and	   I	   am	   very	   thankful	   for	   his	   unconditional	   understanding	   and	  
encouragement.	   I	   am	   also	   thankful	   for	  my	   second	   family,	   the	  Hornes.	   They	   have	   provided	   so	  
much	  encouragement	  and	  support	  over	  the	  years,	  and	  their	  genuine	  interest	  in	  (and	  respect	  for)	  
my	  work	  is	  something	  that	  I	  have	  always	  cherished.	  My	  mom	  has	  always	  supported	  me	  and	  also	  
showed	  me	  how	  to	  be	  a	  strong,	  independent	  woman.	  Lastly,	  I	  must	  thank	  my	  late	  father.	  From	  
an	  early	  age,	  he	  convinced	  me	  that	  I	  could	  do	  anything	  that	  I	  put	  my	  mind	  to.	  He	  was	  truly	  my	  
biggest	  fan,	  and	  I	  never	  once	  doubted	  that	  he	  was	  proud	  of	  me.	  
	   v	  
	  




DEDICATION	  	  ..................................................................................................................................	  	  ii	  
	  
ACKNOWLEDGEMENTS	  .................................................................................................................	  	  iii	  
	  
TABLE	  OF	  CONTENTS	  ......................................................................................................................	  	  v	  
	  
LIST	  OF	  TABLES	  ................................................................................................................................	  x	  
	  
LIST	  OF	  FIGURES	  ............................................................................................................................	  xii	  
	  






I. INTRODUCTION	  .................................................................................................................	  	  1	  
	  
Neurodegenerative	  diseases	  share	  common	  features	  ...............................................	  	  2	  
Age-­‐dependent	  disease	  onset	  ..............................................................................	  	  2	  
Selective	  neuronal	  vulnerability	  ...........................................................................	  	  3	  
Mitochondrial	  dysfunction	  ...................................................................................	  	  5	  
Types	  of	  cell	  death	  associated	  with	  neurodegenerative	  pathology	  ...........................	  	  6	  
Apoptosis	  ..............................................................................................................	  	  6	  
Apoptosis	  in	  C.	  elegans	  ..................................................................................	  	  8	  
Necrosis	  ..............................................................................................................	  	  10	  
Necrosis	  in	  C.	  elegans	  ..................................................................................	  	  12	  
Intermediate	  cell	  death	  pathways	  ......................................................................	  	  12	  
Mitochondria	  in	  cell	  death	  .................................................................................	  	  13	  
An	  integrated	  model	  of	  necrosis	  and	  apoptosis	  .................................................	  	  15	  
Coenzyme	  Q	  is	  important	  for	  cellular	  homeostasis	  and	  viability	  ..............................	  	  17	  
Coenzyme	  Q	  functions	  .......................................................................................	  	  17	  
Coenzyme	  Q	  biosynthesis	  ...................................................................................	  	  18	  
Coenzyme	  Q	  deficiencies	  ....................................................................................	  	  20	  
Coenzyme	  Q	  supplementation	  ...........................................................................	  	  21	  
Models	  of	  Coenzyme	  Q	  deficiency	  .....................................................................	  	  22	  
Coenzyme	  Q	  deficiency	  in	  C.	  elegans	  as	  a	  model	  for	  neurodegenerative	  disease	  ...	  	  24	  
	  	  
II. COENZYME	  Q	  PROTECTS	  CAENORHABDITIS	  ELEGANS	  GABA	  NEURONS	  FROM	  CALCIUM-­‐
DEPENDENT	  DEGENERATION	  ..........................................................................................	  	  27	  
	  
Introduction	  ..............................................................................................................	  	  28	  
Materials	  and	  Methods	  .............................................................................................	  	  30	  
	   vi	  
Results	  .......................................................................................................................	  	  36	  
Knockdown	  of	  coq-­‐1	  results	  in	  age-­‐dependent	  loss	  of	  coordinated	  	  
movement	  ..........................................................................................................	  	  36	  
RNAi	  or	  genetic	  depletion	  of	  CoQ	  induces	  age-­‐dependent	  degeneration	  of	  GABA	  
neurons	  ..............................................................................................................	  	  36	  
GABA	  neurons	  are	  preferentially	  sensitive	  to	  CoQ	  Depletion-­‐induced	  
degeneration	  ......................................................................................................	  	  42	  
coq-­‐1	  RNAi-­‐mediated	  degeneration	  is	  calcium-­‐dependent	  ...............................	  	  46	  
Specific	  apoptotic	  genes	  are	  required	  for	  GABA	  neuron	  cell	  death	  in	  CoQ-­‐
depleted	  animals	  ................................................................................................	  	  46	  
coq-­‐1	  knockdown-­‐induced	  cell	  death	  depends	  on	  the	  mitochondrial	  fission	  gene	  
drp-­‐1	  ...................................................................................................................	  	  51	  
Discussion	  .................................................................................................................	  	  51	  
CoQ	  depletion	  triggers	  a	  cell	  death	  pathway	  featuring	  elements	  of	  both	  
apoptosis	  and	  necrosis	  .......................................................................................	  	  54	  
Mitochondrial	  morphogenesis	  protein,	  DRP-­‐1,	  is	  required	  for	  the	  death	  of	  CoQ-­‐
depleted	  GABA	  neurons	  .....................................................................................	  	  55	  
CQ	  deficiency	  in	  C.	  elegans	  as	  a	  model	  for	  human	  disease	  ................................	  	  56	  
	  
III. CHARACTERIZATION	  OF	  A	  CONSERVED	  COENZYME	  Q	  BIOSYNTHESIS	  PATHWAY	  
IMPLICATES	  INTERCELLULAR	  UBIQUINONE	  TRANSPORT	  MECHANISMS	  	  ........................	  	  58	  
	  
Introduction	  ..............................................................................................................	  	  58	  
Materials	  and	  Methods	  .............................................................................................	  	  60	  
Results	  .......................................................................................................................	  	  73	  
Mutations	  that	  disrupt	  different	  steps	  in	  the	  CoQ	  biosynthetic	  pathway	  display	  
heterogeneous	  phenotypes	  	  ..............................................................................	  	  73	  
The	  regulatory	  Coenzyme	  Q	  synthetic	  gene	  coq-­‐8	  is	  also	  required	  for	  
GABA	  neuron	  viability	  ...............................................................................	  	  76	  
Dietary	  CoQ	  influences	  developmental	  progression	  and	  GABA	  
neurodegeneration	  ............................................................................................	  	  79	  
Apoptotic	  GABA	  neuron	  death	  occurs	  rarely	  under	  distinct	  dietary	  CoQ	  
conditions	  .................................................................................................	  	  81	  
Knockdown	  of	  coq-­‐1	  exclusively	  in	  GABA	  neurons	  does	  not	  induce	  	  
degeneration	  ......................................................................................................	  	  81	  
Exogenous	  COQ-­‐1::GFP	  localizes	  to	  mitochondria	  and	  rescues	  	  
coq-­‐1(ok749)	  defects	  ..........................................................................................	  	  86	  
COQ-­‐1::GFP	  expression	  in	  specific	  tissues	  restores	  fertility	  to	  coq-­‐1	  mutant	  	  
animals	  ...............................................................................................................	  	  88	  
Localization	  and	  function	  of	  human	  CoQ	  biosynthetic	  proteins	  are	  conserved	  in	  
C.	  elegans	  	  ..........................................................................................................	  	  90	  
COQ-­‐1	  shares	  phylogenetic	  similarity	  to	  PDSS1	  .......................................	  	  90	  
Exogenous	  PDSS2::GFP	  localizes	  to	  mitochondria	  ....................................	  	  92	  
Fertility	  of	  C.	  elegans	  coq-­‐2(ok1066)	  is	  rescued	  with	  expression	  of	  human	  
COQ2	  .........................................................................................................	  	  92	  
Discussion	  and	  Future	  Directions	  ..............................................................................	  	  96	  
A	  narrow	  range	  of	  CoQ	  levels	  permits	  both	  animal	  viability	  and	  GABA	  neuron	  
death	  ..................................................................................................................	  	  98	  
	   vii	  
C.	  elegans	  as	  a	  model	  system	  to	  study	  intercellular	  CoQ	  transport	  .................	  	  100	  
GABA	  neuron-­‐specific	  COQ-­‐1	  production	  is	  not	  necessary	  for	  their	  	  
survival	  ....................................................................................................	  	  100	  
Muscle-­‐specific	  CoQ	  production	  overcomes	  developmental	  defects	  of	  	  
coq-­‐1	  mutants	  .........................................................................................	  	  100	  
Human	  COQ2,	  a	  CoQ	  biosynthetic	  protein,	  is	  functionally	  conserved	  in	  
C.	  elegans	  ..........................................................................................................	  103	  
Future	  Directions	  ..............................................................................................	  	  103	  
	  
IV. CED-­‐3/CASPASE	  ANTAGONIZES	  A	  CED-­‐4/APAF-­‐1-­‐DEPENDENT	  PATHWAY	  IN	  COENZYME	  
Q-­‐DEFICIENT	  GABA	  NEURONS	  .......................................................................................	  	  106	  
	  
Introduction	  ............................................................................................................	  	  106	  
Materials	  and	  Methods	  ...........................................................................................	  	  108	  
Results	  	  ....................................................................................................................	  	  116	  
Loss	  of	  CED-­‐3	  enhances	  GABA	  neurodegeneration	  induced	  by	  CoQ	  	  
depletion	  ..........................................................................................................	  	  116	  
Caspase	  activity	  of	  CED-­‐3	  is	  cell	  autonomously	  required	  to	  protect	  GABA	  
neurons	  ............................................................................................................	  	  119	  
Forced	  CED-­‐3	  activation	  kills	  GABA	  neurons	  through	  apoptosis	  ......................	  	  119	  
Apoptosis	  is	  impaired	  in	  GABA	  neuron	  precursor	  cells	  in	  ced-­‐3	  and	  ced-­‐4	  
mutants	  ............................................................................................................	  	  120	  
Cholinergic	  neuron	  sensitivity	  to	  CoQ	  depletion	  is	  not	  enhanced	  by	  loss	  of	  	  
CED-­‐3	  ................................................................................................................	  	  123	  
ced-­‐4/Apaf-­‐1	  functions	  cell	  autonomously	  and	  is	  epistatic	  to	  	  
ced-­‐3/caspase	  ...................................................................................................	  	  125	  
GABA	  neurons	  adopt	  necrotic	  or	  apoptotic	  features	  in	  coq-­‐1	  mutants	  fed	  KO229	  
E.	  coli	  ................................................................................................................	  	  125	  
Discussion	  and	  Future	  Directions	  ............................................................................	  	  127	  
Restricted	  CED-­‐3	  activation	  protects	  GABA	  neurons	  from	  CoQ	  depletion-­‐induced	  
death	  ................................................................................................................	  	  130	  
CED-­‐3	  and	  CED-­‐4	  adopt	  opposing	  roles	  in	  CoQ-­‐depleted	  GABA	  neurons	  ........	  	  130	  
GABA	  neuron	  degeneration	  and	  regeneration	  pathways	  share	  common	  
components	  ...............................................................................................	  	  131	  
Mechanisms	  of	  caspase-­‐dependent	  proteolysis	  of	  Apaf-­‐1	  are	  	  
conserved	  ...................................................................................................	  	  133	  
A	  novel	  mechanism	  for	  CED-­‐4	  activation	  and	  execution	  of	  necrotic-­‐like	  	  
death	  ................................................................................................................	  	  135	  
Apoptotic	  and	  necrotic	  death	  of	  CoQ-­‐deficient	  GABA	  neurons	  occurs	  
independently	  of	  CED-­‐3	  	  ...................................................................................	  	  136	  
	  
V. GENETIC	  AND	  ULTRASTRUCTURAL	  ANALYSIS	  OF	  A	  NECROTIC	  DEATH	  PATHWAY	  
ACTIVATED	  IN	  COENZYME	  Q-­‐DEFICIENT	  MOTOR	  NEURONS	  ........................................	  	  	  138	  
	  
Introduction	  ............................................................................................................	  	  138	  
Materials	  and	  Methods	  ...........................................................................................	  	  140	  
Results	  .....................................................................................................................	  	  145	  
	   viii	  
Global	  electron	  transport	  chain	  knockdown	  results	  in	  developmental	  arrest	  
and/or	  lack	  of	  GABA	  neuron	  degeneration	  ......................................................	  	  145	  
	   GABA	  neurons	  in	  hypomorphic	  mutants	  of	  Complex	  I	  and	  Complex	  II	  do	  not	  
degenerate	  .................................................................................................	  	  145	  
	   Global	  RNAi	  of	  ETC	  genes	  induces	  developmental	  arrest	  ..........................	  	  145	  
GABA	  neuron-­‐specific	  knockdown	  of	  ETC	  genes	  does	  not	  induce	  their	  
degeneration	  ....................................................................................................	  	  146	  
Specific	  calpain	  and	  cathepsin	  proteases	  are	  differentially	  required	  in	  the	  GABA	  
neurodegeneration	  pathway	  ............................................................................	  	  149	  
RME	  GABA	  neurons	  are	  severely	  affected	  by	  CoQ	  depletion	  in	  tra-­‐3	  	  
mutants	  ............................................................................................................	  	  150	  
Transmission	  electron	  microscopy	  reveals	  ultrastructural	  features	  of	  Coenzyme	  
Q	  deficient	  motor	  neurons	  ...............................................................................	  	  150	   	  
Longitudinal	  sectioning	  allows	  ultrastructural	  features	  of	  motor	  neurons	  to	  
be	  viewed	  side-­‐by-­‐side	  using	  transmission	  electron	  microscopy	  ..............	  	  153	  
Ultrastructural	  analysis	  of	  coq-­‐1	  knockdown	  animals	  reveals	  necrotic	  
characteristics	  in	  dying	  motor	  neurons	  .....................................................	  	  155	  
Autophagic	  characteristics	  are	  observed	  in	  coq-­‐1-­‐depleted	  neurons	  .......	  	  157	  
Discussion	  and	  Future	  Directions	  	  ...........................................................................	  	  159	  
Electron	  transport	  chain	  knockdown	  does	  not	  phenocopy	  GABA	  
neurodegeneration	  observed	  with	  Coenzyme	  Q	  depletion	  .............................	  	  159	  
Necrotic	  proteases	  adopt	  opposing	  roles	  in	  the	  CoQ	  deficiency-­‐induced	  GABA	  
cell	  death	  pathway	  ...........................................................................................	  	  161	  
TRA-­‐3/calpain	  antagonizes	  GABA	  neurodegeneration	  ..............................	  	  161	  
ASP-­‐4/cathepsin	  promotes	  GABA	  neurodegeneration	  ..............................	  	  162	  
Ultrastructural	  studies	  reveal	  canonical	  necrotic	  features	  in	  dying	  motor	  
neurons	  and	  implicate	  autophagy	  as	  a	  mechanism	  of	  neuroprotection	  ..........	  	  163	  
	  
VI. GENERAL	  DISCUSSION	  AND	  FUTURE	  DIRECTIONS	  	  ........................................................	  	  165	  
	  
Specific	  proteases	  antagonize	  CoQ	  deficiency-­‐induced	  GABA	  	  
neurodegeneration	  	  ................................................................................................	  	  165	  
CED-­‐3/caspase	  	  .................................................................................................	  	  165	  
Investigating	  the	  role	  of	  autophagy	  under	  CoQ-­‐deficient	  conditions	  	  .............	  	  168	  
TRA-­‐3/calpain	  ...................................................................................................	  	  169	  
CED-­‐4/Apaf-­‐1	  promotes	  necrosis	  in	  CoQ-­‐deficient	  GABA	  neurons	  	  .......................	  	  171	  
Potential	  mechanisms	  of	  CED-­‐4	  activation	  	  ......................................................	  	  172	  
Intercellular	  Coenzyme	  Q	  transport	  in	  C.	  elegans	  	  .................................................	  	  174	  
Model	  of	  CoQ	  deficiency-­‐induced	  GABA	  neurodegeneration	  	  ...............................	  	  175	  
Events	  that	  lead	  to	  GABA	  neuron	  death	  under	  CoQ-­‐deficient	  conditions	  	  ......	  	  175	  
Mechanisms	  that	  antagonize	  GABA	  neurodegeneration	  .................................	  	  177	  
Conclusions	  	  ............................................................................................................	  	  178	  
	  





	   ix	  
APPENDICES	  ...............................................................................................................................	  	  198	  
	  
A. LIMITATIONS	  OF	  USING	  RNA	  INTERFERENCE	  AS	  A	  BIOASSAY	  TO	  IDENTIFY	  COMPONENTS	  
OF	  A	  MOLECULAR	  PATHWAY	  	  .......................................................................................	  	  198	  
Summary	  .................................................................................................................	  	  198	  
Materials	  and	  Methods	  ...........................................................................................	  	  198	  
Results	  .....................................................................................................................	  	  201	  
Mislabeled	  clones	  in	  the	  Ahringer	  RNAi	  library	  ................................................	  	  201	  
Transgene	  silencing	  by	  the	  RNAi	  pathway	  limits	  use	  of	  extrachromasomal	  
transgenic	  arrays	  	  .............................................................................................	  	  202	  
Interpretation	  of	  GABA	  neurodegeneration	  levels	  induced	  by	  coq-­‐1	  knockdown	  
is	  difficult	  due	  to	  varying	  sensitivities	  of	  genetic	  backgrounds	  to	  RNAi	  	  
treatment	  	  ........................................................................................................	  	  204	  
Discussion	  and	  Future	  Directions	  ............................................................................	  	  206	  
	  
B. MODIFICATION	  OF	  AN	  IN	  VIVO	  CASPASE	  REPORTER	  TO	  DETECT	  CED-­‐3	  PROTEOLYTIC	  
ACTIVITY	  IN	  C.	  ELEGANS	  	  ...............................................................................................	  	  209	  
Summary	  .................................................................................................................	  	  209	  
Materials	  and	  Methods	  ...........................................................................................	  	  209	  
Results	  .....................................................................................................................	  	  215	  
Optimizing	  reporter	  expression	  and	  caspase	  recognition	  ................................	  	  215	  
Modifying	  the	  caspase	  consensus	  sequence	  	  ............................................	  	  215	  
The	  egl-­‐1	  promoter-­‐driven	  Apoliner	  (DEVD)	  is	  dimly	  expressed	  in	  cells	  
undergoing	  PCD	  	  ........................................................................................	  	  217	  
Modifying	  the	  membrane	  localization	  sequence	  	  ......................................	  	  219	  
Apoworm	  detects	  forced	  CED-­‐3	  activation	  in	  GABA	  neurons	  	  .........................	  	  219	  
Apoworm	  is	  cleaved	  independent	  of	  CED-­‐3	  in	  select	  neurons	  that	  do	  not	  
die	  	  ....................................................................................................................	  	  221	  
Apoworm	  does	  not	  detect	  all	  apoptotic	  events	  	  ..............................................	  	  223	  
Discussion	  and	  Future	  Directions	  ............................................................................	  	  223	  
	  
C. List	  of	  plasmids	  (pMLH	  #1-­‐303,	  pMBM	  #1-­‐9)	  ................................................................	  	  227	  
	  
D. List	  of	  Gifts	  to	  Mal	  plasmids	  (pG2M	  #1-­‐64)	  	  ...................................................................	  233	  	  
	  
	  
APPENDICES	  REFERENCES	  	  .........................................................................................................	  	  236	  
	  
	   	  
	   x	  
LIST	  OF	  TABLES	  
	  
Table	  1.1	  Isoprene	  tail	  length	  of	  Coenzyme	  Q	  varies	  among	  species	  	  ..........................................	  	  18	  
Table	  2.1	  Mutant	  alleles	  (or	  transgenic	  arrays),	  their	  source,	  and	  genotyping	  primers	  used	  in	  this	  
chapter	  .........................................................................................................................................	  	  31	  
Table	  2.2	  Strains	  generated	  for	  analysis	  in	  this	  study	  ..................................................................	  	  32	  
Table	  3.1	  Alleles,	  genotyping	  primers,	  and	  sources	  of	  mutants	  used	  in	  this	  study	  	  .....................	  	  61	  
Table	  3.2	  List	  of	  strains	  that	  were	  used	  in	  this	  study	  ...................................................................	  	  62	  
Table	  3.3	  Primers	  used	  for	  molecular	  biology	  in	  this	  study	  	  .........................................................	  	  63	  
Table	  3.4	  Plasmids	  that	  were	  used	  and/or	  produced	  for	  this	  chapter	  	  ........................................	  	  64	  
Table	  3.5	  Transgenic	  arrays	  that	  were	  generated	  for	  this	  work.	  ..................................................	  	  66	  
Table	  3.6	  Mutants	  of	  Coenzyme	  Q	  biosynthetic	  pathway	  genes	  display	  a	  range	  of	  	  
phenotypes	  	  ..................................................................................................................................	  	  75	  
Table	  3.7	  COQ-­‐1	  expression	  in	  body-­‐wall	  muscle	  restores	  fertility	  to	  coq-­‐1	  mutants	  .................	  	  89	  
Table	  4.1	  Mutant	  alleles	  used	  in	  this	  study	  and	  their	  source	  of	  origin	  	  ......................................	  	  109	  
Table	  4.2	  Table	  of	  strains	  used	  in	  this	  study	  	  ..............................................................................	  	  110	  
Table	  4.3	  Molecular	  cloning	  primers	  used	  in	  this	  work	  	  .............................................................	  	  111	  
Table	  4.4	  Plasmids	  generated	  and/or	  used	  in	  this	  study	  	  ...........................................................	  	  111	  
Table	  4.5	  Plasmid	  concentrations	  that	  were	  microinjected	  to	  generate	  the	  transgenic	  arrays	  
used	  in	  this	  study	  	  .......................................................................................................................	  	  112	  
Table	  5.1	  List	  of	  Chapter	  5	  mutant	  alleles	  and	  transgenes	  with	  their	  respective	  genotyping	  
primers	  .......................................................................................................................................	  	  141	  
Table	  5.2	  Strains	  used	  in	  Chapter	  5	  ............................................................................................	  	  142	  
	   xi	  
Table	  5.3	  Knockdown	  of	  electron	  transport	  chain	  components	  developmentally	  arrests	  juIs76;	  
eri-­‐1(mg366)	  animals.	  ................................................................................................................	  	  147	  
Table	  5.4	  Animals	  without	  eri-­‐1(mg366)	  treated	  with	  ETC	  RNAi	  develop	  to	  later	  stages	  but	  do	  
not	  have	  GABA	  neuron	  degeneration	  ........................................................................................	  	  147	  
Table	  5.5	  Ultrastructural	  features	  that	  distinguish	  apoptotic	  versus	  necrotic	  cell	  death	  ..........	  	  153	  	  	  
Table	  A.1	  C.	  elegans	  strains	  used	  in	  this	  appendix	  	  ....................................................................	  	  200	  
Table	  A.2	  Plasmids	  used	  in	  this	  work	  	  .........................................................................................	  	  200	  
Table	  A.3	  Plasmid	  concentrations	  used	  to	  make	  transgenic	  arrays	  used	  for	  this	  study.	  	  ...........	  	  201	  
Table	  B.1	  Molecular	  cloning	  primers	  used	  to	  generate	  plasmids	  used	  in	  this	  study	  	  .................	  	  213	  
Table	  B.2	  A	  list	  of	  plasmids	  used	  and/or	  generated	  in	  this	  work	  	  ..............................................	  	  214	  	  
Table	  B.3	  Plasmid	  concentrations	  of	  transgenic	  arrays	  generated	  for	  this	  study	  	  .....................	  	  215	  
	   	  
	   xii	  
LIST	  OF	  FIGURES	  
	  
Figure	  1.1	  Age-­‐related	  disease	  onset	  and	  selective	  neuronal	  vulnerability	  are	  common	  features	  
of	  neurodegenerative	  diseases	  ............................................................................................	  	  4	  
Figure	  1.2	  The	  mitochondrial	  electron	  transport	  chain	  (ETC)	  is	  often	  disrupted	  in	  
neurodegenerative	  diseases	  	  ................................................................................................	  	  7	  
Figure	  1.3	  Apoptotic	  regulators	  are	  conserved	  from	  C.	  elegans	  to	  mammals	  	  .................................	  	  9	  
Figure	  1.4	  Necrotic	  events	  are	  conserved	  in	  C.	  elegans	  ....................................................................	  	  11	  
Figure	  1.5	  Common	  insults	  account	  for	  a	  cell	  death	  continuum	  between	  apoptosis	  and	  necrosis	  ..	  	  16	  
Figure	  1.6	  Coenzyme	  Q	  and	  its	  biosynthetic	  proteins	  are	  highly	  conserved	  	  ....................................	  	  19	  
Figure	  1.7	  C.	  elegans	  GABA	  nervous	  system	  	  ....................................................................................	  	  25	  
Figure	  2.1	  RNAi	  knockdown	  of	  coq-­‐1	  results	  in	  progressive	  loss	  of	  motor	  coordination	  ..................	  	  37	  
Figure	  2.2	  CoQ	  depletion	  results	  in	  GABA	  neuron	  degeneration	  ......................................................	  	  38	  
Figure	  2.3	  GABA	  neuron	  degeneration	  in	  coq-­‐1(ok749)	  animals	  ......................................................	  	  41	  
Figure	  2.4	  GABA	  neurons	  are	  more	  sensitive	  than	  neighboring	  cholinergic	  neurons	  to	  coq-­‐2	  
depletion	  ..............................................................................................................................	  	  43	  
Figure	  2.5	  coq-­‐1	  RNAi	  triggers	  preferential	  degeneration	  of	  GABA	  neurons	  ....................................	  	  44	  
Figure	  2.6	  Apoptotic	  genes	  and	  calcium	  and	  are	  required	  for	  coq-­‐1	  RNAi-­‐induced	  GABA	  neuron	  
degeneration	  ........................................................................................................................	  	  48	  
Figure	  2.7	  Apoptotic	  genes	  egl-­‐1	  and	  ced-­‐9	  are	  not	  required	  for	  coq-­‐1	  RNAi-­‐induced	  GABA	  
neuron	  degeneration	  ...........................................................................................................	  	  49	  
Figure	  2.8	  ced-­‐4	  suppresses	  degeneration	  of	  GABA	  neuron	  cell	  bodies	  in	  coq-­‐1	  RNAi-­‐treated	  
animals	  .................................................................................................................................	  	  50	  
	   xiii	  
Figure	  2.9	  RNAi	  of	  mitochondrial	  ﬁssion	  and	  fusion	  genes	  inﬂuences	  GABA	  neuron	  degeneration	  
induced	  by	  coq-­‐1	  RNAi	  .........................................................................................................	  	  52	  
Figure	  2.10	  Mitochondrial	  ATP	  levels	  are	  reduced	  in	  CoQ-­‐depleted	  animals	  ...................................	  	  53	  
Figure	  3.1	  Deletion	  alleles	  of	  Coenzyme	  Q	  biosynthetic	  genes	  .........................................................	  	  74	  
Figure	  3.2	  Necrotic	  GABA	  neuron	  degeneration	  occurs	  in	  older	  coq-­‐8(ok540)	  adults	  ......................	  	  77	  
Figure	  3.3	  Bacterial	  diet	  influences	  developmental	  progression	  and	  GABA	  neurodegeneration	  of	  
coq-­‐1(ok749)	  mutants	  ..........................................................................................................	  	  80	  
Figure	  3.4	  GABA	  neurons	  adopt	  an	  apoptotic	  morphology	  in	  coq-­‐1	  and	  coq-­‐2	  mutants	  fed	  an	  
alternative	  E.	  coli	  strain	  KO229	  ............................................................................................	  	  82	  
Figure	  3.5	  GABA	  neuron-­‐specific	  knockdown	  of	  coq-­‐1	  does	  not	  produce	  a	  GABA	  
neurodegeneration	  defect	  ...................................................................................................	  	  84	  
Figure	  3.6	  COQ-­‐1::GFP	  localizes	  to	  mitochondria	  and	  rescues	  coq-­‐1	  defects	  with	  either	  
ubiquitous	  or	  muscle-­‐specific	  expression	  ............................................................................	  	  87	  
Figure	  3.7	  C.	  elegans	  COQ-­‐1	  is	  homologous	  to	  mitochondrially-­‐localized	  human	  PDSS1	  and	  	  	  	  	  
PDSS2	  ....................................................................................................................................	  	  91	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Figure	  3.8	  Human	  COQ2	  rescues	  infertility	  of	  coq-­‐2(ok1066)	  	  ..........................................................	  	  94	  
Figure	  3.9	  Coenzyme	  Q	  level	  threshold	  for	  viability	  and	  GABA	  neurodegeneration	  ........................	  	  99	  
Figure	  3.10	  Model	  for	  intercellular	  Coenzyme	  Q	  transport	  as	  a	  mechanism	  to	  protect	  GABA	  
neurons	  from	  degeneration	  .................................................................................................	  	  101	  
Figure	  4.1	  CED-­‐3	  caspase	  activity	  protects	  GABA	  neurons	  from	  degeneration	  induced	  by	  
depletion	  of	  Coenzyme	  Q	  .....................................................................................................	  	  117	  
Figure	  4.2	  Forced	  CED-­‐3	  activation	  kills	  GABA	  neurons	  through	  apoptosis	  ......................................	  	  121	  
Figure	  4.3	  ced-­‐3	  alleles	  block	  apoptosis	  in	  GABA	  neuron	  precursor	  cells	  .........................................	  	  122	  
	   xiv	  
Figure	  4.4	  Cholinergic	  neurons	  are	  not	  more	  sensitive	  to	  Coenzyme	  Q	  depletion	  in	  ced-­‐3	  
mutants	  ................................................................................................................................	  	  124	  
Figure	  4.5	  ced-­‐4	  is	  epistatic	  to	  ced-­‐3	  and	  functions	  cell	  autonomously	  to	  kill	  GABA	  neurons	  ..........	  	  126	  
Figure	  4.6	  Coenzyme	  Q	  deficiency-­‐induced	  GABA	  neuron	  death	  occurs	  independently	  of	  CED-­‐3	  ...	  	  128	  
Figure	  4.7	  Proposed	  models	  to	  explain	  epistatic	  interactions	  between	  ced-­‐3	  and	  ced-­‐4	  	  ................	  	  132	  
Figure	  5.1	  GABA	  neuron-­‐specific	  knockdown	  of	  electron	  transport	  chain	  (ETC)	  genes	  does	  not	  
phenocopy	  the	  robust	  GABA	  neurodegeneration	  of	  Coenzyme	  Q-­‐depleted	  animals	  .........	  	  148	  
Figure	  5.2	  Specific	  proteases	  from	  the	  necrotic	  pathway	  are	  differentially	  required	  for	  GABA	  
neurodegeneration	  induced	  by	  Coenzyme	  Q	  depletion	  	  .....................................................	  	  151	  
Figure	  5.3	  GABA	  neuron	  degeneration	  is	  enhanced	  in	  coq-­‐2;	  tra-­‐3	  double	  mutants	  .......................	  	  152	  
Figure	  5.4	  Transmission	  electron	  micrograph	  shows	  ultrastructural	  features	  of	  wild-­‐type	  ventral	  
nerve	  cord	  (VNC)	  motor	  neurons	  	  ........................................................................................	  	  154	  
Figure	  5.5	  Ultrastructural	  analysis	  of	  coq-­‐1	  knockdown	  animals	  reveals	  necrotic	  features	  of	  dying	  
motor	  neurons	  .....................................................................................................................	  	  156	  
Figure	  5.6	  Diverse	  cellular	  responses	  to	  coq-­‐1	  depletion	  are	  revealed	  by	  transmission	  electron	  
micrographs	  ..........................................................................................................................	  	  158	  
Figure	  6.1	  Models	  of	  how	  autophagy	  could	  prevent	  or	  promote	  neurodegeneration	  .....................	  	  170	  
Figure	  6.2	  Model	  of	  CoQ	  deficiency-­‐induced	  GABA	  neurodegeneration	  	  .........................................	  	  176	  
Figure	  A.1	  Neuronal	  mitochondria	  are	  visualized	  by	  outer-­‐mitochondrial	  membrane	  tagged	  
(TOM20)	  fluorophores	  .........................................................................................................	  	  203	  
Figure	  A.2	  Sensitivity	  to	  feeding	  RNAi	  is	  variable	  between	  control	  strains	  and	  among	  animals	  
with	  different	  ced-­‐3	  mutant	  backgrounds	  ............................................................................	  	  205	  
Figure	  A.3	  Knockdown	  of	  unc-­‐25/GAD	  reveals	  differential	  sensitivity	  to	  RNAi	  in	  GABA	  neurons	  
among	  mutants	  used	  for	  CoQ	  neurodegeneration	  assays	  ...................................................	  	  207	  
	   xv	  
Figure	  B.1	  Modifications	  to	  the	  Drosophila	  caspase	  biosensor	  (Apoliner)	  for	  enhanced	  expression	  
and	  caspase	  recognition	  in	  C.	  elegans	  (Apoworm)	  ..............................................................	  	  216	  
Figure	  B.2	  The	  egl-­‐1	  promoter-­‐driven	  Apoliner(DEVD)	  is	  dimly	  expressed	  in	  cells	  undergoing	  
programmed	  cell	  death	  ........................................................................................................	  	  218	  
Figure	  B.3	  Apoworm	  detects	  forced	  CED-­‐3	  activation	  in	  GABA	  neurons	  ..........................................	  	  220	  
Figure	  B.4	  Apoworm	  is	  cleaved	  in	  select	  neurons	  that	  do	  not	  die,	  independent	  of	  CED-­‐3	  ...............	  	  222	  
Figure	  B.5	  Apoworm	  does	  not	  detect	  all	  CED-­‐3-­‐dependent	  apoptotic	  events	  induced	  by	  loss	  of	  
CED-­‐9	  function	  ......................................................................................................................	  	  224	  
	  
	   xvi	  
LIST	  OF	  ABBREVIATIONS	  	  	  
Abbreviation	   Description	   Abbreviation	   Description	  
Ach	   Cholinergic	   GFP	   Green	  Flurorescent	  Protein	  
AD	   Alzheimer's	  Disease	   HBx	   Hepatitis	  B	  Virus	  X	  
AECOM	  
Albert	  Einstein	  College	  of	  
Medicine	   HD	   Huntington's	  Disease	  
ALS	   Amyotrophic	  Lateral	  Sclerosis	   HPF	   High-­‐Pressure	  Freezing	  
ANT	  
Adenine	  Nucleotide	  
Translocator	   KAP-­‐1	   Kinesin-­‐Associated	  Protein	  1	  
Apaf-­‐1	  
Apoptosis	  Protease	  Activating	  
Factor	  1	   LAS-­‐AF	  
Leica	  Application	  Suite	  Advanced	  
Fluorescence	  
APTX	   Aprataxin	   LB	   Luria-­‐Bertani	  
ATP	   Adenosine	  TriPhosphate	   LMP	  
Lysosomal	  Membrane	  
Permeabilization	  





Recruitment	  Domain	   mRFP	  




Center	   mtHtt	   Mutant	  Huntingtin	  
CNS	   Central	  Nervous	  System	   NBRP	   National	  BioResource	  Project	  
CoQ	   Coenzyme	  Q	   NO	   Nitric	  Oxide	  
CoQOX	   CoQ	  -­‐	  Oxidized	   OD	   Optical	  Density	  
CoQRED	   CoQ	  -­‐	  Reduced	   PD	   Parkinson's	  Disease	  
CRT-­‐1	   Calreticulin	   PDSS1/2	  
Polyprenyl	  Diphosphate	  
Synthesase	  Subunit	  1/2	  
d	   day	   PTP	   Permeability	  Transition	  Pore	  
DA	   Dorsal	  A-­‐type	   Q	   Coenzyme	  Q	  
DB	   Dorsal	  B-­‐type	   rec-­‐CED-­‐3	   Reconstituted	  CED-­‐3	  
DD	   Dorsal	  D-­‐type	   RNAi	   RNA	  Interference	  
DIC	  
Differential	  Interference	  
Contrast	   ROS	   Reactive	  Oxygen	  Species	  
DMQ	   Demthoxy-­‐Coenzyme	  Q	   RPM	   Revolutions	  Per	  Minute	  
DRP-­‐1	   Dynamin-­‐Related	  Protein	  1	   sbo	   small	  boy	  
dsRNA	  
double-­‐stranded	  RiboNucleic	  
Acid	   SOD-­‐1	   SuperOxide	  Dismutase	  1	  
Egl	   Egg-­‐Laying	  Defective	   TEM	   Transmission	  Electron	  Microscopy	  
EGTA	  
Ethylene	  Glycol	  Tetraacetic	  
Acid	   Unc	   Uncoordinated	  
ETC	   Electron	  Transport	  Chain	   VD	   Ventral	  D-­‐type	  
ETFDH	  
Electron-­‐Transferring-­‐
Flavoprotein	  Dehydrogenase	   VNC	   Ventral	  Nerve	  Cord	  
EV	   Empty	  Vector	   WAN-­‐1	  
Worm	  Adenine	  Nucleotide	  
translocator	  1	  
GABA	  
Gamma	  Amino	  isoButyric	  
Acid	   WT	   Wild-­‐Type	  
	  




Neurons	  are	  specialized	  cells	  that	  transmit	  information	  through	  electrochemical	  signals.	  The	  
nervous	   system	   is	   composed	   of	   various	   types	   of	   neurons,	   or	   nerve	   cells,	   that	   form	   elaborate	  
signaling	   networks	   to	   control	   many	   processes,	   including	   movement,	   behavior	   and	   learning.	  
Neurodegenerative	   diseases	   are	   characterized	   by	   dysfunction	   or	   death	   of	   discrete	   neuronal	  
populations.	   The	   pathogenic	   outcome	   of	   this	   neuronal	   loss	   includes	   impaired	   movement	   (i.e.,	  
ataxias)	   and/or	   reduced	   mental	   capacity	   (i.e.,	   dementia).	   Despite	   the	   wide	   range	   of	   symptoms	  
presented	  by	  these	  diseases,	  they	  share	  features	  such	  as	  an	  age-­‐dependent	  onset	  and	  progressive	  
death	  of	  specific	  neuronal	  subtypes.	  Studies	  based	  on	  genetic	  mutations	  linked	  to	  these	  diseases	  are	  
beginning	   to	   reveal	   the	  underling	  molecular	  mechanisms	  of	  neuronal	  degeneration.	  This	  work	  has	  
identified	  a	  wide	  variety	  of	  putative	  disease-­‐causing	  events	  (i.e.,	  oxidative	  stress,	  energy	  depletion,	  
calcium	   overload)	   and	   show	   that	   these	   cellular	   stresses	   are	   associated	   with	   mitochondrial	  
dysfunction,	  a	  universal	  denominator	  of	  neurodegenerative	  diseases.	  Mitochondria	  are	  key	  energy-­‐
providing	   organelles	   and	   their	   impairment	   causes	   adverse	   cellular	   effects,	   including	   increased	  
reactive	  oxygen	  species	   (ROS)	  and	  deficient	  ATP	  production	   (Brookes	  et	  al.	  2004).	  The	  deleterious	  
effects	  of	  these	  insults	  and	  the	  central	  role	  that	  mitochondria	  play	  in	  cell	  death	  regulation	  underlie	  
the	  need	  to	  understand	  how	  dysfunction	  of	  this	  organelle	  contributes	  to	  disease	  pathogenesis.	  
Despite	  recent	  progress,	  much	   is	  still	  unknown	  about	  how	  age-­‐dependent	  cellular	  changes	  
lead	  to	  the	  selective	  death	  of	  specific	  types	  of	  neurons.	  Part	  of	  the	  challenge	  of	  understanding	  basic	  
biological	   responses	   to	   injury	   in	   the	   nervous	   system	   is	   due	   to	   the	   complexity	   of	   the	  mammalian	  
brain,	  which	   is	  composed	  of	  billions	  of	  neurons	  that	  make	  trillions	  of	  neuronal	  connections	  (Wang	  
2010).	   To	   circumvent	   this	   challenge,	   I	   have	   used	   the	   nematode	  C.	   elegans	   as	   a	  model	   system	   to	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study	  how	  mitochondrial	  dysfunction	  leads	  to	  neuronal	  degeneration.	  In	  contrast	  to	  the	  mammalian	  
brain,	   the	   C.	   elegans	   nervous	   system	   is	   composed	   of	   only	   302	   neurons	   (White	   et	   al.	   1986).	   The	  
strong	  conservation	  of	  key	  biological	  pathways	  between	  C.	  elegans	  and	  mammals	  suggests	  that	  my	  
findings	   could	   enhance	   the	   understanding	   of	   how	   mitochondrial	   impairment	   contributes	   to	  
neurodegenerative	   disease.	   In	   this	   Introduction,	   common	   features	   of	   neurodegenerative	   diseases	  
are	  reviewed,	  with	  a	  focus	  on	  cellular	  stresses	  that	  are	  shared	  among	  these	  disorders.	  These	  injuries	  
trigger	   cell	   death	   responses	   that	   are	   also	  prominent	   in	  neurodegenerative	  diseases.	   Finally,	  many	  
aspects	  of	  Coenzyme	  Q	  (an	  essential	  mitochondrial	  molecule	  that	  antagonizes	  many	  of	  these	  cellular	  
stresses)	  are	  discussed.	  These	  features	  of	  Coenzyme	  Q	  include	  its	  diverse	  functions,	   its	  association	  
with	   neurodegenerative	   disease	   and	   the	   advantages	   of	   using	   C.	   elegans	   to	   study	   Coenzyme	   Q	  
deficiency.	  
	  
Neurodegenerative	  diseases	  share	  common	  features	  
Age-­‐dependent	  disease	  onset	   	  	  
Advanced	  age	  is	  the	  primary	  risk	  factor	  for	  neurodegenerative	  diseases	  (T.	  Farooqui	  &	  A.	  A.	  
Farooqui	  2009)	  and	  enhanced	   life	  expectancy	   is	  projected	  to	  correlate	  with	  a	  dramatic	   increase	   in	  
the	   frequency	   of	   these	   disorders.	   An	   unfortunate	   consequence	   of	   aerobic	   metabolism	   is	   the	  
generation	  of	  reactive	  oxygen	  species	  (ROS).	  Overproduction	  of	  ROS	  damages	  biomolecules	  such	  as	  
proteins,	   lipids	   and	  DNA.	   To	   counteract	   these	   insults,	   cells	   use	   several	   adaptive	  mechanisms	   (i.e.,	  
antioxidant	  molecules	  and	  enzymes)	  that	  reduce	  ROS	  levels	  below	  toxic	  thresholds.	  However,	  these	  
defenses	  decrease	  with	  age,	  leading	  to	  overall	  increased	  oxidative	  stress	  (Mattson	  &	  Magnus	  2006).	  
Resultant	  damage	  to	  proteins,	  membranes	  and	  nucleotides	  accumulates	  over	  time,	  impairing	  other	  
cellular	   processes	   (i.e.,	   energy	   production,	   calcium	   buffering,	   DNA	   stability).	   Thus,	   the	   inherent	  
cellular	   changes	   that	   accompany	  aging	  may	   sensitize	  neurons	   to	   genetic	  or	   environmental	   factors	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that	  contribute	  to	  a	  neurodegenerative	  condition.	  Additionally,	  familial	  forms	  of	  neurodegenerative	  
disorders	   have	   earlier	   disease	   onset	   than	   sporadic	   cases	   (Fig.	   1.1A)	   due	   to	   inherited	   genetic	  
mutations	  whose	  impaired	  function	  adversely	  affects	  neuron	  viability	  (Bertram	  2005).	  Similarities	  in	  
clinical	  and	  pathological	  presentations	  between	  both	  early-­‐	  and	  late-­‐onset	  forms	  of	  these	  diseases	  
are	   suggestive	   of	   shared	   cellular	   events	   that	   may	   be	   accelerated	   by	   specific	   genetic	   mutations	  
(Mattson	  &	  Magnus	  2006).	  
	  
Selective	  neuronal	  vulnerability	  
Another	   hallmark	   of	   neurodegenerative	   diseases	   is	   the	   selective	   degeneration	   of	   distinct	  
neuronal	   populations	   (Fig.	   1.1B).	   These	   disorders	   manifest	   with	   unique	   clinical	   outcomes	   that	  
originate	  with	  dysfunction	  or	  degeneration	  of	  specific	  brain	  regions.	  For	  example,	  neuronal	   loss	   in	  
the	   hippocampus	   and	   cerebral	   cortex	   in	   Alzheimer’s	   Disease	   is	   correlated	   with	   symptoms	   of	  
impaired	   learning	   and	  memory	   (Bird	   et	   al.	   1983).	  Motor	   dysfunction	   is	   a	   hallmark	   of	   Parkinson’s	  
disease	  due	   to	  degeneration	  of	  dopaminergic	  neurons	  of	   the	  substantia	  nigra	   (Obeso	  et	  al.	  2008).	  
Amyotrophic	  Lateral	  Sclerosis	   (ALS)	   is	  characterized	  by	   loss	  of	  motor	  neurons	  of	   the	  cerebrospinal	  
axis	  that	  control	  voluntary	  muscles	  (Kawamura	  et	  al.	  1981).	  Huntington’s	  Disease	  is	  associated	  with	  
discoordinated	   movement	   (i.e.,	   chorea)	   and	   degraded	   cognitive	   function	   that	   are	   linked	   to	  
degeneration	  of	  glutamatergic	  neurons	  in	  the	  striatum	  (Martin	  &	  Gusella	  1986).	  Although	  the	  types	  
of	   neurons	   injured	   in	   these	   diseases	   are	   known,	   the	   molecular	   foundation	   for	   their	   selective	  
hypersensitivity	  in	  each	  of	  these	  diseases	  is	  not	  well-­‐understood.	  
Efforts	   to	  delineate	   the	  basis	   for	  neuron	  vulnerability	  have	   revealed	   that	   common	  cellular	  
processes	   are	   often	   disrupted	   in	   these	   sensitive	   neuronal	   populations.	   These	   studies	   compared	  
affected	  versus	  resistant	  populations	  of	  neurons	  from	  similar	  brain	  regions	  and	  reported	  potentially	  
harmful	  differences	  in	  oxidative	  stress	  load,	  energy	  production,	  calcium	  regulation	  and	  




Figure	  1.1:	  Age-­‐related	  disease	  onset	  and	  selective	  neuronal	  vulnerability	  are	  common	  features	  of	  
neurodegenerative	   diseases.	   A.	   Both	   familial	   and	   sporadic	   types	   have	   age-­‐related	   disease	   onset,	  
with	   familial	   forms	   of	   neurodegenerative	   disorders	   having	   earlier	   onset	   than	   sporadic	   cases.	   B.	  
Affected	  brain	  regions	  of	  major	  neurodegenerative	  diseases	  correlate	  with	  clinical	  symptoms.	  Figure	  
modified	  from	  (Mattson	  &	  Magnus	  2006).	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mitochondrial	  function	  (Wang	  2010).	  These	  variances	  do	  not	  solely	  cause	  vulnerable	  neurons	  to	  die	  
but	   are	   predicted	   to	   confer	   sensitivity	   to	   subsequent	   insults	   that	   can	   lead	   to	   their	   demise.	  
Additionally,	   expression	   profiling	   of	   neurons	   with	   distinct	   vulnerabilities	   in	   murine	   models	   of	  
Parkinson’s	  Disease	  (C.	  Y.	  Chung	  et	  al.	  2005)	  and	  Amyotrophic	  Lateral	  Sclerosis	  (Hedlund	  et	  al.	  2010)	  
uncovered	   many	   gene	   classes	   that	   are	   differentially	   expressed	   compared	   to	   resistant	   neurons.	  
Notably,	  mitochondrial	  and	  apoptosis-­‐related	  genes	  are	  differentially	  expressed	  in	  vulnerable	  versus	  
resistant	  populations.	  Despite	  these	  correlations	  between	  altered	  cellular	  homeostasis	  and	  unique	  




Mitochondria	   are	   essential	   organelles	   that	   provide	  many	   important	   functions	   for	   the	   cell,	  
such	   as	   ATP	   production,	   antioxidant	   defense	   and	   calcium	   homeostasis	   (Petrozzi	   et	   al.	   2007).	   Not	  
surprisingly,	   disruption	   of	   these	   mitochondrial-­‐dependent	   processes	   is	   associated	   with	  
neurodegenerative	   diseases	   (Beal	   2005).	   Additionally,	   both	   age-­‐related	   cellular	   changes	   and	  
differential	   neuronal	   sensitivities	   implicate	   oxidative	   stress	   as	   a	   key	   event	   in	   neurodegenerative	  
diseases.	   Oxidative	   stress	   arises	   from	   damage	   to	   molecules	   (i.e.,	   proteins,	   lipids,	   nucleotides)	   by	  
reactive	   oxygen	   species	   (ROS).	   The	   highly	   reactive	   superoxide	   anion	   is	   one	   of	   the	   major	   ROS	  
produced,	  and	  it	  is	  primarily	  generated	  as	  a	  by-­‐product	  of	  the	  energy-­‐producing	  process	  of	  oxidative	  
phosphorylation	  in	  the	  mitochondrial	  electron	  transport	  chain	  (ETC)	  (Zeevalk	  et	  al.	  2005).	  
Genetic	   analyses	   of	   patients	   with	   familial	   forms	   of	   neurodegenerative	   diseases	   identified	  
mutations	   in	  proteins	  associated	  with	  the	  mitochondria.	  For	  example,	  many	  of	  the	  genes	  linked	  to	  
Parkinson’s	  Disease	  (i.e.,	  PINK1,	  Parkin,	  DJ-­‐1)	  have	  mitochondrial	   roles	   (Valente	  et	  al.	  2004;	  Darios	  
2003;	  Taira	  et	  al.	  2004).	  Several	  genetic	  mutations	  linked	  to	  these	  diseases	  also	  disrupt	  the	  function	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of	  the	  electron	  transport	  chain	  (ETC)	  (Fig.	  1.2)	  (Lin	  &	  Beal	  2006).	  For	  example,	  β-­‐amyloid	  deposits	  in	  
the	  brain	  are	  a	  hallmark	  pathology	  of	  Alzheimer’s	  Disease	  and	  a	  fragment	  of	  β-­‐amyloid	  disrupts	  the	  
activity	   of	   ETC	   Complex	   IV	   (Canevari	   et	   al.	   1999).	   Additionally,	   chemical	   inhibitors	   of	   the	   ETC	  
produce	   symptoms	   reminiscent	   of	   neurodegenerative	   diseases,	   providing	   further	   evidence	   of	   a	  
connection	  between	  ETC	  dysfunction	  and	  neuronal	  degeneration	  (Knott	  et	  al.	  2008).	  Specifically,	  3-­‐
nitropropionic	   acid	   (3-­‐NP),	   an	   inhibitor	  of	  Complex	   II	   of	   the	  ETC,	   causes	   selective	  degeneration	  of	  
GABAergic	   neurons	   in	   the	   striatum	   which	   is	   also	   a	   prominent	   feature	   of	   Huntington’s	   Disease	  
(Brouillet	  et	  al.	  1999).	  Thus,	  ETC	  dysfunction	  resulting	   in	  decreased	  ATP	  synthesis,	  or	  alternatively,	  
increased	  ROS	  production	  is	  linked	  to	  neurodegenerative	  disease.	   	  
	  
Types	  of	  cell	  death	  associated	  with	  neurodegenerative	  pathology	  
Aberrant	  neuronal	  cell	  death	  underlies	  the	  pathogenesis	  of	  neurodegenerative	  diseases.	  Cell	  
death	   pathways,	   initiated	   by	   a	   wide-­‐range	   of	   cellular	   stressors,	   have	   been	   implicated	   in	   these	  
disorders.	   Two	   of	   the	   most	   well-­‐characterized	   types	   of	   cell	   death	   associated	   with	  
neurodegeneration	  are	  apoptosis	  and	  necrosis	  (Bredesen	  et	  al.	  2006).	  Neuronal	  death	  by	  apoptosis	  
or	  necrosis	  is	  linked	  to	  Alzheimer’s	  (Bonfoco	  et	  al.	  1995),	  Huntington’s	  (Portera-­‐Cailliau	  et	  al.	  1995),	  
Parkinson’s	   Diseases	   (Jellinger	   2000),	   and	   Amyotrophic	   Lateral	   Sclerosis	   (Matyja	   et	   al.	   2005).	  
Evidence	  for	  both	  of	  these	  death	  pathways	  in	  neurodegenerative	  diseases	  suggests	  that	  a	  common	  
set	  of	  insults	  and	  proteins	  may	  regulate	  the	  killing	  mechanisms	  that	  remove	  damaged	  neurons.	  
	  
Apoptosis	  
	   Programmed	  cell	  death	  (i.e.,	  apoptosis)	   is	   important	  for	  embryonic	  development	  and	  adult	  
tissue	   homeostasis	   (Kerr	   et	   al.	   1972).	   However,	   misregulation	   of	   this	   process	   is	   associated	   with	  
disease.	  For	  example,	  insufficient	  apoptosis	  is	  linked	  to	  the	  pathogenesis	  of	  cancer	  	  







Figure	   1.2:	   The	   mitochondrial	   electron	   transport	   chain	   (ETC)	   is	   often	   disrupted	   in	  
neurodegenerative	   diseases.	   Genetic	  mutations	   linked	   to	   neurodegenerative	   diseases,	   SOD1	   and	  
amyloid	  beta	  (Aβ),	  reduce	  the	  activity	  of	  ETC	  complexes	  in	  models	  of	  Amyotrophic	  Lateral	  Sclerosis	  
(ALS)	   (Menzies	   et	   al.	   2002)	   and	   Alzheimer’s	   Disease	   (AD)	   (Canevari	   et	   al.	   1999),	   	   respectively.	  
Pharmacological	   inhibitors	  of	  Complex	   I	   (MPTP	  and	  rotenone)	   induce	  Parkinsonian	   (PD)	  symptoms	  
(Langston	  et	  al.	  1983;	  Betarbet	  et	  al.	  2000)	  and	  3-­‐nitropropionic	  acid	  (3-­‐NP)	  and	  malonate	  interfere	  
with	  Complex	   II	  and	  produce	  symptoms	  associated	  with	  Huntington’s	  Disease	  (HD)	   (Brouillet	  et	  al.	  
1999).	   Coenzyme	   Q	   deficiency	   reduces	   the	   levels	   of	   Coenzyme	   Q	   (Q)	   and	   often	   presents	   with	  
neurological	  symptoms	  such	  as	  cerebellar	  ataxia.	  IMS	  =	  intermembrane	  space,	  cyt	  c	  =	  cytochrome	  C.	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(Bergmann	   &	   Steller	   2010)	   and	   excessive	   apoptosis	   leads	   to	   inappropriate	   cell	   loss	   in	  
neurodegenerative	   disease	   (Mattson	   2000).	   Oxidative	   stress	   and	   DNA	   damage	   are	   established	  
apoptotic	  triggers	  that	  are	  also	  commonly	  found	  in	  stressed	  or	  aging	  neurons.	  	  
Apoptosis	  (i.e.,	  Type	  I	  cell	  death)	  is	  an	  energy-­‐driven	  process	  that	  largely	  functions	  through	  a	  
family	   of	   cysteine	   proteases	   known	   as	   caspases.	   Forward	   genetic	   screens	   in	  C.	   elegans	   identified	  
conserved	  apoptotic	  machinery	   (Fig.	  1.3)	  and	  outlined	  a	  cascade	  of	  events	   that	   leads	   to	  apoptotic	  
death	  (Metzstein	  et	  al.	  1998).	  Whereas	  apoptosis	  in	  vertebrates	  is	  inherently	  more	  complex,	  central	  
events	   such	   as	   the	   anti-­‐apoptotic	   activity	   of	   CED-­‐9/Bcl2	   and	   CED-­‐3/caspase	   activation	   by	   CED-­‐
4/Apaf-­‐1	  are	  maintained.	  Because	  of	  the	  conservation	  of	  core	  death	  machinery,	  the	  simple	  anatomy	  
and	  defined	  nervous	  system	  of	  C.	  elegans	  make	  it	  a	  useful	  organism	  for	  studies	  of	  how	  cellular	  injury	  
activates	  neuron	  death	  pathways.	  	  
	  	  
Apoptosis	  in	  C.	  elegans	  
In	  C.	  elegans,	  131	  of	  1090	  somatic	  cells	  reproducibly	  die	  by	  apoptosis	  during	  development	  
(Dong	   et	   al.	   2009)	   and	   80%	   of	   these	   cells	   are	   derived	   from	   neuronal	   lineages	   (Putcha	   &	   E.	   M.	  
Johnson	  2004).	  Apoptotic	  cells	  show	  a	  raised	  button-­‐like	  morphology	  and	  are	  readily	  distinguished	  
by	   differential	   interference	   contrast	   (DIC)	   microscopy	   (Ellis	   &	   Horvitz	   1986).	   In	   this	   genetically	  
programmed	  pathway	  (Fig.	  1.3),	  an	  apoptotic	  signal	  stimulates	  transcriptional	  upregulation	  of	  EGL-­‐1,	  
a	  BH3-­‐only	  protein	  (Conradt	  &	  Horvitz	  1998;	  Thellmann	  et	  al.	  2003).	  EGL-­‐1	  binds	  to	  CED-­‐9,	  a	  Bcl-­‐2	  
family	  member	  that	  normally	  sequesters	  CED-­‐4/Apaf-­‐1	  at	  the	  outer	  mitochondrial	  membrane.	  The	  
EGL-­‐1-­‐CED-­‐9	   interaction	  releases	  CED-­‐4	   to	  aggregate	  as	  an	  active	  “apoptosome”	   (Yan	  et	  al.	  2004).	  
The	  CED-­‐4	  oligomer	   interacts	  with	  CED-­‐3/caspase	   to	   trigger	  an	   intramolecular	   cleavage	  at	   specific	  
sites	   that	   activates	  CED-­‐3	   (X.	   Yang	  et	   al.	   1998).	   The	   resultant	   CED-­‐3	   caspase	   activity	   executes	   the	  
apoptotic	  program	  by	  targeting	  downstream	  substrates	  for	  proteolytic	  degradation.	  




Figure	   1.3:	   Apoptotic	   regulators	   are	   conserved	   from	   C.	   eleagns	   to	   mammals.	   Programmed	   cell	  
death	  in	  C.	  elegans	   is	  regulated	  by	  four	  core	  components	  that	  have	  clear	  mammalian	  homologues:	  
EGL-­‐1/BH3-­‐only,	   CED-­‐9/Bcl2,	   CED-­‐4/Apaf-­‐1,	   CED-­‐3/caspase.	   Additionally,	   the	   cascade	   of	   apoptotic	  
events	   is	   also	   conserved	   between	   C.	   elegans	   and	   mammals:	   BH3-­‐only	   proteins	   inhibit	   the	   anti-­‐
apoptotic	   Bcl2	   regulator	   leading	   to	   Apaf-­‐1-­‐dependent	   activation	   of	   caspases.	   Adapted	   from	   (Yi	   &	  
Yuan	  2009).	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This	   genetically	   programmed	   pathway	   is	   widely	   studied	   in	   developmental	   contexts	   but	  
stress-­‐induced	  apoptosis	  has	  also	  been	  observed.	  DNA	  damage-­‐induced	  germ	  cell	  apoptosis	  requires	  
the	   core	   apoptotic	   machinery	   (Fig.	   1.3)	   and	   is	   regulated	   by	   CEP-­‐1,	   the	   p53	   tumor	   suppressor	  
homologue	  (Gartner	  et	  al.	  2008).	  Additionally,	  in	  a	  C.	  elegans	  model	  of	  Huntington’s	  disease,	  loss-­‐of-­‐
function	   mutations	   in	   ced-­‐3/caspase	   prevented	   neuronal	   cell	   death	   (Faber	   et	   al.	   1999).	   The	  
existence	   of	   non-­‐programmed	   apoptotic	   deaths	   in	   the	   worm	   suggests	   that	   apoptotic	   machinery	  
responds	  to	  both	  developmental	  and	  stress-­‐related	  cues	  to	  facilitate	  cell	  death	  execution.	  	  
	  
Necrosis	  
Necrotic	   cell	   death	   is	   morphologically	   distinct	   from	   apoptosis	   and	   typically	   occurs	   under	  
conditions	   of	   severe	   cellular	   injury	   (i.e.,	   high	   levels	   of	   oxidative	   stress,	   calcium	   overload,	   drastic	  
energy	  depletion).	  Necrotic	  cells	  exhibit	  prominent	  cellular	  swelling,	  distortion	  of	  organelles	  such	  as	  
the	  mitochondria	  and	  endoplasmic	  reticulum,	  and	  vacuolization	  of	  the	  cytoplasm	  (Hall	  et	  al.	  1997).	  
In	   contrast	   to	   the	   tightly	   regulated	   mechanism	   of	   apoptosis,	   necrosis	   (i.e.,	   Type	   III	   death)	   was	  
initially	  regarded	  as	  a	  chaotic,	  uncontrollable	  process.	  However,	  recent	  studies	  reveal	  that	  inhibition	  
of	  key	  proteolytic	  events	  prevents	  necrosis,	  thus	  paralleling	  the	  pivotal	  enzymatic	  regulation	  of	  the	  
apoptotic	  program.	  
The	   “Calpain-­‐Cathepsin	   Hypothesis”	   originated	   with	   studies	   of	   ischemia	   in	   mammals	  
(Yamashima	  2000)	  and	  involves	  the	  activation	  of	  two	  proteolytic	  families	  (calpains	  and	  cathepsins)	  
to	  execute	  necrotic	  cell	  death.	  In	  this	  model	  (Fig.	  1.4),	  necrotic	  stimuli	  trigger	  increased	  intracellular	  
calcium	   that	   then	   activates	   calcium-­‐dependent	   calpain	   proteases.	   Calpain	   activation	   leads	   to	  
lysosomal	   membrane	   permeabilization	   (LMP)	   and	   the	   consequent	   release	   of	   harmful	   cathepsin	  
proteases	  into	  the	  cytosol.	  Robust	  proteolysis	  by	  the	  combined	  effects	  of	  activated	  calpains	  and	  	  
	  





Figure	   1.4:	   Necrotic	   events	   are	   conserved	   in	   C.	   elegans.	   A.	  According	   to	   the	   “Calpain-­‐Cathepsin	  
Hypothesis,”	  necrosis-­‐initiating	  insults	  stimulate	  a	  rise	  in	  intracellular	  calcium	  that	  activates	  a	  family	  
of	   calcium-­‐dependent	   proteases	   (calpains).	   Activated	   calpains	   trigger	   lysosomal	   membrane	  
permeabilization	   and	   rupture	   that	   releases	   harmful	   cathepsin	   proteases	   into	   the	   cytosol.	   This	  
proteolytic	  cascade	   leads	   to	  necrotic	  cell	  death.	  B.	  Key	  events	   in	   this	  pathway	  are	  conserved	   in	  C.	  
elegans.	   Hyperactive	   ion	   channels	   stimulate	   a	   CRT-­‐1/calreticulin-­‐dependent	   increase	   in	   cytosolic	  
calcium	   levels.	  Two	  calpain	  proteases	   (CLP-­‐1	  and	  TRA-­‐3)	  are	  activated	  and	   lead	  to	   the	  subsequent	  
release	  of	  two	  cathepsin	  proteases	  (ASP-­‐3	  and	  ASP-­‐4)	  from	  the	  lysosome.	  Genetic	  inhibition	  of	  these	  
proteins	  inhibits	  necrosis	  in	  C.	  elegans.	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cathepsins	  results	  in	  necrotic	  cellular	  demise.	  As	  is	  also	  the	  case	  for	  apoptosis,	  key	  events	  in	  necrotic	  
pathway	  are	  conserved	  in	  C.	  elegans.	  
	  
Necrosis	  in	  C.	  elegans	  	  
Mutations	   that	   result	   in	   constitutive	   cation	   channel	   activity	   have	   been	   shown	   to	   trigger	  
necrotic	  cell	  death	  in	  C.	  elegans	  (Syntichaki	  et	  al.	  2002).	  As	  was	  previously	  reported	  for	  necrotic	  cell	  
death	   in	  mammals,	   necrosis	   in	   C.	   elegans	   requires	   elevated	   intracellular	   calcium	   that	   activates	   a	  
series	  of	  proteases	  ultimately	   leading	   to	  cell	  destruction	   (Xu	  et	  al.	  2001).	  Specific	  members	  of	   the	  
calpain	  (CLP-­‐1,	  TRA-­‐3)	  and	  cathepsin	  (ASP-­‐3,	  ASP-­‐4)	  protease	  families	  are	  required	  for	  necrotic	  cell	  
death	   (Fig.	   1.4)	   (Syntichaki	   et	   al.	   2002)	   in	   this	   pathway.	   These	   proteases	   promote	   necrotic	   death	  
initiated	  by	  several	  mechanisms,	  including	  hyperactive	  ion	  channels	  (i.e.,	  degenerin	  channels	  deg-­‐1	  
and	   mec-­‐4,	   acetylcholine	   receptor	   channel	   subunit	   deg-­‐3,	   and	   the	   Gs	   protein	   α-­‐subunit	   gsa-­‐1	  
(Syntichaki	  et	  al.	  2002))	  and	  by	  ectopic	  expression	  of	  Hepatitis	  B	  virus	  X	  protein	  (Geng	  et	  al.	  2012).	  
Alternatively,	   SRP-­‐6	   (an	   intracellular	   serpin	   that	   inhibits	   cysteine	   peptidases)	   protects	   against	  
intestinal	  necrotic	  death	  in	  a	  pathway	  requires	  TRA-­‐3	  and	  ASP-­‐3	  but	  not	  CLP-­‐1	  or	  ASP-­‐4	  (Luke	  et	  al.	  
2007).	  Furthermore,	  additional	  calpain	  and	  cathepsins	  that	  do	  not	  control	  hyperactive	  ion	  channel-­‐
mediated	  necrosis	  (i.e.,	  W05G11.4	  and	  ASP-­‐1)	  were	  also	  identified	  in	  the	  SRP-­‐6	  pathway.	  This	  result	  
suggests	  that	  members	  of	  these	  protease	  families	  respond	  differently	  to	  necrotic	  signals,	  depending	  
on	  the	  cellular	  context	  (i.e.,	  cell	  type,	  necrotic	  stimulus).	  
	  
Intermediate	  cell	  death	  pathways	  
Despite	  the	  wealth	  of	  literature	  describing	  apoptosis	  and	  necrosis	  as	  two	  distinct,	  mutually	  
exclusive	  forms	  of	  cell	  death,	  recent	  studies	  have	  revealed	  extensive	  cross	  talk	  between	  these	  two	  
pathways.	   “Aponecrosis”	   is	   one	   such	   alternative	   form	   of	   cell	   death	   that	   shares	   morphological	  
	   13	  
features	   of	   apoptosis	   (i.e.,	   nuclear	   chromatin	   fragmentation)	   and	   necrosis	   (i.e.,	   mitochondrial	  
swelling,	  translucent	  cytoplasm,	  and	  plasma	  membrane	  rupture)	  (Formigli	  et	  al.	  2000).	  Additionally,	  
common	  molecular	  mechanisms	  have	  been	  connected	   to	  both	  apoptosis	  and	  necrosis	   (Brennan	  &	  
Cookson	  2000;	  Wang	  et	  al.	  2003).	  For	  example,	  the	  apoptotic	  components	  caspase-­‐8	  and	  Bid	  (a	  Bcl-­‐
2	   family	  member)	   regulate	  necrotic	  cell	  death	  resulting	   from	  oxidative	  stress	   (Brennan	  &	  Cookson	  
2000;	   Wang	   et	   al.	   2003).	   Another	   shared	   regulator	   of	   these	   two	   forms	   of	   cell	   death	   is	   the	  
mitochondrion,	  as	  release	  of	  mitochondrial	   factors	   into	  the	  cytosol	   is	   implicated	   in	  both	  apoptosis	  
and	  necrosis	  (Galluzzi	  et	  al.	  2007).	  This	  finding	  suggests	  that	  the	  cellular	  response	  to	  mitochondrial	  
dysfunction	  may	  activate	  either	  of	  these	  pathways	  or	  specific	  elements	  of	  both.	  
	  
Mitochondria	  in	  cell	  death	  
A	   role	   for	   mitochondria	   in	   mammalian	   cell	   death	   is	   well-­‐established.	   Mitochondrial	  
membrane	  permeabilization	  (MMP)	  is	  linked	  to	  both	  apoptosis	  and	  necrosis,	  with	  two	  mechanisms	  
that	   can	   cause	   MMP	   (Kroemer	   et	   al.	   2007).	   For	   apoptosis,	   mitochondrial	   outer	   membrane	  
permeabilization	   (MOMP)	   mediated	   by	   pro-­‐apoptotic	   Bcl-­‐2	   family	   members	   form	   a	   protein-­‐
permeable	  pore	  that	  releases	  factors	  such	  as	  cytochrome	  c	  (X.	  Liu	  et	  al.	  1996)	  and	  DIABLO/Smac	  (Du	  
et	  al.	  2000),	  which	  stimulate	  caspase	  activation.	  Additionally,	  MMP	  can	  occur	  with	   the	  opening	  of	  
the	   mitochondrial	   permeability	   transition	   pore	   (PTP)	   (Galluzzi	   et	   al.	   2010).	   PTP	   is	   a	   multisubunit	  
structure	   spanning	   from	   the	   mitochondrial	   matrix	   to	   the	   outer	   mitochondrial	   membrane.	   The	  
precise	  composition	  is	  unclear	  but	  three	  components	  have	  been	  identified:	  the	  voltage-­‐gated	  anion	  
channel	  (VDAC),	  the	  adenine	  nucleotide	  translocase	  (ANT)	  and	  cyclophilin	  D	  (CypD).	  Following	  pore	  
opening,	  mitochondrial	  membrane	  potential	  drops	  and	  osmotic	  swelling	  occurs	  as	  solutes	  enter	  the	  
mitochondria.	   Ultimately,	   outer	   mitochondrial	   membrane	   breakdown	   leads	   to	   release	   of	  
mitochondrial	  contents	  into	  the	  cytosol.	  Since	  energy	  collapse	  (due	  to	  loss	  mitochondrial	  membrane	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potential)	   and	   release	   of	   apoptogenic	   factors	   both	   occur	  with	   PTP	   opening,	   the	   cell	   can	   undergo	  
necrosis	  or	  apoptosis.	  Inhibition	  of	  permeability	  transition	  pore	  opening	  can	  block	  both	  types	  of	  cell	  
death	  (Roy	  et	  al.	  2006).	  The	  key	  role	  of	  the	  mitochondrion	  in	  cell	  death	  mechanisms	  might	  explain	  
why	  dysfunction	  of	  this	  organelle	  is	  so	  tightly	  correlated	  with	  neurodegenerative	  diseases.	  
Unlike	  mammalian	   systems	   in	   which	  mitochondria	   have	   been	   closely	   linked	   to	   cell	   death	  
mechanisms,	  evidence	  of	  mitochondrial	  death	  regulation	  in	  C.	  elegans	  is	  controversial.	  Homologs	  of	  
mammalian	  Endonuclease	  G	  (EndoG/csp-­‐6)	  and	  Apoptosis	  Inducing	  Factor	  (AIF/wah-­‐1)	  contribute	  to	  
apoptotic	   death	   by	   mediating	   DNA	   degradation	   and	   phosphatidyl	   serine	   exposure,	   respectively	  
(Parrish	  et	  al.	  2001;	  Wang	  et	  al.	  2007).	  A	  recent	  study	  identified	  a	  specific	  interaction	  between	  CED-­‐
4/Apaf-­‐1	  and	  a	  member	  of	  the	  adenine	  nucleotide	  translocase	  (ANT)	  family,	  wan-­‐1,	  that	  serves	  as	  a	  
key	  regulator	  of	  programmed	  cell	  death	  in	  C.	  elegans	  (Q.	  Shen	  et	  al.	  2009).	  ANT	  is	  a	  core	  component	  
of	  the	  mitochondrial	  permeability	  transition	  pore	  (MPTP)	  whose	  opening	  releases	  death-­‐promoting	  
factors	   in	  mammals	   (Kroemer	  et	  al.	  2007).	  This	   finding	  supports	   the	  hypothesis	   that	  mitochondria	  
also	  serve	  as	  important	  regulators	  of	  cell	  death	  in	  the	  nematode.	  
Further	  evidence	  for	  the	  role	  of	  mitochondrial	  dysfunction	   in	  cell	  death	   is	  provided	  by	  the	  
observation	  that	  excessive	  mitochondrial	   fission	  (i.e.,	   fragmentation)	   is	  an	  early	  event	   in	  apoptosis	  
that	  precedes	  caspase	  activation.	  Mitochondria	  normally	  divide	  and	  fuse	  to	  meet	  the	  cell’s	  changing	  
energy	  demands	  (Knott	  et	  al.	  2008;	  Knott	  &	  Bossy-­‐Wetzel	  2008).	  An	  imbalance	  in	  the	  fission/fusion	  
cycle	  has	  been	  implicated	  in	  various	  neurodegenerative	  diseases	  (Knott	  &	  Bossy-­‐Wetzel	  2008).	  Drp1	  
is	  a	  conserved	  large	  GTPase	  that	  is	  essential	  in	  the	  regulation	  of	  mitochondrial	  fission	  (Bossy-­‐Wetzel	  
et	  al.	  2003).	  In	  mammals,	  overexpression	  of	  Drp1	  initiates	  apoptosis	  and	  expression	  of	  a	  dominant-­‐
negative	  Drp1	   can	  prevent	   apoptotic	   cell	   death	   (Shani	   et	   al.	   2001).	  A	  Drp1-­‐mediated	  necrotic	   cell	  
death	  pathway	  has	   also	  been	   identified	   (Bras	   et	   al.	   2007).	   These	   findings	   suggest	   that	   changes	   in	  
mitochondrial	  morphology	  may	  be	  linked	  with	  the	  execution	  of	  cell	  death.	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An	  integrated	  model	  of	  necrosis	  and	  apoptosis	   	  
The	  shared	   features	  of	  pathways	   leading	   to	  both	  apoptosis	  and	  necrosis	  are	   suggestive	  of	  
the	  idea	  of	  a	  continuum	  of	  cell	  death	  signals	  can	  lead	  to	  either	  outcome	  (Fig.	  1.5)	  (Yakovlev	  &	  Faden	  
2004).	  In	  this	  model,	  cellular	  damage	  such	  as	  oxidative	  stress	  or	  impaired	  calcium	  homeostasis	  is	  in	  a	  
balance	   with	   ATP	   levels	   to	   dictate	   whether	   an	   injured	   cell	   undergoes	   apoptosis	   or	   necrosis.	   For	  
example,	   mild	   cellular	   damage	   provides	   a	   cell-­‐killing	   signal	   that	   is	   transduced	   by	   an	   energy-­‐
dependent	   apoptotic	   program.	   Conversely,	   severe	   intracellular	   damage	   coupled	   with	   a	   sharp	  
decrease	   in	   cellular	   ATP	   levels	   triggers	   a	   necrotic	   death	   pathway.	   This	   continuum	   explains	   how	  
similar	  cellular	  insults,	  depending	  on	  severity,	  can	  activate	  necrotic	  or	  apoptotic	  pathways	  and	  may	  
also	   explain	   how	   common	   upstream	   regulators	   (i.e.,	   Bcl2	   family,	   caspase,	   calpains)	   can	   promote	  
either	  an	  apoptotic	  or	  necrotic	  response.	  	  
Interestingly,	   CED-­‐9/Bcl2	   was	   recently	   identified	   as	   a	   key	   regulator	   of	   Hepatitis	   B	   virus	   X	  
(HBx)-­‐induced	   cell	   death	   in	   C.	   elegans	   (Geng	   et	   al.	   2012).	   Ectopic	   expression	   of	   HBx	   triggers	  
apoptotic	   and	   necrotic	   death,	   both	   of	   which	   rely	   on	   CED-­‐9	   function.	   CED-­‐9-­‐dependent	   apoptosis	  
occurs	   through	  the	  canonical	  pathway	   (i.e.,	  CED-­‐4	  release	  and	  CED-­‐3	  activation,	  Fig.	  1.3),	  whereas	  
CED-­‐9-­‐dependent	   necrosis	   requires	   mitochondrial	   permeability	   transition	   (MPT)	   to	   increase	   Ca2+	  
levels	  and	  activate	  necrotic	  proteases	  (i.e.,	  TRA-­‐3,	  CLP-­‐1,	  ASP-­‐3,	  ASP-­‐4,	  Fig.	  1.4).	  The	  dual	  function	  of	  
CED-­‐9	  in	  C.	  elegans	   is	  suggestive	  of	  an	  evolutionarily	  ancient	  link	  between	  key	  cell	  killing	  functions	  
and	  alternative	  cell	  death	  pathways.	  
It	   is	   clear	   that	   mitochondrial	   dysfunction	   plays	   a	   key	   role	   in	   cell	   death	   mechanisms;	  
however,	   less	   is	   known	   about	   how	   dysfunction	   of	   this	   organelle	   results	   in	   the	   degeneration	   of	  
specific	   types	  of	  neurons.	  Hallmarks	  of	   aging	  and	  vulnerable	  neurons,	   such	  as	   increased	  oxidative	  
stress,	   impaired	   calcium	  homeostasis,	   and	   disrupted	   energy	  metabolism,	   are	   also	   associated	  with	  
mitochondrial	  dysfunction	  and	  ultimately	  trigger	  apoptotic	  or	  necrotic	  cell	  death.	  Cells	  have	  	  














Figure	  1.5:	  Common	  insults	  account	  for	  a	  cell	  death	  continuum	  between	  apoptosis	  and	  necrosis.	  
Mild	  cellular	  damage	  coupled	  with	  abundant	  ATP	  levels	  allows	  cells	  to	  expend	  the	  energy	  required	  
for	   apoptotic	   cell	   death.	   Severe	  damage	   in	   the	   absence	  of	  ATP	   triggers	   a	   necrotic	   death	  pathway	  
that	  occurs	  through	  an	  energy-­‐independent	  mechanism.	  Intermediate	  levels	  of	  damage	  and	  ATP	  can	  
lead	  to	  cell	  death	  that	  shares	  features	  of	  both	  apoptosis	  and	  necrosis.	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numerous	  adaptive	  mechanisms	  that	  defend	  against	  stress-­‐induced	  cell	  death.	  The	  next	  section	  
highlights	  one	  of	  these	  protective	  molecules,	  Coenzyme	  Q.	  	  
	  
Coenzyme	  Q	  is	  important	  for	  cellular	  homeostasis	  and	  viability	  
	   Coenzyme	  Q	  	  (CoQ)	  is	  a	  highly	  conserved	  lipophilic	  molecule	  present	  in	  all	  tissues,	  cells	  and	  
membranes	   (Turunen	   et	   al.	   2004).	   CoQ	   primarily	   functions	   as	   an	   electron	   carrier	   in	   the	   ATP-­‐
producing	  mitochondrial	  oxidative	  respiratory	  chain	  (Fig	  1.2)	  (Crane	  et	  al.	  1957),	  but	  other	  roles	  for	  
this	  fat-­‐soluble	  molecule	  have	  been	  described,	  including	  electron	  transfer	  for	  plasma	  and	  lysosomal	  
membranes	   (I.	   L.	   Sun	   et	   al.	   1992;	   Nohl	   &	   Gille	   2001),	   regulation	   of	   apoptosis	   through	   the	  
mitochondrial	  permeability	  transition	  pore	  (PTP)	  (Fontaine	  et	  al.	  1998;	  Papucci	  et	  al.	  2003;	  Devun	  et	  
al.	   2010;	   Sahach	   et	   al.	   2007),	   and	   as	   a	  membrane	   antioxidant	   (Navas	   et	   al.	   2002).	   The	   variety	   of	  
these	  CoQ-­‐dependent	  cellular	  processes	  highlights	  the	  importance	  of	  biosynthesis,	  maintenance	  and	  
distribution	  of	  this	  vitamin-­‐like	  quinone.	  
	  
Coenzyme	  Q	  functions	  
	   Coenzyme	   Q	   has	   a	   prominent	   role	   in	   the	   mitochondria	   where	   it	   shuttles	   electrons	   from	  
Complexes	  I	  and	  II	  to	  Complex	  III	  in	  the	  electron	  transport	  chain	  (ETC)	  (Crane	  et	  al.	  1957)	  (Fig.	  1.2).	  
Coenzyme	  Q	  is	  therefore	  essential	  for	  ATP	  production.	  	  In	  addition,	  the	  close	  association	  of	  CoQ	  with	  
the	   free	   radical-­‐generating	   ETC	   likely	   accounts	   for	   its	   key	   antioxidant	   role	   to	   prevent	   oxidative	  
mitochondrial	  overload.	  CoQ	  also	  has	  energy	  coupling	  roles	  in	  lysosomal	  acidification	   (Gille	  &	  Nohl	  
2000)	   and	   plasma	   membrane	   Na+/H+	   exchange	   (Crane	   2001).	   Furthermore,	   as	   the	   only	  
endogenously	   synthesized	   lipid-­‐soluble	   antioxidant	   (Ernster	   &	   Dallner	   1995),	   Coenzyme	   Q	   is	  
essential	   for	   protecting	   against	   free	   radical	   damage	   in	   cellular	   membranes.	   Interestingly,	   studies	  
have	  shown	  that	  Coenzyme	  Q	  prevents	  apoptotic	  death	  by	  preventing	  mitochondrial	  permeability	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transition	  pore	  (PTP)	  opening	  (Fontaine	  et	  al.	  1998;	  Papucci	  et	  al.	  2003;	  Devun	  et	  al.	  2010;	  Sahach	  et	  
al.	  2007).	  	  These	  diverse	  roles	  of	  Coenzyme	  Q	  are	  indicative	  of	  a	  key	  regulator	  that	  protects	  against	  
cell	   death,	   either	   by	   direct	   (i.e.,	   PTP	   inhibition)	   or	   indirect	   (i.e.,.	  ATP	   production,	   ROS	   reduction)	  
mechanisms.	  
	  
Coenzyme	  Q	  biosynthesis	  
Coenzyme	  Q	  biosynthesis	  requires	  at	  least	  nine	  genes	  (Coq1-­‐Coq9)	  that	  are	  conserved	  from	  
yeast	   to	   humans	   (Fig.	   1.6)	   (Tran	  &	   Clarke	   2007).	   These	   nuclear	   genes	   encode	   proteins	  with	   both	  
catalytic	  (Coq1,	  Coq2,	  Coq3,	  Coq5,	  Coq6,	  Coq7/Clk1)	  and	  regulatory	  functions	  	  (Coq4,	  Coq8,	  Coq9),	  
and	  most	  of	  these	  proteins	  are	  predicted	  to	  form	  a	  multisubunit	  complex	  in	  the	  mitochondria	  (Tran	  
&	   Clarke	   2007).	   CoQ	   structure	   is	   conserved	   among	   species,	   with	   the	   exception	   of	   length	   of	   the	  
isoprene	  tail	  (Table	  1.1),	  which	  ranges	  from	  CoQ6	  (S.	  cerevisiae)	  to	  CoQ10	  (humans).	  The	  polyprenyl	  
diphosphate	  synthase	  (COQ-­‐1	  enzyme)	  determines	  the	  length	  of	  this	  tail	  and	  thus	  dictates	  the	  CoQ	  
isoform	  synthesized	  in	  each	  organism	  (Okada	  et	  al.	  1996;	  K	  et	  al.	  1997).	  Many	  biological	  functions	  of	  
Coenzyme	  Q	  are	  correlated	  with	  its	  molecular	  structure:	  the	  lipid-­‐soluble	  isoprene	  tail	  anchors	  CoQ	  
in	  cellular	  membranes	  and	  the	  benzoquinone	  ring	  accounts	  for	  its	  redox	  properties	  (Fig.	  1.6A).	  	  
	  
	  
Table	   1.1:	   Isoprene	   tail	   length	   of	   Coenzyme	   Q	   varies	   among	   species.	   The	   COQ1	   gene	   encodes	  
polyprenyl	  diphosphate	  synthase	  that	  determines	  species-­‐specific	  isoprene	  tail	  length	  (Tran	  &	  Clarke	  
2007).	  	  
	  
Species	   Coenzyme	  Q	  Isoform	  
S.	  cerevisiae	   CoQ6	  
E.	  coli	   CoQ8	  
C.	  elegans	   CoQ9	  
S.	  pombe	   CoQ10	  
M.	  musculus	   CoQ9	  
H.	  sapiens	   CoQ10	  








Figure	   1.6:	   Coenzyme	  Q	   and	   its	   biosynthetic	   proteins	   are	   highly	   conserved.	   A.	   Coenzyme	  Q	   is	   a	  
redox	   molecule	   that	   switches	   between	   reduced	   (ubiquinol/CoQRED)	   and	   oxidized	   (ubiquinone/	  
CoQOX)	   states.	   The	   number	   of	   isoprene	   units	   (n)	   varies	   among	   species	   (Table	   1.1).	   B.	   The	   CoQ	  
biosynthetic	   pathway	  with	   enzymes	   at	   each	   step	   indicated	   (C.	   elegans	   in	   red,	  H.	   sapiens	   in	   blue).	  
DMQ	  =	  demethoxy	  ubiquinone.	  Panel	  B	  is	  adapted	  from	  Tran	  and	  Clarke	  Mitochondrion	  2007	  (Tran	  
&	  Clarke	  2007;	  Beal	  2005;	  Metzstein	  et	  al.	  1998).	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Coenzyme	  Q	  deficiencies	  
Coenzyme	  Q	  deficiency	  is	  a	  rare,	  autosomal	  recessive	  mitochondrial	  syndrome	  that	  is	  both	  
clinically	   and	   genetically	   heterogeneous	   (Emmanuele	   et	   al.	   2012).	   The	   most	   common	   clinical	  
presentations	  are	  myopathy	   (Horvath	  et	  al.	  2006)	  and	   the	  neurological	  motor	  disorder,	   cerebellar	  
ataxia	   (Emmanuele	   et	   al.	   2012).	   This	   neuromuscular	   pathology	   is	   likely	   due	   to	   mitochondrial	  
dysfunction,	   as	   ETC	   activity	   is	   significantly	   reduced	   in	   patients	   with	   CoQ	   deficiency	   (Nohl	   &	   Gille	  
2001;	  Catarina	  M	  Quinzii	  2007;	  Canevari	  et	  al.	  1999;	  Ellis	  &	  Horvitz	  1986).	  
There	   are	   two	   types	   of	   Coenzyme	   Q	   deficiency,	   primary	   and	   secondary.	   Primary	   CoQ	  
deficiency	   results	   from	   mutations	   in	   Coenzyme	   Q	   biosynthetic	   genes	   (Fig.	   1.6).	   Patients	   with	  
mutations	  in	  PDSS1	  (Mollet	  et	  al.	  2007),	  PDSS2	  (López	  et	  al.	  2006),	  COQ2	  (Mollet	  et	  al.	  2007;	  Jakobs	  
et	   al.	   2013;	   Quinzii	   et	   al.	   2006;	   Diomedi-­‐Camassei	   et	   al.	   2007),	   COQ6	   (Heeringa	   et	   al.	   2011),	  
ADCK3/CABC1	  (Mollet	  et	  al.	  2008),	  COQ9	  (Andrew	  J	  Duncan	  2009)	  have	  been	  identified.	  A	  reduction	  
of	  CoQ	  levels	  that	  is	  not	  attributed	  directly	  to	  mutations	  in	  the	  Coenzyme	  Q	  biosynthetic	  pathway	  is	  
known	   as	   secondary	   Coenzyme	   Q	   deficiency.	   The	   mechanism	   of	   how	   these	   defects	   impact	   CoQ	  
levels	   is	   not	   well-­‐understood.	   For	   example,	   a	   mutation	   in	   the	   electron-­‐transferring-­‐flavoprotein	  
dehydrogenase	   (ETFDH)	  gene	   is	   linked	  to	  secondary	  CoQ	  deficiency	   (Gempel	  et	  al.	  2007).	  Because	  
ETFDH	   directly	   transfers	   electrons	   to	   CoQ,	   it	   is	   postulated	   that	   impaired	   ETFDH	   function	   either	  
causes	  down-­‐regulation	  or	  degradation	  of	  Coenzyme	  Q.	  Other	  mutations	  associated	  with	  secondary	  
CoQ	  deficiency,	  such	  as	   the	  DNA	  repair	  gene	  aprataxin	   (APTX),	  do	  not	  have	  a	  clear	   relationship	   to	  
CoQ	  homeostasis	  (Quinzii	  et	  al.	  2005).	  The	  heterogeneity	  of	  clinical	  presentations	  of	  CoQ	  deficiency	  
is	   likely	  due	  to	  both	  the	  diverse	  cellular	   functions	  of	  Coenzyme	  Q	  as	  well	   the	  variety	  of	  mutations	  
linked	  to	  the	  disease.	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Coenzyme	  Q	  supplementation	  
Coenzyme	   Q	   deficiency	   is	   the	   only	   treatable	   mitochondrial	   disorder;	   early	   CoQ10	  
supplementation	  shows	  significant	  improvement	  of	  clinical	  symptoms	  (Rötig	  et	  al.	  2000;	  Montini	  et	  
al.	   2008).	   The	   rationale	   for	   CoQ	   supplementation	   in	   CoQ	   deficiency	   is	   clear	   and	   its	   potent	  
antioxidant	   properties	   make	   it	   a	   reasonable	   therapeutic	   candidate	   for	   administration	   during	  
neurodegenerative	   diseases,	   which	   are	   tightly	   linked	   to	   both	   oxidative	   stress	   and	   mitochondrial	  
dysfunction.	   Additionally,	   increased	   levels	   of	   oxidized	   CoQ10	  was	   detected	   in	   Amyotrophic	   Lateral	  
Sclerosis	   (ALS)	   patients	   and	   is	   strongly	   correlated	  with	   disease	   progression	   (Sohmiya	   et	   al.	   2005).	  
Decreased	  Coenzyme	  Q	  levels	  are	  reported	  in	  Parkinson’s	  Disease	  patients	  (Hargreaves	  et	  al.	  2008)	  
and	   normal	   declines	   in	   CoQ	   levels	   also	   occur	   with	   aging	   (Kalén	   et	   al.	   1989).	   Animal	  
neurodegeneration	  models	  show	  neuroprotective	  effects	  of	  Coenzyme	  Q	  administration	  in	  affected	  
brain	  regions	  (Matthews	  et	  al.	  1998;	  Ferrante	  et	  al.	  2002).	  Despite	  success	  in	  murine	  models,	  clinical	  
supplementation	  of	  CoQ10	  in	  neurodegenerative	  diseases	  has	  produced	  mixed	  outcomes	  (Galpern	  &	  
Cudkowicz	  2007).	  The	  lack	  of	  significant	  neuronal	  improvement	  might	  be	  due	  to	  poor	  bioavailability	  
of	   Coenzyme	   Q	   and	   its	   difficulty	   crossing	   the	   blood-­‐brain	   barrier	   (Mancuso	   et	   al.	   2009).	  
Nevertheless,	   the	  positive	   impact	  of	  CoQ10	  supplementation	  on	  CoQ	  deficiency	  patients	   implicates	  
the	  existence	  of	  active	  mechanisms	  of	  distributing	   this	   lipophilic	  molecule	   to	  deficient	   tissues	  and	  
subcellular	  compartments.	  
Currently,	   the	   process	   of	   exogenous	   CoQ	   incorporation	   into	   cells	   is	   not	   well	   understood.	  
Limited	  information	  about	  this	  mechanism	  indicates	  that	  the	  endomembrane	  system	  is	  required	  for	  
CoQ	  uptake	  and	  intracellular	  distribution	  (Padilla-­‐López	  et	  al.	  2009;	  Fernández-­‐Ayala	  et	  al.	  2005).	  My	  
work	   in	  Chapter	   3	   discusses	   observations	   in	  C.	   elegans	   that	   support	   a	  model	   of	   intercellular	   CoQ	  
transport	   between	   tissues.	   This	   experimental	   paradigm	   could	   provide	   a	   useful	   genetic	   tool	   for	   an	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unbiased	   approach	   to	   identify	   regulators	   of	   CoQ	   transport.	   An	   enhanced	   understanding	   of	   this	  
process	  may	  help	  develop	  more	  effective	  CoQ	  treatment	  strategies.	  
	  
Models	  of	  Coenzyme	  Q	  deficiency	  
	   Genes	   in	   the	   Coenzyme	   Q	   biosynthetic	   pathway	   were	   initially	   discovered	   as	   S.	   cerevisiae	  
mutants	  with	   impaired	  respiration	  (Tran	  &	  Clarke	  2007).	  Strong	  sequence	  homology	   indicates	  that	  
these	  genes	  are	  highly	  conserved	  in	  aerobic	  organisms.	  Characterization	  of	  corresponding	  proteins	  
in	   single-­‐cell	   systems	   significantly	   advanced	   our	   understanding	   of	   biochemical	   function	   during	  
Coenzyme	  Q	   synthesis	   (Tran	  &	   Clarke	   2007).	   However,	   analysis	   of	   CoQ	   deficiency	   in	  multicellular	  
organisms	  is	  needed	  to	  understand	  the	  tissue-­‐specific	  effects	  of	  CoQ	  depletion.	  
Two	  Drosophila	  CoQ	  biosynthetic	  pathway	  mutants	  have	  been	  characterized.	  A	  mutation	  in	  
the	   COQ2	  homologue,	   small	   boy	   (sbo),	   results	   in	   larval	   arrest	   but	   the	   authors	   did	   not	   investigate	  
neuronal	  or	  muscular	  defects	   (J.	   Liu	  et	   al.	   2011).	  A	  missense	  mutation	   in	  qless,	   the	  human	  PDSS1	  
orthologue	   (Fig.	   1.6),	   results	   in	   embryonic	   lethality	   accompanied	   with	   neuroblast	   growth	   defects	  
(Grant	  et	  al.	  2010).	  The	  central	  nervous	  system	  (CNS)	  of	  qless	  larvae	  showed	  signs	  of	  mitochondrial	  
stress	   and	   caspase	   activation,	   and	   expression	   of	   the	   pan-­‐caspase	   inhibitor	   p35	   was	   sufficient	   to	  
rescue	   neuroblast	   clonal	   growth	   in	   qless	   mutants.	   This	   result	   demonstrates	   death-­‐promoting	  
caspases	  likely	  contribute	  to	  neuron	  inviability	  in	  CoQ-­‐deficient	  animals.	  
Vertebrate	  models	  of	  CoQ	  deficiency	  primarily	  exist	   in	  mice	  and	   include	  reports	  of	   loss-­‐of-­‐
function	   Pdss2	   (Peng	   et	   al.	   2008;	   Saiki,	   Lunceford,	   Shi,	   et	   al.	   2008b),	   COQ7	   (Nakai	   et	   al.	   2001;	  
Levavasseur	   et	   al.	   2001)	   and	   COQ9	   (Garcia-­‐Corzo	   et	   al.	   2012)	   genes	   (Fig.	   1.6).	   A	   spontaneous	  
missense	   mutation	   in	   Pdss2	   results	   in	   renal	   dysfunction	   (Peng	   et	   al.	   2008).	   Interestingly,	   liver-­‐
specific	  conditional	  knockout	  of	  Pdss2	  did	  not	  develop	  an	  overt	  phenotype	  while	  knockouts	  targeted	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to	   podocytes	   caused	   renal	   disease.	   This	   finding	   is	   suggestive	   of	   tissue-­‐specific	   metabolic	  
requirements	  for	  Coenzyme	  Q	  that	  are	  revealed	  under	  deficiency	  conditions.	  
A	  role	  of	  Coenzyme	  Q	   in	  C.	  elegans	  was	   initially	  suggested	  by	  studies	  of	  mutations	   in	  coq-­‐
7/clk-­‐1	  mutants.	  COQ-­‐7/CLK-­‐1	   is	  a	  hydroxylase	  that	  modifies	  the	  quinone	  ring	  at	  a	  step	   late	   in	  the	  
CoQ	   synthesis	   pathway	   (Fig.	   1.6).	   Impaired	   COQ-­‐7/CLK-­‐1	   function	   causes	   accumulation	   of	   a	   CoQ	  
intermediate,	  demethoxy-­‐CoQ	   (DMQ).	  Additionally,	  clk-­‐1/coq-­‐7	  mutants	   live	   longer	   than	  wild-­‐type	  
animals	   (Larsen	   &	   Clarke	   2002).	   While	   the	   mechanism	   responsible	   for	   lifespan	   extension	   is	  
controversial,	  coq-­‐7/clk-­‐1	  mutants	  have	  decreased	  mitochondrial	  membrane	  potential	  (Lemire	  et	  al.	  
2009),	   reduced	   ROS	   damage,	   and	   decreased	   mitochondrial	   respiration	   (Y.-­‐Y.	   Yang	   et	   al.	   2009)	  
compared	  to	  wild-­‐type.	  Notably,	  coq-­‐7/clk-­‐1	  mutants	  still	  produce	  small	  amounts	  of	  CoQ9	  (Hihi	  et	  al.	  
2003)	  and	   the	   intermediate	  5-­‐demethoxylated	  ubiquinone	   (DMQ)	   is	   sufficient	   to	  permit	   fertility	   if	  
animals	  also	  receive	  CoQ8	  from	  their	  E.	  coli	  diet	  (Jonassen	  et	  al.	  2001).	  The	  DMQ	  intermediate	  that	  
accumulates	   partially	   supports	   respiration	   but	   does	   not	   substitute	   for	   CoQ	   in	   non-­‐mitochondrial	  
sites	   (Arroyo	   et	   al.	   2006;	  Hihi	   et	   al.	   2002),	  where	   exogenous	  CoQ	   is	   necessary	   for	   viability.	   These	  
findings	   suggest	   that	   dietary	   CoQ	   can	   be	   functionally	   incorporated	   in	   C.	   elegans	   CoQ-­‐deficiency	  
mutants.	  
Studies	   describing	   other	   Coenzyme	   Q	   biosynthetic	   mutants	   are	   limited,	   likely	   due	   to	   the	  
lethality	  that	  accompanies	  these	  genetic	  knockouts	  (Gavilan	  et	  al.	  2005).	  Developmental	  and	  sterility	  
defects	   are	   reported	   phenotypes	   of	   coq-­‐3	   (Gomez	   et	   al.	   2012)	  and	   coq-­‐8	  mutants	   (Asencio	   et	   al.	  
2009).	   The	   viability	   of	   coq-­‐7/clk-­‐1	  animals	   compared	   to	   other	   CoQ	   knockouts	   suggests	   that	   these	  
mutants	   represent	   varying	   degrees	   of	   Coenzyme	   Q	   deficiency.	   Indeed,	   lifespan	   extension	   occurs	  
with	  moderate	   levels	  of	  CoQ	  depletion	   (<	  50%)	   (as	   in	  coq-­‐7/clk-­‐1	  mutants	   (Larsen	  &	  Clarke	  2002))	  
but	   is	   not	   supported	   by	   severe	   CoQ	  depletion	   (as	   reported	   for	   coq-­‐3	   (Hihi	   et	   al.	   2002)	  and	   coq-­‐8	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mutants	  (Asencio	  et	  al.	  2009)).	  These	  results	  are	  supportive	  of	  a	  model	  in	  which	  distinct	  Coenzyme	  
Q	  levels	  regulate	  diverse	  processes	  including	  development,	  fertility	  and	  lifespan.	  	  
Interestingly,	  unlike	  Coenzyme	  Q	  pathway	  mutants	  in	  other	  organisms	  that	  invariably	  result	  
in	  early	  lethality	  (J.	  Liu	  et	  al.	  2011;	  Grant	  et	  al.	  2010;	  Peng	  et	  al.	  2004;	  Peng	  et	  al.	  2008;	  Nakai	  et	  al.	  
2001;	   Levavasseur	   et	   al.	   2001;	   Garcia-­‐Corzo	   et	   al.	   2012),	   some	   loss-­‐of-­‐function	   C.	   elegans	   CoQ	  
pathway	  mutants	   animals	   reach	  adulthood	   (Gavilan	  et	   al.	   2005;	  Gomez	  et	   al.	   2012;	  Asencio	  et	   al.	  
2009).	   This	   developmental	   progression	   is	   attributed	   both	   to	   maternally	   supplied	   mRNA	   and/or	  
Coenzyme	  Q	  as	  well	  as	  CoQ8	  obtained	  from	  the	  E.	  coli	  diet.	   In	  any	  case,	  the	  availability	  of	  an	  adult	  
Coenzyme	   Q-­‐deficient	   population	   is	   useful	   for	   experimental	   studies	   of	   the	   potential	   role	   of	  
mitochondrial	  function	  in	  neurological	  disease.	  	  
	  
Coenzyme	  Q	  deficiency	  in	  C.	  elegans	  as	  a	  model	  for	  neurodegenerative	  disease	  
The	   common	   features	   of	   neurodegenerative	   diseases	   such	   as	   age-­‐dependent	   onset,	  
selective	  neuronal	  vulnerability	  and	  mitochondrial	  dysfunction-­‐associated	  pathogenesis	  suggest	  that	  
shared	   pathways	   regulate	   these	   clinically	   distinct	   disorders.	   To	   understand	   mechanisms	   that	  
underlie	  mitochondrial	  dysfunction-­‐associated	  neuronal	  degeneration,	  we	  developed	  a	  Coenzyme	  Q	  
deficiency	   model	   of	   neurodegeneration	   in	   C.	   elegans.	   This	   model	   parallels	   hallmarks	   of	   human	  
neurodegeneration,	  with	  an	  age-­‐related	  and	  selective	  degeneration	  of	  GABA	  motor	  neurons	  arising	  
from	  deficiency	   of	   CoQ	   (an	   essential	  mitochondrial	   component).	  GABA	  neurons	   produce	  Gamma-­‐
Aminobutryic	  Acid	   (GABA),	   the	  main	   inhibitory	  neurotransmitter	   in	  the	  nervous	  system.	   	  Based	  on	  
the	  observation	  that	  GABA	  neurons	  (Fig.	  1.7)	  are	  the	  most	  sensitive	  neuronal	  population	  to	  reduced	  
CoQ	  levels,	  I	  focused	  my	  studies	  on	  characterizing	  the	  cell	  death	  pathway	  activated	  in	  GABA	  neurons	  
that	   leads	  to	  their	  selective	  degeneration	  (Chapters	  2,	  4,	  5).	  A	  candidate	  gene	  approach	  identified	  
distinct	  components	  of	  apoptotic	  (Chapter	  2	  and	  Chapter	  4)	  and	  necrotic	  (Chapter	  2	  and	  Chapter	  5)	  	  









Figure	  1.7	  C.	  elegans	  GABA	  nervous	  system.	  Schematic	  depicts	  adult	  hermaphrodite,	  anterior	  left,	  
ventral	  down.	  26	  GABA	  neurons	  control	  movement	  (D-­‐type	  motor	  neurons:	  6	  DD,	  13	  VD),	  head	  
foraging	  (4	  RME	  motor	  neurons)	  or	  defecation	  (AVL	  and	  DVB	  motor	  neurons).	  Adapted	  from	  
(Schuske	  et	  al.	  2004)
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pathways	   that	   adopt	   both	   killing	   and	   neuroprotective	   roles	   in	   CoQ-­‐deficient	   GABA	   neurons.	   The	  
relevance	   of	   these	   studies	   is	   underscored	   by	   the	   functional	   conservation	   of	   a	   human	   CoQ	  
biosynthetic	  protein	  through	  its	  rescue	  of	  C.	  elegans	  defects	  (Chapter	  3).	  	  
With	  its	  simple	  body	  plan	  and	  powerful	  genetic	  tools,	  C.	  elegans	  is	  especially	  well-­‐suited	  to	  
an	  experimental	  approach	  that	  uses	  genetic	  manipulation	  to	  identify	  key	  neurodegenerative	  disease	  
genes.	   The	   strong	   conservation	   of	   known	   components	   of	   C.	   elegans	   necrotic	   and	   apoptotic	  
pathways	  suggests	  that	  the	  signals	  that	  deploy	  these	  processes	  may	  also	  provide	  similar	  functions	  in	  
mammals.	  Thus,	  an	  understanding	  of	  the	  mechanisms	  whereby	  mitochondrial	  dysfunction	  initiates	  
cell	  death	  in	  C.	  elegans	  could	  lead	  to	  possible	  therapies	  that	  prevent	  neurodegeneration	  in	  humans.	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CHAPTER	  II	  
COENZYME	  Q	  PROTECTS	  CAENORHABDITIS	  ELEGANS	  GABA	  NEURONS	  	  
FROM	  CALCIUM-­‐DEPENDENT	  DEGENERATION	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INTRODUCTION	  
Mitochondrial	   dysfunction,	   selective	   neuronal	   vulnerability,	   and	   progressive	   onset	   are	  
unifying	   features	   of	   major	   human	   neurodegenerative	   diseases	   including	   amyotrophic	   lateral	  
sclerosis	   (ALS),	   Alzheimer's	   disease	   (AD),	   Parkinson's	   disease	   (PD),	   and	   Huntington's	   disease	   (HD)	  
(Petrozzi	  et	  al.	  2007).	  Genetic	  mutations	   linked	   to	   these	  diseases	  have	  been	  shown	   to	  disrupt	   the	  
electron	  transport	  chain	  (ETC)	  (Fig.	  1.2)	  (Lin	  &	  Beal	  2006),	  a	  mitochondrial	  pathway	  that	  accounts	  for	  
the	   majority	   of	   cellular	   energy	   production.	   Chemical	   inhibitors	   of	   the	   ETC	   can	   also	   produce	  
symptoms	   reminiscent	   of	   neurodegenerative	   diseases	   (Brouillet	   et	   al.	   1999).	   Despite	   the	   broad	  
disruption	   of	   mitochondrial	   function	   in	   these	   cases,	   specific	   neuron	   classes	   are	   preferentially	  
targeted.	  The	  molecular	  basis	  for	  this	  selectivity	  is	  largely	  unknown	  (Bossy-­‐Wetzel	  et	  al.	  2008).	  
The	   key	   role	   of	  mitochondrial	   fragmentation	   in	   both	   necrosis	   and	   apoptosis	   (Young	   et	   al.	  
2010)	   parallels	   emerging	   evidence	   that	   excessive	   mitochondrial	   fission	   may	   contribute	   to	  
neurodegenerative	  disease	  (Knott	  et	  al.	  2008).	  Inhibition	  of	  the	  fission-­‐promoting	  dynamin	  GTPase,	  
Drp-­‐1,	  for	  example,	  blocks	  mitochondrial	  fragmentation	  and	  death	  induced	  by	  overexpression	  of	  the	  
mutant	   Huntingtin	   protein	   (mtHtt)	   in	   cultured	   cells	   (Wang	   et	   al.	   2008).	   The	   progressive	   onset	   of	  
these	   diseases	   is	   correlated	   with	   an	   age-­‐dependent	   decline	   in	   mitochondrial	   function,	   but	   the	  
mechanistic	   link	   between	   diminished	   mitochondrial	   activity	   and	   neurodegeneration	   is	   poorly	  
understood.	  
Although	  the	  cell	  death	  pathways	  of	  necrosis	  and	  apoptosis	  feature	  distinct	  biochemical	  and	  
morphological	   components,	   recent	   studies	   have	   revealed	   “aponecrotic”	   cell	   killing	   pathways	   that	  
include	   elements	   of	   both	  mechanisms	   (Formigli	   et	   al.	   2000).	   Additionally,	   apoptosis	   and	   necrosis	  
share	  common	  molecular	  triggers,	  such	  as	  oxidative	  stress	  and	  energy	  depletion,	  two	  hallmarks	  of	  
mitochondrial	   dysfunction	   (Wochna	   et	   al.	   2007;	   Zhang	   et	   al.	   2009).	   These	   findings	   suggest	   that	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apoptotic	  and	  necrotic	  pathways	  may	  represent	  related	  cell	  death	  responses	  and	  can	  be	  activated	  
by	  mitochondrial	  impairment.	  
Coenzyme	   Q	   (CoQ)	   transfers	   electrons	   from	   complexes	   I	   and	   II	   to	   complex	   III	   in	   the	  
mitochondrial	  ETC	  (Fig.	  1.2)	  and	  fulfills	  a	  critical	  role	   in	  mitochondrial	  ATP	  production	   (Crane	  et	  al.	  
1957).	  CoQ	  also	  limits	  the	  production	  of	  reactive	  oxygen	  species	  that	  can	  damage	  cellular	  processes.	  
Human	   patients	   with	   CoQ	   deficiency	   exhibit	   diverse	   symptoms	   ranging	   in	   severity	   from	   infantile	  
multiorgan	  disease	   (Quinzii	   et	  al.	  2006;	  Mollet	  et	  al.	  2007)	   to	  discrete	   late	  onset	   cerebellar	  ataxia	  
(Lagier-­‐Tourenne	   et	   al.	   2008;	   Mollet	   et	   al.	   2008).	   Although	   the	   essential	   roles	   of	   CoQ	   in	  
mitochondrial	   energy	   production	   and	   cell	   survival	   are	   likely	   to	   account	   for	   these	   deficits,	   the	  
molecular	  basis	  for	  this	  heterogeneity	  is	  unclear,	  as	  are	  the	  specific	  cellular	  pathologies	  arising	  from	  
CoQ	  deficiency	  (DiMauro	  et	  al.	  2007).	  
We	   developed	   a	   model	   of	   CoQ	   deficiency	   for	   the	   purpose	   of	   delineating	   the	   molecular	  
events	  that	  contribute	  to	  cell	  death	  arising	  from	  mitochondrial	  dysfunction.	  Because	  of	  its	  short	  life	  
span,	   anatomic	   simplicity,	   and	   genetic	   tractability,	   the	   nematode	  Caenorhabditis	   elegans	  is	  
particularly	   amenable	   to	   this	   approach.	  We	  used	  RNA	   interference	   (RNAi)	   and	  genetic	   ablation	   to	  
knock	   down	   genes	   in	   the	   CoQ	   synthesis	   pathway	   (Fig.	   1.6)	   (coq-­‐1,	  coq-­‐2,	   coq-­‐3)	   to	   mimic	   CoQ	  
deficiency.	  These	  treatments	  result	   in	  age-­‐dependent	   loss	  of	  motor	  coordination	  that	   is	  correlated	  
with	  progressive	  degeneration	  of	  GABA	  neurons	  (Fig.	  1.7).	  Our	  results	  show	  that	  CoQ	  deficiency	  in	  C.	  
elegans	  results	   in	   a	   selective	   cell	   death	   pathway	   that	   includes	   features	   of	   both	   apoptotic	   and	  
necrotic	   processes	   and,	   therefore,	   suggest	   that	   this	   experimental	   model	   may	   be	   useful	   for	  
delineating	   the	   mechanism	   of	   neuron	   cell	   death	   in	   human	   CoQ	   deficiency	   and	   in	   related	  
neurodegenerative	  diseases	  that	  are	  also	  linked	  to	  defective	  mitochondrial	  function.	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MATERIALS	  AND	  METHODS	  
Strains	  and	  Maintenance	  
C.	   elegans	  mutants	   and	   strains	   used	   in	   this	   chapter	   are	   listed	   in	   Table	   2.1	   and	   Table	   2.2,	  
respectively.	   Strains	   were	   maintained	   at	   20°C	   unless	   otherwise	   indicated	   (Brenner	   1974).	   GFP	  
reporters	   and	   the	  ced-­‐3(n717),	   ced-­‐4(n1162),	   crt-­‐1(bz30),	  and	  drp-­‐1(tm1108)	  mutant	   alleles	   were	  
crossed	   into	   the	   RNAi-­‐hypersensitive	   strain	  eri-­‐1(mg366).	   The	  unc-­‐25::mCherry	  was	   generated	   by	  




	  	   RNAi	  assays	  were	  performed	  by	  feeding	  (Kamath	  et	  al.	  2003).	  Briefly,	  3	  mL	  of	  LB/ampicillin	  
(50	  mg/mL)	  was	  inoculated	  with	  30	  μL	  of	  overnight	  culture	  and	  grown	  in	  a	  37	  °C	  shaker.	  At	  OD600	  ≈	  
0.800,	   the	   culture	   was	   diluted	   to	   6	   mL	   with	   LB/amp	   +	   IPTG	   (40	   mM	   final	   concentration)	   and	  
incubated	  at	  37	   °C	   for	   another	  4	  h.	  Bacteria	  were	  pelleted,	  dispersed	   in	  250	  mL	  of	  M9/IPTG,	   and	  
spread	   onto	   60-­‐mm	  NGM	  plates.	   L4	   larvae	  were	   added	   to	   plates	   and	   incubated	   at	   20	   °C	   for	   5	   d	  
before	  scoring	  progeny.	  RNAi	  clones	  were	  sequenced	  to	  confirm	  inserts.	  EGTA	  (0.5	  mM)	  was	  added	  
to	  media	  before	  pouring	  plates.	  
	  
Combinatorial	  RNAi	  
Cultures	  for	  combinatorial	  RNAi	  experiments	  (i.e.,	  coq-­‐1	  +	  drp-­‐1,	  coq-­‐1	  +	  kap-­‐1,	  coq-­‐1	  +	  fzo-­‐
1)	  were	   grown	   separately	   and	   then	  mixed	  before	  plating.	  kap-­‐1	   is	   an	  unrelated	   gene	   that	   has	   no	  
visible	  phenotype	  by	  RNAi	  and	  was	  used	  as	  a	  control	  for	  potential	  competitive	  effects	  of	  combining	  
two	  RNAi	  constructs	  (Fig.	  2.9).	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Table	  2.1.	  Mutant	  alleles	  (or	  transgenic	  arrays),	  their	  source,	  and	  genotyping	  primers	  that	  were	  used	  
in	  this	  chapter.	  
	  
Mutant	   Source	   Genotyping	  Primers	   Reference	  
ced-­‐3	  (n717)	  IV	   CGC	   AGACTTTGCCAAACACGAATCA	   (Yuan	  et	  al.	  1993)	  
TCAGCAGCTCAACAACATCC	  




CGC	   CGGACAACTCGCTGACGAAT	   (Hengartner	  &	  Horvitz	  1994)	  
TTCCTTCCAGTTGTTGCGGA	  
coq-­‐1	  (ok749)	  I	   CGC	   AAAAATGTTACGGCCGACTG	   (Gavilan	  et	  al.	  2005)	  
CGTGTCCCTCAAAATGACCT	  
AGTCAGTGCTCGTCGGAGAT	  
coq-­‐2	  (ok1066)	  III	   CGC	   ATGCACATGGAGCATAGCAATG	   (Gavilan	  et	  al.	  2005)	  
GCGTGGTTTCACACAGATACAA	   	  
coq-­‐3(ok506)	  IV	   CGC	   GCTGTAAGGGAGATTTTCCCAT	   (Gomez	  et	  al.	  2012)	  
ACGGCGAGCAAAATAGGGAAAT	  
crt-­‐1(bz30)	  V	   CGC	   ACGTTATCCTTAACTACAAGGG	   (Xu	  et	  al.	  2001)	  
CCAGCTTTCATAAGAGTAGAGT	  
drp-­‐1(tm1108)	  IV	   Ding	  Xue	   CCGGAAAGTCTTCAGTGCTC	   (Breckenridge	  et	  al.	  2008)	  
CTGGTACGAAAAGAGCTGGC	  




CGC	   CCGATTAGTCGTATTCTAACTTC	   (Conradt	  &	  Horvitz	  1998)	  
TCATGGTACAAATTGGAGAAAAGT	  
egl-­‐1(ok1418)	  V	   CGC	   GTCTGTGACGTCACATGAGGTT	   N/A	  
GCTTGCCTTGTGCCTTCGCCTG	  
eri-­‐1(mg366)	  IV	   CGC	   CATGCAATTTCAATGCCTTTTA	   (Kennedy	  et	  al.	  2004)	  
TGCATCATCCAATCCACTATGT	  
	  
Transgene	   Source	   Array	   Reference	  
juIs76	  II	   CGC	   punc-­‐25::GFP,	  lin-­‐15(+)	   (Jin	  et	  al.	  1999)	  
hT2	  (I;III)	   CGC	   bli-­‐4(e937)	  let(q782)	  qIs48	   (McKim	  et	  al.	  1993)	  
juIs14	  	   CGC	   pacr-­‐2::GFP,	  lin-­‐15(+)	   (Hallam	  et	  al.	  2000)	  
adI1240	   CGC	   peat-­‐4::sGFP,	  lin-­‐15(+)	   (Lee	  et	  al.	  1999)	  
stEx30	   CGC	   pmyo-­‐3::MYO-­‐3::GFP,	  rol-­‐6(d)	   (Campagnola	  et	  al.	  2002)	  
mgIs42	   CGC	   ptph-­‐1::GFP,	  rol-­‐6(d)	   (Sze	  et	  al.	  2000)	  
pRN2003	   Randy	  
Blakely	  
pdat-­‐1::GFP	   (Nass	  et	  al.	  2002)	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Table	  2.2:	  Strains	  generated	  for	  analysis	  in	  this	  study.	  
	  
Strain	   Genotype	  
NC1400	   pRN2003[pdat-­‐1::GFP	  rol-­‐6(su1006)];	  juIs96	  [punc-­‐25::GFP	  lin-­‐15(+)];	  eri-­‐1(mg366);	  lin-­‐
15B(n744)	  
NC1404	   juIs14[pacr-­‐2::GFP	  lin-­‐15(+)];	  eri-­‐1(mg366);	  lin-­‐15B(n744)	  
NC1405	   juIs76[punc-­‐25::GFP	  lin-­‐15(+)];	  eri-­‐1(mg366);lin-­‐15B(n744)	  
	  
NC1407	   juIs76[punc-­‐25::GFP	  lin-­‐15(+)];	  ced-­‐4(n1162);	  eri-­‐1(mg366);	  lin-­‐15B(n744)	  
	  
NC1420	   myo-­‐3(st386);	  eri-­‐1(mg366);	  lin-­‐15B(n744);	  stEx30[myo-­‐3::GFP	  rol-­‐6(su1006)]	  
	  
NC1436	   adIs1240[eat-­‐4::GFP	  lin-­‐15(+)];	  eri-­‐1(mg366);	  lin-­‐15B(n744)	  
	  
NC1437	   juIs76[punc-­‐25::GFP	  lin-­‐15(+)];	  eri-­‐1(mg366);	  crt-­‐1(bz30);	  lin-­‐15B(n744)	  
NC1439	   mgIs42[tph-­‐1::GFP	  rol-­‐6(su1006)];	  eri-­‐1(mg366);	  lin-­‐15B(n744)	  
	  
NC1778	   juIs76[punc-­‐25::GFP	  lin-­‐15(+)];	  eri-­‐1(mg366)	  drp-­‐1(tm1108)	  
	  
NC1635	   coq-­‐1(ok749)/dpy-­‐5(e61);	  juIs14[acr-­‐2::GFP	  lin-­‐15(+)]	  
	  
NC1660	   coq-­‐1(ok749)/dpy-­‐5(e61);	  juIs76[punc-­‐25::GFP	  lin-­‐15(+)]	  
NC1647	   juIs76[punc-­‐25::GFP	  lin-­‐15(+)];	  eri-­‐1(mg366)	  ced-­‐3(n717)	  
	  
NC1941	   juIs76[punc-­‐25::GFP	  lin-­‐15(+)];	  eri-­‐1(mg366);	  egl-­‐1(n1084n3082)	  
	  
NC1959	   juIs76[punc-­‐25::GFP	  lin-­‐15(+)];	  coq-­‐2(ok1066)/hT2	  
	  
NC1974	   juIs76[punc-­‐25::GFP	  lin-­‐15(+)];	  coq-­‐3(ok506)/nT1	  
	  
NC1993	   coq-­‐2(ok1066)/hT2;	  juIs14[pacr-­‐2::GFP	  lin-­‐15(+)]	  
NC1999	   juIs76[punc-­‐25::GFP	  lin-­‐15(+)];	  ced-­‐4(n1162);	  coq-­‐3(ok506)/nT1	  
NC2020	   coq-­‐2(ok1066)/hT2;	  juIs14[pacr-­‐2::GFP	  lin-­‐15(+)];	  wdEx658[punc-­‐25::mcherry	  unc-­‐
119(+)]	  




	   	  
	   33	  
Thrashing	  assay	  
Swimming	   assays	   were	   performed	   as	   described	   (Miller	   et	   al.	   1996).	   In	   brief,	   individual	  
worms	   treated	  with	  either	   control	   (empty	  vector,	   EV)	  or	  coq-­‐1	  RNAi	  were	  placed	   in	  60μL	  M9	  and	  
thrashes	  were	   counted	   for	   2	  minutes	   (following	   a	   2	  minute	   stabilization	  period),	  with	   an	   average	  
number	  of	  thrashes	  per	  minute	  reported.	  	  
	  
Neuron	  degeneration	  assays	  
Animals	  were	   anesthetized	   in	   0.1%	   tricaine/tetramisole	   on	   2%	   agar	   pads	   (McCarter	   et	   al.	  
1997).	   Percent	   (%)	   degeneration	   was	   determined	   by	   counting	   the	   number	   of	   degenerating	   (i.e.,	  
neurite	   beading)	   or	   missing	   (i.e.,	   break	   in	   GFP	   signal)	   GABAergic	   processes	   (using	   juIs76	   [punc-­‐
25::GFP])	   between	   cell	   soma	   and	   dividing	   by	   the	   total	   number	   of	   segments.	   There	   are	   ten	   total	  
segments	   that	   are	   divided	   as	   follows:	   DD1/VD1/VD2	   -­‐(1)-­‐	   VD3	   -­‐(2)-­‐	   DD2/VD4	   -­‐(3)-­‐	   VD5	   -­‐(4)-­‐	  
DD3/VD6	  -­‐(5)-­‐	  VD7	  -­‐(6)-­‐	  DD4/VD8	  -­‐(7)-­‐	  VD9	  -­‐(8)-­‐	  DD5/VD10	  -­‐(9)-­‐	  VD11	  -­‐(10)-­‐	  VD12/DD6/VD13	  (see	  
Fig.	  1.7).	  For	  example,	  if	  3	  VNC	  intervals	  are	  scored	  as	  degenerating	  of	  a	  total	  of	  10	  total	  intervals	  in	  
a	   given	   animal,	   the	   percent	   VNC	   degeneration	  would	   be	   3/10	   or	   30%.	   Commissures	  were	   scored	  
similarly,	   with	   the	   number	   of	   degenerating	   commissures	   divided	   by	   the	   total	   number	   of	   discrete	  
GABA	  neuron	   commissures	   per	   animal	   (16	   total).	   A	   63x	   objective	   on	   a	   Zeiss	   Axioplan	  microscope	  
was	   used	   for	   scoring.	   The	   observer	  was	   blinded	   to	   experimental	   versus	   control	   samples	   to	   avoid	  
bias.	  punc-­‐25::GFP(juIs76)	  was	   used	   to	  mark	  GABA	   neurons	   for	   experiments	  with	  coq-­‐1	  RNAi,	  coq-­‐
1(ok749),	   coq-­‐2(ok1066),	  and	  coq-­‐3(ok506).	   punc-­‐25::mCherry(wdEx658)	  was	   also	   used	   to	   mark	  
GABA	  neurons	   in	  coq-­‐2(ok1066)	   for	   results	   shown	   in	   Fig.	   2.2.	   coq-­‐3(ok506)	  and	  coq-­‐3(ok506);	   ced-­‐
4(n1162)	  animals	  were	  scored	  as	  7	  day-­‐old	  adults	  (Fig.	  2.6B).	  The	  following	  mutants	  and	  treatments	  
did	   not	   perturb	  GABA	  neuron	  morphology:	  ced-­‐4(n1162),	   ced-­‐3(n717);	   crt-­‐1(bz30);	   drp-­‐1(tm1108),	  
CoQ10,	  0.5	  mM	  EGTA.	  GABA	  neuron	  degeneration	  was	  observed	  in	  coq-­‐1(ok749)	  maintained	  at	  15°C.	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Cholinergic	   neurons	  marked	  with	  pacr-­‐2::GFP	   (Hallam	   et	   al.	   2000)	   were	   quantiﬁed	   in	   the	  
same	   manner,	   and	   no	   signiﬁcant	   degeneration	   was	   detected.	   Additional	   neuron	   classes	   were	  
examined	  (Fig.	  2.7),	  but	  no	  differences	  between	  control	  (empty	  vector)	  and	  coq-­‐1	  RNAi	  knockdown	  
animals	   were	   observed	   in	   these	   neurons.	   For	   GFP	   knockdown	   in	   reporter	   strains	   (Fig.	   2.7),	  
quantiﬁcation	  of	  ﬂuorescence	   in	  Z	  series	  of	  confocal	  optically	  sectioned	   images	  was	  done	  by	  using	  
histogram	  analysis	  in	  ImageJ.	  
	  
Molecular	  biology	  
unc-­‐25	  Promoter	  (GABA	  neurons)	  
pG2M60	   (a	   gift	   from	   Yishi	   Jin)	   was	   used	   as	   template	   to	   amplify	   1.8	   kb	   of	   the	   unc-­‐25	  
promoter	   (GoTaq,	   Promega).	   The	   amplicon	  was	   inserted	   into	   a	   pENTR	  D-­‐TOPO	   vector	   (pMLH001)	  
using	  a	  TOPO	  TA	  reaction.	  	  
	  
punc-­‐25::mCherry	  +	  unc-­‐119	  minigene	  (pMLH41)	  
The	   unc-­‐25	   promoter	   was	   added	   to	   pCJS53	   by	   using	   5ʹ′SphI	   and	   3ʹ′AscI.	   pCJS53	   already	  
contained	   the	   unc-­‐119	  minigene	   from	   pG2M41	   (Maduro	   &	   Pilgrim	   1995)	   that	   inserted	   into	   the	  
vector	  backbone	  between	  5’ApaI	  and	  3’PacI.	  
	  
ATP	  measurement	  
Crude	  mitochondria	  were	  isolated	  from	  lysates	  (Bossy-­‐Wetzel	  et	  al.	  2008;	  Grad	  et	  al.	  2007)	  
obtained	   from	  a	  mixed	  population	  of	  eri-­‐1;	  unc-­‐25::GFP(juIs76)	   animals	   treated	  with	  either	  empty	  
vector	  (EV)	  or	  coq-­‐1	  RNAi.	  A	  Roche	  Cell-­‐Titer	  Glow	  Luminescent	  Cell	  Viability	  Assay	  kit	  was	  used	  to	  
measure	  ATP	   levels	  with	   a	   FluorStar	  Optima	   luminometer.	   ATP	   levels	  were	   normalized	   to	   protein	  
concentrations	  and	  represented	  in	  arbitrary	  units.	  A	  Bio-­‐Rad	  protein	  assay	  kit	  was	  used	  to	  measure	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   Animals	  were	  imaged	  in	  a	  Zeiss	  Axioplan	  compound	  microscope	  with	  a	  CCD	  camera	  (ORCA	  I;	  
Hamamatsu).	   Confocal	   images	   were	   obtained	   on	   a	   Zeiss	   LSM	   510	   confocal	   microscope	   and	   on	   a	  
Leica	  TCS	  SP5	  confocal	  microscope.	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RESULTS	  
Knockdown	  of	  coq-­‐1	  results	  in	  age-­‐dependent	  loss	  of	  coordinated	  movement	  
COQ-­‐1	   catalyzes	   the	   first	   step	   in	   Coenzyme	   Q	   synthesis	   (Fig.	   1.6),	   the	   assembly	   of	   the	  
lipophillic	  polyisoprenoid	  tail	   (Tran	  &	  Clarke	  2007).	  RNAi	  knockdown	  of	  coq-­‐1	  is	  reported	  to	   induce	  
uncoordinated	  (Unc)	  and	  Egg-­‐laying	  defective	  (Egl)	  phenotypes,	  but	  the	  mechanism	  of	  these	  effects	  
has	  not	  been	  studied	  (Rodríguez-­‐Aguilera	  et	  al.	  2005).	  We	  replicated	  this	  experiment,	  using	  the	  RNAi	  
“feeding”	  method	   to	   expose	   an	  RNAi-­‐hypersensitive	   strain,	  eri-­‐1(mg366)	  (Kennedy	   et	   al.	   2004),	   to	  
bacteria	  expressing	  coq-­‐1	  double-­‐stranded	  RNA	  (dsRNA).	  Loss	  of	  motor	  coordination	  first	  appeared	  
at	   the	   L4	   larval	   stage	   as	   a	   kink	   in	   the	   normal	   sinusoidal	  wave	   that	   drives	   locomotion.	  Movement	  
then	   gradually	   declined	   in	   adults,	   often	   culminating	   in	   paralysis	   (Fig.	   2.1A).	   Quantification	   of	  
movement	  loss	  with	  a	  swimming	  assay	  (Miller	  et	  al.	  1996)	  verified	  the	  developmental	  progression	  of	  
the	  Unc	  phenotype	  (Fig.	  2.1B).	  
	  
RNAi	  or	  genetic	  depletion	  of	  CoQ	  induces	  age-­‐dependent	  degeneration	  of	  GABA	  neurons	  
	  Observation	   of	   GABA	   motor	   neurons	   in	   the	   ventral	   nerve	   cord	   (Fig.	   1.7),	   labeled	   with	  
the	  unc-­‐25::GFP	  reporter	   (Fig.	   2.2A),	   suggested	   a	   possible	   explanation	   for	   the	   loss	   in	   motor	  
coordination.	  These	  GABA	  neurons	  degenerate	  in	  coq-­‐1	  knockdown	  animals,	  and	  cell	  bodies,	  viewed	  
under	  differential	   interference	  contrast	   (DIC),	  demonstrated	  the	  swollen	  appearance	  characteristic	  
of	   necrotic	   cell	   death	   (Fig.	   2.2C).	   GABAergic	   processes	   in	   the	   ventral	   nerve	   cord,	   circumferential	  
commissures	   and	   GABAergic	   processes	   in	   the	   dorsal	   cord	   appear	   discontinuous	   with	   apparent	  
breaks	   (Fig.	   2.2B).	   These	   morphological	   defects	   first	   appeared	   in	   late	   larval	   development	   and	  
progressed	   as	   animals	   aged	   (Fig.	   2.2D),	   thereby	  mirroring	   the	   age-­‐dependent	   pattern	   of	   the	   Unc	  
phenotype.	  
	  










Figure	  2.1:	  RNAi	  knockdown	  of	  coq-­‐1	  results	  in	  progressive	  loss	  of	  motor	  coordination.	  	  
A.	  Examples	  of	  the	  abnormal	  postures	  adopted	  by	  L4	  larvae	  and	  adults	  after	  exposure	  to	  coq-­‐1	  RNAi.	  
B.	  Swimming	  assay	  quantifying	  movement	  defects	  (bars	  represent	  avg	  ±	  SD,	  **	  p	  <	  0.005,	  n	  =	  10).	  
	   	  







	   	  










Figure	  2.2:	  CoQ	  depletion	  results	   in	  GABA	  neuron	  degeneration.	  A.	  Wild-­‐type	  adult	  GABA	  neuron	  
cell	   bodies	   (asterisks),	   processes	   in	   the	   ventral	   nerve	   cord	   (VNC)	   (arrow),	   and	   dorsally	   projecting	  
commissures	   (arrowhead)	   labeled	   with	   unc-­‐25::GFP.	   B.	   Adult	   coq-­‐1	   RNAi-­‐treated	   worm	   showing	  
signs	  of	  degeneration	  (white	  arrowhead,	  dorsal	  process	  beading;	  white	  arrow,	  degenerating	  GABA	  
cell	   body;	   yellow	   arrow,	   degenerating	   commissure;	   yellow	   arrowhead,	   VNC	  process	   break).	   (Scale	  
bars:	   50	   μm.)	  C.	  unc-­‐25::GFP-­‐labeled	  GABA	  neurons	   appear	   swollen	   in	   coq-­‐1	   RNAi-­‐treated	   adults.	  
Shown	   is	   the	   ventral	   view	  of	  GABAergic	   cell	   bodies	   (arrowheads)	   and	  VNC	   (arrow).	   (Scale	  bar:	   10	  
μm.)	   D.	   Quantification	   of	   progressive	   degeneration	   of	   GABA	   neuron	   VNC	   processes	   and	  
commissures	   (n	   ≥	   3,	   error	   bars	   =	   SEM;	   **p	   <	   0.001	   vs.	   empty	   vector-­‐treated	   animals).	   No	  
degeneration	   was	   observed	   in	   empty	   vector-­‐treated	   animals.	   E.	   Progressive	   GABA	   neuron	  
degeneration	   in	   coq-­‐2(ok1066)	   and	   coq-­‐3(ok506)	   mutants.	   GABA	   neuron	   degeneration	   was	   not	  
observed	  in	  L1–L3	  larval	  stages	  but	  was	  detectable	  in	  L4	  larvae	  and	  pronounced	  in	  adults	  (day,	  d).	  #p	  
<	  0.04	  and	  *p	  <	  0.001	  vs.	  heterozygous	  controls,	  n	  ≥	  20	  for	  each	  developmental	  stage.	  F.	  Enlarged	  
cell	  size	  of	  degenerating	  GABA	  neuron	  (arrowhead)	  compared	  with	  an	  unaffected	  GABA	  neuron	  cell	  
body	  (arrow).	  (F–H)	  Swollen	  D-­‐class	  (F	  and	  H)	  and	  RME	  GABA	  neurons	  (G)	  in	  coq-­‐2(ok1066)	  (F	  and	  G)	  
and	  coq-­‐3(ok506)	  (H)	  mutants	  visualized	  with	  unc-­‐25::GFP.	  (Scale	  bars:	  10	  μm.)	  Cholinergic	  neurons	  
(acr-­‐2::GFP)	   (I)	   are	   unaffected,	   whereas	   GABA	   neurons	   (unc-­‐25::mcherry)	   (J)	   show	   degenerating	  
processes	   (arrowheads)	   and	   cell	   bodies	   (arrows)	   in	   a	   single	   coq-­‐2(ok1066)	   animal.	   (Scale	   bar:	   30	  
μm.)	  K.	  VNC	  acr-­‐2::GFP-­‐cholinergic	  neurons	  were	  counted	  from	  VA2–VA11	  (30	  total)	  and	  VNC	  unc-­‐
25::mcherry-­‐GABA	   neurons	   from	   VD3–VD11	   (13	   total).	   Fraction	   of	   missing	   cholinergic	   vs.	   GABA	  
neurons	  in	  coq-­‐2(ok1066).	  **P	  <	  0.001,	  n	  =	  16.	  Anterior	  left,	  ventral	  down	  in	  A–C	  and	  F–J.	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We	   also	   validated	   the	  coq-­‐1	  RNAi	   results	   by	   examining	  coq-­‐1(ok749)	  mutant	   animals	   (Fig.	  
2.3).	  The	  ok749	  deletion	  removes	  a	  C-­‐terminal	  region	  comprising	  ≈70%	  of	  the	  coding	  sequence	  and	  
is	   therefore	  a	   likely	  null	   allele	   (Fig.	  3.1).	  Prior	   studies	  of	  coq-­‐1(ok749)	  reported	  paralysis	  and	  early	  
larval	  lethality	  (Gavilan	  et	  al.	  2005).	  We	  observed	  that	  homozygous	  coq-­‐1	  animals	  develop	  to	  at	  least	  
the	   third	   larval	   stage	   with	   a	   few	   adult	   escapers.	   This	   finding	   is	   likely	   to	   mean	   that	   the	  coq-­‐
1(ok749)	  mutation	   results	   in	   a	   maternal	   effect	   lethal	   phenotype	   in	   which	   the	   first	   generation	   of	  
viable	   offspring	   progress	   through	   larval	   development	   with	   maternally	   provided	   CoQ	   (Hihi	   et	   al.	  
2002).	   Homozygous	  coq-­‐1	  mutants	   appear	   Unc	   as	   L3	   larvae.	   Degeneration	   of	   GABA	   neurons	   is	  
initially	  observed	  in	  young	  adults	  (Fig.	  2.3B-­‐C);	  a	  swollen	  ventral	  cord	  cholinergic	  motor	  neuron	  was	  
observed	   in	   a	   single	   animal	   at	   this	   stage	   (n	  =	   20).	   Older	  coq-­‐1(ok749)	  animals	   show	   extensive	  
swelling	  and	  degeneration	  of	  other	  tissues	  as	  reported	  (Gavilan	  et	  al.	  2005).	  
We	   tested	   deletion	  mutants	   for	  coq-­‐2	  and	  coq-­‐3	  to	   ask	   whether	   genetic	   ablation	   of	   other	  
CoQ	  biosynthetic	  genes	  phenocopies	  coq-­‐1	  knockdown	  (Asencio	  et	  al.	  2003).	  GABA	  neurons	  of	  coq-­‐
2(ok1066)	  and	  coq-­‐3(ok506)	  animals	  also	  show	  the	  swollen	  morphology	  (Fig.	  2.2F-­‐H)	  and	  progressive	  
degeneration	   of	  coq-­‐1-­‐deficient	   animals	   (Fig.	   2.2E).	   The	   similar	   phenotypes	   displayed	   by	  coq-­‐
2	  and	  coq-­‐3	  mutants	  substantiate	  the	  idea	  that	  the	  movement	  and	  degenerative	  defects	  result	  from	  
reduced	  CoQ	  synthesis,	  rather	  than	  off-­‐target	  effects	  or	  additional	  roles	  of	  the	  COQ-­‐1	  enzyme.	  
The	  similar	  degenerative	  pattern	  and	  age-­‐dependence	  shown	  by	  the	  coq-­‐1,	  coq-­‐2,	  and	  coq-­‐
3	  knockout	   animals	   validates	   the	   specificity	   of	   the	  coq-­‐1	  RNAi	   treatment.	   Hence,	   for	   most	  
subsequent	   experiments	   in	   this	   chapter,	   we	   used	   RNAi	   knockdown	   of	  coq-­‐1	  to	   bypass	   the	  
developmental	   delay	   of	   the	   CoQ	   pathway	  mutants	   and	   to	   produce	   large	   numbers	   of	   viable	   adult	  
animals	  with	  CoQ-­‐deficient	  phenotype.	  
	  
	  




Figure	   2.3:	   GABA	   neuron	   degeneration	   in	   coq-­‐1(ok749)	   animals.	  A-­‐B.	  DIC	   (Left)	   and	  GFP	   (Right)	  
views	   of	   unc-­‐25::GFP-­‐labeled	   GABA	   neurons	   in	   coq-­‐1(ok749)	   at	   the	   L3	   (A)	   and	   adult	   (B)	   stages.	  
Arrow	   denotes	   intact	   ventral	   nerve	   cord	   (VNC)	   in	   L3	   larva	   (A)	   and	   arrowhead	   marks	   swollen	  
GABAergic	   motor	   neuron	   cell	   body	   in	   adult	   (B).	   C.	   Enlarged	   (arrow)	   and	   normal	   (arrowhead)	  
GABAergic	  cell	  bodies	  in	  the	  VNC.	  Scale	  bars:	  A	  and	  B,	  20	  μm;	  C,	  10	  μm.	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GABA	  neurons	  are	  preferentially	  sensitive	  to	  CoQ	  Depletion-­‐induced	  degeneration	  
	  	   Having	   observed	   that	   CoQ	   deficiency	   results	   in	   GABA	   neuron	   degeneration,	   we	   asked	  
whether	   nearby	   cholinergic	  motor	   neurons	   in	   the	   ventral	   nerve	   cord	  were	   similarly	   affected.	   The	  
results	  of	  this	  analysis	  revealed	  that	  GABA	  neurons	  are	  significantly	  more	  sensitive	  to	  CoQ	  depletion	  
(Fig.	  2.2I-­‐J	  and	  Fig.	  2.4).	  For	  example,	  in	  coq-­‐2(ok1066)	  adults	  in	  which	  >35%	  of	  GABA	  neurons	  have	  
degenerated,	  <5%	  of	  ventral	  cord	  cholinergic	  motor	  neurons	  are	  affected	  (Fig.	  2.2K).	  
We	   next	   used	   cell-­‐specific	   GFP	   reporters	   to	   evaluate	   the	   sensitivity	   of	   additional	   neuron	  
subtypes	   to	   CoQ	   depletion	   by	  coq-­‐1	  RNAi.	   Populations	   tested	   were	   cholinergic	   (acr-­‐2::GFP),	  
serotonergic	   (tph-­‐1::GFP),	   glutamatergic	   (eat-­‐4::GFP),	   and	   dopaminergic	   (dat-­‐1::GFP)	   neurons.	  
Although	   all	   animals	   displayed	   age-­‐dependent	   Unc	   phenotype	   with	  coq-­‐1	  RNAi,	   none	   of	   these	  
neuron	  classes	  showed	  signs	  of	  degeneration	  comparable	  with	  that	  observed	  for	  GABA	  neurons	  at	  a	  
similar	  developmental	  stage	  (Fig.	  2.5A-­‐E).	  We	  considered	  the	  possibility	  that	  this	  differential	  effect	  
could	  be	  due	  to	  the	  relative	  insensitivity	  of	  these	  neuron	  classes	  to	  RNAi.	  This	  explanation	  is	  made	  
less	  likely,	  however,	  by	  the	  finding	  that	  all	  of	  these	  neuronal	  types	  were	  equally	  vulnerable	  to	  RNAi	  
against	  GFP	  (Fig.	  2.5G).	  
Like	  neurons,	  muscle	   is	  also	  a	  highly	  metabolic	   tissue,	  and	  muscle	  degeneration	   is	   seen	   in	  
some	  cases	  of	  CoQ	  deficiency	  (Lalani	  et	  al.	  2005).	  Therefore,	  we	  used	  a	  GFP-­‐labeled	  myosin	  heavy	  
chain	  protein	  (MYO-­‐3::GFP)	  (Campagnola	  et	  al.	  2002)	  to	  examine	  muscle	  structure	  in	  the	  coq-­‐1	  RNAi	  
knockdown	  animals.	  We	  detected	  no	  morphological	   abnormalities	   in	  body	  wall	  muscle	   (Fig.	  2.5F),	  
verifying	   that	   the	   Unc	   phenotype	   associated	  with	   this	   RNAi	   construct	   is	   not	   the	   result	   of	  muscle	  
degeneration.	   We	   also	   examined	   vulval	   muscle,	   reasoning	   that	   defects	   in	   these	   muscles	   might	  
explain	  the	  Egl	  phenotype.	  However,	  we	  observed	  no	  structural	  differences	  between	  vulval	  muscles	  
in	  control	  versus	  coq-­‐1	  RNAi-­‐treated	  animals.	  











Figure	   2.4:	   GABA	   neurons	   are	   more	   sensitive	   than	   neighboring	   cholinergic	   neurons	   to	   coq-­‐2	  
depletion.	  A.	  A	  swollen	  GABAergic	  neuron	  (yellow	  arrowhead,	  punc-­‐25::mcherry)	  next	  to	  unaffected	  
cholinergic	  neurons	  (pacr-­‐2::GFP)	   in	  the	  head	  of	  a	  coq-­‐2(ok1066)	  animal.	  Scale	  bar	  =	  25µM.	  B.	  DIC	  
image	  shows	  a	   large,	  swollen	  necrotic	  GABA	  neuron	  (yellow	  arrowhead).	  C.	  The	  number	  of	  absent	  
cholinergic	   (acr-­‐2::GFP)	   and	   GABAergic	   (unc-­‐25::mcherry)	   neurons	   (between	   VA2-­‐VA11	   and	   VD3-­‐
VD11,	  respectively)	  in	  adult	  coq-­‐2	  animals.**p	  <	  0.002;	  n	  =	  16.	  	  
	  
	   	  








	   	  










Figure	  2.5:	  coq-­‐1	  RNAi	  triggers	  preferential	  degeneration	  of	  GABA	  neurons.	  Confocal	  images	  (40×)	  
of	  empty	  vector	  treated	  control	  or	  coq-­‐1	  RNAi-­‐treated	  animals	  expressing	  GFP	  reporters	  speciﬁc	  for	  
different	  neurotransmitter	  classes	  of	  neurons.	  A.	  GABAergic	  neurons	  detected	  by	  unc-­‐25::GFP.	  coq-­‐1	  
RNAi-­‐treated	  animals	  show	  both	  VNC	  degeneration	  (arrow)	  and	  swollen	  neurons	  (arrowhead).	  Other	  
classes	  of	  neurons	  and	  muscle	   cells	  do	  not	   show	  degeneration	   in	  age-­‐matched	  animals	   subject	   to	  
coq-­‐1	   RNAi-­‐treatment	   for	   the	   same	   period.	   B.	   Cholinergic	   neurons,	   acr-­‐2::GFP.	   C.	   Dopaminergic	  
neurons,	   dat-­‐1::GFP.	   Arrowhead,	   CEP	   neuron.	  D.	   Glutamatergic	   neurons,	   eat-­‐4::GFP.	   Arrowheads	  
point	   to	   AVM	   (Left)	   and	   ALM	   (Right).	   E.	   Serotonergic	   neurons,	   tph-­‐1::GFP.	   NSM	   cell	   body	  
(arrowheads)	   and	   HSN	   axonal	   projection	   (arrow)	   are	   shown.	   F.	   Muscle,	  myo-­‐3::GFP.	   Arrowheads	  
point	  to	  body	  wall	  muscle	  cells.	  G.	  Sensitivity	  to	  RNAi	  knockdown	  in	  each	  GFP-­‐labeled	  cell	  type	  was	  
determined	   by	   measuring	   GFP	   ﬂuorescence	   after	   RNAi	   against	   GFP.	   GFP	   ﬂuorescence	   intensity	  
values	   were	   obtained	   from	   a	   through	   focus	   Z-­‐series	   collected	   in	   a	   confocal	   microscope	   and	  
quantiﬁed	  by	  histogram	  analysis	   in	   ImageJ	   (n	  =	  6,	  avg	  ±	  SD).	  Fluorescence	   intensities	   for	  each	  GFP	  
strain	   were	   normalized	   to	   measurements	   obtained	   from	   a	   control	   (RNAi	   with	   empty	   vector)	   to	  
calculate	  %	  control	  GFP	  expression.	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Although	  our	  results	  do	  not	  preclude	  the	  possibility	  that	  non-­‐GABAergic	  neurons	  or	  muscle	  
are	   functionally	   affected	   by	  coq-­‐1	  RNAi,	   the	   earliest	   degenerative	   phenotype	   was	   exclusively	  
observed	  in	  GABA	  neurons.	  In	  fact,	  functional	  deficits	  in	  other	  neurons	  or	  muscle	  are	  likely	  because	  
the	  movement	  defects	  of	  mutants	   in	  which	  GABA	  neurons	  are	   selectively	  disabled	  are	   less	   severe	  
than	   the	  paralyzed	  adult	  phenotype	   that	   results	   from	  RNAi	  ablation	  of	  coq-­‐1	  (McIntire,	   Jorgensen,	  
Kaplan,	  et	  al.	  1993b).	  Ultimately,	  coq-­‐1	  RNAi-­‐treated	  adults	  and	  become	  completely	  paralyzed	  and	  
show	  widespread	  cell	  swelling	  and	  tissue	  necrosis	  after	  5	  days	  of	  RNAi	  treatment;	  non-­‐GABA	  neuron	  
cell	  types	  were	  similarly	  affected	  in	  older	  coq-­‐2	  and	  coq-­‐3	  adults.	  
	  
coq-­‐1	  RNAi-­‐mediated	  degeneration	  is	  calcium-­‐dependent	  
Calcium	  is	  a	  key	  effector	  of	  neurodegenerative	  diseases	  involving	  mitochondrial	  dysfunction	  
(Mattson	   2007).	   Calreticulin	   (crt-­‐1)	   functions	   in	   the	   ER	   lumen	   to	   maintain	   Ca2+	  levels	   for	   ready	  
release	   on	   appropriate	   stimuli	   (Michalak	   et	   al.	   1999).	   In	  C.	   elegans,	  crt-­‐1	  mutants	   block	   necrotic	  
degeneration	   of	   motor	   neurons	   (Xu	   et	   al.	   2001).	   We	   tested	   a	  crt-­‐1	   null	   mutant	   (bz30)	   in	   our	  
paradigm	  and	  found	  that	  it	  prevented	  the	  progressive	  degeneration	  of	  GABA	  neurons	  in	  coq-­‐1	  RNAi-­‐
treated	  animals	  (Fig.	  2.6A).	  The	  calcium-­‐chelating	  agent	  EGTA	  (0.5	  mM)	  was	  similarly	  protective	  (Fig.	  
2.6A).	   Taken	   together,	   these	   results	   demonstrate	   that	   Ca2+	  signaling	   is	   important	   for	  coq-­‐1	  RNAi-­‐
mediated	  degeneration	  of	  GABA	  neurons.	  
	  
Specific	  apoptotic	  genes	  are	  required	  for	  GABA	  neuron	  cell	  death	  in	  CoQ-­‐depleted	  animals	  
Ca2+	  release	   from	   the	   endoplasmic	   reticulum	   can	   result	   in	   necrotic	   (Driscoll	   &	   Gerstbrein	  
2003)	   or	   apoptotic	   (Demaurex	  &	  Distelhorst	   2003)	   cell	   death.	   The	   cell	   swelling	   observed	   in	  coq-­‐1	  
knockdown	   mutants	   is	   consistent	   with	   a	   necrotic	   mechanism.	   To	   investigate	   whether	   apoptotic	  
genes	  are	  required	  for	  GABA	  cell	  death,	  we	  tested	  mutants	  of	  the	  canonical	  apoptotic	  pathway,	  egl-­‐
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1,	  ced-­‐9,	   ced-­‐4,	  and	  ced-­‐3	   (Fig.	   2.6	  and	   Fig.	   2.7).	   In	   apoptotic	   cells,	   the	   BH3-­‐only	   protein,	   EGL-­‐1,	  
interacts	  with	  CED-­‐9	  (Bcl-­‐2)	  to	  release	  CED-­‐4	  (Apaf-­‐1)	  for	  activation	  of	  CED-­‐3	  (caspase)	  that,	  in	  turn	  
dismembers	   sensitive	   target	   proteins	   that	   normally	  maintain	   cellular	   integrity	   (Fig.	   1.3)	   (Lettre	   &	  
Hengartner	   2006).	   Loss-­‐of-­‐function	  mutations	   in	  egl-­‐1	  did	   not	   prevent	  GABA	  neuron	  degeneration	  
after	  coq-­‐1	  knockdown.	   A	   gain-­‐of-­‐function	   allele	   of	   the	   anti-­‐apoptotic	   protein	   CED-­‐9	  was	   similarly	  
ineffective	   (Fig.	   2.7).	   Surprisingly,	   mutations	   in	  ced-­‐4	  and	  ced-­‐3	  attenuated	   both	   the	  coq-­‐1	  RNAi-­‐
dependent	   GABA	   neuron	   degeneration	   and	   Unc	   phenotype	   (Fig.	   2.6A,	   C).	   These	   genetic	   results	  
indicate	  that	  CED-­‐4	  is	  activated	  in	  coq-­‐1–depleted	  GABA	  neurons	  by	  a	  pathway	  that	  is	  not	  regulated	  
by	   either	  egl-­‐1	  or	  ced-­‐9.	   In	   addition	   to	   strongly	   suppressing	   degeneration	   of	   GABA	   ventral	   nerve	  
cord	   (VNC)	   processes,	   the	  ced-­‐4	  mutation	   also	   attenuates	   the	   elimination	   of	   GABA	   neuron	   cell	  
bodies	   in	  coq-­‐1	  RNAi-­‐treated	   animals	   (Fig.	   2.8),	   which	   suggests	   that	   GABA	   neuron	   cell	   death	   is	  
blocked.	   This	   result	   is	   supported	   by	   our	   finding	   of	   comparably	   strong	  ced-­‐4	  suppression	   of	   GABA	  
neuron	   degeneration	   in	  coq-­‐3(ok506)	  animals	   (Fig.	   2.6B).	   Curiously,	  we	   note	   that	   a	   strong	   loss-­‐of-­‐
function	   allele	   of	  ced-­‐3	  (n717)	   only	   partially	   rescued	   the	   uncoordinated	   and	   GABA	   neuron	  
degeneration	  phenotypes,	  whereas	  the	  ced-­‐4	  mutation	  affords	  almost	  complete	  suppression	  of	  both	  
defects	   in	  coq-­‐1	  RNAi-­‐treated	  animals	   (Fig.	   2.6).	   In	  Chapter	   4,	  we	  describe	  a	  more	   comprehensive	  
analysis	   of	   ced-­‐3	   loss-­‐of-­‐function	   in	   an	   RNAi-­‐independent	   CoQ	   deficiency	  model	   that	   surprisingly	  
suggests	   the	  opposite	   role	   for	  CED-­‐3	  as	  a	  negative	   regulator	  of	  GABA	  neuron	  death.	  Nonetheless,	  
the	  cytoplasmic	  swelling	  of	  CoQ-­‐depleted	  GABA	  neurons	   in	  conjunction	  with	  the	  essential	   roles	  of	  
CED-­‐4/Apaf-­‐1	   and	   CRT-­‐1/calreticulin	   suggest	   that	   loss	   of	   CoQ	   synthetic	   activity	   triggers	   selected	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Figure	  2.6:	  Apoptotic	   genes	  and	   calcium	  and	  are	   required	   for	  coq-­‐1	  RNAi-­‐induced	  GABA	  neuron	  
degeneration.	  A.	  ced-­‐4(n1162),	  ced-­‐3(n717),	  crt-­‐1(bz30),	  and	  EGTA	  (0.5	  mM)-­‐treated	  animals	  were	  
tested	   for	   coq-­‐1	   knockdown-­‐induced	   GABA	   neuron	   degeneration.	   All	   results	   were	   obtained	   from	  
coq-­‐1	   RNAi-­‐treated	   animals	   containing	   eri-­‐1(mg366);	   unc-­‐25::GFP.	   GABA	   neurons	   were	   scored	   in	  
adults	  as	   in	  Fig.	  2.2.	  n	  ≥	  3	  experiments	   for	  each	  genotype.	  Error	  bars	  =	  SEM,	  **p	  <	  0.0001	  vs.	  WT	  
(wild-­‐type).	   B.	   ced-­‐4(n1162)	   suppresses	   GABA	   neuron	   degeneration	   in	   coq-­‐3(ok506)	   adults,	   *p	   <	  
0.02	  vs.	  coq-­‐3(ok506),	   n	  >	  14.	  C.	  Movement	  assay	  of	  ced-­‐4	   and	  ced-­‐3	  mutants	   treated	  with	  coq-­‐1	  
RNAi.	  Adults	  were	  tapped	  on	  the	  head	  and	  the	  tail	  and	  scored	  for	  movement:	  “partial	  unc”	  worms	  
are	  uncoordinated	  and	  “very	  unc”	  worms	  are	  unable	   to	  move,	  n	  >	  100	  worms.	  D.	  drp-­‐1	   (tm1108)	  
suppresses	  coq-­‐1	  knockdown-­‐induced	  GABA	  degeneration,	  **p	  <	  0.001	  vs.	  WT,	  n	  >	  60.	  
	   	  









Figure	  2.7:	  Apoptotic	  genes	  egl-­‐1	  and	  ced-­‐9	  are	  not	  required	  for	  coq-­‐1	  RNAi-­‐induced	  GABA	  neuron	  
degeneration.	  A.	  egl-­‐1(ok1418)	  and	  ced-­‐9(n1950)	  were	  assayed	  for	  GABA	  neuron	  degeneration	  after	  
coq-­‐1	  knockdown	  as	  in	  Fig.	  2.2	  (n	  >	  40).	  Results	  with	  egl-­‐1	  and	  ced-­‐9	  do	  no	  differ	  signiﬁcantly	  from	  
the	   wild-­‐type	   control	   in	   these	   experiments.	   B.	   In	   a	   separate	   experiment,	   another	   egl-­‐1	   loss-­‐of-­‐
function	   allele,	   n1084n3082,	   was	   treated	   with	   coq-­‐1	   RNAi	   and	   assayed	   for	   GABA	   neuron	  
degeneration	  (n	  >	  20),	  with	  no	  signiﬁcant	  difference	  from	  the	  wild-­‐type	  control.	  
	  
	   	  









Figure	   2.8:	   ced-­‐4	   suppresses	   degeneration	   of	   GABA	   neuron	   cell	   bodies	   in	   coq-­‐1	   RNAi-­‐treated	  
animals.	  punc-­‐25::GFP-­‐positive	   GABA	   neurons	   in	   the	   VNC	   interval	   from	  VD3-­‐DD11	   (13	   total	   cells)	  
were	  counted	  in	  coq-­‐1	  RNAi-­‐treated	  wild-­‐type	  (WT)	  and	  ced-­‐4(n1162)	  and	  for	  the	  negative	  control	  
of	  wild-­‐type	  treated	  with	  empty	  vector	  (EV	  RNAi	  +	  WT),	  **p	  <	  0.0001,	  n	  >	  50.	  All	  strains	  include	  the	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coq-­‐1	  knockdown-­‐induced	  cell	  death	  depends	  on	  the	  mitochondrial	  fission	  gene	  drp-­‐1	  
Calcium	   has	   been	   shown	   to	   stimulate	   mitochondrial	   fission	   (Breckenridge	   et	   al.	   2003),	  
which,	  in	  turn,	  has	  been	  linked	  to	  both	  apoptosis	  and	  necrosis	  in	  mammals	  (Young	  et	  al.	  2010;	  Youle	  
&	  Karbowski	   2005)	   and	   in	  C.	   elegans	   (Dacey	  et	   al.	   2005).	  We	   reasoned	   that	  CoQ	  deficiency	  might	  
sensitize	  mitochondria	  to	  Ca2+-­‐dependent	  fission-­‐related	  cell	  death.	  To	  test	  this	  idea,	  we	  used	  RNAi	  
knockdown	  of	  coq-­‐1	  in	  drp-­‐1	  mutant	  animals	   (Fig.	  2.6D)	  DRP-­‐1	   (dynamin-­‐related	  protein)	  has	  been	  
shown	   to	   function	   in	   both	   mitochondrial	   fission	   (Dacey	   et	   al.	   2005)	   and	   in	   a	  ced-­‐3–dependent	  
and	  ced-­‐9–independent	   cell	   death	   pathway	   (Breckenridge	   et	   al.	   2008).	   The	  drp-­‐1	  mutant	   blocked	  
GABA	  neuron	  degeneration	   (Fig.	  2.6D),	   thereby	   implicating	   the	   fission	  machinery	   in	   the	  pathology	  
associated	  with	  coq-­‐1	  knockdown	  in	  C.	  elegans.	  Similar	  results	  were	  obtained	  in	  coq-­‐1+drp-­‐1	  double	  
RNAi	   experiments	   (Fig.	   2.9A).	   We	   also	   used	   double	   RNAi	   to	   test	  fzo-­‐1,	   a	   gene	   required	   for	  
mitochondrial	  fusion	  (Takayuki	  Kanazawa	  2008).	  In	  this	  case,	  fzo-­‐1	  knockdown	  actually	  enhances	  the	  
GABA	  neuron	  degeneration	  phenotype	  of	  coq-­‐1–deficient	  animals	  as	  expected	  for	  a	  treatment	  that	  
impairs	  mitochondrial	  fusion	  (Fig.	  2.9B-­‐C).	  The	  conclusion	  that	  mitochondrial	  function	  is	  defective	  in	  
CoQ-­‐depleted	  animals	  is	  also	  supported	  by	  our	  finding	  that	  mitochondrial	  ATP	  levels	  are	  significantly	  
reduced	   by	  coq-­‐1	  RNAi	   treatment	   (Fig.	   2.10).	   Together,	   these	   results	   indicate	   that	   CoQ	   depletion	  
disrupts	   mitochondrial	   function	   and	   activates	   a	   cell	   death	   pathway	   that	   depends	   on	   the	  




We	  have	  shown	  that	  depletion	  of	  Coenzyme	  Q	  (CoQ)	  through	  RNAi	  and	  genetic	  ablation	  of	  
CoQ	  biosynthetic	  genes,	  coq-­‐1,	  coq-­‐2,	  and	  coq-­‐3,	  leads	  to	  the	  progressive	  loss	  of	  motor	  coordination	  
and	  preferential	  degeneration	  of	  GABA	  neurons.	  The	  mechanism	  of	  cell	  death	  relies	  strongly	  on	  the	  	  




Figure	  2.9:	  RNAi	  of	  mitochondrial	  ﬁssion	  and	  fusion	  genes	  inﬂuences	  GABA	  neuron	  degeneration	  
induced	  by	  coq-­‐1	  RNAi.	  A.	  Double	  RNAi	  with	  empty	  vector	  (EV)	  and	  coq-­‐1	  results	   in	  GABA	  neuron	  
degeneration	   (≈44%).	   Double	   RNAi	   of	   coq-­‐1	   with	   the	   mitochondrial	   ﬁssion	   gene	   drp-­‐1	   results	   in	  
signiﬁcantly	   less	   GABA	   neuron	   degeneration	   than	   EV	   +	   coq-­‐1	   RNAi	   control.	   Double	   RNAi	   with	   a	  
randomly	   selected	   control	   gene	   kap-­‐1	   (kinesin-­‐associated	   protein)	   did	   not	   inhibit	   coq-­‐1	   RNAi-­‐
induced	  GABA	  neuron	  degeneration.	  n	  =	  60,	  **P	  <	  0.0001;	  *p	  <	  0.0003.	  B.	  Combinatorial	  RNAi	  with	  
fzo-­‐1	  (mitochondrial	  outer	  membrane	  fusion	  gene)	  and	  coq-­‐1	  enhance	  the	  GABA	  neurodegeneration	  
observed	  with	  coq-­‐1	  and	  an	  unrelated	  gene,	  kap-­‐1,	  n	  >	  100,	  **p	  <	  0.0001.	  C.	  fzo-­‐1	  RNAi	  enhances	  
coq-­‐1	   knockdown-­‐induced	   GABA	   neuron	   degeneration	   in	   animals	   lacking	   the	   RNAi	   sensitive	  
mutation	  eri-­‐1(mg366).	  n	  >	  15,	  *p	  <	  0.002	  (Student’s	  t	  test).	  










Figure	   2.10:	   Mitochondrial	   ATP	   levels	   are	   reduced	   in	   CoQ-­‐depleted	   animals.	   ATP	   levels	   in	  
mitochondria	  isolated	  from	  whole	  animal	  lysates	  are	  reduced	  in	  coq-­‐1	  RNAi-­‐treated	  animals	  versus	  
empty	  vector-­‐treated	  control	  (EV	  RNAi).	  **p	  <	  0.0008,	  n	  =	  3.	  Each	  sample	  contained	  0.2	  μg	  of	  total	  
protein.	  Relative	  ATP	  levels	  are	  denoted	  (AU,	  arbitrary	  units).	  ATP	  levels	  were	  measured	  by	  using	  a	  
luminescence	  assay	  and	  normalized	  to	  protein	  concentration	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function	   of	  ced-­‐4	   (Apaf-­‐1).	   The	   GABA	   neuron	   pathology	   that	   accompanies	   CoQ	   depletion	   also	  
involves	   calcium	   signaling,	   possibly	   from	   ER	   stores,	   and	   the	  mitochondrial	   fission	   protein	   DRP-­‐1.	  
These	   results	   emphasize	   an	   important	   role	   for	   CoQ	   in	   neuron	   survival	   and	   link	   mitochondrial	  
dysfunction	  to	  a	  calcium-­‐dependent	  mechanism	  of	  selective	  neuron	  degeneration	  in	  C.	  elegans.	  
	  
CoQ	  depletion	  triggers	  a	  cell	  death	  pathway	  featuring	  elements	  of	  both	  apoptosis	  and	  necrosis	  	  
Our	   findings	   suggest	   that	   CoQ	   depletion	   in	  C.	   elegans	  GABA	   neurons	   triggers	   a	   cell	   death	  
mechanism	   that	   includes	   features	   of	   both	   apoptotic	   and	   necrotic	   pathways.	   The	   affected	   GABA	  
neurons	   morphologically	   resemble	   necrotic	   cells	   (i.e.,	   swollen	   soma)	   yet	   requires	   a	   downstream	  
component	   of	   apoptosis,	  ced-­‐4.	   In	  C.	   elegans,	   necrosis	   and	   apoptosis	   have	   been	   reported	   to	  
function	  as	  separate	  pathways	  (S.	  Chung	  et	  al.	  2000);	  however,	  our	  results	  indicate	  that	  a	  subset	  of	  
apoptotic	   genes	   is	   required	   for	   a	   pathology	   (cell	   swelling)	   normally	   restricted	   to	   a	   necrotic	  
mechanism.	   In	   the	   canonical	   apoptotic	   pathway	   (Fig.	   1.3),	   CED-­‐9	   tethers	   CED-­‐4	   to	   the	   outer	  
mitochondrial	   membrane.	   EGL-­‐1	   binding	   to	   CED-­‐9	   releases	   CED-­‐4	   for	   incorporation	   into	   the	  
apoptosome	  and	  subsequent	  activation	  of	  CED-­‐3/caspase	   (Lettre	  &	  Hengartner	  2006).	  Our	   finding	  
that	  neither	  EGL-­‐1	  nor	  CED-­‐9	  affects	  coq-­‐1	  RNAi-­‐induced	  GABA	  neuron	  death	   indicates	   that	  CED-­‐4	  
must	  be	  activated	  by	  an	  alternative	  mechanism	  in	  this	  case.	  Our	  results	  also	  suggest	  that	  CED-­‐4	   is	  
likely	   to	   activate	   novel	   downstream	   effectors.	   CED-­‐4–dependent,	   CED-­‐3–independent	   cell	   killing	  
programs	  have	  been	  reported	  for	  yeast	  in	  which	  CED-­‐4	  is	  overexpressed	  (Tao	  et	  al.	  1999)	  and	  in	  C.	  
elegans	  with	  RNAi	  knockdown	  of	  the	  presumptive	  anti-­‐apoptotic	  protein,	   ICD-­‐1	  (Bloss	  et	  al.	  2003).	  
Mechanisms	  whereby	  CED-­‐4	  might	   activate	   these	  pathways	  are	  unknown.	   In	   the	   future,	   it	  will	   be	  
interesting	  to	  determine	  whether	  the	  downstream	  CED-­‐3-­‐independent	  program	  that	  is	  triggered	  in	  
CoQ-­‐depleted	   GABA	   neurons	   includes	   other	   members	   of	   the	  C.	   elegans	  caspase	   family	   (Shaham	  
1998)	  or	  novel	  components	  (Barsoum	  et	  al.	  2006).	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Mitochondrial	  morphogenesis	   protein,	  DRP-­‐1,	   is	   required	   for	   the	   death	   of	   CoQ-­‐depleted	  GABA	  
neurons	  
	  	   Mitochondrial	  fragmentation,	  which	  can	  trigger	  apoptosis,	  depends	  on	  the	  dynamin-­‐related	  
protein,	   DRP-­‐1	   (Knott	   et	   al.	   2008).	   Previous	   studies	   have	   shown	   that	  coq-­‐1	  RNAi	   induces	  
mitochondrial	   fragmentation	   in	  C.	   elegans	   (Ichishita	   et	   al.	   2008).	   Thus,	   our	   finding	   that	   DRP-­‐1	   is	  
required	  for	  the	  execution	  of	  GABA	  neurons	  in	  CoQ-­‐deficient	  animals	  (Fig.	  2.6,	  Fig.	  2.9)	  is	  consistent	  
with	   a	   model	   in	   which	   the	   mitochondrial	   fragmentation	   or	   “excessive	   fission”	   accounts	   for	   the	  
neurodegenerative	  effect	  of	  CoQ	  depletion.	  Enhancement	  of	  this	  effect	  by	  RNAi	  knockdown	  of	  the	  
mitochondrial	   fusion	   gene,	  fzo-­‐1,	   also	   supports	   this	   idea	   (Fig.	   2.9).	   In	   addition	   to	   mediating	  
mitochondrial	   fusion,	   the	   mammalian	   homolog	   of	   FZO-­‐1,	   Mfn2,	   promotes	   expression	   of	   ETC	  
proteins	   (Pich	   et	   al.	   2005).	   This	   finding	   suggests	   that	   the	   loss	   of	  mitochondrial	   energy	  production	  
in	  fzo-­‐1–deficient	   animals	   could	   also	   contribute	   to	   cell	   death	   in	   CoQ-­‐depleted	   GABA	   neurons.	  
Although	  mitochondrial	   fission	   has	   been	   linked	   to	   apoptosis	   in	  mammals,	   conflicting	   results	   have	  
been	  obtained	  in	  C.	  elegans	  (Dacey	  et	  al.	  2005;	  Breckenridge	  et	  al.	  2008).	  However,	  our	  finding	  that	  
DRP-­‐1	  is	  required	  for	  GABA	  neuron	  degeneration	  in	  C.	  elegans	  parallels	  results	  with	  mammalian	  cells	  
showing	  that	  mitochondrial	  fission	  is	  a	  necessary	  step	  in	  experimental	  models	  of	  neurodegenerative	  
disease	   resulting	   from	   mitochondrial	   injury.	   For	   example,	   exposure	   of	   cortical	   neurons	   to	   high	  
concentrations	   of	   the	   neurotransmitter	   NO	   (nitric	   oxide)	   triggers	   a	   caspase-­‐independent	   death	  
pathway	   that	   requires	   mitochondrial	   fission	   (Barsoum	   et	   al.	   2006).	   NO-­‐induced	   degeneration	   is	  
accompanied	  by	  ATP	  depletion	  and	  production	  of	  free	  radicals.	  Both	  of	  these	  traits	  are	  also	  induced	  
by	  either	  environmental	  or	  genetic	  defects	  that	  block	  mitochondrial	  ETC	  (Bossy-­‐Wetzel	  et	  al.	  2008;	  
Wallace	  &	   Starkov	   2000;	   Atamna	  &	   Frey	   2007).	  We	   therefore	   speculate	   that	   CoQ	   depletion	   in	  C.	  
elegans	  disrupts	   mitochondrial	   ETC	   function	   (discussed	   in	   Chapter	   5),	   which	   in	   turn,	   triggers	   a	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degenerative	   pathway	   that	   shares	   common	   features	   such	   as	   downstream	   signals	   and	   effector	  
molecules	  that	  also	  mediate	  neurodegeneration	  in	  mammalian	  neurons.	  
	  
CoQ	  deficiency	  in	  C.	  elegans	  as	  a	  model	  for	  human	  disease	  
The	   selective,	   age-­‐dependent	   death	   of	   GABA	   neurons	   and	   loss	   of	   coordinated	  movement	  
seen	  in	  CoQ-­‐depleted	  worms	  are	  shared	  features	  of	  CoQ	  deficiency	  in	  humans.	  The	  most	  common	  
outcome	   of	   this	   deficiency	   is	   cerebellar	   ataxia	   (Montero	   et	   al.	   2007),	   although	   mutations	   that	  
disrupt	  CoQ	  biosynthesis	  can	  also	  result	   in	  a	  more	  severe	  early-­‐onset	  pathology	   involving	  multiple	  
tissues	  (Mollet	  et	  al.	  2007;	  Catarina	  M	  Quinzii	  2007).	  
Despite	   the	   rarity	   of	   CoQ	   deficiency	   in	   humans,	   it	   shares	   important	   pathologies	   with	  
prevalent	  glutamine	   repeat	  diseases.	  These	   include	   the	  autosomal	  dominant	  Huntington's	  Disease	  
(HD)	  and	  spinocerebellar	  ataxias.	  The	  age-­‐related	  death	  of	  medium	  spiny	  GABAergic	  neurons	  of	  the	  
striatum	  occurs	   in	  HD	  (Martin	  &	  Gusella	  1986)	  and	  GABAergic	  Purkinje	  cells	  are	  significant	   targets	  
for	   degeneration	   in	   the	   cerebellar	   ataxias	   (Zoghbi	   1995).	   Recent	   studies	   have	   linked	   neuronal	  
degeneration	   in	  HD	  to	  disrupted	  mitochondrial	   function	   (Orr	  et	  al.	  2008).	  For	  example,	  exogenous	  
CoQ	   is	   neuroprotective	   in	  mouse	  models	   of	   HD	   (Ferrante	   et	   al.	   2002).	   In	   addition,	   the	   pathology	  
induced	   by	   overexpression	   of	   mutant	   Huntingtin	   (mtHtt)	   in	   mammalian	   cells	   or	   in	  
C.	  elegans	  depends	   on	   the	  mitochondrial	   fission	  machinery	   (Wang	   et	   al.	   2008).	   Lastly,	   coq-­‐1	  RNAi	  
in	  C.	  elegans	  enhances	  the	  toxicity	  of	  a	  mutant	  form	  of	  human	  tau	  that	  has	  been	  implicated	  in	  the	  
pathology	   of	   AD	   (Kraemer	   et	   al.	   2006).	   It	   is	   striking	   that	   salient	   features	   of	   these	   human	   genetic	  
diseases	   including	   selective	   neuron	   sensitivity,	   mitochondrial	   dysfunction,	   Ca2+	  dependence,	   and	  
aberrant	   cell	   death	   (Dueñas	   et	   al.	   2006;	   Kwong	   et	   al.	   2006)	   are	   observed	   in	  C.	   elegans	  with	   the	  
depletion	   of	   CoQ.	   These	   parallels	   suggest	   that	   neurodegenerative	   mechanisms	   arising	   from	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CHAPTER	  III	  
CHARACTERIZATION	  OF	  A	  CONSERVED	  COENZYME	  Q	  BIOSYNTHESIS	  PATHWAY	  
IMPLICATES	  INTERCELLULAR	  UBIQUINONE	  TRANSPORT	  MECHANISMS	  
	  
INTRODUCTION	  
	   Coenzyme	   Q	   is	   synthesized	   in	   the	   mitochondria	   and	   is	   incorporated	   into	   all	   cellular	  
membranes	   (Kalén	   et	   al.	   2002).	   Because	   of	   robust	   de	   novo	   production,	   exogenous	   CoQ	   is	   not	  
required	   under	   normal	   conditions.	   However,	   symptoms	   arising	   from	   Coenzyme	   Q	   deficiency	   are	  
improved	   with	   oral	   Coenzyme	   Q10	   supplementation	   (Rötig	   et	   al.	   2000;	   Montini	   et	   al.	   2008).	   The	  
therapeutic	   benefit	   of	   CoQ	   treatment	   implicates	   active	   mechanisms	   of	   cellular	   uptake	   and	  
distribution	   under	   conditions	   in	   which	   biosynthesis	   or	   maintenance	   of	   CoQ	   is	   impaired.	  
Unfortunately,	   the	   bioavailability	   of	   Coenzyme	   Q	   limits	   its	   efficiency	   as	   a	   dietary	   supplement.	  
Coenzyme	  Q	  is	  a	  large,	  insoluble	  molecule	  that	  requires	  high	  doses	  and	  long-­‐term	  administration	  for	  
successful	   clinical	   improvement	   (Catarina	   M	   Quinzii	   2007).	   Therefore,	   treatments	   that	   enhance	  
utilization	   of	   exogenous	   CoQ	   are	   of	   significant	   therapeutic	   value.	   In	   addition	   to	  mechanisms	   that	  
control	   its	  uptake,	  externally	  provided	  CoQ	  must	  also	  be	  distributed	  to	  a	  variety	  of	  membranes	   in	  
the	   cell.	   Normally,	   intracellular	   distribution	   mechanisms	   are	   active,	   because	   Coenzyme	   Q	   is	  
synthesized	  in	  the	  mitochondria	  but	  is	  also	  present	  in	  other	  membranes	  (Tran	  &	  Clarke	  2007).	  Our	  
current	  understanding	  of	  CoQ	  uptake	  and	  distribution	  is	  based	  on	  limited	  reports	  that	  implicate	  the	  
endomembrane	   system	   (Fernández-­‐Ayala	   et	   al.	   2005;	   Padilla-­‐López	   et	   al.	   2009).	   However,	   these	  
studies	  used	  single-­‐cell	  models	  and	  therefore	  do	  not	  recapitulate	  the	  complex,	  cell-­‐cell	  interactions	  
that	  must	  occur	  during	  CoQ	  transport	  in	  multicellular	  organisms.	  Additionally,	  specific	  Coenzyme	  Q-­‐
binding	  proteins	  that	  regulate	  CoQ	  uptake	  or	  intracellular	  trafficking	  have	  not	  been	  identified.	  Active	  
transport	   of	   Coenzyme	   Q	   to	   specific	   cellular	   locations	   is	   suggested	   by	   the	   function	   of	   Coq10p,	   a	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protein	   that	   captures	   CoQ	   from	   its	   site	   of	   biosynthesis	   (matrix	   side	   of	   the	   inner	   mitochondrial	  
membrane)	  and	  transports	  it	  to	  the	  mitochondrial	  electron	  transport	  chain	  (ETC)	  (Barros	  et	  al.	  2005;	  
Busso	   et	   al.	   2010).	   It	   therefore	   seems	   likely	   that	   other	   CoQ-­‐binding	   proteins	   could	   facilitate	   the	  
movement	  of	  CoQ	  among	  tissues	  and	  CoQ	  localization	  within	  specific	  cellular	  membranes.	  
	   This	  chapter	  focuses	  on	  fundamental	  aspects	  of	  Coenzyme	  Q	  deficiency	  that	  are	  conserved	  
in	   C.	   elegans.	   Coenzyme	   Q	   deficiency	   is	   a	   clinically	   heterogeneous	   disorder,	   with	   mutations	   in	  
different	  genes	  of	  this	  pathway	  producing	  a	  wide	  range	  of	  symptoms.	  Mutations	  in	  C.	  elegans	  CoQ	  
biosynthetic	   pathway	   genes	   share	   this	   heterogeneity	   as	   evident	   by	   diverse	   developmental	   and	  
neurodegenerative	  defects.	  Additionally,	  experiments	   in	  this	  chapter	  reveal	  that	  GABA	  neurons	  do	  
not	   require	   endogenous	   CoQ	   biosynthesis	   to	   maintain	   viability.	   This	   finding	   suggests	   that	   CoQ-­‐
deficient	   GABA	   neurons	   are	   rescued	   by	   importation	   of	   CoQ	   from	   other	   tissues.	   An	   intercellular	  
Coenzyme	  Q	  transport	  model	   is	  also	  supported	  by	  the	  discovery	  that	  restoration	  of	  CoQ	  synthesis	  
exclusively	   in	   body	   muscle	   rescues	   developmental	   and	   fertility	   defects	   of	   coq-­‐1	   mutants.	   These	  
findings	  indicate	  that	  mechanisms	  of	  uptake	  and	  distribution	  of	  exogenous	  CoQ	  could	  be	  conserved	  
between	   nematodes	   and	   mammals.	   Additionally,	   this	   work	   reports	   the	   first	   functional	  
complementation	  of	  a	  CoQ	  mutant	  with	  a	  human	  Coenzyme	  Q	  biosynthetic	  gene.	  The	  pathogenic	  
effects	  of	  a	  patient-­‐isolated	  COQ2	  mutation	  are	  also	   recapitulated	   in	  our	  C.	  elegans	  model.	  Taken	  
together,	   this	  chapter	  describes	  several	  aspects	  of	  human	  CoQ	  deficiency	   that	  are	  conserved	   in	  C.	  
elegans	  and	  therefore,	  underscores	  its	  strengths	  as	  a	  genetic	  model	  of	  mechanisms	  that	  control	  the	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MATERIALS	  AND	  METHODS	  
Nematode	  Strains	  and	  Genetics	  
Nematodes	   were	   cultured	   using	   standard	   methods	   (Brenner	   1974).	   Mutants,	   genotyping	  
primers,	  and	  strain	  sources	  are	  listed	  in	  Table	  3.1.	  A	  list	  of	  strains	  generated	  for	  this	  study	  is	  located	  
in	  Table	  3.2.	  	  
	  
Molecular	  Biology	  and	  Transgenic	  Strains	  
Molecular	  cloning	  primers	  and	  plasmids	  used	  for	  this	  work	  are	  listed	  in	  Tables	  3.3	  and	  3.4,	  
respectively.	  Table	  3.5	  contains	  the	  DNA	  concentrations	  used	  to	  generate	  transgenic	  arrays	  for	  this	  
study.	  Refer	  to	  Materials	  and	  Methods	  section	  of	  Chapter	  2	  for	  unc-­‐25	  promoter	  construction.	  
	  
cDNA	  Preparation	  	  
cDNA	   was	   synthesized	   from	   by	   RT-­‐PCR	   from	   total	   RNA	   derived	   from	   the	   N2	   (wild-­‐type)	  
strain.	  (poly-­‐dT	  primers	  (Affy	  100)	  and	  Superscript	  II	  Reverse	  Transcriptase	  (Invitrogen)).	  
	  
coq-­‐1	  cDNA	  RNAi	  
A	  complete	  coq-­‐1	  cDNA	  clone	  pG2M57	  (yk1514f03)	  was	  obtained	  from	  Yuji	  Kohara	  (National	  
Institute	  of	  Genetics,	  Japan)	  and	  used	  as	  template	  to	  amplify	  coq-­‐1,	  which	  was	  TOPO	  TA	  cloned	  into	  
pCR8/GW/TOPO	   (Invitrogen)	   to	  make	   pMLH003.	   The	   coq-­‐1	   cDNA	  was	   then	   inserted	   into	   pL4440-­‐
Gateway	   (pG2M13)	   via	   an	   LR	  Clonase	  Gateway	   reaction	   (Invitrogen)	   to	   yield	   pMLH018.	   pMLH018	  
was	  transformed	  in	  HT115	  (DE3),	  an	  RNAse	  III-­‐deficient	  E.	  coli	  strain	  with	  T7	  polymerase	  activity	  that	  
is	  IPTG-­‐inducible	  for	  enhanced	  dsRNA	  production/RNAi	  efficiency	  (Timmons	  et	  al.	  2001).	  	  
	  
	  
	   61	  
Table	  3.1:	  Alleles,	  genotyping	  primers	  and	  sources	  of	  mutants	  used	  in	  this	  study.	  	  
	  
Mutant	   Source	   Genotyping	  Primers	   Reference	  
coq-­‐1	  (ok749)	  I	   Caenorhabditis	  
Genetics	  Center	  
AAAAATGTTACGGCCGACTG	   (Gavilan	  et	  al.	  2005)	  
CGTGTCCCTCAAAATGACCT	  
AGTCAGTGCTCGTCGGAGAT	  
coq-­‐2	  (ok1066)	  III	   Caenorhabditis	  
Genetics	  Center	  
ATGCACATGGAGCATAGCAATG	   (Gavilan	  et	  al.	  2005)	  
	   GCGTGGTTTCACACAGATACAA	  
coq-­‐3	  (ok506)	  IV	   Caenorhabditis	  
Genetics	  Center	  
GCTGTAAGGGAGATTTTCCCAT	   (Gomez	  et	  al.	  2009)	  
	   ACGGCGAGCAAAATAGGGAAAT	  
coq-­‐4	  (ok1490)	  I	   Caenorhabditis	  
Genetics	  Center	  







N/A	   N/A	  
N/A	  
coq-­‐8	  (ok840)	  III	   Caenorhabditis	  
Genetics	  Center	  
ATGGCAGCAAAGCGGC	   (Asencio	  et	  al.	  2009)	  
CGGGATACTGTACTTTTACAGC	  
CAAGTCTTCCGATACGA	  
eri-­‐1	  (mg366)	  IV	   Caenorhabditis	  
Genetics	  Center	  
CATGCAATTTCAATGCCTTTTA	   (Kennedy	  et	  al.	  2004)	  
TGCATCATCCAATCCACTATGT	  
	  
Transgene	   Source	   Array	  or	  Translocation	   Reference	  
hT2	  (I;III)	   Caenorhabditis	  
Genetics	  Center	  
bli-­‐4(e937)	  let(q782)	  qIs48	   (McKim	  et	  al.	  1993)	  
juIs76	  II	   Caenorhabditis	  
Genetics	  Center	  
punc-­‐25::GFP,	  lin-­‐15(+)	   (Jin	  et	  al.	  1999)	  






wpIs36	  I	   Marc	  
Hammarlund	  
punc-­‐47::mCherry	   Unpublished	  
wpIs39	  X	   Marc	  
Hammarlund	  
punc-­‐47::mCherry	   Unpublished	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Table	  3.2:	  List	  of	  strains	  that	  were	  used	  in	  this	  study.	  
	  
Strain	  	   Genotype	  
NC1405	   juIs76	  [punc-­‐25::GFP,	  lin-­‐15(+)]	  II;	  eri-­‐1	  (mg366)	  IV	  
NC1958	   juIs76	  [punc-­‐25::GFP,	  lin-­‐15(+)]	  II;	  coq-­‐5+tag-­‐277(gk379)	  III	  /	  hT2	  (I;	  III)	  
NC1959	   juIs76	  [punc-­‐25::GFP,	  lin-­‐15(+)]	  II;	  coq-­‐2(ok1066)	  III	  /	  hT2	  (I;	  III)	  
NC1974	   juIs76	  [punc-­‐25::GFP,	  lin-­‐15(+)]	  II;	  coq-­‐3(ok506)	  IV/	  nT1	  (IV;	  V)	  
NC2066	   juIs76	  [punc-­‐25::GFP,	  lin-­‐15(+)]	  II;	  coq-­‐8(ok840)	  III	  /	  hT2	  (I;	  III)	  
NC2513	   juIs76	   [punc-­‐25::GFP,	   lin-­‐15(+)]	   II;	   eri-­‐1(mg366)IV;	  wdEx831	   [pttr-­‐39::coq-­‐1	   RNAi	   FWD,	  
pttr-­‐39::coq-­‐1	  RNAi	  REV,	  punc-­‐25::mCherry,	  pceh-­‐22::GFP]	  
NC2556	   juIs76	   [punc-­‐25::GFP,	   lin-­‐15(+)]	   II;	   coq-­‐1(ok749)	   I;	   wdEx807	   [psur-­‐5::C.briggsae	   coq-­‐1	  
cDNA,	  psur-­‐5::NLS::GFP]	  
NC2617	   trIs10	   [pmyo-­‐3::MB::YFP,	   pmyo-­‐2::YFP,	   pceh-­‐23::HcRed,	   punc-­‐25::DsRed,	   unc-­‐
129nsp::CFP]	  I;	  eri-­‐1	  (mg366)	  IV	  
NC2627	   trIs10	   [pmyo-­‐3::MB::YFP,	   pmyo-­‐2::YFP,	   pceh-­‐23::HcRed,	   punc-­‐25::DsRed,	   unc-­‐129nsp::CFP]	  I;	  ced-­‐3	  (ok2734)	  eri-­‐1	  (mg366)	  IV	  
NC2743	   juIs76	  [punc-­‐25::GFP,	  lin-­‐15(+)]	  II;	  coq-­‐1(ok749)	  I	  /	  hT2	  (I;	  III)	  
NC2750	   coq-­‐1(ok749)	   I;	   juIs223	   [pttr-­‐39::mcherry,	   pttx-­‐3::GFP];	   wdEx926	   [psur-­‐5::coq-­‐1::GFP,	  
podr-­‐1::mCherry]	  
NC2792	   coq-­‐1(ok749)/hT2	   (I;	   III);	   juIs223	   [pttr-­‐39::mcherry,	   pttx-­‐3::GFP];	   wdEx933	   [punc-­‐
25::COQ-­‐1::GFP,	  coel::GFP]	  
NC2793	   coq-­‐1(ok749)/hT2	   (I;	   III);	   juIs223	   [pttr-­‐39::mcherry,	   pttx-­‐3::GFP];	   wdEx934	   [pmyo-­‐
3::COQ-­‐1::GFP,	  coel::GFP]	  
NC2795	   wdEx935	  [pmyo-­‐3::coq-­‐1::GFP,	  pmyo-­‐3::TOM20mRFP,	  rol-­‐6(d)]	  
NC2810	   wdEx938	  [pmyo-­‐3::hPDSS2::GFP,	  pmyo-­‐3::TOM20::mRFP,	  rol-­‐6(d)]	  
NC2821	   coq-­‐1(ok749)/hT2	  (I;	  III);	  wdEx939	  [pceh-­‐22::COQ-­‐1::GFP,	  rol-­‐6(d)]	  
NC2822	   coq-­‐1(ok749)/hT2	  (I;	  III);	  wdEx940	  [pF25B3.3::COQ-­‐1::GFP,	  rol-­‐6(d)]	  
NC2823	   coq-­‐1(ok749)/hT2	  (I;	  III);	  wdEx941	  [pelt-­‐2::COQ-­‐1::GFP,	  rol-­‐6(d)]	  
NC2824	   wdEx942	   [psur-­‐5::human	  COQ2-­‐wt,	   psur-­‐5::NLS::GFP];	   coq-­‐2(ok1066)	   III;	  wpIs39	   [punc-­‐
47::mCherry]	  X	  
NC2826	   wdEx943	   [psur-­‐5::human	   COQ2-­‐mutant,	   psur-­‐5::NLS::GFP];	   coq-­‐2(ok1066)	   III;	   wpIs39	  
[punc-­‐47::mCherry]	  X	  
XE1375	   lin-­‐15(n744)	   X	   ;	   eri-­‐1(mg366)	   IV	   ;	   rde-­‐1(ne219)	   V	   ;	   wpSi1[Punc-­‐47::rde-­‐1:SL2:sid-­‐1,	  
Cbunc-­‐119(+)]	  II	  ;	  wpIs36[Punc-­‐47::mCherry]	  I	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Table	  3.3:	  Primers	  used	  for	  molecular	  biology	  in	  this	  study.	  
	  
DNA	  amplified	   Primer	  Name	   Primer	  Sequence	  
coq-­‐1	  cDNA	   coq-­‐1_5p_AscI	   GGGGCGCGCCATGGGTGTTCTACCGAAAAT	  
	   coq-­‐1_3p_SacII	   CCCCGCGGTTAGAATTTTCGATCCG	  
coq-­‐1::GFP	   coq-­‐1_5p_AscI	   GGGGCGCGCCATGGGTGTTCTACCGAAAAT	  
coq-­‐1_3p_SacII_nostop	   AACCGCGGGAATTTTCGATCCGACTGTGAC	  







C.	  briggsae	  coq-­‐1	   br-­‐coq-­‐1_5p_AscI	   ATGGCGCGCCATGGGTGTACTTCCAAAAATT	  
	   br-­‐coq-­‐1_3p_SacII	   ATCCGCGGTTAGAATTTCCTATCCGTTTGA	  
Human	  PDSS1	   PDSS1_5p_AscI	   AAGGCGCGCCATGGCCTCGCGCTGGTGG	  
	   PDSS1_r3p_SacII	   CCCCGCGGTCATTTATCTCTTGTGAGTACAATTTC	  
PDSS1::mCherry	   PDSS1_5p_AscI	   AAGGCGCGCCATGGCCTCGCGCTGGTGG	  
PDSS1_tag3p_SacII	   CCCCGCGGTTTATCTCTTGTGAGTACAATTTCTGAA	  
Human	  PDSS2	   PDSS2_5p_AscI	   GGGGCGCGCCATGAACTTTCGGCAGCTGCT	  
	   PDSS2_3p_SacII	   CCCCGCGGTCATGAAAATCTGGTCACAGCA	  
Human	  PDSS2::GFP	  	   PDSS2_5p_AscI	   GGGGCGCGCCATGAACTTTCGGCAGCTGCT	  
	   PDSS2_tag3p_SacII	   CCCCGCGGTGAAAATCTGGTCACAGCAAAC	  
Human	  COQ2	  	   hQ2_5p_KpnI	   GGGGTACCTAAGCTCGCCCTTATGACCC	  
	   pYESQ2_3p_EcoRIstop	   TTGAATTCTCGAAGCTCGCCCTTAATTTTCTATT	  
C-­‐terminal	  GFP	   GFP-­‐C-­‐tag_5p_SacII	   GGGCCGCGGAGAGAAAAAATGAGTAAAGGA	  
	   unc-­‐54_3p_ApaI	   GGGGGCCCGTACGGCCGACTAGTAGGAAAC	  
C-­‐terminal	  mCherry	   C-­‐Mcherry-­‐5p_SacII	   GGGCCGCGGGTAGAAAAAATGCTCGAGATG	  
	   unc-­‐54_3p_ApaI	   GGGGGCCCGTACGGCCGACTAGTAGGAAAC	  
TOM20::mRFP	   TOM20_5p_AscI	   AAGGCGCGCCAATGTCGGACACAATTCTTG	  
	   mRFP_3p_SacII	   TTCCGCGGTTAGGCGCCGGTGGAGTG	  
ttr-­‐39	  promoter	   pC04G2.1_5p_SphI	   GGGCATGCATTATTATTTCTATCGGCTAC	  
	   pC04G2.1_3p_AscI	   GGGGCGCGCCATGATTTTTTGTTTTAACAA	  
unc-­‐25	  promoter	   punc-­‐
25_5p_HindIIISphI	  
GGAAGCTTGCATGCAAAAAACACCCAC	  
	   punc-­‐25_3p_AscI	   GGGGCGCGCCATTTTTGGCGGTGAACTGAGC	  
sur-­‐5	  promoter	   psur-­‐5_5p_SphI	   GGGCATGCCTGCATTGCTAAATTGCAACCC	  
	   psur-­‐5_3p_AscI	   GGGGCGCGCCAAAATGTAAAGTTCAAAGGT	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Table	  3.4:	  Plasmids	  that	  were	  used	  and/or	  produced	  for	  this	  chapter.	  
	  
Vector	   DNA	   Notes	  
pMBM009	   unc-­‐25	  RNAi	  in	  pL4440	  in	  HT115	  E.	  coli	   	  
pMLH001	   punc-­‐25	  (5’SphI/3’AscI)	  FWD	  in	  pENTR	  D-­‐TOPO	   	  
pMLH004	   pttr-­‐39	  (5’SphI/3’AscI)	  FWD	  in	  pENTR	  D-­‐TOPO	   	  
pMLH009	   punc-­‐25::gateway::mCherry::unc-­‐10	  3’UTR	   	  
pMLH035	   punc-­‐25::TOM20::mRFP	   	  
pMLH018	   coq-­‐1	  cDNA	  RNAi	  clone	   	  
pMLH080	   psur-­‐5	  (5’SphI/3’AscI)	  REV	  in	  pCR8/GW/TOPO	   	  
pMLH081	   pF25B3.3	  minus	  5’106bp	  in	  pCR8/GW/TOPO	   	  
pMLH103	   pttr-­‐39::mCherry::unc-­‐54	  3’UTR	   	  
pMLH107	   pttr-­‐39::coq-­‐1	  RNAi	  FWD	  +	  	  punc-­‐25::mCherry	   	  
pMLH112	   pttr-­‐39::coq-­‐1	  RNAi	  REV	   	  
pMLH129	   “Miller	  coq-­‐1”	  RNAi	  clone	   	  
pMLH132	   punc-­‐25::mcherry::unc-­‐54	  3’UTR	   	  
pMLH158	   ced-­‐9	  RNAi	  in	  pL4440	  in	  HT115	  E.	  coli	   	  
pMLH167	   punc-­‐25::C.	  briggsae	  coq-­‐1	  cDNA	   	  
pMLH171	   psur-­‐5::C.briggsae	  coq-­‐1	  cDNA	   	  
pMLH181	   psur-­‐5::SOD-­‐2::GFP::unc-­‐54	  3’UTR	   	  
pMLH235	   pmyo-­‐3::GFP::unc-­‐10	  3’UTR	   	  
pMLH258	   psur-­‐5::COQ-­‐1::GFP::unc-­‐54	  3’UTR	   	  
pMLH260	   punc-­‐25::COQ-­‐1::GFP::unc-­‐54	  3’UTR	   	  
pMLH262	   punc-­‐25(HindIII-­‐SphI—XbaI-­‐AscI)::TOM20::GFP	   	  
pMLH263	   pceh-­‐22::TOM20::GFP::unc-­‐10	  3’UTR	   	  
pMLH264	   pmyo-­‐3::TOM20::GFP::unc-­‐10	  3’UTR	   	  
pMLH269	   pceh-­‐22::COQ-­‐1::GFP::unc-­‐54	  3’UTR	   	  
pMLH270	   pmyo-­‐3::COQ-­‐1-­‐GFP::unc-­‐54	  3’UTR	   	  
pMLH272	   pmyo-­‐3::COQ-­‐1::mCherry::unc-­‐54	  3’UTR	   	  
pMLH271	   pmyo-­‐3::TOM20mRFP::unc-­‐10	  3’UTR	   	  
pMLH284	   pmyo-­‐3::PDSS2::GFP::unc-­‐54	  3’UTR	   	  
pMLH289	   pF25B3.3::COQ-­‐1::GFP::unc-­‐54	  3’UTR	   	  
pMLH290	   pdpy-­‐7::COQ-­‐1::GFP::unc-­‐54	  3’UTR	   	  
pMLH291	   pelt-­‐2::COQ-­‐1::GFP::unc-­‐54	  3’UTR	   	  
pMLH297	   pmyo-­‐3::PDSS1::mCherry::unc-­‐54	  3’UTR	   	  
pMLH298	   punc-­‐25(SphI-­‐XbaI—KpnI-­‐AscI)::COQ-­‐1::GFP	   	  
pMLH300	   psur-­‐5::human	  PDSS1::mCherry::unc-­‐54	  3’UTR	   	  
pMLH301	   psur-­‐5::human	  COQ2::unc-­‐54	  3’UTR	   	  
pMLH302	   psur-­‐5::human	  COQ2	  (N401fsX415)	   	  
pMLH303	   psur-­‐5::PDSS2-­‐GFP::unc-­‐54	  3’UTR	   	  
	   	   	  
pG2M02	   pmyo-­‐3::TOM20::mRFP	   a	  gift	  from	  Toshihiko	  Oka	  
pG2M07	   podr-­‐1::mCherry	   a	  gift	  from	  Geraldine	  Maro	  
pG2M10	   psur-­‐5::NLS::GFP	  (pTG96)	   a	  gift	  from	  David	  Fay	  
pG2M19	   pceh-­‐22::GFP	  (pCW2.1)	   a	  gift	  from	  Oliver	  Hobert	  
pG2M20	   punc-­‐122::GFP	   a	  gift	  from	  Daniel	  Colon-­‐Ramoz	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pG2M26	   GD1	  (delta	  ubiG	  E.	  coli)	   a	  gift	  from	  Cathy	  Clarke	  
pG2M27	   KO229::pSN18	  (Q9)	   a	  gift	  from	  Cathy	  Clarke	  
pG2M30	   pBlueScript	  II	   	  
pG2M31	   rol-­‐6(d)	  (pRF4)	   	  
pG2M36	   pmyo-­‐3::dsRed	  (pJER1)	   	  
pG2M43	   Human	  PDSS1	  wild-­‐type	   a	  gift	  from	  Agnes	  Rotig	  
pG2M44	   Human	  PDSS1	  D308E	   a	  gift	  from	  Agnes	  Rotig	  
pG2M45	   Human	  PDSS2	  wild-­‐type	   a	  gift	  from	  Agnes	  Rotig	  
pG2M46	   Human	  PDSS2	  S382L	   a	  gift	  from	  Agnes	  Rotig	  
pG2M47	   Human	  COQ2	  wild-­‐type	   a	  gift	  from	  Agnes	  Rotig	  
pG2M48	   Human	  COQ2	  N401fsX415	   a	  gift	  from	  Agnes	  Rotig	  
pG2M49	   elt-­‐2	  promoter	   a	  gift	  from	  Jim	  McGhee	  
pG2M50	   pdpy-­‐7::swip-­‐10::unc-­‐54	  3’UTR	   a	  gift	  from	  A.	  Hardaway	  
pG2M52	   psur-­‐5::luc+GFP	  (pSLGCV)	   a	  gift	  from	  Cristina	  Lagido	  
pG2M57	   yk1514f03	  in	  pME18S-­‐FL3	   a	  gift	  from	  Yuji	  Kohara	  
pG2M58	   yk1479d10	  in	  pME18S-­‐FL3	   a	  gift	  from	  Yuji	  Kohara	  
pG2M60	   punc-­‐25::CFP	  (pSC392)	   a	  gift	  from	  Yishi	  Jin	  
pG2M61	   KO229:pKA3	  (Q8)	   a	  gift	  from	  Cathy	  Clarke	  
pG2M62	  	   KO229:pLD23	  (Q10)	   a	  gift	  from	  Cathy	  Clarke	  
pRLS26	   goa-­‐1	  RNAi	  in	  pL4440	   made	  by	  Rachel	  Skelton	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Table	  3.5:	  Transgenic	  arrays	  that	  were	  generated	  for	  this	  work.	  
	  




N2	   pMLH171	   25	  ng/μL	  
pG2M30	   25	  ng/μL	  
pG2M10	   25	  ng/μL	  
wdEx831	  	  
[pttr-­‐39::coq-­‐1	  RNAi	  FWD,	  
pttr-­‐39::coq-­‐1	  RNAi	  REV,	  
punc-­‐25::mCherry,	  pceh-­‐
22::GFP]	  
eri-­‐1(mg366)	  juIs223	  IV	   pMLH107	   10	  ng/μL	  
pMLH112	   10	  ng/μL	  
pMLH132	   15	  ng/μL	  
pG2M19	   15	  ng/μL	  




coq-­‐1(ok749)/hT2	  (I;	  III);	  juIs223	  IV	   pMLH258	   25	  ng/μL	  
pG2M07	   25	  ng/μL	  




coq-­‐1(ok749)/hT2	  (I;	  III);	  juIs223	  IV	   pMLH260	   25	  ng/μL	  
pG2M20	   25	  ng/μL	  




coq-­‐1(ok749)/hT2	  (I;	  III);	  juIs223	  IV	   pMLH270	   20	  ng/μL	  
pG2M20	   25	  ng/μL	  





N2	   pMLH270	   20	  ng/μL	  
pMLH271	   20	  ng/μL	  
pG2M31	   25	  ng/μL	  





N2	   pMLH271	   20	  ng/μL	  
pMLH284	   20	  ng/μL	  
pG2M31	   25	  ng/μL	  




coq-­‐1(ok749)/hT2	  (I;	  III)	   pMLH269	   10	  ng/μL	  
pG2M31	   25	  ng/μL	  




coq-­‐1(ok749)/hT2	  (I;	  III)	   pMLH289	   20	  ng/μL	  
pG2M31	   25	  ng/μL	  




coq-­‐1(ok749)/hT2	  (I;	  III)	   pMLH291	   10	  ng/μL	  
pG2M31	   25	  ng/μL	  




coq-­‐2(ok1066)/hT2	  (III;I);	  wpIs39	  X	  
	  
	   	  
pMLH301	   25	  ng/μL	  
pG2M10	   25	  ng/μL	  




coq-­‐2(ok1066)/hT2	  (III;I);	  wpIs39	  X	  
	  
	   	  
pMLH302	   25	  ng/μL	  
pG2M10	   25	  ng/μL	  
pG2M30	   50	  ng/μL	  
	  
	   	  
	   67	  
Miller	  coq-­‐1	  RNAi	  
The	   Miller	   coq-­‐1	   RNAi	   clone	   (573bp	   of	   coq-­‐1	   cDNA,	   Fig.	   3.4A)	   was	   amplified	   (GoTaq,	  
Promega)	   from	   pMLH018	   and	   inserted	   into	   pCR8/GW/TOPO	   using	   a	   TOPO	   TA	   reaction	   to	   make	  
pMLH104.	  PmeI	  (added	  to	  both	  primers)	  was	  used	  to	  subclone	  the	  Miller	  coq-­‐1	  RNAi	  into	  pRLS26	  to	  
create	   pMLH129	   that	   was	   subsequently	   transformed	   into	   HT115	   (DE3)	   E.	   coli	   for	   RNAi	   studies	  
(Timmons	  et	  al.	  2001).	  
	  
Miller	  unc-­‐25	  RNAi	  
The	  Miller	  unc-­‐25	  RNAi	  clone	  was	  generated	  by	  amplifying	   (GoTaq,	  Promega)	  1.1kb	  of	   the	  
unc-­‐25	  cDNA	  from	  N2	  cDNA	  using	  primers	  that	  flanked	  the	  amplicon	  with	  PmeI	  restriction	  sites.	  unc-­‐
25	   RNAi	   was	   inserted	   into	   pMLH158	   between	   PmeI	   sites	   to	   create	   pMBM009	  which	   is	   in	   HT115	  
(DE3)	  E.	  coli	  (Timmons	  et	  al.	  2001).	  
	  
C-­‐terminal	  GFP	  and	  mCherry	  tags	  
pCJS93	   used	   as	   a	   template	   to	   PCR	   amplify	  GFP::unc-­‐54	   3’UTR	   (Phusion	   High-­‐Fidelity	   DNA	  
Polymerase,	   New	   England	   Biolabs)	   for	   insertion	   into	   pMLH171	   with	   5’SacII/3’ApaI	   (added	   to	   the	  
primers).	   mCherry::unc-­‐54	   3’UTR	   was	   amplified	   from	   pMLH103	   (Phusion	   High-­‐Fidelity	   DNA	  
Polymerase,	   New	   England	   Biolabs)	   and	   inserted	   into	   pMLH270	   with	   5’SacII/3’ApaI	   (added	   to	   the	  
primers)	  to	  make	  pMLH272.	  	  
Both	   mCherry	   and	   GFP	   are	   kept	   in	   frame	   by	   removing	   the	   stop	   codon	   (last	   three	  
nucleotides)	   of	   the	   CDS	   (coding	   DNA	   sequence);	   this	   C-­‐terminal	   fluorescent	   tag	   is	   linked	   to	   the	  
protein	  by	  a	  5	  amino	  acid	  linker	  (PREEK).	  COQ-­‐1,	  PDSS1	  and	  PDSS2	  were	  fluorescently	  tagged	  using	  
this	  method.	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coq-­‐1::GFP	  
Due	   to	  a	   frame-­‐shifting	  nucleotide	   insertion	   in	  exon	  8	  of	  coq-­‐1	   in	  pG2M57	   (yk1514f03),	   a	  
second	  coq-­‐1	  cDNA	  clone	  pG2M58	  (yk1479d10)	  was	  obtained	  from	  Yuji	  Kohara	  (National	  Institute	  of	  
Genetics,	   Japan).	   yk1479d10	   was	   PCR	   amplified	   (GoTaq,	   Promega)	   and	   TOPO	   TA	   cloned	   into	  
pCR8/GW/TOPO	   to	   create	   pMLH023.	   A	   coq-­‐1::GFP	   fusion	   construct	   was	   generated	   by	   amplifying	  
coq-­‐1	  from	  pMLH023	  (Phusion	  High-­‐Fidelity	  DNA	  Polymerase,	  New	  England	  Biolabs)	  and	  inserting	  it	  
into	  pMLH188	  using	  5’AscI/3’SacII	  (added	  to	  the	  primers)	  to	  create	  pMLH260.	  
	  
C.	  briggsae	  coq-­‐1	  cDNA	  
Whole-­‐animal	   C.	   briggsae	   cDNA	   was	   obtained	   by	   RT-­‐PCR	   from	   total	   RNA	   from	   AF16	  
(obtained	   from	  the	  CGC).	  The	  C.	  briggsae	  coq-­‐1	   cDNA	  (1.2kb)	  was	  amplified	   (Phusion	  High-­‐Fidelity	  
DNA	  Polymerase,	  New	  England	  Biolabs)	  and	  inserted	  into	  pMLH35	  with	  5’AscI/3’SacII	  (added	  to	  the	  
primers)	   to	  make	   pMLH167.	   The	   sur-­‐5	   promoter	   was	   subcloned	   from	   pMLH90	   (5’SphI/3’AscI’)	   to	  
make	  pMLH171.	  
	  
ttr-­‐39	  Promoter	  (D-­‐Type	  GABA	  Neurons)	  
The	  891	  bp	   ttr-­‐39	   promoter	  was	   amplified	   (GoTaq,	   Promega)	   from	  N2	   genomic	  DNA	  with	  
primers	  that	  added	  5’SphI/3’AscI	  sites	  and	  TA	  TOPO	  cloned	  into	  a	  pENTR	  D-­‐TOPO	  (Invitrogen)	  vector	  
to	  make	  pMLH004.	  The	  ttr-­‐39	  promoter	  inserted	  via	  5’SphI/3’AscI	  to	  make	  pMLH107	  and	  pMLH112.	  
	  
sur-­‐5	  Promoter	  (All	  Cells)	  
The	  3.7kb	  sur-­‐5	  promoter	   (Gu	  et	  al.	  1998)	  was	  amplified	   (GoTaq,	  Promega)	   from	  pG2M52	  
(Lagido	  et	  al.	  2008)	  with	  primers	  that	  added	  5’SphI/3’AscI	  and	  cloned	  into	  pCR8-­‐TOPO	  (Invitrogen)	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using	   a	   TOPO	   TA	   reaction	   (pMLH080).	   pMLH258	  was	   created	   by	   subcloning	   sur-­‐5	   from	   pMLH080	  
(5’SphI/3’AscI)	  into	  pMLH256.	  
	  
myo-­‐3	  Promoter	  (Body	  Wall	  Muscle)	  	  
The	   unc-­‐25	   promoter	   from	   pMLH132	   was	   amplified	   (adding	   5’HindIII/SphI	   and	  
3’XbaI/AscI/XbaI	  restriction	  sites	  to	  the	  primers)	  to	  create	  the	  intermediate	  vector	  (pMLH262)	  used	  
to	   subclone	   the	  myo-­‐3	  promoter.	   A	   5’HindIII/3’XbaI	   digest	   added	  pmyo-­‐3	   (2.4	   kb)	   (Okkema	   et	   al.	  
1995)	   from	   pG2M36	   to	   make	   pMLH264	   and	   5’AscI/3’ApaI	   was	   used	   to	   add	   COQ-­‐1::GFP	   from	  
pMLH260	  to	  create	  pMLH270.	  
	  
ceh-­‐22	  Promoter	  (Pharynx)	  
The	  intermediate	  vector	  (pMLH262)	  described	  above	  for	  the	  myo-­‐3	  promoter	  was	  also	  used	  
to	  subclone	  pceh-­‐22	  (2.8	  kb)	  5’SphI/3’XbaI	  from	  pG2M19	  (Okkema	  et	  al.	  1997)	  to	  create	  pMLH263.	  
pMLH269	   was	   made	   by	   digesting	   COQ-­‐1::GFP	   5’AscI/3’ApaI	   from	   pMLH260	   and	   adding	   it	   to	  
pMLH263.	  
	  
dpy-­‐7	  Promoter	  (Hypodermis)	  
pMLH290	  was	  created	  by	  subcloning	  the	  dpy-­‐7	  promoter	  (346	  bp)	  (Gilleard	  et	  al.	  1997)	  from	  
pG2M50	  (a	  gift	  from	  Andrew	  Hardaway,	  Blakely	  lab)	  with	  5’SphI/3’AscI	  into	  pMLH260.	  	  
	  
elt-­‐2	  Promoter	  (Intestine)	  
pMLH298	   is	   an	   intermediate	   plasmid	   that	   was	   generated	   by	   PCR	   amplifying	   the	   unc-­‐25	  
promoter	   from	  pMLH132	   (with	  primers	   that	  add	  5’SphI/XbaI	  and	  3’AscI/KpnI)	  and	   inserting	   it	   into	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pMLH290	   (5’SphI/3’AscI).	   The	   elt-­‐2	   promoter	   (5	   kb)	   (Fukushige	   et	   al.	   1998)	   was	   subcloned	   from	  
pG2M49	  (a	  gift	  from	  Jim	  McGhee)	  into	  pMLH298	  with	  5’XbaI/3’KpnI	  to	  create	  pMLH291.	  
F25B3.3/rgef-­‐1	  Promoter	  (All	  Neurons)	  
The	   F25B3.3/pan-­‐neural	   promoter	   (3.5kb)	   (Altun-­‐Gultekin	   et	   al.	   2001)	   was	   PCR	   amplified	  
(GoTaq,	   Promega)	   from	   pG2M59	   and	   inserted	   into	   pCR8-­‐TOPO	   (Invitrogen)	   using	   a	   TOPO	   TA	  
reaction	   to	   create	   pMLH081.	   The	   pan-­‐neural	   promoter	   was	   then	   inserted	   into	   pMLH102	   with	  
5’SphI/3’AscI	   (added	   to	   the	   primers)	   to	   produce	   pMLH113.	   Due	   to	   an	   SphI	   site	   100bp	   into	   the	  
F25B3.3	  promoter,	  a	  second	  SphI	  digest	  was	  performed	  to	  include	  this	  5’	  fragment	  from	  pMLH081,	  
which	   was	   lost	   in	   pMLH113,	   to	   make	   pMLH121.	   COQ-­‐1::GFP	   from	   pMLH270	   was	   added	   using	   a	  
5’AscI/3’PacI	  digest	  to	  create	  pMLH289.	  
	  
TOM20::mRFP	  (Outer	  Mitochondrial	  Membrane	  Localization)	  
The	  outer	  mitochondrial	  membrane	  marker,	  TOM20::mRFP,	  was	  created	  by	  fusing	  the	  first	  
54	   nucleotides	   of	   TOM20	   (F23H12.2)	   to	   mRFP	   (Ichishita	   et	   al.	   2008).	   TOM20::mRFP	   was	   PCR	  
amplified	  (GoTaq,	  Promega)	  from	  pG2M002	  (a	  gift	  from	  Toshihiko	  Oka)	  and	  inserted	  into	  pMLH009	  
using	  5’AscI/3’SacII	  added	  to	  primers	  to	  create	  pMLH035.	  
	  
Human	  PDSS1	  	  
	   PDSS1	   was	   amplified	   (Phusion	   High-­‐Fidelity	   DNA	   Polymerase,	   New	   England	   Biolabs)	   from	  
pG2M43	  (Mollet	  et	  al.	  2007)	  and	  ligated	  into	  pMLH272	  (5’AscI/3’SacII)	  to	  make	  pMLH297.	  
	  
Human	  PDSS2	  
PDSS2	   was	   amplified	   (Phusion	   High-­‐Fidelity	   DNA	   Polymerase,	   New	   England	   Biolabs)	   from	  
pG2M45	  (López	  et	  al.	  2006)	  and	  inserted	  into	  pMLH270	  (5’AscI/3’SacII)	  to	  make	  pMLH284.	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Human	  COQ2	  
	   Wild-­‐type	  and	  mutant	  COQ2	  were	  amplified	  (KAPA	  HiFi	  DNA	  Polymerase)	  from	  pG2M47	  and	  
pG2M48	  (Mollet	  et	  al.	  2007),	  respectively,	  and	  inserted	  into	  pMLH280	  with	  5’KpnI/3’EcorI	  (added	  to	  
the	  primers)	  to	  make	  pMLH301	  and	  pMLH302.	  
	  
Generation	  of	  CoQ9-­‐producing	  bacterial	  feeding	  plates	  
	   KO229	  E.	   coli	   (pKA3/Q8	   or	   pSN18/Q9)	  was	   grown	  overnight	   in	   Luria-­‐Bertani	   (LB)	   ampicillin	  
(AMP)	   +	   chloramphenicol	   (CAM)	   cultures.	   This	   overnight	   starter	   culture	   (125uL)	   was	   used	   to	  
inoculate	  12.5mL	  LB	  +	  AMP	  cultures.	  After	  approximately	  8	  hours	  of	  growth	  (OD	  ~1.0),	  cultures	  were	  
centrifuged	   (3.8K	   RPM,	   6	   minutes)	   and	   the	   pellet	   was	   resuspended	   in	   0.5mL	   M9.	   NGM	   plates	  
(60mm)	  were	  seeded	  with	  0.25mL	  bacterial	  slurry.	  E.	  coli	   strains	   (KO229:pKA3	  (Q8),	  KO229:pSN18)	  
were	  provide	  by	  Cathy	  Clarke	  (UCLA)	  (Gomez	  et	  al.	  2009;	  Saiki,	  Lunceford,	  Bixler,	  et	  al.	  2008a).	  
	  
RNAi	  
	   Feeding	   RNAi	   was	   performed	   as	   described	   in	   Chapter	   2	   –	   Materials	   and	   Methods.	   DNA	  
concentrations	  used	  to	  create	  the	  transgenic	  coq-­‐1-­‐csRNAi	  array	  are	  listed	  in	  Table	  3.5.	  
	  
Brood	  size	  assays	  
For	   COQ-­‐1::GFP	   rescue	   experiments,	   WT,	   coq-­‐1(ok749),	   or	   transgenic	   coq-­‐1	  mutants	   (all	  
sharing	   the	   juIs223	   transgene	   to	   mark	   D-­‐type	   GABA	   neurons)	   were	   picked	   at	   the	   L4	   stage	   to	  
individual	  plates	  and	  maintained	  at	  20°C.	  The	  number	  of	  hatched	  L1s	  per	  animal	  was	  quantified	  and	  
averaged	  across	  a	  population	  to	  generate	  the	  average	  brood	  size	  per	  genotype	  (Hodgkin	  &	  Barnes	  
1991).	   The	   Human	   COQ2	   rescue	   experiment	   used	   the	   same	   technique	   except	   that	   all	   strains	  
contained	  wpIs39	  to	  label	  GABA	  neurons	  instead	  of	  juIs223.	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GABA	  neurodegeneration	  assay	  
	   Percent	  GABA	  neurodegeneration	  was	  performed	  as	  described	  in	  Chapter	  2	  –	  Materials	  and	  
Methods.	   RME	   and	   D-­‐type	   neurons	   were	   counted	   for	   the	   data	   in	   Figure	   3.5D;	   wild-­‐type	   animals	  
have	  four	  RME	  and	  19	  D-­‐type	  neurons.	  The	  experimenter	  was	  blinded	  to	  genotype	  to	  avoid	  bias.	  
	  
Protein	  sequence	  alignments	  and	  phylogenetic	  tree	  generation	  
The	   DNAstar	  Megalign	   software	   (use	   provided	   by	   the	   Blakely	   lab)	   was	   used	   for	   Clustal	   V	  
protein	   sequence	   alignments	   and	   phylogenetic	   tree	   generation.	   Accession	   numbers	   for	   proteins	  
used	   are	   as	   follows:	  M.	   musculus:	   NP_062374.2	   (PDSS1);	   D.	   rerio:	   NP_001017656.1	   (pdss1);	   H.	  
sapiens:	   NP_055132.2	   (PDSS1),	   NP_065114.3	   (PDSS2),	   NP_056512.5	   (COQ2);	   D.	   melanogaster:	  
NP_733425.1	   (qless);	   C.	   elegans:	   NP_491588.1	   (COQ-­‐1),	   NP_498513.1	   (COQ-­‐2A),	   NP_498512.1	  
(COQ-­‐2B),	   NP_871682.1	   (COQ-­‐2C),	   NP_871683.1	   (COQ-­‐2D),	   NP_871684.1	   (COQ-­‐2E);	   C.	   briggsae:	  
XP_002639605.1	  (COQ-­‐1);	  S.	  pombe:	  NP_595276.1	  (dps1);	  S.	  cerevisiae:	  NP_009557.1	  (COQ1).	  
	  
Microscopy	  
A	   Zeiss	   Axioplan	   compound	   microscope	   with	   a	   100x	   objective	   was	   used	   to	   capture	   the	  
images	  in	  Figure	  3.2	  and	  3.4.	  The	  representative	  images	  collected	  for	  Figure	  3.5	  and	  3.7	  were	  taken	  
on	   a	   Leica	   TCS-­‐SP5	   confocal	   microscope	   with	   a	   63x	   objective	   using	   the	   Leica	   Application	   Suite	  
Advanced	  Fluorescence	  (LAS-­‐AF)	  software.	  
	  
Experimental	  contributions	  
Meg	  Mitchell	  built	  pMBM009	  (unc-­‐25	  RNAi).	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RESULTS	  
Mutations	   that	   disrupt	   different	   steps	   in	   the	   CoQ	   biosynthetic	   pathway	   display	   heterogeneous	  
phenotypes	  
We	  have	  previously	  shown	  that	  RNAi	  knockdown	  of	  the	  biosynthetic	  enzyme	  coq-­‐1	  results	  in	  
selective	  degeneration	  of	  GABAergic	  neurons	  in	  C.	  elegans	  (Earls	  et	  al.	  2010)	  (Chapter	  2).	  However,	  
given	  my	  recent	  discovery	  that	  RNAi	  efficacy	  can	  vary	  with	  genotype	  (see	  Appendix	  A),	   I	  have	  also	  
pursued	   an	   RNAi-­‐independent	   method	   to	   induce	   CoQ	   deficiency.	   For	   this	   approach,	   GABA	  
neurodegeneration	  was	  assayed	   in	  mutants	  with	  defects	   in	  the	  Coenzyme	  Q	  biosynthetic	  pathway	  
genes	  coq-­‐1,	  coq-­‐2,	  coq-­‐3,	  coq-­‐4,	  coq-­‐5	  and	  coq-­‐8	  (Fig.	  3.1,	  Table	  3.6).	  
Chapter	   2	   describes	   experiments	   with	   coq-­‐1,	   coq-­‐2,	   and	   coq-­‐3	   mutants	   that	   resulted	   in	  
necrotic	   cell	   death	   (i.e.,	   swollen	   cell	   soma)	   of	   adult	   GABA	  motor	   neurons	   (Fig.	   2.2,	   Fig.	   2.3).	   The	  
similar	   neurodegenerative	   phenotypes	   of	   mutants	   in	   these	   three	   different	   CoQ	   biosynthetic	  
pathway	  genes	  confirm	  the	  hypothesis	   that	  CoQ	  deficiency	   is	   responsible	   for	  GABA	  neuron	  death.	  
However,	   these	  mutants	   also	   showed	  phenotypic	   differences	   in	   other	   traits	   that	   are	   indicative	   of	  
heterogeneous	  effects.	  For	  example,	  most	  coq-­‐1(ok749)	  animals	  arrest	  at	   the	  L3	   larval	   stage,	  with	  
few	  adult	  escapers.	  L3	  arrest	  has	  been	  observed	  for	  other	  mitochondrial-­‐impaired	  mutants	  and	  has	  
been	  attributed	   the	  need	   for	   a	   large	  mitochondrial	   expansion	   (at	   the	   L3-­‐to-­‐L4	   transition)	   to	  meet	  
increasing	   energy	   demands	   (Tsang	   et	   al.	   2001).	   In	   contrast,	   coq-­‐2	   and	   coq-­‐3	  mutants	   develop	   to	  
become	   sterile	   adults	   (Table	  3.6).	   Thus,	  mutations	  affecting	  distinct	   steps	   in	   the	  CoQ	  biosynthetic	  
pathway	  (coq-­‐1	  versus	  coq-­‐2,	  coq-­‐3)	  result	  in	  developmental	  arrest	  at	  different	  developmental	  ages	  
(L3	   versus	   adult).	   Our	   analysis	   determined	   that	   mutations	   in	   other	   CoQ	   biosynthetic	   genes	   also	  
display	  a	  range	  of	  phenotypic	  defects.	  For	  example,	  coq-­‐4	  mutants	  are	  viable,	  coq-­‐5	  animals	  arrest	  
larvae	  and	  coq-­‐8	  mutants	  reach	  the	  adult	  stage	  but	  are	  sterile	  (Table	  3.6).	  Of	  these	  three	  mutants,	  
only	  coq-­‐8	  shows	  a	  GABA	  neuron	  degeneration	  defect	  (Fig.	  3.2).	  This	  phenotype	  could	  not	  be	  scored	  	  





Figure	  3.1:	  Deletion	  alleles	  of	  Coenzyme	  Q	  biosynthetic	  genes.	  A.	  ok749	  is	  an	  1860bp	  deletion	  that	  
removes	   the	   C-­‐terminal	   7	   exons	   of	   (of	   11	   total)	   of	   coq-­‐1.	   B.	   coq-­‐2	   is	   predicted	   to	   encode	   five	  
isoforms,	  and	  ok1066	  corresponds	   to	  a	  708	  bp	  deletion	   that	  disrupts	  all	   five	  coq-­‐2	  splice	  variants.	  
ok1066	  also	   introduces	  a	  premature	  stop	  codon	  (*).	  C.	  There	  are	  two	  predicted	   isoforms	  of	  coq-­‐3.	  
The	  ok506	  allele	  deletes	  957bp	  of	   the	  genomic	   sequence,	   removing	   the	   third	  exon	  of	  coq-­‐3A	   and	  
adds	  an	  early	   stop	  codon	   in	  exon	  4	   (*).	  D.	  The	  N-­‐terminus	  of	  coq-­‐4	   is	  not	  affected	  by	   the	  ok1490	  
deletion	   (1210bp).	  E.	   The	  gk379	  mutation	   (1228	  bp	  deletion)	   removes	   5’	   terminal	   exons	  of	   coq-­‐5	  
and	   adjacent	   gene,	   tag-­‐277.	   F.	   coq-­‐8(ok840)	   is	   a	   1238bp	   deletion	   that	   removes	   sequences	   from	  
exons	  2,	  3,	  and	  4	  and	  creating	  a	  premature	  stop	  codon	  in	  exon	  5	  (*).	  Genomic	  regions	  and	  deletions	  
were	  compiled	  from	  genomic	  models	  provided	  on	  WormBase.	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Table	  3.6:	  Mutants	  of	  Coenzyme	  Q	  biosynthetic	  pathway	  genes	  display	  a	  range	  of	  phenotypes.	  The	  
developmental	   and	   GABA	   neurodegeneration	   phenotypes	   of	   homozygous	   CoQ	   biosynthetic	  
pathway	  mutants	  are	  listed.	  Adults	  with	  mutations	  in	  coq-­‐1,	  coq-­‐2,	  coq-­‐3,	  or	  coq-­‐8	  display	  features	  
of	   necrotic	   GABA	   neurodegeneration.	   There	   are	   no	   signs	   of	   GABA	   neuron	   degeneration	   in	   coq-­‐4	  







	   	  
Gene	  (Allele)	   Developmental	  Phenotype	   GABA	  Neurodegeneration	  
coq-­‐1(ok749)	   larval	  arrest	   Yes	  (in	  adult	  escapers)	  
coq-­‐2(ok1066)	   sterile	  adults	   Yes	  
coq-­‐3(ok506)	   sterile	  adults	   Yes	  
coq-­‐4(ok1490)	   viable	   No	  
coq-­‐5(gk379)	   larval	  lethal	   N/A*	  
coq-­‐8(ok840)	   sterile	  adults	   Yes	  
*	  no	  adults	  to	  score	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in	  coq-­‐5	  animals	  due	  to	  their	  early	  larval	  arrest.	  The	  severe	  phenotype	  of	  coq-­‐5	  animals	  could	  result	  
from	  the	  gk379	  deletion	  that	   is	  predicted	  to	  disable	  both	  coq-­‐5	  and	  the	  adjacent	  tag-­‐277	  gene.	   In	  
contrast,	   coq-­‐4	  mutant	   animals	   are	   viable	   and	   fertile	   and	   do	   not	   show	  evidence	   of	  GABA	  neuron	  
degeneration.	  Although	  the	  exact	  enzymatic	  function	  of	  COQ-­‐4	  has	  not	  been	  directly	  determined,	  it	  
is	  predicted	  to	  serve	  as	  a	  hydroxylase	  or	  carboxylase	  to	  modify	  the	  benzoquinone	  ring	  (Tran	  &	  Clarke	  
2007).	  The	  relatively	  mild	  coq-­‐4	  phenotype	  could	  also	  be	  indicative	  of	  a	  hypomorphic	  effect	  arising	  
from	   the	   C-­‐terminal	  ok1490	  deletion	   (Fig.	   3.1).	   Additionally,	   Coenzyme	  Q	   deficiency	   is	   a	   clinically	  
heterogeneous	   syndrome	   that	  presents	  with	   symptoms	   ranging	   from	  severe	   infantile	  multisystem	  
disease	  to	  adult-­‐onset	  cerebellar	  ataxia	  (Emmanuele	  et	  al.	  2012).	  These	  differences	  could	  arise	  from	  
a	   combination	   of	   gene-­‐specific	   effects	   and	   allelic	   differences.	   The	   diverse	   phenotypic	   effects	   of	  
mutations	  in	  different	  genes	  of	  the	  C.	  elegans	  CoQ	  pathway	  parallel	  observations	  of	  CoQ	  deficiency	  
in	  humans	  and	  thus	  could	  be	  useful	  for	  modeling	  the	  roles	  of	  specific	  genetic	  alleles	  in	  pathological	  
effects	  arising	  from	  inadequate	  biosynthesis	  of	  CoQ.	  	  
	  
The	  regulatory	  Coenzyme	  Q	  gene	  coq-­‐8	  is	  also	  required	  for	  GABA	  neuron	  viability	  	  
	   Examination	   of	   coq-­‐8(ok840)	   animals	   confirmed	   previous	   reports	   of	   an	   adult	   sterile	  
phenotype	   (Table	  3.6)	   (Asencio	  et	  al.	  2006;	  Asencio	  et	  al.	  2009).	  Other	  CoQ	  knockouts	   (coq-­‐2	  and	  
coq-­‐3)	   show	   signs	   of	   GABA	   neuron	   cell	   death	   early	   in	   adulthood,	   typically	   within	   4-­‐6	   days	   after	  
hatching	   (Fig.	   2.2).	   Notably,	   coq-­‐8	   mutants	   do	   not	   display	   characteristics	   of	   GABA	  
neurodegeneration	  (i.e.,	  defasciculation,	  neuronal	  process	  beading	  or	  breaks,	  cell	  soma	  loss)	  until	  a	  
later	   stage,	   7-­‐8	  days	   after	  hatching	   (Fig.	   3.2A).	  Nonetheless,	   degenerating	  GABA	  neurons	   in	  coq-­‐8	  
animals	  share	  morphological	  	  
	  
	  








Figure	   3.2:	   Necrotic	   GABA	   neuron	   degeneration	   occurs	   in	   older	   coq-­‐8(ok540)	   adults.	   A.	   GABA	  
neuron	  degeneration	  is	  pronounced	  in	  8	  day	  old	  homozygous	  coq-­‐8(ok540)	  mutants	  but	  not	  in	  coq-­‐8	  
heterozygous	  animals.	  **	  p<0.0001.	  B.	  The	  VD7	  GABAergic	  neuron,	  adjacent	  to	  the	  vulva,	  shows	  a	  
swollen,	   necrotic	   appearance	   (yellow	   arrowhead).	   Scale	   bar	   =	   10µM.	   C.	   punc-­‐25::GFP	   expression	  
confirms	  GABAergic	  identity	  (yellow	  arrowhead).	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features	   (i.e.,	   swollen,	   necrotic-­‐like	   soma)	   of	   other	   CoQ	   biosynthetic	   pathway	   mutants	   and	   thus	  
suggest	  activation	  of	  a	  comparable	  death	  program	  with	  later	  onset	  of	  degeneration	  (Fig.	  3.2B-­‐C).	  	  
The	   function	   of	   COQ-­‐8	   in	   the	   CoQ	   biosynthetic	   pathway	   is	   not	   well	   understood.	   As	   with	  
other	   CoQ	   synthetic	  mutant	   strains,	   yeast	   Coq8	  mutants	   are	   CoQ-­‐deficient	   and	   show	   respiratory	  
defects	   (Do	   et	   al.	   2001).	   However,	   unlike	   other	   CoQ	   synthetic	   proteins,	   COQ-­‐8	   is	   not	   believed	   to	  
directly	   modify	   CoQ	   intermediates	   during	   biosynthesis.	   Instead,	   COQ-­‐8	   is	   predicted	   to	   have	   a	  
regulatory	  role,	  based	  on	  its	  homology	  to	  the	  ABC-­‐1	  family	  of	  protein	  kinases	  (Asencio	  et	  al.	  2006;	  
Asencio	   et	   al.	   2009).	   Kinase-­‐dependent	   activation	   of	   other	   CoQ	   enzymes	   by	   COQ8	   has	   been	  
proposed,	  and	  Coq3p,	  Coq5p	  and	  Coq7p	  are	  phosphorylated	  in	  a	  Coq8p-­‐dependent	  manner	  (Xie	  et	  
al.	   2011).	   However,	   Coq8	   kinase	   activity	   has	   not	   been	   experimentally	   confirmed.	   Interestingly,	  
patients	   with	   ADCK3/COQ8	   mutations	   present	   with	   milder	   symptoms	   compared	   to	   those	   with	  
mutations	  that	  disrupt	  catalytic	  CoQ	  enzymes	  (Lagier-­‐Tourenne	  et	  al.	  2008).	  This	  finding	  parallels	  the	  
mild	   GABA	   neurodegeneration	   defect	   (i.e.,	   late-­‐onset)	   in	   coq-­‐8	   animals	   compared	   to	   other	   CoQ	  
biosynthetic	  pathway	  mutants	  (e.g.,	  coq-­‐2)	  and	  could	  reflect	  similar	  roles	  for	  the	  COQ-­‐8	  protein	   in	  
nematodes	  and	  humans.	  
Except	   for	   coq-­‐4(ok1490),	   which	   may	   not	   result	   in	   a	   null	   phenotype,	   GABA	   neuron	  
degeneration	   is	  observed	   in	  CoQ	  pathway	  mutants	   that	  develop	   to	  adult	   stages	   (Fig.	   2.2,	   Fig.	   3.2,	  
Table	  3.6).	  As	  noted	  above,	  GABA	  neuron	  degeneration	  is	  not	  observed	  in	  mutant	  animals	  that	  die	  
during	   larval	   development	   (e.g.,	   coq-­‐5).	   The	   correlation	   between	   developmental	   stage	   and	  
neurodegeneration	  also	  suggests	  that	  age-­‐dependent	  mechanism	  contribute	  to	  GABA	  neuron	  death	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Dietary	  CoQ	  influences	  developmental	  progression	  and	  GABA	  neurodegeneration	  
Experimental	  use	  of	  coq-­‐1(ok749)	  is	  limited	  because	  the	  majority	  of	  these	  animals	  fail	  reach	  
the	  adult	  stage	  at	  which	  GABA	  neuron	  degeneration	  is	  observed.	  This	  severe	  phenotype	  is	  observed	  
even	  for	  coq-­‐1	  animals	  grown	  on	  an	  E.	  coli	  strain	  (OP50)	  which	  produces	  CoQ8.	  coq-­‐1(ok749)	  viability	  
is	   substantially	   enhanced,	   however,	   by	   growth	   on	   an	   E.	   coli	   strain	   that	   produces	   CoQ9	   (the	  
endogenous	  C.	   elegans	  CoQ	   isoform,	   Table	   1.1)	   (Rodríguez-­‐Aguilera	   et	   al.	   2005).	   This	   observation	  
suggests	  that	  coq-­‐1	  mutants	  fed	  CoQ9-­‐producing	  bacteria	  incorporate	  sufficient	  levels	  of	  CoQ9	  from	  
their	   diet	   to	   develop	   to	   adulthood	   and	   thereby	   increase	   the	   frequency	   of	   the	   GABA	  
neurodegeneration	   phenotype.	   I	   have	   confirmed	   this	   result	   by	   growing	   coq-­‐1	   animals	   on	   a	   CoQ9-­‐
producing	  bacterial	  strain.	  An	  E.	  coli	  strain	  (KO229)	  that	  is	  mutant	  for	  the	  coq-­‐1	  homolog	  (ispB)	  was	  
used	   for	   this	   experiment.	   The	   ispB	   mutation	   is	   lethal	   but	   can	   be	   complemented	   with	   plasmids	  
encoding	  polyprenyl	  diphosphate	  transferases	  from	  other	  species	  (K	  et	  al.	  1997;	  Okada	  et	  al.	  1998).	  
With	   this	  approach,	   it	   is	  possible	   to	  engineer	  viable	  bacterial	   strains	   that	  produce	  CoQ	  derivatives	  
with	  isoprenoid	  side	  chains	  of	  different	  lengths.	  For	  example,	  the	  ispB	  mutant	  strain	  KO229:pSN18	  
produces	  CoQ9.	  coq-­‐1	  mutants	   fed	  CoQ9-­‐producing	  KO229	  bacteria	  showed	  a	  significant	  shift	   from	  
L3	   arrest	   to	   the	   adult	   stage	   (Fig.	   3.3B)	   thus	   confirming	   earlier	   results	   suggesting	   that	   a	   CoQ9-­‐
containing	  diet	  is	  sufficient	  to	  restore	  viability	  to	  coq-­‐1	  mutant	  animals.	  Although	  the	  presence	  of	  a	  
mature	  vulva	   indicated	   that	   these	  coq-­‐1	   animals	  were	  adults,	   they	  were	   significantly	   smaller	   than	  
heterozygous	   siblings	   (Figure	   3.3A)	   and	   displayed	   severe	   morphological	   abnormalities	   including	  
large	  vacuolated	  regions	  in	  various	  tissues	  (Fig.	  3.3D).	  This	  result	  suggests	  that	  uptake	  and	  utilization	  
of	  exogenous	  CoQ9	  may	  be	  less	  efficient	  than	  that	  of	  endogenously	  synthesized	  CoQ.	  Nonetheless,	  
coq-­‐1	   adults	   fed	   CoQ9-­‐producing	   E.	   coli	   (KO229)	   showed	   significantly	   more	   degenerating	   GABA	  
neurons	  (Fig.	  3.3C)	  than	  animals	  grown	  on	  the	  CoQ8-­‐producing	  OP50	  E.	  coli	  strain	  (arrest	  at	  the	  L3	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Figure	  3.3:	  Bacterial	  diet	   influences	  developmental	  progression	  and	  GABA	  neurodegeneration	  of	  
coq-­‐1(ok749)	  mutants.	  A.	  Homozygous	  coq-­‐1	  animals	  cultured	  on	  OP50	  (CoQ8-­‐producing)	  bacteria	  
arrest	  as	  L3	  larvae.	  Dietary	  CoQ9	  from	  KO229	  E.	  coli	  allows	  coq-­‐1	  mutants	  to	  develop	  to	  adults	  that	  
are	   significantly	   smaller	   than	  heterozygous	  animals	   siblings.	   Scale	  bar	  =	  500µM.	  B.	   coq-­‐1	  mutants	  
fed	   a	   CoQ8-­‐producing	   diet	   (OP50)	   arrest	   at	   the	   L3	   stage;	   homozygous	   coq-­‐1	   animals	   cultured	   on	  
KO229	  (CoQ9-­‐producing)	  progress	  to	  adult	  stages.	  C.	  GABA	  neuron	  cell	  death	  increases	  with	  age	  in	  
CoQ9/KO229	   fed	   coq-­‐1	   animals.	   Animals	   grown	   on	   OP50	   (CoQ8)	   arrest	   at	   the	   L3	   stage	   without	  
missing	  GABA	  neurons	  (data	  not	  shown)	  D.	  coq-­‐1	  adults	  show	  severe	  morphological	  defects.	  Scale	  
bar	  =	  20	  µM.	  
	  
	   	  
	   81	  
stage	   without	   GABA	   neuron	   death,	   data	   not	   shown).	   These	   results	   are	   consistent	   with	   the	  
hypothesis	  that	  provision	  of	  the	  dietary	  CoQ9	  isoform	  promotes	  development	  to	  the	  adult	  stage	  and	  
consequent	  appearance	  of	  the	  GABA	  neuron	  degeneration	  phenotype.	  
	  
Apoptotic	  GABA	  neuron	  death	  can	  occur	  rarely	  under	  distinct	  dietary	  CoQ	  conditions	  
	   CoQ	  deficiency	  arising	  from	  coq-­‐1	  RNAi	  (Fig.	  2.2C)	  or	  knockouts	  of	  coq-­‐1	  (Fig.	  2.3B-­‐C),	  coq-­‐2	  
(Fig.	  2.2F-­‐G),	  coq-­‐3	  (Fig.	  2.2H),	  or	  coq-­‐8	  (Fig.	  3.2B)	  reproducibly	  induces	  necrotic	  (i.e.,	  swollen)	  GABA	  
neurons.	   These	   experiments	  were	   performed	   animals	  with	   growth	   on	   either	   HT115	  E.	   coli	   (coq-­‐1	  
RNAi)	   or	  OP50	  E.	   coli	   (coq-­‐1,	   coq-­‐2,	   coq-­‐3,	   coq-­‐8	  mutants).	   Growth	   on	   the	   CoQ9-­‐producing	  E.	   coli	  
strain	  KO229,	  however,	   resulted	   in	   rare	   instances	  of	  apoptotic	  GABA	  neurons	   for	  coq-­‐1	  and	  coq-­‐2	  
mutants	  (Fig.	  4.6,	  Fig.	  3.4A-­‐B).	  Apoptotic	  (i.e.,	  raised,	  button-­‐like)	  GABA	  neurons	  were	  also	  identified	  
in	  coq-­‐1	  mutants	  fed	  KO229:pKA3	  (Q8-­‐producing	  diet)	  (Fig.	  3.4C-­‐D)	  (Fig.	  4.6).	   It	   is	  currently	  unclear	  
why	  GABA	  neurons	  predominantly	  die	  through	  necrosis	  under	  most	  CoQ	  deficiency	  paradigms	  and	  
occasionally	   switch	   to	  death	  by	  apoptosis	  with	  other	  dietary	   conditions.	  Nevertheless,	   this	   finding	  
indicates	  that	  CoQ-­‐deficient	  GABA	  neurons	  are	  competent	  to	  undergo	  apoptotic	  as	  well	  as	  necrotic	  
death.	  
	  
Knockdown	  of	  coq-­‐1	  exclusively	  in	  GABA	  neurons	  does	  not	  induce	  degeneration	  	  
Global	   reduction	   of	   coq-­‐1	   in	   C.	   elegans	   produces	   an	   age-­‐dependent	   loss	   in	   motor	  
coordination	   and	   preferential	   degeneration	   of	   GABA	  motor	   neurons	   (see	   Chapter	   2)	   (Earls	   et	   al.	  
2010).	   This	   finding	   highlights	   the	   importance	   of	   CoQ	   for	   GABA	   neuron	   viability	   but	   does	   not	  
distinguish	   between	   cell	   autonomous	   verses	   non-­‐cell	   autonomous	   roles	   of	   CoQ	   in	   GABA	   neuron	  
survival.	   To	   investigate	  whether	  GABA	   neuron-­‐specific	   production	   of	   coq-­‐1	   is	   required	   to	   prevent	  
neurodegeneration,	  I	  used	  two	  methods	  to	  induce	  cell-­‐specific	  RNAi	  (csRNAi)	  knockdown	  of	  coq-­‐1	  in	  	  












Figure	   3.4:	   GABA	   neurons	   adopt	   apoptotic	   morphology	   in	   coq-­‐1	   and	   coq-­‐2	   mutants	   fed	   an	  
alternative	  E.	  coli	  strain	  KO229.	  A.	  Five	  GABA	  neurons	  are	  marked	  by	  punc-­‐25::GFP	  expression	  in	  a	  
coq-­‐2(ok1066)	  animal	  cultured	  on	  KO229:pSN18	  (Q9-­‐diet).	  B.	  All	  five	  GABA	  neurons	  show	  a	  button-­‐
like	  morphology	  (yellow	  arrowheads)	  consistent	  with	  apoptotic	  death.	  C.	  A	  single	  GABA	  neuron	  in	  a	  
coq-­‐1(ok749)	  animal	  fed	  KO229:pKA3	  (Q8-­‐diet).	  D.	  The	  apoptotic	  GABA	  neuron	  (yellow	  arrowhead)	  
lies	  in	  the	  ventral	  nerve	  cord	  immediately	  beneath	  a	  single	  cell	  embryo	  (*)	  in	  the	  uterus.	  Scale	  bars	  =	  
10µM.	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GABA	   neurons	   (Fig.	   3.5).	   First,	   a	   coq-­‐1	   feeding	   RNAi	   experiment	   was	   performed	   using	   transgenic	  
strain	  XE1375	  (provided	  by	  Marc	  Hammarlund,	  described	  in	  Chapter	  5)	  in	  which	  GABA	  neurons	  are	  
specifically	  sensitized	  to	  the	  RNAi	  effect.	  This	  experiment	  failed	  to	  produce	  evidence	  of	  dying	  GABA	  
neurons	  in	  adult	  animals	  (data	  not	  shown)	  despite	  the	  fact	  that	  XE1375	  includes	  the	  RNAi-­‐sensitizing	  
mutation,	  eri-­‐1(mg366),	  that	  facilitated	  global	  coq-­‐1	  knockdown	  and	  GABA	  neuron	  degeneration	  in	  
the	   earlier	   RNAi	   feeding	   experiments	   (Fig.	   2.2).	   Control	   RNAi	   knockdown	   of	  unc-­‐25/glutamic	   acid	  
decarboxylase	  (GAD)	  generated	  a	  robust	  “shrinker”	  phenotype	  and	  therefore	  confirmed	  that	  GABA	  
neurons	  are	  sensitive	  to	  RNAi	  in	  the	  XE1375	  genetic	  background	  (Fig.	  5.1).	  This	  result	  suggests	  that	  
cell-­‐specific	  knockdown	  of	  CoQ	  synthesis	  in	  GABA	  neurons	  is	  not	  sufficient	  to	  induce	  degeneration.	  
In	   a	   second	   independent	   experimental	   paradigm,	   I	   used	   an	   established	   method	   of	   cell-­‐
specific	   gene	   knockdown	   in	   which	   the	   forward	   and	   reverse	   strands	   of	   a	   coq-­‐1	   cDNA	   sequence	  
(“Miller	  coq-­‐1	  RNAi”,	   Fig.	  3.5A)	  are	   transgenically	  expressed	  under	   the	  control	  of	  a	  GABA	  neuron-­‐
specific	  promoter	  (Tavernarakis	  et	  al.	  2000;	  Petersen	  et	  al.	  2011).	  The	  coq-­‐1	  RNAi	  sequence	  in	  these	  
constructs	   does	   not	   share	   significant	   homology	  with	   any	   other	   regions	   of	   the	  C.	   elegans	  genome	  
(from	   BLAST	   sequence	   analysis)	   and	   therefore	   should	   selectively	   target	   the	   coq-­‐1	   transcript	   (Fig.	  
3.5A).	  A	  global	  feeding	  coq-­‐1	  RNAi	  assay	  with	  this	  “Miller	  coq-­‐1	  RNAi”	  clone	  produces	  GABA	  neuron	  
degeneration	  levels	  comparable	  to	  that	  of	  previous	  experiments	  with	  the	  Ahringer	  RNAi	  clone	  (Fig.	  
3.5B),	   and	   thus	   demonstrates	   that	   the	   “Miller	   coq-­‐1	  RNAi”	   region	   is	   sufficient	   to	   induce	   a	   potent	  
coq-­‐1	  RNAi	  phenotype.	  For	  cell-­‐specific	  RNAi,	  the	  pGABA::coq-­‐1	  RNAi	  transgenes	  were	  expressed	  in	  
the	   eri-­‐1(mg366);	   punc-­‐25::GFP(juIs76)	   background	   that	   was	   also	   used	   for	   induction	   of	   GABA	  
degeneration	  by	  global	  coq-­‐1	  RNAi	  knockdown	  (Fig.	  2.2).	  pGABA::coq-­‐1	  RNAi	  alone	  (no	  global	  RNAi	  
treatment,	   data	   not	   shown)	   and	   control	   (empty-­‐vector)	   RNAi	   conditions	   did	   not	   result	   in	   GABA	  
neuron	   death	   (Fig.	   3.5C-­‐D).	   Furthermore,	  pGABA::coq-­‐1	   RNAi	  does	   not	   enhance	   the	   degeneration	  
induced	  by	  global	  coq-­‐1	  RNAi	  (Fig.	  3.5C-­‐D).	  	  























Figure	   3.5:	   GABA	   neuron-­‐specific	   knockdown	   of	   coq-­‐1	   does	   not	   produce	   a	   GABA	  
neurodegeneration	   defect.	   A.	   Schematic	   of	   coq-­‐1	   genomic	   DNA,	   coq-­‐1	   coding	   sequence	   (gray	  
boxes),	   and	   ok749	   	   deletion	   (1860bp).	   Regions	   of	   coq-­‐1	   targeted	   by	   RNAi	   clones	   are	   indicated:	  
Ahringer	   (genomic),	   coq-­‐1	   cDNA	   (cDNA),	   Miller	   coq-­‐1	   (cDNA).	   B.	   “Miller	   coq-­‐1	   RNAi”	   GABA	  
neurodegeneration	   levels	   are	   not	   significantly	   (n.s.)	   different	   than	   with	   “Ahringer	   coq-­‐1	   RNAi”	  
treatment.	   The	   “cDNA	   coq-­‐1	  RNAi”	   clone	   targets	   the	   entire	   coding	   sequence	   of	   coq-­‐1	  and	   shows	  
significantly	  higher	  levels	  of	  GABA	  neuron	  degeneration,	  #	  p<0.02,	  *	  p	  <0.005,	  n>20.	  C.	  Cell-­‐specific	  
RNAi	   (i.e.,	   csRNAi)	   of	   coq-­‐1	   exclusively	   in	   GABA	   neurons	   does	   not	   induce	   degeneration	   of	   GABA	  
neuron	  processes.	  Under	  global	  coq-­‐1	  RNAi	  treatment,	  the	  csRNAi	  transgene	  does	  not	  significantly	  
(n.s.)	   enhance	   GABA	   degeneration	   versus	   animals	   without	   GABA	   neuron-­‐specific	   knockdown.	   D.	  
Quantification	  of	  the	  number	  of	  GABA	  neurons	  (RME,	  D-­‐type)	  remaining	  after	  feeding	  control	  (EV)	  
or	  coq-­‐1	  RNAi.	  Cell-­‐specific	  RNAi	  of	  coq-­‐1	  does	  not	  reduce	  GABA	  neuron	  number	  or	  enhance	  the	  loss	  
of	  GABA	  neuron	  cell	  bodies	  by	  global	  coq-­‐1	  knockdown.	  E.	  Global	  RNAi	  of	  unc-­‐25	   induces	  equally	  
penetrant	  “shinker”	  (Unc)	  phenotypes	  in	  both	  the	  wild-­‐type	  (WT)	  and	  coq-­‐1	  csRNAi	  strains.	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The	   coq-­‐1-­‐csRNAi	   transgenic	   array	   did	   not	   impair	   GABA	   neuron	   RNAi	   sensitivity	   as	   indicated	   by	  
identical	  “shrinker”	  phenotypes	   in	  a	  global	  unc-­‐25	  RNAi	  knockdown	  assay	  (Fig.	  3.5E).	  These	  results	  
suggest	   that	   robust	   coq-­‐1	  production	   in	  GABA	  neurons	   is	   not	   required	   for	   their	   viability	   provided	  
CoQ	   production	   is	   maintained	   in	   other	   tissues.	   Thus,	   the	   viability	   of	   GABA	   neurons	   under	   these	  
conditions	  (i.e.,	  GABA	  neuron-­‐specific	  coq-­‐1	  RNAi)	  likely	  results	  from	  the	  provision	  of	  CoQ	  by	  other	  
cells.	  This	  model	  is	  supported	  by	  findings	  reported	  below,	  that	  the	  overall	  viability	  of	  CoQ-­‐deficient	  
animals	   can	   be	   rescued	   by	   CoQ	   expression	   in	   specific	   tissues.	   Alternatively,	   GABA	   neuron	  
degeneration	  arising	  from	  a	  global	  CoQ	  deficit	  could	  be	  triggered	  by	  a	  “death	  signal”	  from	  another	  
CoQ-­‐deficient	   tissue.	   This	   question	   can	   be	   resolved	   by	   determining	   if	   CoQ	   synthesis	   in	   other	   cell	  
types	  (e.g.,	  body	  muscle,	  Fig.	  3.6)	  can	  restore	  GABA	  neuron	  viability	  under	  conditions	  that	  otherwise	  
result	  in	  GABA	  neuron	  degeneration	  (e.g,	  coq-­‐2	  mutant).	  	  	  	  
	  
Exogenous	  COQ-­‐1::GFP	  localizes	  to	  mitochondria	  and	  rescues	  coq-­‐1(ok749)	  defects	  
CoQ	  biosynthesis	   is	  predicted	  to	  occur	   in	  mitochondria	  because	  terminal	  CoQ	  biosynthetic	  
enzymes	  (e.g.,	  Coq2)	  localize	  to	  the	  inner	  mitochondrial	  matrix	  (Gin	  &	  Clarke	  2005;	  A.	  Johnson	  et	  al.	  
2005;	   Tran	   &	   Clarke	   2007).	   To	   determine	   the	   subcellular	   localization	   of	   COQ-­‐1	   in	   C.	   elegans,	   I	  
generated	  a	  C-­‐terminal	  GFP	  fusion	  (Fig.	  3.6A)	  and	  co-­‐expressed	  it	  in	  body-­‐wall	  muscle	  with	  an	  outer	  
mitochondrial	   membrane	   marker	   (TOM20::mRFP)	   (Ichishita	   et	   al.	   2008).	   Co-­‐localization	   of	   COQ-­‐
1::GFP	  and	  TOM20::mRFP	  confirms	  that	  COQ-­‐1	  also	  localizes	  to	  the	  mitochondria	  in	  C.	  elegans	  (Fig	  
3.6B).	  	  
Most	   coq-­‐1(ok749)	   animals	   arrest	   at	   the	   L3	   larval	   stage	   and	   are	   infertile.	   However,	  
ubiquitous	  expression	  of	  COQ-­‐1::GFP	  with	  the	  sur-­‐5	  promoter	  restored	  coq-­‐1	  mutant	  development	  
and	   resulted	   in	   fertile	   adults	   that	   generated	   viable	   offspring	   (Fig	   3.6C).	   The	   incomplete	   rescue	   of	  
coq-­‐	  1(ok749)	  brood	  size	  by	  psur-­‐5::COQ-­‐1::GFP	  is	  likely	  due	  to	  mosaic	  inheritance	  of	  the	  rescuing	  	  







Figure	  3.6:	  COQ-­‐1::GFP	  localizes	  to	  mitochondria	  and	  rescues	  coq-­‐1	  defects	  with	  either	  ubiquitous	  
or	   muscle-­‐specific	   expression.	   A.	   coq-­‐1	   cDNA	   is	   C-­‐terminally	   tagged	  with	   GFP.	   The	   region	   of	   the	  
ok749	   deletion	   is	   indicated	   (black	   rectangle)	   B.	   TOM20::mRFP	   labels	   the	   outer	   mitochondrial	  
membrane	  in	  body-­‐wall	  muscle.	  Scale	  bar	  =	  2µM.	  C.	  COQ-­‐1::GFP	  also	  localizes	  to	  mitochondrial,	  as	  
depicted	   in	   the	   merged	   image	   (D).	   E.	   Restoration	   of	   fertility	   in	   the	   coq-­‐1(ok749)	   [i.e.,	   coq-­‐1(-­‐
)]mutant	  with	  ubiquitous	   (psur-­‐5)	  or	  body-­‐wall	  muscle-­‐specific	   (pmyo-­‐3)	  expression	  of	  COQ-­‐1::GFP	  
demonstrates	   restoration	   of	   function	   with	   the	   exogenous	   fusion	   protein.	   All	   strains	   contain	   the	  
juIs223	   (pttr-­‐39::mCherry)	   transgenic	  background.	  **p<0.0001	  vs	  coq-­‐1(+),	  ##p<0.0001	  vs	  coq-­‐1(-­‐),	  
#p<0.0001	   vs	   coq-­‐1(-­‐);	   psur-­‐5::COQ-­‐1::GFP,	   n=20.	   Note:	   coq-­‐1(-­‐)	   animals	   never	   produce	   progeny	  
(brood	  size	  =	  0),	  and	  p<0.03	  for	  coq-­‐1(-­‐);	  pmyo-­‐3::COQ-­‐1::GFP	  vs	  coq-­‐1(-­‐).	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transgenic	  array.	  This	  result	  shows	  that	  the	  COQ-­‐1::GFP	  fusion	  protein	  is	  functional	  and	  thus	  that	  the	  
C-­‐terminal	  GFP	  tag	  does	  not	  disrupt	  COQ-­‐1	  enzymatic	  activity.	  
	  
COQ-­‐1::GFP	  expression	  in	  specific	  tissues	  restores	  fertility	  to	  coq-­‐1	  mutant	  animals	  
Since	  GABA	  neuron-­‐specific	  knockdown	  of	  coq-­‐1	  did	  not	  recapitulate	  the	  neurodegeneration	  
phenotype	   observed	  with	   global	   CoQ	  depletion	   (Fig.	   3.5)	   and	   because	   intercellular	   CoQ	   transport	  
has	   been	   detected	   in	   other	   organisms	   (Padilla-­‐López	   et	   al.	   2009;	   Fernández-­‐Ayala	   et	   al.	   2005),	   I	  
hypothesized	   that	  CoQ	   from	  other	  cell	   types	  can	  compensate	   for	  a	   lack	  of	  CoQ	  synthesis	   in	  GABA	  
neurons.	  This	  model	  predicts	  that	  CoQ	  production	  in	  a	  subset	  of	  cells	  could	  be	  sufficient	  to	  restore	  
viability	  to	  coq-­‐1	  mutants.	  
Because	  dietary	  CoQ9	  overcame	  the	  L3	  lethality	  of	  coq-­‐1	  mutants	  (Fig.	  3.3),	  I	  reasoned	  that	  
this	   phenotype	   (i.e.,	   developmental	   arrest)	   would	   be	   a	   useful	   readout	   for	   CoQ	   intercellular	  
transport.	   Based	   on	   previous	   experiments	   demonstrating	   functional	   rescue	   of	   coq-­‐1	  mutants	   by	  
ubiquitous	   COQ-­‐1::GFP	   (Fig.	   3.6),	   I	   constructed	   transgenic	   lines	   for	   expression	   of	   COQ-­‐1::GFP	   in	  
several	   different	   C.	   elegans	   tissues.	   Transgenic	   expression	   of	   COQ-­‐1::GFP	   in	   pharyngeal	   muscle,	  
intestine,	   nervous	   system,	   or	   GABA	   motor	   neurons	   did	   not	   overcome	   the	   larval	   arrest	   of	   coq-­‐
1(ok749)	  mutants	  (Table	  3.7).	  Expression	  of	  the	  COQ-­‐1	  fusion	  protein	  was	  confirmed	  by	  presence	  of	  
a	  GFP	   signal	   in	   these	   cell	   types	   (data	   not	   shown).	   In	   contrast,	   body	  muscle-­‐specific	   expression	   of	  
COQ-­‐1::GFP	  overcame	  the	  developmental	  and	  sterility	  defects	  of	  coq-­‐1	  animals	  (Fig.	  3.6,	  Table	  3.2).	  
In	   these	  animals,	   the	  GFP	  signal	   (from	  COQ-­‐1::GFP)	  was	  exclusively	  detected	   in	  body	  muscle	   (data	  
not	   shown)	  and	   therefore	  suggests	  Coenzyme	  Q	  production	   is	   restricted	   to	   this	   tissue.	  Since	  body	  
muscle	  function	  is	  not	  directly	  required	  for	  fertility,	  this	  result	  strongly	  supports	  the	  hypothesis	  that	  
CoQ	  synthesized	  from	  muscle	  is	  transported	  to	  other	  CoQ-­‐deficient	  tissues	  (e.g.,	  germline,	  somatic	  
gonad,	  etc)	  that	  are	  required	  for	  viability	  and	  fertility.	  The	  lack	  of	  rescue	  by	  COQ-­‐1::GFP	  expression	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Table	  3.7:	  COQ-­‐1	  expression	  in	  body-­‐wall	  muscle	  restores	  fertility	  to	  coq-­‐1	  mutants.	  	  
COQ-­‐1::GFP	   was	   expressed	   in	   specific	   tissues	   in	   the	   coq-­‐1(ok749)	  mutant.	   Fertility	   is	   selectively	  





Promoter	   Genotype	   Developmental	  
Stage	  
Fertile	  
None	   None	   coq-­‐1	   L3	   No	  
Ubiquitous	   sur-­‐5	   coq-­‐1;	  wdEx926	   Adult	   Yes	  (Fig.	  3.6)	  
Pharynx	   ceh-­‐22	   coq-­‐1;	  wdEx939	   L3	   No	  
Intestine	   elt-­‐2	   coq-­‐1;	  wdEx941	   L3	   No	  
All	  neurons	   F25B3.3	   coq-­‐1;	  wdEx940	   L3	   No	  
Body	  wall	  muscle	   myo-­‐3	   coq-­‐1;	  wdEx934	   Adult	   Yes	  (Fig.	  3.6)	  
GABA	  neurons	   unc-­‐25	   coq-­‐1;	  wdEx933	   L3	   No	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in	   the	  pharynx,	   intestine	  or	  nervous	  system	  could	  mean	  that	  CoQ	  production	   from	  specific	   tissues	  
(e.g.,	  muscle)	  is	  necessary	  for	  normal	  development.	  Alternatively,	  differential	  rescue	  could	  be	  due	  to	  
higher	   levels	   of	   CoQ	   synthesis	   in	   muscle.	   This	   question	   could	   be	   resolved	   by	   quantifying	   CoQ	  
production	  in	  these	  transgenic	  animals	  (Gomez	  et	  al.	  2012).	  
	  
Localization	  and	  function	  of	  human	  CoQ	  biosynthetic	  proteins	  are	  conserved	  in	  C.	  elegans	  
Proteins	  required	  for	  Coenzyme	  Q	  biosynthesis	  (Fig.	  1.6)	  are	  highly	  conserved	  across	  phyla	  
based	   on	   sequence	   homology	   and	   function;	   yeast	   Coq1,	   Coq2,	   Coq3	   and	   Coq7	   mutants	   are	  
complemented	   by	   human	   homologues	   (Saiki	   et	   al.	   2005;	   Forsgren	   et	   al.	   2004;	   Jonassen	  &	   Clarke	  
2000;	   Vajo	   et	   al.	   1999).	   However,	   human	   CoQ	   biosynthetic	   proteins	   have	   not	   been	   tested	   for	  
function	   in	  multicellular	   organisms.	   To	   address	   this	   question,	   I	   obtained	  wild-­‐type	   human	   PDSS1,	  
PDSS2	   (COQ-­‐1	   homologues)	   and	   COQ2	   (Mollet	   et	   al.	   2007).	   The	   Rotig	   lab	   also	   kindly	   provided	  
mutant	  versions	  of	  these	  genes	  that	  were	  originally	  isolated	  from	  patients	  with	  Primary	  Coenzyme	  Q	  
Deficiency.	   Here,	   I	   describe	   results	   demonstrating	   that	   the	   human	   COQ2	   enzyme	   can	   drive	   CoQ	  
biosynthesis	  in	  C.	  elegans.	  
	  
COQ-­‐1	  shares	  phylogenetic	  similarity	  to	  PDSS1	  	  
Human	  PDSS1	  and	  PDSS2	  (Prenyl	  Diphosphate	  Synthase,	  Subunit	  1	  &	  2)	  are	  homologues	  of	  
C.	  elegans	  COQ-­‐1.	  Long-­‐chain	  trans-­‐prenyl	  diphosphate	  synthases	  function	  as	  either	  homomers	  (i.e.,	  
S.cerevisiae,	  A.	  thaliana)	  or	  heteromers	  (i.e.,	  S.	  pombe,	  M.	  musculus,	  H.	  sapiens)	  (Saiki	  et	  al.	  2005),	  
and	   the	   presence	   of	   only	   one	   polyprenyl	   diphosphate	   synthase	   in	   C.	   elegans	   suggests	   that	   it	  
functions	  as	  a	  homomer.	  Phylogenetic	  analysis	  and	  protein	  sequence	  alignment	  reveals	  that	  COQ-­‐1	  
most	   strongly	   resembles	  PDSS1	   (Fig.	  3.7),	  because	  PDSS2	   lacks	   the	  aspartate-­‐rich	  motifs	   in	   two	  of	  
the	  seven	  conserved	  domains	  (II	  and	  IV)	  of	  trans-­‐prenyl	  diphosphate	  synthases	  (Saiki	  et	  al.	  2005).	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Figure	  3.7:	  C.	  elegans	  COQ-­‐1	  is	  homologous	  to	  mitochondrially-­‐localized	  human	  PDSS1	  and	  PDSS2.	  
A.	   Phylogenetic	   analysis	   of	   polyprenyl	   transferases	   implicated	   in	   Coeznyme	  Q	   production	   reveals	  
that	  C.	  elegans	  COQ-­‐1	  (blue	  arrow)	  is	  more	  similar	  to	  human	  PDSS1	  than	  PDSS2.	  B.	  Protein	  sequence	  
alignment	   of	   Human	   PDSS1	   and	   C.	   elegans	   COQ-­‐1	   shows	   47%	   identity	   (black	   boxes)	   and	   64%	  
similarity	  (gray	  boxes).	  The	  seven	  conserved	  domains	  of	  polyprenyl	  transferases	  are	  denoated	  with	  
the	   red	   underline	   (Jun	   et	   al.	   2004).	   A	  missense	  mutation	   (S215N)	   in	   the	  Drosophila	   qless	   locus	   is	  
marked	  (#)	  (Grant	  et	  al.	  2010).	  A	  conserved	  aspartate	  (D)	  residue	  (*,	  green)	  is	  mutated	  (D308E)	  in	  a	  
Coenzyme	  Q	  deficiency	  patient	   (Mollet	  et	  al.	  2007).	  C-­‐E.	  C.	  elegans	  body	  muscle	  mitochondria	  are	  
labeled	  with	  the	  mitochondrial	  marker	  TOM20::mRFP	  (C)	  and	  with	  PDSS2::GFP	  (D).	  A	  merged	  image	  
(E)	  confirms	  localization	  of	  PDSS2::GFP	  to	  mitochondria.	  Scale	  bar	  =	  2	  µM.	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Exogenous	  PDSS2::GFP	  localizes	  to	  mitochondria	  	  
Trans-­‐prenyl	  diphosphate	  synthases	  are	  reported	  to	  localize	  to	  mitochondrial	  (Gin	  &	  Clarke	  
2005)	  and	  also	  to	  ER,	  Golgi,	  and	  peroxisome	  membranes	  in	  some	  species	  (Jun	  et	  al.	  2004;	  Turunen	  
et	   al.	   2004).	   Subcellular	   localization	   of	   the	   human	   proteins	   (PDSS1	   and	   PDSS2)	   has	   not	   been	  
investigated.	  PDSS2	  labeled	  with	  a	  C-­‐terminal	  GFP	  tag	  (PDSS2::GFP)	  was	  co-­‐expressed	  with	  an	  outer	  
mitochondrial	  membrane	  marker	   (TOM20::mRFP)	   in	  C.	  elegans	  body	  wall	  muscle.	  This	  experiment	  
revealed	   that	   PDSS2::GFP	   localizes	   to	   mitochondria	   (Fig.	   3.7C-­‐E).	   Ubiquitously	   expressed	  
PDSS1::mCherry	   also	   displays	   a	   punctate	   pattern	   consistent	   with	  mitochondrial	   localization	   (data	  
not	  shown).	  This	  conclusion	  is	  also	  supported	  by	  the	  mitochondrial	  localization	  of	  PDSS2	  since	  these	  
proteins	  are	  predicted	  to	  form	  heteromeric	  complex	  (Saiki	  et	  al.	  2005).	  
The	   mitochondrial	   localization	   of	   PDSS1	   and	   PDSS2	   in	   C.	   elegans	   suggests	   that	   these	  
enzymes	   are	   properly	   trafficked	   to	   the	   site	   of	   CoQ	   biosynthesis	   (Fig.	   3.7)	   (Tran	   &	   Clarke	   2007).	  
Future	  experiments	  could	  investigate	  whether	  these	  human	  homologues	  of	  COQ-­‐1	  also	  complement	  
the	   C.	   elegans	   coq-­‐1	   mutation.	   As	   mentioned	   previously,	   human	   PDSS1	   and	   PDSS2	   form	   a	  
heterotetrameric	  enzyme	  that	  assembles	  the	  isoprenoid	  tail	  of	  Coenzyme	  Q	  (Saiki	  et	  al.	  2005).	  Both	  
PDSS1	   and	   PDSS2	   are	   required	   to	   rescue	   defects	   in	   E.	   coli	   and	   S.	   pombe	   (Saiki	   et	   al.	   2005),	   and	  
expression	   of	   wild-­‐type	   PDSS1	   alone	   was	   not	   sufficient	   to	   rescue	   growth	   defects	   to	   S.	   cerevisiae	  
coq1	  mutants	   (Mollet	   et	   al.	   2007).	   Based	   on	   these	   observations,	   I	   hypothesize	   that	   expression	   of	  
both	  PDSS1	  and	  PDSS2	  will	  be	  required	  in	  C.	  elegans	  to	  rescue	  coq-­‐1	  defects.	  	  
	  
Fertility	  of	  C.	  elegans	  coq-­‐2(ok1066)	  is	  rescued	  with	  expression	  of	  human	  COQ2	  
	   COQ2	   corresponds	   to	   the	  parahydroxybenzoate	  polyprenyl	   transferase	   that	   generates	   the	  
first	  membrane-­‐bound	  molecule	  in	  the	  CoQ	  biosynthetic	  pathway	  (attaches	  the	  benzoquinone	  ring	  
to	  the	  isoprene	  tail)	  (Fig.	  1.6).	  Additionally,	  COQ2	  is	  predicted	  to	  be	  an	  integral	  membrane	  protein	  in	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the	   CoQ	   pathway.	   Tran	   and	   Clarke	   proposed	   that	   COQ2	   is	   also	   a	   key	   structural	   component	   that	  
anchors	  the	  CoQ	  biosynthetic	  complex	  to	  the	  inner	  mitochondrial	  membrane	  (Tran	  &	  Clarke	  2007).	  
These	  results	  suggest	  that	  COQ2	  is	  not	  only	  required	  for	  a	  specific	  step	  in	  CoQ	  synthesis	  but	  that	  it	  is	  
also	  needed	  for	  proper	  positioning	  of	  soluble	  protein	  components	  of	  the	  CoQ	  biosynthetic	  pathway.	  	  
The	  C.	  elegans	  homologue	  of	  COQ2	  is	  predicted	  to	  produce	  five	  coq-­‐2	   isoforms	  (COQ-­‐2A-­‐E,	  
Fig.	  3.1).	  The	  coq-­‐2	  developmental	  and	  GABA	  neurodegeneration	  phenotypes	  were	  generated	  by	  a	  
deletion	  allele	  (ok1066)	  that	  is	  predicted	  to	  disrupt	  expression	  of	  all	  five	  coq-­‐2	  isoforms	  (Fig.	  3.1).	  It	  
is	  currently	  unclear	  if	  a	  specific	  coq-­‐2	  splice-­‐variant	  is	  responsible	  for	  tissue-­‐specific	  phenotypes	  (i.e.,	  
fertility	  or	  GABA	  neuron	  protection),	  but	  this	  question	  would	  be	  interesting	  to	  investigate	  in	  future	  
studies.	  
To	  date,	  six	  COQ2	  mutations	  have	  been	   identified	   in	  patients	  with	  Primary	  CoQ	  Deficiency	  
(Quinzii	  et	  al.	  2006;	  Mollet	  et	  al.	  2007;	  Diomedi-­‐Camassei	  et	  al.	  2007;	   Jakobs	  et	  al.	  2013).	  Protein	  
sequence	  alignment	  indicates	  that	  C.	  elegans	  COQ-­‐2A	  is	  the	  closest	  homologue	  of	  the	  human	  COQ2	  
protein	   (Fig.	  3.8A).	  All	   five	  of	   the	   residues	   that	  are	  altered	   in	  human	  CoQ	  missense	  mutations	  are	  
conserved	  in	  C.	  elegans	  (Fig.	  3.8A)	  (Quinzii	  et	  al.	  2006;	  Mollet	  et	  al.	  2007;	  Diomedi-­‐Camassei	  et	  al.	  
2007;	   Jakobs	   et	   al.	   2013).	   A	   sixth	   mutation	   (N401fsX415)	   deletes	   nucleotide	   1198	   to	   produce	   a	  
frame	  shift	  that	  alters	  the	  last	  21	  amino	  acids	  of	  human	  COQ2.	  This	  region	  changes	  the	  global	  charge	  
of	  the	  C-­‐terminus	  and	  also	  disrupts	  part	  of	  a	  transmembrane	  domain	  of	  COQ2	  (Mollet	  et	  al.	  2007).	  
Therefore,	   the	   N401fsX415	   mutation	   could	   interfere	   with	   COQ2	   localization	   to	   the	   inner	  
mitochondrial	  membrane	  and	  thus	  also	  disrupt	  co-­‐localization	  of	  other	  CoQ	  biosynthetic	  proteins	  to	  
this	  region.	  Mollet	  et	  al.	  demonstrated	  that	  wild-­‐type	  COQ2	  rescued	  growth	  defects	  of	  S.	  cerevisae	  
coq2	   and	   showed	   that	   COQ2	   N401fsX415	   was	   insufficient	   to	   complement	   the	   yeast	   mutation	  
(Mollet	  et	  al.	  2007).	  	  
	  


















Figure	  3.8:	  Human	  COQ2	   rescues	   infertility	  of	  coq-­‐2(ok1066).	  A.	  Alignment	  of	  H.	  sapiens	  COQ2	  and	  C.	  elegans	  COQ-­‐2A	  demonstrates	  strong	  
conservation	  at	  the	  protein	  level	  (identity	  =	  black	  boxes,	  similarity	  =	  gray	  boxes).	  Homozygous	  (*)	  and	  heterozygous	  (±)	  mutations	  isolated	  from	  
Primary	  Coenzyme	  Q	  Deficiency	  patients	  are	  indicated	  in	  red	  text	  (Quinzii	  et	  al.	  2006;	  Diomedi-­‐Camassei	  et	  al.	  2007;	  Jakobs	  et	  al.	  2013).	  The	  red	  
box	   denotes	   the	   region	   of	   COQ2	   altered	   by	   the	   c1198	   delT,	  N401fsX415	  mutation	   (Mollet	   et	   al.	   2007).	   Predicted	   protein	   domains	   include	   a	  
substrate	   (i.e.,	   isoprenoid	   tail)-­‐binding	   site	   (orange	   underline)	   and	   six	   transmembrane	   regions	   (blue	   underline)	   (Forsgren	   et	   al.	   2004).	   B.	  
Ubiquitous	  expression	  of	  wild-­‐type	  (wt)	  Human	  COQ2	  rescues	  the	  infertility	  defects	  of	  coq-­‐2(ok1066)	  whereas	  the	  mutant	  COQ2	  (N401fsX415,	  
red	  box	  in	  Panel	  A)	  does	  not	  fully	  rescue	  (i.e.,	  embryos	  produced	  but	  they	  are	  inviable).	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Functional	   conservation	   of	   COQ2	   in	   a	   more	   complex	   organism	   has	   not	   been	   previously	  
tested.	  To	  address	   this	  question,	  human	  COQ2	  was	  expressed	   in	  C.	  elegans	  coq-­‐2(ok1066)	  mutant	  
with	  a	  ubiquitous	  promoter	  (sur-­‐5).	  Normally,	  coq-­‐2(ok1066)	  animals	  develop	  to	  adulthood	  but	  do	  
not	  produce	  viable	  embryos	   (Table	  3.6).	  However,	  ubiquitous	  expression	  of	  human	  COQ2	  restores	  
fertility	   to	   coq-­‐2(ok1066)	   animals	   (Fig.	   3.8B).	   This	   result	   provides	   the	   first	   direct	   evidence	   that	   a	  
protein	   from	   the	   human	   Coenzyme	   Q	   biosynthetic	   pathway	   can	   complement	   CoQ	   biosynthesis	  
defects	  in	  a	  different	  multicellular	  organism.	  
The	  N401fsX415	  COQ2	  mutation	  was	  isolated	  from	  a	  patient	  with	  fatal	  infantile	  multiorgan	  
disease	   (Mollet	   et	   al.	   2007).	   In	   contrast	   to	  wild-­‐type	   COQ2,	   ubiquitous	   expression	   of	   the	  mutant	  
version	  of	  COQ2	  (N401fsX415)	   in	  coq-­‐2(ok1066)	  mutants	  resulted	   in	   limited	  rescue;	  embryos	  were	  
produced	  but	  did	  not	  hatch	  (Fig.	  3.8B).	  The	  incomplete	  rescue	  of	  the	  coq-­‐2	  defect	  is	  consistent	  with	  
the	   pathogenic	   effects	   of	   the	   COQ2	   N401fsX415	  mutation	   in	   humans	   and	   parallels	   the	   failure	   to	  
complement	  a	  coq2	  mutation	  in	  yeast	  (Mollet	  et	  al.	  2007).	  
	  
	  
DISCUSSION	  AND	  FUTURE	  DIRECTIONS	  
Summary	  
Coenzyme	  Q	  is	  synthesized	  in	  the	  mitochondria	  by	  a	  set	  of	  highly	  conserved	  enzymes	  (Coq1-­‐
Coq9,	  Fig.	  1.6)	  (Turunen	  et	  al.	  2004).	  Despite	  its	  mitochondrial	  production,	  CoQ	  is	  present	  in	  other	  
cell	  membranes	  where	  it	  performs	  a	  variety	  of	  functions	  (discussed	  in	  Chapter	  1).	  The	  presence	  of	  
CoQ	  in	  non-­‐mitochondrial	  locations	  indicates	  that	  there	  are	  cellular	  mechanisms	  for	  its	  distribution.	  
Additionally,	   the	   clinical	   improvement	   of	   Coenzyme	   Q	   deficiency	   patients	   with	   CoQ10	  
supplementation	   suggests	   that	   exogenous	   CoQ	   can	   be	   both	   imported	   into	   a	   cell	   and	   also	  
transported	   to	  distinct	  membrane	   locations	   to	   rescue	  metabolic	  defects.	  Therefore,	   in	  addition	   to	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mechanisms	  that	  distribute	  CoQ	  throughout	  the	  cellular	  membranes,	  there	  are	  also	  processes	  that	  
incorporate	  exogenous	  Coenzyme	  Q	  into	  the	  cell.	  	  
In	  this	  chapter,	  I	  performed	  cell-­‐specific	  knockdown	  and	  transgenic	  rescue	  experiments	  that	  
suggest	   CoQ	   transport	   mechanisms	   are	   conserved	   in	   C.	   elegans.	   The	   existence	   of	   robust	  
mechanisms	  of	  intercellular	  CoQ	  transport	  likely	  explains	  my	  observation	  that	  selective	  knockdown	  
of	  CoQ	  in	  GABA	  neurons	  does	  not	  result	  in	  degeneration	  whereas	  global	  CoQ	  deficiency	  consistently	  
results	   in	   GABA	   neuron	   death.	   (Fig.	   3.5).	   To	   test	   this	   model,	   I	   generated	   transgenic	   lines	   that	  
expressed	   wild-­‐type	   COQ-­‐1	   (i.e.,	   restored	   CoQ	   production)	   in	   specific	   tissues.	   This	   experiment	  
revealed	  that	  COQ-­‐1	  production	  in	  body	  muscle	  rescued	  coq-­‐1	  mutants	  whereas	  expression	  of	  COQ-­‐
1	  in	  other	  cell	  types	  (pharynx,	  intestine,	  nervous	  system,	  GABA	  neurons)	  failed	  to	  restore	  viability	  to	  
coq-­‐1	   animals	   (Fig.	  3.6).	  This	   finding	  supports	   the	  hypothesis	   that	  Coenzyme	  Q	  can	  be	   transferred	  
between	   cells	   in	   cases	   of	   CoQ	   deficiency	   but	   may	   also	   indicate	   that	   intercellular	   transport	   from	  
some	   tissues	   (e.g.,	   body	   muscle)	   is	   more	   efficient	   than	   from	   other	   cell	   types	   (e.g.,	   intestine).	  
Alternatively,	  overall	  CoQ	  production	   in	  muscle	  may	  be	  significantly	  greater	  than	   in	  cell	   types	  that	  
do	  not	  restore	  viability	  to	  coq-­‐1	  mutants.	   It	  should	  be	  possible	  resolve	  this	  question	  by	  comparing	  
overall	   CoQ	   levels	   in	   rescuing	   (e.g.,	   body	   muscle)	   versus	   non-­‐rescuing	   (e.g.,	   intestine)	   COQ-­‐1	  
expressing	  transgenic	  lines.	  	  
Additionally,	   coq-­‐2	  mutants	   were	   complemented	   with	   human	   COQ2,	   thus	   demonstrating	  
the	  conservation	  of	  CoQ	  biosynthetic	  enzymes	  in	  C.	  elegans.	  A	  pathogenic	  COQ2	  mutation	  originally	  
isolated	   from	  a	  patient	  with	  Primary	  Coenzyme	  Q	  deficiency	  was	  unable	   to	   fully	   rescue	   fertility	  of	  
the	  coq-­‐2	  mutant,	  paralleling	  similar	  attempts	  to	  complement	  a	  mutant	  yeast	  coq2	  allele	  (Mollet	  et	  
al.	  2007).	  These	  studies	  broadly	  address	  how	  cells	  adapt	  to	  Coenzyme	  Q	  deficiency	  and	  provide	  the	  
first	   evidence	   that	   wild-­‐type	   and	   pathogenic	   features	   of	   human	   CoQ	   biosynthetic	   enzymes	   are	  
conserved	  in	  a	  multicellular	  model	  organism.	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A	  narrow	  range	  of	  CoQ	  levels	  permits	  both	  animal	  viability	  and	  GABA	  neuron	  death	  
I	  propose	  a	  Coenzyme	  Q	  threshold	  model	  to	  explain	  the	  range	  in	  phenotypes	  observed	  with	  
various	  CoQ	  deficiency	  backgrounds	  (Table	  3.6,	  Fig.	  3.9).	  This	  model	  assumes	  that	  a	  minimum	  level	  
of	  Coenzyme	  Q	  is	  necessary	  for	  development	  to	  adulthood	  and	  but	  is	  not	  sufficient	  to	  protect	  GABA	  
neurons	  from	  degeneration.	  CoQ	  levels	  outside	  of	  this	  range	  result	   in	  either	  animal	   inviability	  (i.e.,	  
CoQ	   concentration	   is	   too	   low)	   or	   lack	   of	  GABA	  neurodegeneration	   (i.e.,	   CoQ	   concentration	   is	   too	  
high).	   This	   threshold	   model	   could	   explain	   why	   the	   different	   means	   of	   disrupting	   Coenzyme	   Q	  
synthesis	  produced	  a	   range	  of	  developmental	  phenotypes	  and	  varying	   levels	   (and	  onset)	  of	  GABA	  
neuron	  degeneration.	  	  
The	  fact	  that	  coq-­‐1	  animals	  grown	  on	  dietary	  CoQ9	  overcome	  L3	  arrest	  and	  reach	  adulthood	  
(Fig.	   3.3)	   also	   aligns	  with	   a	   CoQ	   threshold	  model	   of	   development	   and	   neurodegeneration.	   In	   this	  
instance,	   dietary	   CoQ9	   allows	   coq-­‐1	  animals	   to	   reach	   adult	   stages	   but	   is	   not	   sufficient	   to	   prevent	  
GABA	  neurodegeneration.	  However,	  these	  coq-­‐1	  animals	  also	  show	  severe	  defects	   in	  other	  tissues	  
and	  thus	  degeneration	  is	  not	  limited	  to	  GABA	  neurons	  under	  these	  conditions.	  	  
coq-­‐1	  RNAi	  resulted	  in	  conditions	  that	  produce	  robust	  GABA	  neurodegeneration	  while	  also	  
maintaining	  the	  viability	  of	  other	  neuron	  subtypes	  (e.g.,	  adjacent	  cholinergic	  neurons	  in	  the	  ventral	  
nerve	  cord)	  (Fig.	  2.2).	  Mutants	  in	  CoQ	  biosynthetic	  enzymes	  also	  result	  in	  GABA	  neuron	  death	  (Fig.	  
2.2,	   Fig.	   3.2).	   These	   CoQ	   pathway	  mutants,	   however,	   are	   typically	   subviable	   due	   to	   either	   larval	  
arrest	   or	   sterility	   (Table	   3.6).	   These	   results	   underscore	   the	   idea	   that	   the	   selective	   death	   of	  GABA	  
neurons	  may	  occur	  at	  a	  specific	  CoQ	  threshold	  such	  that	  higher	  levels	  of	  CoQ	  do	  not	   induce	  GABA	  
neurodegeneration	   whereas	   lower	   levels	   of	   CoQ	   result	   in	   ubiquitous	   tissue	   degeneration.	   Future	  
studies	   could	   directly	   test	   this	   threshold	  model	   by	   quantifying	   CoQ9	   levels	   in	   the	   CoQ	   deficiency	  
strains	  described	  in	  this	  chapter.	  
	  




Figure	  3.9:	  Coenzyme	  Q	  level	  threshold	  for	  viability	  and	  GABA	  neurodegeneration.	  A	  narrow	  range	  
of	   Coenzyme	  Q	   concentration	   in	  C.	   elegans	   is	   required	   to	   observe	  GABA	   neuron	   degeneration	   in	  
adult	   animals.	  A.	  Coenzyme	  Q	  biosynthetic	  pathway	  mutants	  with	   severe	  defects	  and	   thus	   strong	  
reduction	   in	   CoQ	   levels	   are	   inviable	   and	   their	   GABA	   neurodegeneration	   cannot	   be	   assessed.	   B.	  
Robust	  GABA	  neurodegeneration	  occurs	  in	  animals	  with	  enough	  CoQ	  to	  maintain	  animal	  viability	  but	  
other	  tissues	  are	  also	  severely	  affected	  by	  low	  CoQ	  levels	  (i.e.,	  coq-­‐1	  mutants	  fed	  dietary	  CoQ9).	  C.	  
Selective	  GABA	  neuron	  death	  occurs	   in	  animals	   that	  develop	  normally	  but	  signs	  of	  CoQ	  deficiency	  
manifest	  as	  adults	  (i.e.,	  coq-­‐1	  RNAi	  or	  coq-­‐2	  mutants).	  D.	  Alternatively,	  weak	  depletion	  of	  CoQ	  levels	  
permits	   animal	   viability	   but	   GABA	   neurons	   do	   not	   degenerate,	   likely	   due	   to	   intercellular	   CoQ	  
transport	  mechanisms	  that	  supplement	  GABA	  neurons	  with	  CoQ	  (Fig.	  3.10D).	  E.	  Wild-­‐type	  animals	  
are	  viable	  and	  do	  not	  show	  GABA	  neuron	  death.	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C.	  elegans	  as	  a	  model	  system	  to	  study	  intercellular	  CoQ	  transport	  
GABA	  neuron-­‐specific	  COQ-­‐1	  production	  is	  not	  necessary	  for	  their	  survival	  
Results	  from	  this	  chapter	  point	  to	  robust	  mechanisms	  of	  intercellular	  transport	  in	  C.	  elegans.	  
This	  idea	  was	  initially	  suggested	  by	  the	  surprising	  finding	  that	  experiments	  designed	  to	  deplete	  CoQ	  
specifically	   in	  GABA	  neurons	  (i.e.,	  cell-­‐specific	  RNAi)	  did	  not	  produce	  the	  GABA	  neurodegeneration	  
phenotype	  that	  arises	  from	  global	  knockdown	  of	  CoQ	  levels	  (Fig.	  3.4).	  One	  potential	  explanation	  for	  
this	  result	  is	  that	  coq-­‐1-­‐deficient	  GABA	  neurons	  receive	  CoQ	  from	  other	  cells	  and	  thus	  are	  protected	  
from	   degeneration	   (Fig.	   3.10B).	   If	   this	   model	   holds	   true,	   then	   CoQ	   production	   from	   both	   GABA	  
neurons	  as	  well	  as	  other	  from	  nearby	  tissues	  should	  be	  sufficient	  to	  prevent	  neuron	  degeneration	  
(Fig.	  3.10C-­‐D).	  Future	  studies	  could	   test	   this	  hypothesis	  by	   testing	   for	  GABA	  neurodegeneration	   in	  
the	   various	   transgenic	   strains	   that	   express	   COQ-­‐1	   in	   specific	   cell	   types	   (Table	   3.7)	   (see	   Future	  
Directions).	  	  
	  
Muscle-­‐specific	  CoQ	  production	  overcomes	  developmental	  defects	  of	  coq-­‐1	  mutants	  
Further	   evidence	   to	   support	   a	  model	   of	   Coenzyme	  Q	   transfer	   between	   cells	   comes	   from	  
experiments	   in	   which	   COQ-­‐1	   is	   selectively	   expressed	   in	   specific	   tissues.	   Only	   muscle-­‐specific	  
expression	   of	   COQ-­‐1	   rescues	   the	   fertility	   of	   coq-­‐1	  mutants	   (Fig.	   3.6),	   whereas	   the	   restoration	   of	  
COQ-­‐1	  (and	  CoQ	  synthesis)	  to	  the	  pharynx,	  intestine	  or	  nervous	  system	  did	  result	  in	  viable	  offspring	  
(Table	  3.7).	  Normally,	  CoQ	  concentration	  approaches	  saturation	  in	  cellular	  membranes	  (Turunen	  et	  
al.	  2004),	  and	  rescue	  experiments	  of	  CoQ	  pathway	  mutants	  in	  S.	  pombe	  revealed	  that	  1/30th	  of	  	  wild-­‐
type	   levels	   of	   CoQ	  was	   sufficient	   to	   rescue	   growth	   defects	   (Saiki	   et	   al.	   2005).	   These	   observations	  
suggest	   that	   individual	   cells	   normally	   produce	  more	   than	   enough	   CoQ	   to	  meet	   basic	   intracellular	  
needs	  (Saiki	  et	  al.	  2005).	  Therefore,	   it	   is	  seems	  likely	  that	  CoQ	  synthesized	   in	  muscle	   is	  sufficiently	  
high	  to	  afford	  rescue	  of	  other	  CoQ-­‐deficient	  tissues.	  











Figure	   3.10.	   Model	   for	   intercellular	   Coenzyme	   Q	   transport	   as	   a	   mechanism	   to	   protect	   GABA	  
neurons	  from	  degeneration.	  A.	  Under	  conditions	  of	  global	  Coenzyme	  Q	  depletion	  (i.e.,	  coq-­‐1	  RNAi,	  
CoQ	  biosynthetic	  mutants),	  GABA	  neurons	  undergo	  selective	  degeneration.	  B.	  GABA	  neuron-­‐specific	  
knockdown	  of	   CoQ	  production	   (Fig.	   3.5)	   (coq-­‐1	   csRNAi)	   does	   not	   induce	  degeneration	  because	  of	  
CoQ	  transport	  from	  other	  CoQ-­‐rich	  tissues.	  C.	  GABA	  neuron-­‐specific	  restoration	  of	  CoQ	  production	  
rescues	   the	   GABA	   neurodegeneration	   phenotype	   induced	   by	   global	   CoQ	   deficiency.	   D.	   CoQ	  
transport	   from	   specific	   tissues	   rescues	   GABA	   neurodegeneration	   under	   conditions	   of	   global	   CoQ	  
deficiency.	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Two	   alternative	   models	   could	   explain	   how	   CoQ	   is	   transported	   between	   cells:	   (1)	   CoQ	  
distribution	   occurs	   by	   passive	   transport	   (i.e.,	   diffusion)	   or	   (2)	   CoQ	   movement	   is	   controlled	   by	   a	  
specific	  pathway.	  Recent	  studies	  of	  this	  question	  favor	  an	  active	  mechanism	  of	  CoQ	  distribution	  that	  
requires	   the	   endomembrane	   system	   (Fernández-­‐Ayala	   et	   al.	   2005;	   Padilla-­‐López	   et	   al.	   2009).	   For	  
example,	   in	   S.	   cerevisiae,	   exogenous	   CoQ6	   rescues	   growth	   defects	   in	   the	   coq7	   mutant	   strain;	  
however,	  external	  CoQ	   is	  not	   taken	  up	   in	  coq7	  mutants	   in	  which	  endocytosis	   is	   impaired	   (Padilla-­‐
López	   et	   al.	   2009).	   Membrane	   trafficking	   mutants	   that	   disrupt	   endocytosis	   at	   various	   steps	   (i.e.,	  
erg2/internalization,	   tlg2/endosome	   formation,	   pep12/vacuole	   maturation)	   are	   unable	   to	  
incorporate	   exogenous	   CoQ.	   Similarly,	   both	   endogenous	   transport	   from	   the	   mitochondria	   and	  
external	   import	  of	  CoQ	   into	  cultured	  human	  cells	   require	   the	  endomembrane	  system	   (Fernández-­‐
Ayala	  et	  al.	  2005).	  
	   In	   addition	   to	   mechanisms	   that	   bring	   CoQ	   into	   the	   cell,	   it	   also	   seems	   likely	   that	   specific	  
carrier	  proteins	  could	  facilitate	  CoQ	  transport	  to	  distinct	  membrane	  locations.	  Selective	  lipid-­‐binding	  
proteins	   have	   been	   identified	   for	   other	  membrane	   antioxidants	   that	   assist	   transport	   of	   essential	  
lipids.	   For	   example,	   α-­‐Tocopherol	   transfer	   protein	   (αTTP)	   is	   expressed	   in	   the	   liver	   and	   selectively	  
binds	  α-­‐tocopherol	  to	  facilitate	  its	  transport	  between	  membranes	  (Arita	  et	  al.	  1995).	  Coq10p	  is	  the	  
only	   protein	   identified	   thus	   far	   that	   is	   predicted	   to	  bind	   and	   transport	   Coenzyme	  Q	   (Barros	   et	   al.	  
2005;	   Busso	   et	   al.	   2010).	   Coq10p	   shuttles	   CoQ	   from	   its	   site	   of	   synthesis	   (inner	   mitochondrial	  
membrane,	   matrix	   side)	   to	   the	   electron	   transport	   chain	   suggesting	   that	   it	   functions	   in	   the	   inner	  
mitochondrial	  membrane.	  The	  discovery	  of	  Coq10p	  indicates	  that	  CoQ	  movement	  within	  a	  cell	  is	  not	  
simply	   a	   passive	   process	   but	   instead	   requires	   specific	  molecular	   chaperones	   to	   ensure	   its	   proper	  
membrane	  localizations.	  A	  better	  understanding	  of	  CoQ	  transport	  could	  have	  immense	  therapeutic	  
benefit	  and	  thus	  warrants	  further	  investigation.	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Human	  COQ2,	  a	  CoQ	  biosynthetic	  protein,	  is	  functionally	  conserved	  in	  C.	  elegans	  
Experiments	  described	  in	  this	  chapter,	  showed	  that	  ubiquitous	  expression	  of	  human	  COQ2	  
restored	  movement	  and	  fertility	  to	  a	  coq-­‐2	  mutant	  in	  C.	  elegans	  (Fig.	  3.8).	  Conversely,	  expression	  of	  
mutant	   human	   COQ2	   failed	   to	   rescue	   coq-­‐2	   defects.	   Together,	   these	   results	   provide	   the	   first	  
evidence	  of	  functional	  conservation	  of	  both	  wild-­‐type	  and	  pathogenic	  alleles	  of	  a	  CoQ	  biosynthetic	  
gene	  between	  humans	  and	  another	  multicellular	  organism.	  
	  
Future	  Directions	  
Coenzyme	   Q10	   supplementation	   is	   used	   to	   ameliorate	   symptoms	   in	   patients	   with	   CoQ	  
deficiency	   (Rötig	  et	   al.	   2000;	  Montini	   et	   al.	   2008).	   The	  positive	   impact	  of	   this	   treatment	   indicates	  
that	   cells	   use	   active	  mechanisms	  of	   CoQ	  uptake	   in	   states	   of	   deficiency.	  However,	   not	   all	   patients	  
with	  CoQ	  deficiency	  benefit	  from	  treatment	  with	  exogenous	  CoQ10	  and	  myopathic	  forms	  are	  often	  
more	   responsive	   than	   neurologic	   ataxia	   phenotypes	   (Montero	   et	   al.	   2007).	   This	   inefficiency	   and	  
tissue	   selectivity	   has	   been	   attributed	   to	   lack	   of	   CoQ	   bioavailability	   (large	   molecular	   weight	   and	  
insolubility	   in	  water)	   and	   thus	  warrants	   investigations	   to	   enhance	   the	   therapeutic	   benefit	   of	   CoQ	  
supplementation.	   Previous	   attempts	   to	   increase	   CoQ	   uptake	   tested	   Coenzyme	  Q	   derivatives	  with	  
increased	   solubility	   in	   water.	   However,	   these	   hydrophilic	   forms	   of	   CoQ	   were	   largely	   ineffective	  
probably	   because	   the	   lipid	   solubility	   of	   Coenzyme	   Q	   is	   important	   to	   its	   membrane-­‐localized	  
functions	  (Esposti	  et	  al.	  1996).	  These	  results	  warrant	  additional	  research	  on	  the	  mechanism	  of	  CoQ	  
uptake	  and	  intercellular	  distribution	  as	  a	  strategy	  for	  developing	  effective	  therapies	  for	  treating	  CoQ	  
deficiency.	  
	   Vesicular	   transport	   mechanisms	   of	   the	   endomembrane	   system	   have	   been	   identified	   as	  
necessary	  for	  CoQ	  import	  and	  intracellular	  distribution	  in	  yeast	  and	  in	  human	  cells	  (Padilla-­‐López	  et	  
al.	   2009;	   Fernández-­‐Ayala	   et	   al.	   2005).	   Future	   studies	   in	   C.	   elegans	   could	   test	   this	   model	   by	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determining	  if	  mutants	  in	  specific	  endocytic	  components	  (e.g.,	  rme-­‐8)	  prevent	  rescue	  in	  one	  of	  the	  
CoQ	   transport	   systems	   described	   in	   this	   chapter	   (i.e.,	   muscle-­‐specific	   COQ-­‐1	   rescue	   in	   coq-­‐1	  
mutants).	  For	  example,	  if	  the	  endomembrane	  system	  is	  required	  to	  transport	  CoQ	  synthesized	  in	  the	  
muscle	   to	   other	   tissues	   (e.g.,	   somatic	   gonad)	   to	   rescue	   fertility	   defects	   of	   coq-­‐1	  mutants,	   genetic	  
mutations	   in	   endocytic	   genes	   should	   inhibit	   this	   transport	   and	   thus	   result	   in	   animal	   sterility.	  
Additionally,	  the	  muscle-­‐specific	  COQ-­‐1-­‐rescued	  strain	  could	  be	  especially	  well	  suited	  for	  unbiased,	  
forward-­‐genetic	  approaches	   to	   identify	  novel	   regulators	  of	  CoQ	  uptake	   in	  a	  multicellular	  organism	  
(discussed	  in	  Chapter	  6).	  	  
Muscle-­‐specific	   COQ-­‐1	   expression	   rescued	   developmental	   arrest	   and	   infertility	   of	   coq-­‐1	  
mutants	  (Fig.	  3.6),	  whereas	  CoQ	  production	  from	  other	  tissues	  (pharynx,	  intestine,	  nervous	  system)	  
did	  not	  ameliorate	  these	  defects	  (Table	  3.7).	  This	  finding	  raises	  the	  question	  of	  whether	  the	  location	  
of	   CoQ	   production	   is	   important	   (e.g.,	   body	   muscle)	   or	   whether	   a	   minimum	   threshold	   of	   CoQ	  
overcomes	  these	  deficits.	  Future	  studies	  could	  distinguish	  between	  these	  two	  models	  by	  quantifying	  
CoQ9	  levels	  in	  tissue-­‐specific	  COQ-­‐1	  transgenic	  coq-­‐1	  animals.	  Body-­‐wall	  muscle	  is	  a	  large	  tissue	  and	  
perhaps	  CoQ	  production	  from	  muscle	  produces	  such	  robust	  levels	  that	  it	  can	  compensate	  for	  global	  
CoQ	  deficiency.	  However,	  the	  intestine	  is	  also	  a	  large	  organ	  but	  does	  not	  rescue	  coq-­‐1	  mutants	  with	  
intestine-­‐specific	  COQ-­‐1	  production.	  Therefore,	  comparison	  of	  CoQ9	  in	  coq-­‐1	  mutants	  with	  muscle-­‐	  
and	  intestine-­‐specific	  CoQ	  production	  could	  address	  whether	  levels	  or	  location	  of	  CoQ	  is	  important	  
for	  viability.	  If	  both	  tissues	  produce	  comparable	  CoQ	  levels,	  this	  would	  suggest	  that	  the	  location	  of	  
CoQ	  synthesis	  is	   important.	  If	  muscle-­‐specific	  COQ-­‐1	  expression	  has	  significantly	  higher	  CoQ	  levels,	  
this	  would	  implicate	  that	  a	  threshold	  of	  CoQ	  production,	  regardless	  of	  the	  source,	  must	  be	  met.	  In	  
this	   scenario,	   combinations	   of	   tissue-­‐specific	   rescue	   (i.e.,	   intestine	   and	   nervous	   system)	   could	   be	  
used	  to	  elevate	  overall	  CoQ	  levels	  and	  further	  test	  this	  hypothesis.	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A	   key	  question	   surrounding	   the	  GABA	  neuron	  degeneration	   arising	   from	  CoQ	  depletion	   is	  
whether	  activation	  of	   this	  pathway	   is	  due	   to	  an	   inability	  of	  GABA	  neurons	   to	   synthesize	  CoQ	  or	   if	  
CoQ	   deficiency	   in	   other	   cell	   types	   causes	  GABA	   neurons	   to	   die.	   In	   this	   chapter,	   cell-­‐specific	   RNAi	  
experiments	   revealed	   that	   GABA	   neurons-­‐specific	   expression	   of	   coq-­‐1	   is	   not	   required	   for	   their	  
survival	   (Fig.	   3.5).	   This	   result	   implicates	   a	   non-­‐cell	   autonomous	   role	   for	   Coenzyme	  Q	   (Fig.	   3.10B).	  
Future	   studies	   could	   test	   whether	   coq-­‐1	   is	   sufficient	   to	   prevent	   GABA	   neuron	   death	   in	   animals	  
globally	   deficient	   in	   CoQ	   production	   (Fig.	   3.10C).	   Additionally,	   the	   tissue-­‐specific	   COQ-­‐1	   strains	  
described	   in	   this	   chapter	   could	   also	   be	   used	   to	   test	   the	   model	   that	   GABA	   neuron	   viability	   is	  
maintained	  by	  uptake	  of	  CoQ	  from	  other	  cells	  (Fig.	  3.10D).	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CHAPTER	  IV	  
	  
CED-­‐3/CASPASE	  ANTAGONIZES	  A	  CED-­‐4/APAF-­‐1-­‐DEPENDENT	  DEATH	  PATHWAY	  	  
IN	  COENZYME	  Q-­‐DEFICIENT	  GABA	  NEURONS	  
	  
INTRODUCTION	  
	   Members	   of	   the	   core	   apoptotic	   machinery	   (CED-­‐4	   and	   CED-­‐3)	   (Fig.	   1.3)	   are	   required	   for	  
somatic	   and	   germline	   cell	   deaths	   in	  C.	   elegans	   (Dong	   et	   al.	   2009;	  Gartner	   et	   al.	   2008).	   Apoptotic	  
induction	  occurs	  when	  CED-­‐9/Bcl2	  releases	  CED-­‐4/Apaf-­‐1	  for	  oligomerization	  and	  formation	  of	  the	  
“apoptosome.”	  In	  this	  state,	  CED-­‐4	  interacts	  with	  CED-­‐3	  via	  a	  shared	  Caspase	  Activation	  Recruitment	  
Domain	   (CARD)	   to	   trigger	   CED-­‐3	   caspase	   activity.	   In	   addition	   to	   this	   well-­‐documented	   functional	  
relationship	   with	   the	   canonical	   apoptotic	   pathway,	   CED-­‐3	   and	   CED-­‐4	   can	   also	   function	  
independently	  to	  regulate	  cell	  death.	  For	  example,	  PVL-­‐5	  (unknown	  molecular	  identity)	  blocks	  a	  cell	  
death	   pathway	   in	   the	  C.	   elegans	  epidermis	   that	   requires	   ced-­‐3	  but	   not	   ced-­‐4	   (Joshi	  &	   Eisenmann	  
2004).	  Conversely,	  genetic	  ablation	  of	  icd-­‐1/βNAC	  activates	  apoptosis	  in	  neurons	  through	  a	  pathway	  
dependent	  on	  ced-­‐4	  but	  not	  requiring	  ced-­‐3	  (Bloss	  et	  al.	  2003).	  These	  examples	  suggest	  that	  CED-­‐3	  
and	   CED-­‐4	   can	   either	   function	   together	   as	   in	   the	   canonical	   apoptotic	   pathway	   or	   alternatively	   as	  
independent	   players	   in	   atypical	   cell	   death	   mechanisms	   activated	   in	   specific	   tissues	   or	   cellular	  
contexts.	  	  
CED-­‐3	   belongs	   to	   a	   conserved	   family	   of	   caspases	   (cysteine-­‐dependent	   aspartyl	   proteases)	  
that	   are	   known	   for	   their	   essential	   death-­‐promoting	   roles	   in	   apoptosis.	   In	   recent	   years,	   however,	  
many	   non-­‐apoptotic	   duties	   for	   caspases	   have	   been	   identified	   in	   the	   nervous	   system,	   including	  
caspase-­‐dependent	   neuronal	   plasticity	   (Huesmann	   &	   Clayton	   2006),	   ischemic	   preconditioning	  
(McLaughlin	  et	  al.	  2003),	  dendritic	  pruning	  (Williams	  et	  al.	  2006),	  and	  neuronal	  regeneration	  (Pinan-­‐
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Lucarre	  et	  al.	  2011).	  Localized	  and	  highly	  regulated	  activation	  of	  caspases	  in	  these	  cellular	  contexts	  is	  
predicted	  to	  account	  for	  their	  non-­‐death-­‐inducing	  roles,	  as	  uncontrolled	  caspase	  activation	  leads	  to	  
apoptotic	  death	  (Dong	  et	  al.	  2009;	  Williams	  et	  al.	  2006;	  Gartner	  et	  al.	  2008;	  Joshi	  &	  Eisenmann	  2004;	  
Chelur	  &	  Chalfie	  2007).	  
	   In	  Chapter	  2,	  I	  presented	  evidence	  that	  CED-­‐4/Apaf-­‐1	  activity	  is	  required	  for	  degeneration	  of	  
CoQ-­‐deficient	  GABA	  neurons,	  whereas	  ced-­‐3	  mutants	  showed	  partial	   suppression	  of	  GABA	  neuron	  
death	  (Fig.	  2.6).	  Here,	  additional	  experiments	  were	  performed	  to	  better	  understand	  the	  relationship	  
between	  CED-­‐3	  and	  CED-­‐4	  during	  CoQ	  depletion-­‐induced	  GABA	  neuron	  death.	  Our	  data	  now	  suggest	  
that	  CED-­‐3	  antagonizes	  a	  cell	  degeneration	  pathway	  in	  CoQ-­‐deficient	  GABA	  neurons.	  The	  proteolytic	  
activity	   of	   CED-­‐3	   is	   neuroprotective	   in	  GABA	  neurons,	  which	   suggests	   that	   caspase	   activity	   in	   this	  
context	  actually	  blocks	  cell	  death.	  This	  result	  is	  surprising	  because	  it	  suggests	  that	  CED-­‐3	  and	  CED-­‐4	  
have	  opposite	   roles	   in	   this	  cell	  death	  pathway.	  Furthermore,	  epistasis	  analysis	   suggests	   that	  ced-­‐4	  
either	  functions	  downstream	  or	  in	  parallel	  to	  ced-­‐3.	  This	  finding	  was	  also	  unexpected	  given	  the	  well-­‐
studied	   relationship	   between	   these	   two	   proteins	   during	   programmed	   cell	   death	   (i.e.,	   CED-­‐3	   is	  
activated	   downstream	   of	   CED-­‐4).	   Thus,	   these	   findings	   support	   a	   new	  mechanism	   in	  which	   CED-­‐3	  
could	   either	   inhibit	   activation	   of	   CED-­‐4	  or	   potentially	   function	   independently	   to	   oppose	   a	   CED-­‐4-­‐
driven	  neurodegeneration	  pathway	  (Fig.	  4.7).	  Due	  to	  the	  high	  conservation	  of	  apoptotic	  regulators	  
from	  nematode	  to	  vertebrates,	  we	  propose	  that	  similar	  stress-­‐induced	  caspase-­‐dependent	  neuronal	  
protection	  mechanisms	  could	  also	  be	  activated	  in	  mammals.	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MATERIALS	  AND	  METHODS	  
Nematode	  Strains	  and	  Genetics	  
Nematodes	   were	   cultured	   using	   previously	   described	   methods	   (Brenner	   1974).	   Mutant	  
alleles,	  primers	  used	  to	  verify	  the	  mutations	  and	  source	  of	  the	  original	  strains	  used	  for	  this	  study	  are	  
listed	  in	  Table	  4.1.	  Strains	  generated	  for	  data	  analysis	  are	  listed	  in	  Table	  4.2.	  	  
	  
Molecular	  Biology	  and	  Transgenic	  Strains	  
Cloning	  primers	  are	  listed	  in	  Table	  4.3,	  and	  Table	  4.4	  lists	  the	  plasmids	  that	  were	  created	  for	  
this	   study.	   Transgenic	   arrays	  were	   generated	  by	  microinjection	  of	  DNA	  at	   concentrations	   listed	   in	  
Table	   4.5.	   See	   Materials	   and	   Methods	   sections	   of	   Chapter	   2	   for	   a	   description	   of	   the	   unc-­‐25	  
promoter	  and	  Chapter	  3	  for	  details	  of	  the	  ttr-­‐39	  promoter	  construction.	  
	  
Wild-­‐type	  (WT)	  and	  caspase-­‐dead	  (C358S)	  ced-­‐3	  
ced-­‐3	   cDNA	   was	   amplified	   (Phusion	   High-­‐Fidelity	   DNA	   Polymerase,	   New	   England	   Biolabs)	  
from	  pG2M24	  (WT)	  and	  pG2M25	  (C358S)	  and	  inserted	  into	  pMLH117	  with	  5’AscI/3’SacII	  (added	  to	  
primer	   sequences)	   to	   create	   pMLH162	   and	   pMLH163,	   respectively.	   pG2M24	   and	   pG2M25	   were	  
kindly	  provided	  by	  Shai	  Shaham	  (Shaham	  1998).	  
	  
Reconstituted	  ced-­‐3	  
GABA	  neuron-­‐specific	  promoters	  (ttr-­‐39	  and	  unc-­‐25)	  were	  sub-­‐cloned	  into	  TU#806	  [CZ-­‐ced-­‐3	  
(p17)]	  and	  TU#807	  [ced-­‐3(p15)-­‐NZ]	  (Chelur	  &	  Chalfie	  2007)	  (from	  Addgene)	  with	  5’HindIII/3’BamHI	  
to	  make	  pMLH209	  and	  pMLH207,	  respectively.	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Table	  4.1.	  Mutant	  alleles	  used	  in	  this	  study	  and	  their	  source	  of	  origin	  (Caenorhabditis	  Genetics	  
Center	  =	  CGC).	  
	  
Mutant	   Source	   Genotyping	  Primers	   Reference	  
coq-­‐1	  (ok749)	  I	   CGC	   AAAAATGTTACGGCCGACTG	   (Gavilan	  et	  al.	  2005)	  
CGTGTCCCTCAAAATGACCT	  
AGTCAGTGCTCGTCGGAGAT	  
ced-­‐4	  (n1162)	  III	   CGC	   TCATCCACGACTTTGAACCA	   (Yuan	  &	  Horvitz	  1992)	  
GCAAGCGTCACGAAATATCA	  
ced-­‐4	  (n1894)	  III	   CGC	   ATTGGAAAGTCGAGGATTAGTC	   (Yuan	  &	  Horvitz	  1992)	  
TTAACAGCATGCAAAATTTTTGAGG	  
ced-­‐4	  (n3040)	  III	   Robert	  	  
Horvitz	  
GCTATTGTATATTCTCCAGCTA	   (F.	  Chen	  et	  al.	  2000)	  
GAGCTTGTGATGCAATTACTG	  
ced-­‐4	  (ot248)	  III	   CGC	   GCTATTGTATATTCTCCAGCTA	   (Sarin	  et	  al.	  2007)	  
GAGCTTGTGATGCAATTACTG	  
ced-­‐9	  (n1950gf)	  III	   CGC	   CGGACAACTCGCTGACGAAT	   (Hengartner	  &	  Horvitz	  
1994)	  TTCCTTCCAGTTGTTGCGGA	  
coq-­‐2	  (ok1066)	  III	   CGC	   ATGCACATGGAGCATAGCAATG	   (Gavilan	  et	  al.	  2005)	  
GCGTGGTTTCACACAGATACAA	  
eri-­‐1	  (mg366)	  IV	   CGC	   CATGCAATTTCAATGCCTTTTA	   (Kennedy	  et	  al.	  2004)	  
TGCATCATCCAATCCACTATGT	  
ced-­‐3	  (n717)	  IV	   CGC	   AGACTTTGCCAAACACGAATCA	   (Yuan	  et	  al.	  1993)	  
TCAGCAGCTCAACAACATCC	  
ced-­‐3	  (n718)	  IV	   CGC	   ATGATGCGTCAAGATAGAAG	   (Shaham	  et	  al.	  1999)	  
GGCAGAGCGTCCTTTTGCAAGC	  
ced-­‐3	  (n1949)	  IV	   CGC	   ATGATGCGTCAAGATAGAAG	   (Yuan	  et	  al.	  1993)	  
GGCAGAGCGTCCTTTTGCAAGC	  
ced-­‐3	  (n2433)	  IV	   CGC	   AAATTTCCCAGCCTTGTTCC	   (Yuan	  et	  al.	  1993)	  
TCAGCAGCTCAACAACATCC	  
ced-­‐3	  (n2888)	  IV	   CGC	   ATGATGCGTCAAGATAGAAG	   (Shaham	  et	  al.	  1999)	  
TTCGTTGTCACAATTCGAGCATA	  
ced-­‐3	  (ok2734)	  IV	   CGC	   AAATTTCCCAGCCTTGTTCC	   N/A	  
TCAGCAGCTCAACAACATCC	  
CTGATTGGTCGCAGTTTTCA	  
egl-­‐1	  (n1084	  n3082)	  V	   CGC	   CCGATTAGTCGTATTCTAACTTC	   (Conradt	  &	  Horvitz	  
1998)	  TCATGGTACAAATTGGAGAAAAGT	  
eri-­‐1(mg366)	  IV	   CGC	   CATGCAATTTCAATGCCTTTTA	   (Kennedy	  et	  al.	  2004)	  
TGCATCATCCAATCCACTATGT	  
Transgene	   Source	   Array	   Reference	  
juIs76	  II	   CGC	   punc-­‐25::GFP,	  lin-­‐15(+)	   (Jin	  et	  al.	  1999)	  
hT2	  (I;III)	   CGC	   bli-­‐4(e937)	  let(q782)	  qIs48	   (McKim	  et	  al.	  1993)	  
nIs48	   Robert	  	  
Horvitz	  
punc-­‐30::ced-­‐4,	  rol-­‐6(d)	   (Shaham	  &	  Horvitz	  
1996b)	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Table	  4.2.	  Table	  of	  strains	  used	  in	  this	  study.	  
	  
Strain	  	   Genotype	  
NC1405	   juIs76	  [punc-­‐25::GFP,	  lin-­‐15(+)]	  II;	  eri-­‐1	  (mg366)	  IV	  
NC1407	   juIs76	  [punc-­‐25::GFP,	  lin-­‐15(+)]	  II;	  ced-­‐4	  (n1162)	  III;	  eri-­‐1	  (mg366)	  IV	  	  
NC1959	   juIs76	  [punc-­‐25::GFP,	  lin-­‐15(+)]	  II;	  coq-­‐2(ok1066)/hT2	  (I;	  III)	  
NC2322	   juIs76	  [punc-­‐25::GFP,	  lin-­‐15(+)]	  II;	  ced-­‐3(ok2734)	  eri-­‐1(mg366)	  IV	  
NC2536	   juIs76	  [punc-­‐25::GFP,	  lin-­‐15(+)]	  II;	  ced-­‐4	  (n1162)	  III;	  eri-­‐1	  (mg366)	  IV;	  wdEx847	  [pttr-­‐39::ced-­‐4,	  punc-­‐25::mCherry,	  pceh-­‐22::GFP]	  
NC2568	   juIs76	   [punc-­‐25::GFP,	   lin-­‐15(+)]	   II;	   ced-­‐3(ok2734)	   eri-­‐1(mg366)	   IV;	  wdEx865	   [pttr-­‐39::ced-­‐3	  cDNA,	  punc-­‐25::mCherry,	  pceh-­‐22::GFP]	  
NC2590	   juIs76	  [punc-­‐25::GFP,	  lin-­‐15(+)]	  II;	  ced-­‐3(ok2734)	  eri-­‐1(mg366)	  IV;	  wdEx875	  [pttr-­‐39::ced-­‐3	  C358S	  cDNA,	  punc-­‐25::mCherry,	  pceh-­‐22::GFP]	  
NC2617	   trIs10	  [pmyo-­‐3::MB::YFP,	  pmyo-­‐2::YFP,	  pceh-­‐23::HcRed,	  punc-­‐25::DsRed,	  unc-­‐129nsp::CFP]	  I;	  
eri-­‐1	  (mg366)	  IV	  
NC2627	   trIs10	  [pmyo-­‐3::MB::YFP,	  pmyo-­‐2::YFP,	  pceh-­‐23::HcRed,	  punc-­‐25::DsRed,	  unc-­‐129nsp::CFP]	  I;	  ced-­‐3	  (ok2734)	  eri-­‐1	  (mg366)	  IV	  
NC2660	   juIs76	  [punc-­‐25::GFP,	  lin-­‐15(+)]	  II;	  ced-­‐3(n1949)	  eri-­‐1(mg366)	  IV	  
NC2664	   juIs76	  [punc-­‐25::GFP,	  lin-­‐15(+)]	  II;	  ced-­‐3(ok2734)	  eri-­‐1(mg366)	  IV;	  wdEx904	  [punc-­‐25::ced-­‐3-­‐SM-­‐nz,	  pttr-­‐39::cz-­‐ced-­‐3-­‐LG,	  punc-­‐25::mCherry,	  pceh-­‐22::GFP]	  
NC2687	   juIs76	  [punc-­‐25::GFP,	  lin-­‐15(+)]	  II;	  ced-­‐3(n718)	  eri-­‐1(mg366)	  IV	  
NC2743	   coq-­‐1(ok749)/hT2	  (I;	  III);	  juIs76	  [punc-­‐25::GFP,	  lin-­‐15(+)]	  II	  
NC2749	   juIs76	  [punc-­‐25::GFP,	  lin-­‐15(+)]	  II;	  coq-­‐2(ok1066)/hT2	  (I;	  III);	  ced-­‐3(ok2734)	  IV	  
NC2778	   juIs76	  [punc-­‐25::GFP,	  lin-­‐15(+)]	  II;	  ced-­‐4	  (n1894)	  III;	  eri-­‐1	  (mg366)	  IV	  
NC2779	   juIs76	  [punc-­‐25::GFP,	  lin-­‐15(+)]	  II;	  ced-­‐4	  (n3040)	  III;	  eri-­‐1	  (mg366)	  IV	  
NC2790	   juIs76	  [punc-­‐25::GFP,	  lin-­‐15(+)]	  II;	  ced-­‐4	  (not248)	  III;	  eri-­‐1	  (mg366)	  IV;	  otIs114	  [plim-­‐6::GFP,	  rol-­‐6(d)]	  
NC2798	   coq-­‐1(ok749)/hT2	  (I;	  III);	  juIs76	  [punc-­‐25::GFP,	  lin-­‐15(+)]	  II;	  ced-­‐3(ok2734)	  IV	  
NC2802	   juIs76	  [punc-­‐25::GFP,	  lin-­‐15(+)]	  II;	  coq-­‐2(ok1066)/hT2	  (I;	  III);	  ced-­‐3(n717)	  IV	  
NC2803	   coq-­‐1(ok749)/hT2	  (I;	  III);	  juIs76	  [punc-­‐25::GFP,	  lin-­‐15(+)]	  II;	  ced-­‐4(n1162)/hT2	  (I;	  III);	  ced-­‐3(ok2734)	  IV	  
NC2804	   coq-­‐1(ok749)/hT2	  (I;	  III);	  juIs76	  [punc-­‐25::GFP,	  lin-­‐15(+)]	  II;	  ced-­‐4(n1162)/hT2	  (I;	  III)	  
NC2817	   juIs76	  [punc-­‐25::GFP,	  lin-­‐15(+)]	  II;	  coq-­‐2(ok1066)/hT2	  (I;	  III);	  ced-­‐3(n2433)	  IV	  
NC2818	   coq-­‐1(ok749)/hT2	  (I;	  III);	  juIs76	  [punc-­‐25::GFP,	  lin-­‐15(+)]	  II;	  egl-­‐1(n1084	  n3082)	  V	  
NC2825	   coq-­‐1(ok749)/hT2	  (I;	  III);	  juIs76	  [punc-­‐25::GFP,	  lin-­‐15(+)]	  II;	  ced-­‐9(n1950)/hT2	  (I;	  III)	  
NC2828	   juIs76	  [punc-­‐25::GFP,	  lin-­‐15(+)]	  II;	  coq-­‐2(ok1066)/hT2	  (I;	  III);	  ced-­‐3(n2888)	  IV	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Table	  4.3.	  Molecular	  cloning	  primers	  used	  in	  this	  work.	  Restriction	  sites	  added	  to	  the	  primers	  are	  
underlined.	  
	  
Gene	   Primer	  Name	   Primer	  Sequence	  
ced-­‐3	  WT	  
cDNA	  
ced-­‐3_5p_AscI	   GGGGCGCGCCATGATGCGTCAAGATAGAAG	  
ced-­‐3_3p_SacII	   CCCCGCGGTTAGACGGCAGAGTTTCGTGCTTCC	  
ced-­‐3	  C358S	  
cDNA	  
ced-­‐3_5p_AscI	   GGGGCGCGCCATGATGCGTCAAGATAGAAG	  
ced-­‐3_3p_SacII	   CCCCGCGGTTAGACGGCAGAGTTTCGTGCTTCC	  
ced-­‐4	  cDNA	   ced-­‐4_5p_AscI	   GGGGCGCGCCATGCTCTGCGAAATCGAATG	  
ced-­‐4_3p_SacII	   CCCCGCGGTTAACAGCATGCAAAATTTTTG	  
pttr-­‐39	   pC04G2.1_5p_SphI	   GGGGGGGCATGCATTATTATTTCTATCGGCTAC	  
pC04G2.1_3p_AscI	   GGGGGGGGCGCGCCATGATTTTTTGTTTTAACAA	  
punc-­‐25	   punc-­‐25_5p_HindIII_SphI	   GGGGGGAAGCTTGCATGCAAAAAACACCCAC	  








Table	  4.4.	  Plasmids	  generated	  and/or	  used	  in	  this	  study.	  
	  
Vector	   DNA	   Additional	  Information	  
pG2M24	   pET3a::ced-­‐3	  WT	  cDNA::FLAG	   a	  gift	  from	  Shai	  Shaham	  
pG2M25	   pET3a::ced-­‐3	  C358S	  cDNA::FLAG	   a	  gift	  from	  Shai	  Shaham	  
pG2M39	   pmec-­‐18::ced-­‐3(p15)-­‐nz	  [TU#806]	   purchased	  from	  Addgene	  
pG2M40	   pmec-­‐18::cz-­‐ced-­‐3(p17)	  [TU#807]	   purchased	  from	  Addgene	  
pMLH001	   pttr-­‐39	  forward	  in	  pENTR	  D-­‐TOPO	   	  
pMLH004	   punc-­‐25	  forward	  in	  pENTR	  D-­‐TOPO	   	  
pMLH162	   pttr-­‐39::ced-­‐3	  WT	  cDNA::unc-­‐10	  3’UTR	   	  
pMLH163	   pttr-­‐39::ced-­‐3	  C358S	  cDNA::unc-­‐10	  3’UTR	   	  
pMLH174	   pttr-­‐39::ced-­‐4	  cDNA::unc-­‐10	  3’UTR	   	  
pMLH188	   punc-­‐25::ced-­‐3::GFP::unc-­‐54	  3’UTR	   	  
pMLH189	   punc-­‐25::ced-­‐4::GFP::unc-­‐54	  3’UTR	   	  
pMLH190	   punc-­‐25::csp-­‐1B::GFP::unc-­‐54	  3’UTR	   	  
pMLH207	   punc-­‐25::ced-­‐3	  (p15)-­‐NZ::unc-­‐54	  3’UTR	   	  
pMLH209	   pttr-­‐39::CZ-­‐ced-­‐3	  (p17)::unc-­‐54	  3’UTR	   	  
	   	   	  
Coinjection	  Markers	  
pCW2.1	   pceh-­‐22::GFP	   a	  gift	  from	  Oliver	  Hobert	  
pMLH132	   punc-­‐25::mcherry::unc-­‐54	  3’UTR	   	  
pG2M30	   pBluescript	  II	   filler	  DNA	  for	  array	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Table	  4.5.	  Plasmid	  concentrations	  that	  were	  microinjected	  to	  generate	  the	  transgenic	  arrays	  used	  in	  
this	  study.	  Refer	  to	  Table	  4.4	  for	  plasmid	  descriptions.	  
	  





15(+)]	  II;	  ced-­‐3(ok2734)	  
eri-­‐1(mg366)	  IV	  
pMLH162	   25	  ng/μL	  
pMLH132	   25	  ng/μL	  





15(+)]	  II;	  ced-­‐4	  (n1162)	  
III;	  eri-­‐1	  (mg366)	  IV	  
pMLH174	   25	  ng/μL	  
pMLH132	   30	  ng/μL	  





15(+)]	  II;	  ced-­‐3(ok2734)	  
eri-­‐1(mg366)	  IV	  
pMLH163	   25	  ng/μL	  
pMLH132	   25	  ng/μL	  






15(+)]	  II;	  ced-­‐3(ok2734)	  
eri-­‐1(mg366)	  IV	  
pMLH207	   10	  ng/μL	  
pMLH209	   10	  ng/μL	  
pMLH132	   25	  ng/μL	  
pCW2.1	   20	  ng/μL	  
pG2M30	   35	  ng/μL	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ced-­‐4	  
ced-­‐4	   cDNA	   was	   amplified	   (Phusion	   High-­‐Fidelity	   DNA	   Polymerase,	   New	   England	   Biolabs)	  
from	  DNA	  isolated	  from	  nIs48	  (punc-­‐30::ced-­‐4	  cDNA)	  transgenic	  animals	  (Shaham	  &	  Horvitz	  1996b)	  
(a	  gift	  from	  H.	  Robert	  Horvitz)	  and	  inserted	  into	  pMLH162	  with	  5’AscI/3’SacII	  (added	  to	  the	  primers)	  
to	  make	  pMLH174.	  
	  
Synchronizing	  coq-­‐2	  adults	  for	  neurodegeneration	  analysis	  
Strains	  were	   cultured	   at	   20°C.	   Synchronized	   coq-­‐2/hT2	   animals	  were	  maintained	  on	  NGM	  
OP50	   plates,	   and	   coq-­‐2	   homozygotes	   were	   picked	   at	   the	   L3/L4	   stage	   to	   new	   plates	   to	   avoid	  
overgrowing	   and	   starvation.	   On	   Day	   7	   (unless	   otherwise	   indicated),	   homozygous	   coq-­‐2(ok1066)	  
animals	  were	  mounted	  on	  a	  2%	  agarose	  pad	  and	  GABA	  neuron	  degeneration	  was	  examined	  on	  a	  
Zeiss	  Axioplan	  compound	  microscope	  using	  a	  100x	  objective.	  Percent	  (%)	  degeneration	  was	  scored	  
as	  described	  in	  Chapter	  2	  –	  Materials	  and	  Methods.	  The	  experimenter	  was	  blinded	  to	  avoid	  bias.	  
	  
Assay	  for	  “undead”	  RME	  neurons	  
Adult	   animals	   were	   mounted	   on	   a	   2%	   agarose	   pad	   and	   examined	   on	   a	   Zeiss	   Axioplan	  
compound	  microscope	  using	   a	  100x	  objective.	   Total	   number	  of	  RME	  neurons	   (visualized	  by	  punc-­‐
25::GFP)	  were	  counted	  and	  animals	  with	  more	  than	  four	  RMEs	  were	  scored	  as	  “extra	  RME.”	  
	  
coq-­‐1	  RNAi-­‐induced	  GABA	  neurodegeneration	  assay	  
Feeding	   RNAi	   assays	   (Kamath	   et	   al.	   2003)	   were	   performed	   as	   described	   in	   Chapter	   2	   –	  
Materials	  and	  Methods	  (Earls	  et	  al.	  2010).	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GABA	  neuron	  versus	  cholinergic	  neuron	  degeneration	  assay	  
	   A	  coq-­‐1	  RNAi	  assay	  was	  used	  to	  quantify	  the	  number	  of	  GABAergic	  and	  cholinergic	  neurons	  
in	  WT	  and	  ced-­‐3(ok2734)	  mutants	  marked	  with	  the	  trIs10	  multi-­‐color	  reporter	  (Dixon	  2006).	  At	  Day	  
5	   of	   the	   coq-­‐1	   RNAi	   experiment,	   the	   total	   number	   of	   D-­‐type	   GABAergic	   (VD3-­‐VD11)	   and	   DA/DB	  
cholinergic	  neurons	  (DB3-­‐DA9)	  were	  counted.	  Wild-­‐type	  animals	  have	  13	  GABAergic	  (Fig.	  1.7)	  and	  13	  
cholinergic	   neurons	   in	   this	   interval.	   Animals	   grown	   on	   empty	   vector	   (EV)	   control	   bacteria	   (i.e.,	  
backbone	  vector	  lacking	  an	  RNAi	  insert)	  did	  not	  show	  evidence	  of	  GABA	  neuron	  degeneration	  (data	  
not	  shown).	  
	  
Dietary	  Coenzyme	  Q9	  feeding	  plates	  
CoQ9	  bacterial	  plates	  were	  made	  as	  described	  in	  Chapter	  3	  –	  Materials	  and	  Methods.	  
	  
Apoptotic	  versus	  necrotic	  GABA	  neurons	  
Differential	   interference	   contrast	   (DIC)	   microscopy	   on	   a	   Zeiss	   Axioplan	   compound	  
microscope	  (using	  a	  100x	  objective)	  was	  used	  to	  assess	  the	  distribution	  of	  apoptotic	  versus	  necrotic	  
GABA	  neurons.	  Neurons	  with	  a	  raised,	  button-­‐like	  appearance	  were	  scored	  as	  apoptotic	  and	  swollen	  
cells	  were	  scored	  as	  necrotic.	  
	  
Microscopy	  
Images	  in	  Figures	  4.2	  and	  4.4	  were	  obtained	  with	  a	  Leica	  TCS-­‐SP5	  confocal	  microscope	  using	  
the	  Leica	  Application	  Suite	  Advanced	  Fluorescence	   (LAS-­‐AF)	   software	  with	  a	  40x	  objective.	  A	  Zeiss	  
Axioplan	  compound	  microscope	  was	  used	  to	  capture	  the	  images	  in	  Figure	  4.3	  and	  4.6.	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Caspase	  cleavage	  site	  prediction	  
The	   CED-­‐4	   protein	   sequence	   (accession	   number	   NP_001021202.1)	   was	   analyzed	   using	  
CASVM:	  Server	  for	  SVM	  Prediction	  of	  Caspase	  Substrates	  Cleavage	  Sites	  (Wee	  et	  al.	  2006)	  to	  identify	  
a	  single	  predicted	  caspase	  cleavage	  site	  at	  89-­‐DYID-­‐92.	  
	  
Experimental	  contributions	  
	   Meg	  Mitchell	   built	   the	   NC2778,	   NC2779,	   NC2790	   and	   NC2819	   strains	   and	   quantified	   the	  
percent	  extra	  RME	  for	  all	  ced-­‐4	  alleles	  in	  Figure	  4.2.	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RESULTS	  
Loss	  of	  CED-­‐3	  enhances	  GABA	  neurodegeneration	  induced	  by	  CoQ	  depletion	  
	   Our	  initial	  assessment	  of	  the	  role	  of	  CED-­‐3	  during	  GABA	  neurodegeneration	  relied	  on	  coq-­‐1	  
RNAi	   and	   detected	   partial	   suppression	   of	   degeneration	   by	   a	   ced-­‐3(n717)	   mutant	   (Fig.	   2.6).	   This	  
result	   indicated	   that	  CED-­‐3	   functioned	   in	  parallel	   to	  an	  unknown	   factor	   to	  promote	  GABA	  neuron	  
death.	   To	   confirm	   this	   finding	   I	   performed	   a	   parallel	   experiment	   with	   the	   ced-­‐3	   deletion	   allele,	  
ok2734,	   in	   a	   coq-­‐2(ok1066)	   background.	   This	   experiment	   was	   designed	   to	   address	   two	   possible	  
caveats	  with	   the	   interpretation	   of	   the	   results	   obtained	  with	   ced-­‐3(n717).	   First,	   the	   ced-­‐3(ok2734)	  
allele	   corresponds	   to	   a	   large	   deletion	   that	   spans	   the	   caspase	   active	   site	   and	   therefore	   likely	  
represents	  the	  null	  phenotype	  (Fig.	  4.1A).	  In	  contrast,	  the	  ced-­‐3(n717)	  point	  mutation	  perturbs	  the	  
fidelity	  of	  exon	  7	  splicing	  and	  can	  result	  in	  both	  wild-­‐type	  and	  frame-­‐shifted	  versions	  of	  ced-­‐3	  mRNA	  
(Shaham	  et	   al.	   1999).	   Thus,	   ced-­‐3(n717)	  could	   retain	   low	   levels	   of	  wild-­‐type	  or	   neomorphic	  ced-­‐3	  
activity.	  My	  recent	  discovery	  of	  the	  sensitivity	  of	  coq-­‐1	  RNAi	  effect	  to	  different	  genetic	  backgrounds	  
(see	  Appendix	  A)	  also	  emphasizes	  the	  importance	  of	  validating	  the	  role	  of	  ced-­‐3	  by	  using	  a	  genetic	  
mutant	  to	  disable	  CoQ	  biosynthesis.	  Thus,	  I	  used	  the	  coq-­‐2(ok1066)	  mutation	  to	  reduce	  CoQ	  levels	  
in	   this	   experiment.	   In	   contrast	   to	   earlier	   experiments	   with	   ced-­‐3(n717),	   the	   ced-­‐3(ok2734)	   allele	  
reproducibly	   enhanced	   GABA	   neuron	   degeneration	   in	   the	   coq-­‐2(ok1066)	   background.	   This	   new	  
finding	  suggested	  the	  opposite	  role	  for	  CED-­‐3	  as	  a	  negative	  regulator	  of	  CoQ-­‐deficient	  GABA	  neuron	  
degeneration.	  
	   To	  address	  this	  disparity	  I	  also	  constructed	  double	  mutants	  of	  coq-­‐2(ok1066)	  with	  n717	  and	  
two	  additional	  strong	  apoptotic	   loss-­‐of-­‐function	  ced-­‐3	  alleles:	  n2888	   (early	  stop	  codon)	  and	  n2433	  
(missense	  mutation	   in	  the	  caspase	  active	  site)	   (Shaham	  et	  al.	  1999)	  (Fig.	  4.1A).	   In	  this	  experiment,	  
GABA	  neurodegeneration	  was	  significantly	  enhanced	  by	  all	  four	  ced-­‐3	  loss-­‐of-­‐function	  backgrounds,	  
thereby	  supporting	  the	  hypothesis	  that	  CED-­‐3	  adopts	  a	  protective	  role	  in	  GABA	  neurons	  of	  CoQ-­‐	  







	   	  

















Figure	  4.1:	  CED-­‐3	  caspase	  activity	  protects	  GABA	  neurons	  from	  degeneration	  induced	  by	  depletion	  
of	   Coenzyme	   Q.	   A.	   ced-­‐3	   mutants	   used	   in	   this	   study	   with	   protein	   domains:	   CARD	   =	   Caspase	  
Activation	   Recruitment	   Domain.	   s.a.	   =	   splice	   acceptor	  mutant,	   *	   =	   premature	   stop	   codon,	   CED-­‐3	  
active	   site	   =	   QACRG	   (star).	   n2433	   (G360S)	   mutates	   G	   of	   the	   active	   site	   and	   the	   caspase-­‐dead	  
construct	   (C358S)	   changes	   the	   active	   site	   C	   to	   S.	   B.	   GABA	   neuron	   degeneration	   is	   significantly	  
enhanced	  in	  coq-­‐2(ok1066);	  ced-­‐3(ok2734)	  mutants	  versus	  coq-­‐2	  single	  mutants.	  **	  p<0.003	  vs	  coq-­‐
2/Day	   6,	   *	   p<0.02	   vs	   coq-­‐2/Day	   7.	   C.	   GABA	   neuron-­‐specific	   expression	   of	   CED-­‐3	   reduces	   GABA	  
neurodegeneration	   induced	  by	  coq-­‐1	  RNAi	   in	  ced-­‐3(ok2734)	  mutants.	  Caspase-­‐dead	   (C358S)	  ced-­‐3	  
expression	   does	   not	   suppress	   degeneration	   of	  GABA	  neurons.	   All	   strains	   share	   the	   ced-­‐3(ok2734)	  
eri-­‐1(mg366);	   unc-­‐25::GFP(juIs76)	   genetic	   background.	   n>25,	   **	   p<0.002.	   D.	   Multiple	   loss-­‐of-­‐
function	   ced-­‐3	   alleles	   show	   enhanced	   GABA	   neuron	   degeneration.	   **	   p<0.007,	   n>20.	   E.	  Model:	  
Coenzyme	  Q	  deficiency	  triggers	  a	  GABA	  neuron	  degeneration	  pathway	  that	  is	  opposed	  by	  CED-­‐3.	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deficient	   animals	   (Fig.	   4.1E).	   Although	  GABA	   neurodegeneration	  was	   enhanced,	  we	   note	   a	   highly	  
variable	   phenotype	   in	   ced-­‐3(n717);	   coq-­‐2	   double	  mutants.	   This	   range	   of	   neurodegeneration	  may	  
reflect	  the	  dominant-­‐negative	  nature	  of	  the	  n717	  gene	  product	  that	  we	  speculate	  accounts	  for	  the	  
discrepancy	  between	  the	  coq-­‐1	  RNAi	  assay	  and	  these	  new	  findings.	  
	  
Caspase	  activity	  of	  CED-­‐3	  is	  cell	  autonomously	  required	  to	  protect	  GABA	  neurons	  
CED-­‐3	   is	   a	   caspase	   that	   functions	   cell	   autonomously	   to	   promote	   programmed	   cell	   death	  
during	  development	  (Ellis	  &	  Horvitz	  1986;	  Yuan	  &	  Horvitz	  1990;	  Shaham	  &	  Horvitz	  1996b).	  Our	  data	  
indicate	   that	   this	   otherwise	   canonical	   pro-­‐apoptotic	   gene	   adopts	   a	   novel,	   neuroprotective	   role	   in	  
CoQ-­‐deficient	  animals.	  To	  address	  whether	  the	  death-­‐inhibiting	  role	  of	  CED-­‐3	   is	  cell	  autonomous,	  I	  
asked	   if	   GABA	   neuron-­‐specific	   expression	   of	   wild-­‐type	   CED-­‐3	   could	   rescue	   the	   ced-­‐3	   mutant	  
phenotype	  of	  enhanced	  neurodegeneration	  by	  coq-­‐1	  RNAi.	  GABA	  neuron-­‐specific	  restoration	  of	  ced-­‐
3	   significantly	   reduced	   degeneration	   compared	   to	   control	   ced-­‐3(ok2734)	   animals	   (Fig.	   4.1C).	  
Expression	   of	   CED-­‐3	  with	   an	   active	   site	  mutation	   (C358S,	   Fig.	   4.1A)	   did	   not	   reduce	  GABA	   neuron	  
degeneration	  and	  thus	  suggests	  that	  CED-­‐3	  caspase	  activity	   is	  required	  for	   its	  neuroprotective	  role	  
(Fig.	   	   4.1C).	   This	   results	  parallels	  our	   finding	   that	   the	  ced-­‐3(n2433)	  mutant	   (which	  also	   specifically	  
disrupts	   the	   active	   site)	   shows	   enhanced	   neurodegeneration	   in	   coq-­‐1	   RNAi-­‐treated	   animals	   (Fig.	  
4.1B).	   These	   studies	   demonstrate	   that	   CED-­‐3	   proteolytic	   activity	   is	   required	   in	   GABA	   neurons	   to	  
inhibit	  neurodegeneration	  induced	  by	  CoQ	  deficiency.	  
	  
Forced	  CED-­‐3	  activation	  kills	  GABA	  neurons	  through	  apoptosis	  
	   The	  unexpected	  finding	  that	  CED-­‐3	  inhibits	  a	  cell	  death	  pathway	  in	  GABA	  neurons	  raised	  the	  
question	  of	  whether	  CED-­‐3	   is	  capable	  of	  executing	  an	  apoptotic	  program	  in	  this	  cell	   type.	  We	  and	  
others	   have	   shown	   that	   overexpression	   of	   wild-­‐type	   ced-­‐3	   does	   not	   force	   an	   apoptotic	   death	   in	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GABA	  neurons	  (Fig.	  4.1C)	  (Shaham	  &	  Horvitz	  1996b).	  This	  result	  is	  interesting	  because	  ectopic	  ced-­‐3	  
expression	  is	  sufficient	  to	  induce	  apoptosis	  in	  mechanosensory	  neurons	  (Shaham	  &	  Horvitz	  1996b).	  
To	   investigate	   whether	   robust	   levels	   of	   CED-­‐3	   activation	   are	   neuroprotective,	   we	   used	   a	  
reconstituted	  caspase	  system	  to	  force	  CED-­‐3	  activation	  in	  GABA	  neurons	  (Chelur	  &	  Chalfie	  2007).	  In	  
this	   system,	   large	   and	   small	   caspase	   catalytic	   subunits	   are	   attached	   to	   antiparallel	   leucine-­‐zipper	  
domains	  and	  expressed	  independently	  using	  cell-­‐specific	  promoters.	  Presence	  of	  both	  leucine-­‐zipper	  
domains	   in	   a	   cell	   facilitates	   caspase	   activation	   (Fig.	   4.2A).	   In	   this	   experiment,	   expression	   of	  
constitutively	   active	   CED-­‐3	   in	   GABA	   neurons	   induced	   an	   apoptotic	   response	   with	   GABA	   neurons	  
adopting	   a	   compact,	   button-­‐like	   morphology	   (Fig.	   4.2D-­‐F).	   Movement	   was	   also	   impaired,	   with	  
pGABA::rec-­‐ced-­‐3	   transgenic	   animals	   showing	   a	   “shrinker”	  movement	   defect	   (data	   not	   shown),	   a	  
hallmark	  of	  impaired	  GABA	  neuron	  function	  (McIntire,	  Jorgensen	  &	  Horvitz	  1993a).	  	  
The	  forced	  apoptotic	  death	  by	  CED-­‐3	  reconstitution	  indicates	  a	  high	  level	  of	  CED-­‐3	  caspase	  
activity	   is	   sufficient	   to	   kill	   GABA	   neurons.	   This	   striking	   apoptotic	   response	  was	   not	   altered	   under	  
CoQ-­‐deficient	   conditions	   (Fig.	   4.2G).	   This	   finding	   argues	   that	   CoQ	   deficiency	   activates	   CED-­‐3	   by	   a	  
mechanism	  that	  is	   likely	  independent	  of	  the	  pathway	  that	  triggers	  an	  apoptotic	  role	  for	  CED-­‐3	  and	  
that	  despite	   the	  ability	  of	  GABA	  neurons	   to	  die	   through	  CED-­‐3-­‐dependent	  apoptosis,	  Coenzyme	  Q	  
deficiency	  triggers	  an	  alternative	  function	  for	  this	  caspase.	  
	  
Apoptosis	  is	  impaired	  in	  GABA	  neuron	  precursor	  cells	  in	  ced-­‐3	  and	  ced-­‐4	  mutants	  
	   Our	   discovery	   that	   CED-­‐3	   adopts	   alternative	   roles	   in	   apoptotic	   versus	   neurodegenerative	  
pathways	  prompted	  us	  to	  ask	  if	  these	  CED-­‐3	  functions	  are	  unique	  to	  GABA	  neurons.	  To	  address	  this	  
question,	   we	   considered	   the	   fate	   of	   cells	   that	   are	   generated	   as	   RME	   GABA	   neurons	   in	   the	   head	  
region.	   Normally,	   the	   lineal	   sisters	   of	   RME	   L/R	   and	   the	   “aunt”	   of	   RMEV	   GABA	   neurons	   undergo	  
apoptosis	  (Fig.	  4.3A).	  In	  addition	  to	  robust	  D-­‐type	  GABA	  motor	  neuron	  death,	  we	  also	  observe	  RME	  	  







Figure	   4.2:	   Forced	   CED-­‐3	   activation	   kills	   GABA	   neurons	   through	   apoptosis.	   A.	  CED-­‐3	  procaspase	  
(zymogen)	  subunits.	  B.	  Reconstituted-­‐CED-­‐3	  (rec-­‐CED-­‐3)	  has	  two	  components:	  large	  (blue)	  and	  small	  
(red)	  caspase	  subunit	  domains	  are	  attached	  to	  leucine	  zipper	  domains	  (green	  and	  yellow)	  by	  a	  linker	  
(gray).	  C.	   rec-­‐CED-­‐3	   is	   formed	  by	   interaction	  between	   the	  antiparallel	   leucine	  zipper	  domains	   that	  
activates	  CED-­‐3.	  Panels	  A-­‐C	  are	  modified	  from	  Chelur	  et	  al.	  (Chelur	  &	  Chalfie	  2007).	  D.	  DIC	  image	  of	  
a	  button-­‐like	  neuron	   in	  an	  L2	  ced-­‐3(ok2734)	  animal	   that	  expresses	   rec-­‐CED-­‐3	   in	  GABA	  neurons.	  E.	  
Magnified	   inset	   shows	   an	   apoptotic	   neuron	   (yellow	   arrowhead)	   and	   four	   healthy	   neighboring	  
neurons	   (white	   arrows).	   F.	   The	   apoptotic	   neuron	   expresses	   punc-­‐25::GFP	   	   and	   is	   therefore	  
GABAergic.	  G.	   Forced	   CED-­‐3	   activation	   (pGABA::rec-­‐ced-­‐3)	   kills	   GABA	   neurons	   under	   control	   (EV)	  
RNAi	  conditions	  and	  enhances	  degeneration	  with	  coq-­‐1	  RNAi.	  *p<0.08	  versus	  EV	  RNAi	  +	  rec-­‐ced-­‐3,	  
n>20.	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Figure	   4.3:	   ced-­‐3	   alleles	   block	   apoptosis	   in	   GABA	   neuron	   precursor	   cells.	   A.	   Inhibition	   of	   core	  
apoptotic	   machinery	   (i.e.,	   ced-­‐3	   and	   ced-­‐4)	   prevents	   programmed	   cell	   death	   of	   RME	   cells	   in	   the	  
GABAergic	   lineage	  (image	  adapted	  from	  (Frank	  et	  al.	  2005)).	  B.	  Wild-­‐type	  animals	  have	  four	  punc-­‐
25::GFP(+)	   RME	   neurons	   (white	   arrow).	   C.	   ced-­‐3	   mutants	   have	   additional	   RME-­‐like	   neurons	   that	  
often	   migrate	   anteriorly	   (white	   arrowhead).	   Anterior	   up,	   ventral	   right.	   D.	   Extra/undead	   RME	  
neurons	  are	  not	  found	  in	  wild-­‐type	  animals	  but	  are	  prevalent	  in	  ced-­‐4	  and	  ced-­‐3	  mutants.	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GABA	  neurodegeneration	  under	  CoQ-­‐deficient	  conditions	  (Fig.	  2.4,	  Fig.	  5.3).	  I	  determined	  that	  ced-­‐4	  
mutants	  resulted	  in	  ectopic	  RME-­‐like	  GABA	  neurons	  	  (Fig.	  4.3B)	  to	  confirm	  an	  earlier	  report	  that	  the	  
“undead”	  relatives	  of	  RME	  neurons	  can	  adopt	  a	  GABA	  neuron-­‐like	  fate	  (Frank	  et	  al.	  2005)	  (Fig.	  4.3C).	  
This	  result	  also	  verified	  that	  ced-­‐4	  mutations	  that	  perturb	  neurodegeneration	  in	  CoQ-­‐deficient	  GABA	  
neurons	  are	  also	  sufficient	   to	  block	  apoptosis	   in	   these	  cells.	  As	  shown	   in	  Fig.	  4.3,	  ced-­‐3	  mutations	  
that	   enhanced	   degeneration	   of	   CoQ-­‐deficient	   GABA	   neurons	   also	   prevent	   the	   death	   of	   the	   lineal	  
sisters	   of	   RME	   neurons.	   These	   results	   are	   consistent	   with	   a	   model	   in	   which	   the	   core	   apoptotic	  
components,	  CED-­‐3	  and	  CED-­‐4,	  can	  adopt	  alternative	  roles	   in	  GABA	  neurons	  that	  are	  activated	  for	  
degeneration	  by	  deficient	  CoQ	  production.	  
	  
Cholinergic	  neuron	  sensitivity	  to	  CoQ	  depletion	  is	  not	  enhanced	  by	  loss	  of	  CED-­‐3	  
In	  previous	  studies,	  we	  showed	  that	  CoQ	  deficiency	  preferentially	  affects	  the	  GABA	  neurons,	  
with	  other	  neuronal	  subtypes	  and	  body	  wall	  muscle	  showing	   less	  sensitivity	  to	  CoQ	  depletion	  (Fig.	  
2.2,	   Fig.	   2.4,	   Fig.	   2.5)	   (Earls	   et	   al.	   2010).	   Given	   our	   recent	   discovery	   that	   loss	   of	   CED-­‐3	   activity	  
enhances	   GABA	   neuron	   degeneration	   with	   CoQ	   depletion,	   it	   was	   interesting	   to	   consider	   the	  
possibility	  that	  CED-­‐3	  activity	  might	  also	  protect	  other	  classes	  of	  CoQ-­‐deficient	  neurons	  from	  death.	  
To	  address	  this	  question,	   I	  examined	  ventral	  cord	  cholinergic	  neurons	  (DA/DB)	  for	  degeneration	   in	  
coq-­‐1	  RNAi-­‐treated	  ced-­‐3(ok2734)	  mutants.	  However,	   this	  experiment	  did	  not	   result	   in	  detectable	  
loss	   of	   cholinergic	   neurons	   (Fig.	   4.4).	   Thus,	   these	   data	   suggest	   that	   CED-­‐3	   activity	   protects	   GABA	  
neurons	  from	  the	  stress	  caused	  by	  CoQ	  deficiency	  but	  is	  not	  required	  for	  this	  neuroprotective	  role	  in	  










Figure	  4.4:	  Cholinergic	  neurons	  are	  not	  more	  sensitive	  to	  Coenzyme	  Q	  depletion	  in	  ced-­‐3	  mutants.	  
A.	   Adult	   empty	   vector	   (EV,	   control)	   RNAi-­‐treated	   ced-­‐3	   animal	   retains	   the	   full	   complement	   of	  
GABAergic	  or	  Cholinergic	  neurons	  in	  the	  ventral	  nerve	  cord	  (VNC).	  Scale	  bar	  =	  50	  µM.	  B.	  Cholinergic	  
neurons	   (white	   arrowhead)	   and	  GABAergic	   neurons	   (yellow	   arrowhead)	   in	   EV	   RNAi-­‐treated	   ced-­‐3	  
mutants.	  C.	  VNC	  GABA	  neurons	  either	  missing	  (VD3,	  asterisk)	  or	  appear	  swollen	  (DD2,	  yellow	  arrow)	  
in	  coq-­‐1	  RNAi-­‐treated	  ced-­‐3	  mutants	  but	  cholinergic	  motor	  neurons	  (DB3,	  DA2,	  white	  arrowheads)	  
show	   normal	   morphology.	   Scale	   bar	   =	   10	   µM.	   D.	   coq-­‐1	   RNAi-­‐treated	   ced-­‐3	   mutants	   show	   a	  
significant	   reduction	   in	   the	   number	   of	   VNC	   GABAergic	   neurons	   compared	   to	   wild-­‐type	   (WT),	  
whereas	  the	  wild-­‐type	  number	  of	  VNC	  cholinergic	  neurons	  is	  retained.	  EV	  control	  RNAi-­‐treated	  WT	  
and	  ced-­‐3	  mutant	  adults	  do	  not	  have	  missing	  cells	   from	  VD3-­‐VD11	  (13	  D-­‐type	  GABA	  neurons)	  and	  
DB3-­‐DA9	  (13	  DA/DB	  neurons)	  (data	  not	  shown)	  **	  p<0.001	  vs	  WT	  GABA,	  n>20,	  n.s.	  =	  not	  significant.	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ced-­‐4/Apaf-­‐1	  functions	  cell	  autonomously	  and	  is	  epistatic	  ced-­‐3/caspase	  
The	   Apaf-­‐1	   homologue	   ced-­‐4	   functions	   cell-­‐autonomously	   in	   the	   canonical	   apoptotic	  
pathway	   (Shaham	  &	  Horvitz	   1996a).	  We	  previously	   identified	   ced-­‐4	  as	   an	   essential	   component	  of	  
the	  CoQ	  depletion-­‐induced	  GABA	  cell	  death	  pathway	  (Fig.	  2.6)	   (Earls	  et	  al.	  2010).	  With	  coq-­‐1	  RNAi	  
treatment,	   transgenic	   expression	  of	   CED-­‐4	   in	  GABA	  motor	   neurons	   restored	  degeneration	   to	   ced-­‐
4(n1162)	   mutants	   (Fig.	   4.5B).	   Thus,	   ced-­‐4	   functions	   cell-­‐autonomously	   to	   kill	   GABA	   neurons	   in	  
response	  to	  CoQ	  depletion.	  	   	  
To	  address	  the	  genetic	  relationship	  between	  ced-­‐4	  (promotes	  death)	  and	  ced-­‐3	  (antagonizes	  
death),	   I	  performed	  an	  epistasis	  experiment	  by	  examining	  the	  degeneration	  phenotype	  of	  a	  ced-­‐4;	  
ced-­‐3	   double	   mutant	   in	   a	   coq-­‐1(ok749)	   background.	   For	   this	   experiment,	   coq-­‐1(ok749)	  mutants	  
were	  grown	  on	  an	  E.	  coli	  background	  (KO229)	  that	  produces	  CoQ9	  and	  supports	  growth	  to	  the	  adult	  
stage	   for	   scoring	   signs	   of	   GABA	   neurodegeneration	   (see	   Chapter	   3).	   Consistent	   with	   our	   earlier	  
results	   obtained	   using	   coq-­‐2	  mutants	   (Fig.	   4.1B)	   or	   by	   coq-­‐1	  RNAi	   (Fig	   4.1C),	   coq-­‐1(ok749)	   adults	  
show	  enhanced	  degeneration	  in	  a	  ced-­‐3(ok2734)	  background	  compared	  to	  coq-­‐1	  single	  mutants	  (Fig.	  
4.5C).	  This	  experimental	  paradigm	   is	  also	  validated	  by	   the	   finding	   that	  ced-­‐4	   is	   required	   for	  GABA	  
degeneration	  in	  coq-­‐1	  mutants	  as	  previously	  observed	  in	  other	  CoQ-­‐deficient	  conditions	  (coq-­‐1	  RNAi	  
and	  coq-­‐3	  mutants,	  Fig.	  2.6	  (Earls	  et	  al.	  2010)).	  GABA	  neuron	  degeneration	  is	  significantly	  reduced	  in	  
the	  coq-­‐1;	  ced-­‐4;	  ced-­‐3	  triple	  mutant	  (Fig.	  4.5C)	  which	  indicates	  that	  ced-­‐4	  is	  epistatic	  to	  ced-­‐3	  in	  the	  
GABA	   neuron	   death	   pathway	   of	   CoQ-­‐deficient	   animals.	   This	   genetic	   result	   is	   consistent	   with	   a	  
mechanism	  in	  which	  CED-­‐4	  functions	  either	  downstream	  or	  in	  parallel	  to	  CED-­‐3	  (Fig.	  4.7).	  
	  
GABA	  neurons	  adopt	  apoptotic	  or	  necrotic	  features	  in	  coq-­‐1	  mutants	  fed	  KO229	  E.	  coli	  
	   As	   described	   above,	   we	   used	   E.	   coli	   strain	   KO229	   to	   provide	   sufficient	   dietary	   CoQ9	   to	  
sustain	  coq-­‐1(ok749)	  mutant	  animals	  to	  the	  adult	  stage	  for	  scoring	  GABA	  neuron	  death.	  Although	  	  





Figure	  4.5:	  ced-­‐4	  is	  epistatic	  to	  ced-­‐3	  and	  functions	  cell	  autonomously	  to	  kill	  GABA	  neurons.	  	  
A.	  ced-­‐4	  gene	  model	  with	  the	  location	  of	  CARD	  and	  NB-­‐ARC	  domains.	  Yellow	  boxes	  are	  predicted	  P-­‐
loop/ATP-­‐binding	   sequences	   (Zou	   et	   al.	   1997).	   Red	   star	   =	   putative	   CED-­‐3	   cleavage	   sequence	   (89-­‐
DYID-­‐92)	   (Wee	  et	  al.	  2006).	  Mutant	  alleles	  used	   in	  this	  study	  are	   indicated;	  premature	  stop	  codon	  
(*).	  B.	  GABA	  neuron-­‐specific	  expression	  of	  ced-­‐4	  restores	  degeneration	  with	  coq-­‐1	  RNAi.	  Both	  strains	  
share	   the	   ced-­‐4(n1162)	   eri-­‐1(mg366);	   unc-­‐25::GFP(juIs76)	   background.	   **	   p<0.0001,	   n>50.	   C.	  
Neurodegeneration	  in	  the	  coq-­‐1(ok749);	  ced-­‐4(n1162);	  ced-­‐3(ok2734)	  triple	  mutant	  resembles	  that	  
of	   the	   coq-­‐1(ok749);	   ced-­‐4(n1162),	   indicating	   that	   ced-­‐4	   is	   epistatic	   to	   ced-­‐3	   in	   this	   pathway.	  
**p<0.0001	  vs	  coq-­‐1,	  n>40.	  The	  neurodegeneration	  enhancement	  in	  coq-­‐1;	  ced-­‐3	  is	  not	  statistically	  
significant	   from	   coq-­‐1	   in	   this	   instance	   (p<0.06),	   however	   the	   results	   of	   multiple	   independent	  
experiments	  have	  confirmed	  significantly	  enhanced	  cell	  death	  (data	  not	  shown).	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our	   treatment	   resulted	   in	   the	   expected	   complement	   of	   necrotic	   (i.e.,	   swollen)	   GABA	   neurons,	  
growth	   of	   coq-­‐1	  mutants	   on	   KO229	   bacteria	   also	   produced	   a	   significant	   fraction	   (~20%)	   of	   dying	  
GABA	   neurons	   with	   the	   compact	   nuclei	   that	   are	   hallmarks	   of	   apoptotic	   cells	   (Fig.	   4.6).	   This	  
combination	  of	  GABA	  neurons	  with	  either	  necrotic	  or	  apoptotic	  features	  was	  uniquely	  observed	  in	  
CoQ	  biosynthetic	  mutants	  on	  KO229	  E.	   coli;	   coq-­‐1	  RNAi	   and	  growth	  of	   coq-­‐2,	   coq-­‐3	  and	  coq-­‐8	   on	  
OP50	   (normal	   E.	   coli	   diet)	   exclusively	   resulted	   in	   GABA	   neurons	   with	   swollen	   (i.e.,	   necrotic)	   cell	  
bodies	  (Fig.	  2.2,	  Fig.	  3.2).	  The	  reason	  for	  this	  difference	  is	  unclear	  but	  the	  appearance	  of	  apoptotic	  
cells	   in	   coq-­‐1	   mutants	   indicates	   that	   CoQ-­‐deficiency	   can	   trigger	   either	   of	   these	   cell	   death	  
mechanisms.	   In	   this	   experimental	   paradigm,	   both	   types	   of	   cell	   death	   (necrotic	   and	   apoptotic)	  
require	   ced-­‐4	   (Fig.	   4.5C).	   In	   contrast,	   ced-­‐3	   antagonizes	   GABA	   neuron	   death	   by	   either	   of	   these	  
mechanisms.	   Thus,	   the	   apoptotic	   pathway	   that	   is	   induced	   in	   coq-­‐1	  mutants	  must	   differ	   from	   the	  
canonical	  apoptotic	  mechanism	  for	  which	  ced-­‐3	  function	  is	  essential	  (Ellis	  &	  Horvitz	  1986).	  
	  
	  
DISCUSSION	  AND	  FUTURE	  DIRECTIONS	  
The	  work	  presented	  in	  this	  chapter	  describes	  a	  novel,	  neuroprotective	  role	  for	  the	  canonical	  
apoptotic	   caspase	   CED-­‐3	   in	   CoQ-­‐deficient	   GABA	   neurons	   (Fig.	   4.1).	   We	   demonstrate	   that	   CED-­‐3	  
caspase	  activity	  is	  necessary	  for	  this	  function.	  Furthermore,	  our	  results	  show	  that	  CED-­‐3	  antagonizes	  
a	  cell-­‐killing	  pathway	  that	  is	  promoted	  by	  CED-­‐4/Apaf-­‐1	  	  (Fig.	  4.5).	  Our	  genetic	  results	  showing	  that	  
ced-­‐4	   is	  epistatic	  to	  ced-­‐3	   indicate	  that	  CED-­‐4	  functions	  either	  downstream	  or	   in	  parallel	  to	  CED-­‐3.	  
This	  result	  is	  particularly	  striking	  because	  CED-­‐4/Apaf-­‐1	  functions	  upstream	  of	  CED-­‐3/caspase	  in	  the	  
canonical	  apoptotic	  pathway	  (Shaham	  &	  Horvitz	  1996b;	  Shaham	  &	  Horvitz	  1996a).	  Furthermore,	  we	  
noted	   that	   the	  occurrence	  of	  GABA	  neurons	  with	  apoptotic	   features	   in	  coq-­‐1	  mutant	  animals	  was	  
not	  blocked	  by	  genetic	  ablation	  of	  ced-­‐3	  and	  is	  thus	  also	  suggestive	  of	  a	  novel	  apoptotic	  mechanism.	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Figure	  4.6:	  Coenzyme	  Q	  deficiency-­‐induced	  GABA	  neuron	  death	  occurs	  independently	  of	  CED-­‐3.	  	  
A-­‐A’.	   A	  GABA	  neuron	   in	   a	   coq-­‐1(ok749)	  animal	   (green	   arrowhead)	   is	   swollen	   (i.e.,	  necrotic).	  B-­‐B’.	  
Necrotic	  features	  are	  also	  displayed	  in	  a	  GABA	  neuron	  (green	  arrowhead)	   in	  a	  coq-­‐1;	  ced-­‐3	  double	  
mutant.	  C-­‐C’.	  A	  button-­‐like	  apoptotic	  GABA	  neuron	  (yellow	  arrowhead)	   is	  also	  observed	  in	  a	  coq-­‐1	  
mutant.	  D.	   Three	   apoptotic	   GABA	   neurons	   are	   shown	   in	   coq-­‐1;	   ced-­‐3	   double	   mutants	   along	   the	  
ventral	  nerve	   cord	   (white	  arrowhead).	  E-­‐E’.	   Two	  neighboring	  GABA	  neurons	   from	  Panel	  D	   (yellow	  
arrows)	   show	   pronounced	   apoptotic	   morphology.	   F-­‐F’.	   A	   third	   GABA	   neuron	   shows	   rounded,	  
button-­‐like	  morphological	   features	   in	  coq-­‐1;	   ced-­‐3	  double	  mutants	   (yellow	  arrowhead).	  All	   images	  
were	  collected	  from	  animals	  fed	  KO229:pSN18	  (CoQ9-­‐producing)	  E.	  coli.	  pGABA::GFP	  =	  punc-­‐25::GFP.	  
Scale	  bars	  =	  10μM.	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Nonetheless,	   GABA	   neurons	   can	   undergo	   ced-­‐3-­‐dependent	   apoptotic	   death	   in	   other	   contexts,	   for	  
example,	   with	   over-­‐expression	   of	   activated	   CED-­‐3	   or	   during	   neuronal	   development	   (Fig.	   4.2,	   Fig.	  
4.3).	  These	  results	  are	  indicative	  of	  diverse	  mechanisms	  of	  cell	  death	  in	  GABA	  neurons	  and	  suggest	  
that	  CED-­‐3	  can	  adopt	  different	  roles	  in	  these	  distinct	  pathways.	  
	  
Restricted	  CED-­‐3	  activation	  protects	  GABA	  neurons	  from	  CoQ	  depletion-­‐induced	  death	  
Our	   findings	   indicate	   that	   CED-­‐3	  may	   either	   promote	   or	   inhibit	   cell	   killing	   pathways	   in	  C.	  
elegans	   GABAergic	   neurons	   and	   that	   these	   opposite	   roles	   likely	   depend	   on	   mechanisms	   that	  
regulate	  CED-­‐3	  activity.	  We	  showed	  that	  expression	  of	  an	  activated	   form	  of	  CED-­‐3	   induced	  robust	  
apoptosis	  of	  GABA	  neurons.	  In	  contrast,	  transgenic	  expression	  of	  CED-­‐3	  in	  its	  inactive	  zymogen	  form	  
did	  not	  result	  in	  GABA	  neuron	  death	  but	  was	  sufficient	  to	  antagonize	  degeneration	  induced	  by	  CoQ	  
deficiency.	   Regulation	   of	   caspase	   activity	   is	   also	   a	   likely	   determining	   factor	   in	   other	   neuronal	  
contexts	   in	   which	   caspase-­‐dependent	   pathways	   either	   trigger	   apoptosis	   or	   lead	   to	   alternative	  
outcomes	   such	   as	   regeneration	   (Pinan-­‐Lucarre	   et	   al.	   2011)	   or	   dendritic	   pruning	   (Williams	   et	   al.	  
2006).	  	  
	  
CED-­‐3	  and	  CED-­‐4	  adopt	  opposing	  roles	  in	  CoQ-­‐depleted	  GABA	  neurons	  	  
In	   the	   canonical	   apoptotic	   pathway,	   CED-­‐4	   activates	   CED-­‐3	   to	   trigger	   cell	   death	   (Fig.	   1.3).	  
Our	   results	   indicate	   that	   these	   two	   proteins	   (CED-­‐3	   and	   CED-­‐4)	   can	   also	   function	   through	   an	  
alternative	  mechanism	  in	  adult	  GABA	  motor	  neurons	  under	  CoQ-­‐deficient	  conditions.	  In	  this	  setting,	  
CED-­‐3	   antagonizes	   a	   CED-­‐4-­‐dependent	   death	   pathway.	   In	   addition,	   our	   genetic	   epistasis	   results	  
indicate	   that	   CED-­‐4	   functions	   either	   downstream	  or	   in	   parallel	   to	   CED-­‐3.	  Here,	   I	   discuss	   potential	  
mechanisms	  to	  explain	  the	  novel	  roles	  of	  CED-­‐3	  and	  CED-­‐4	  in	  this	  neurodegeneration	  pathway.	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GABA	  neuron	  degeneration	  and	  regeneration	  pathways	  share	  common	  components	  
Recent	  studies	  have	  revealed	  that	  CED-­‐3	  promotes	  regeneration	  of	  axotomized	  GABAergic	  
and	  mechanosensory	  motor	  neurons	   in	  C.	  elegans	   (Pinan-­‐Lucarre	  et	  al.	  2011).	   In	  this	  experimental	  
paradigm,	   CED-­‐3	   function	   is	   cell	   autonomous	   and	   necessary	   for	   efficient	   regrowth	   of	   injured	  
neuronal	  processes.	  Additionally,	  CED-­‐3	  acts	  upstream	  of	  the	  conserved	  regeneration	  kinase	  DLK-­‐1	  
(p38-­‐like	  MAPK	  pathway).	  We	  speculate	  that	  axotomy	  and	  CoQ	  deficiency	  may	  activate	  a	  common	  
set	  of	   stress	   signals	   to	  counteract	   the	  cellular	   injury.	   It	   is	   reasonable	   to	   imagine	   for	  example,	   that	  
CoQ	   deficiency	   triggers	   a	   neurodegeneration	   pathway	   that	   is	   countered	   by	   a	   regeneration	  
mechanism	   that	   depends	   on	   CED-­‐3.	   Thus,	   in	   this	   model,	   a	   loss-­‐of-­‐function	   ced-­‐3	  mutation	   could	  
indirectly	  enhance	  the	  degeneration	  phenotype	  by	  preventing	  a	  regeneration	  response	  to	  mediate	  
the	   injurious	  pathway	   (Fig.	  4.7A).	   Interestingly,	   a	   recent	   review	  of	  proteomics	   literature	   identified	  
many	   common	   pathways	   (involving	   axonal	   transport,	   molecular	   chaperones,	   cytoskeletal	  
components)	  that	  are	  modified	  in	  response	  to	  both	  regeneration	  and	  degeneration	  (F.	  Sun	  &	  Cavalli	  
2010).	  This	  finding	  is	  consistent	  with	  the	  idea	  that	  cellular	  injury	  (CoQ	  depletion	  or	  axotomy)	  could	  
induce	  similar	  responses	  to	  repair	  damaged	  subcellular	  compartments	  (e.g.,	  neurites).	  
The	  possibility	  of	   shared	  mechanisms	   for	   the	  axotomy-­‐induced	   regeneration	  pathway	  and	  
the	  CoQ-­‐deficient	   response	   that	  we	  have	  discovered	   in	  GABA	  neurons	   is	   also	  underscored	  by	   the	  
parallel	  findings	  that	  the	  upstream	  apoptotic	  regulators	  EGL-­‐1	  and	  CED-­‐9	  are	  not	  required	  for	  either	  
mechanism	   (Pinan-­‐Lucarre	   et	   al.	   2011)	   (Fig.	   2.7).	   In	   addition,	   both	   pathways	   require	   the	   calcium-­‐
binding	  chaperone	  protein	  calreticulin	  (CRT-­‐1)	  (Fig.	  2.6)	  and	  are	  thus	  likely	  regulated	  by	  intracellular	  
calcium.	   The	   roles	   of	   CED-­‐4	   in	   these	   pathways	   may	   differ,	   however.	   Whereas	   CED-­‐4	   promotes	  
degeneration	   with	   CoQ	   deficiency,	   CED-­‐4	   function	   is	   required	   for	   efficient	   regeneration	   of	   GABA	  
neurons	  injured	  by	  axotomy.	  Perhaps	  CoQ	  deficiency	  triggers	  a	  degeneration	  response	  that	  is	  not	  	  
	  









Figure	  4.7:	  Proposed	  models	  to	  explain	  epistatic	  interactions	  between	  ced-­‐3	  and	  ced-­‐4.	  A.	  Model	  
1:	  Reduced	  CoQ	  levels	  triggers	  parallel	  pathways	  in	  GABA	  neurons.	  A	  CED-­‐3-­‐dependent	  mechanism	  
is	   activated	   to	   repair	   the	   damage	   caused	   by	   CoQ	   deficiency	   and	   a	   CED-­‐4-­‐dependent	   pathway	  
promotes	   GABA	   neuron	   cell	   death.	   In	   the	   absence	   of	   both	   ced-­‐4	   and	   ced-­‐3	   function,	   the	   CoQ-­‐
deficiency	  pathway	  is	  blocked	  and	  thus	  accounts	  for	  GABA	  neuron	  survival	  in	  the	  coq-­‐1;	  ced-­‐3;	  ced-­‐4	  
triple	  mutant.	  B.	  Model	  2A:	  CoQ	  deficiency	  activates	  CED-­‐4	  in	  a	  GABA	  neuron	  degeneration	  pathway	  
that	  is	  antagonized	  by	  CED-­‐3.	  A	  ced-­‐3	  mutation	  enhances	  degeneration	  but	  this	  effect	  is	  blocked	  by	  
mutations	   that	   disable	   ced-­‐4.	   C.	  Model	   2B:	   CED-­‐4	   is	   activated	   in	   response	   to	   CoQ	   depletion	   and	  
subsequently	   activates	   both	   CED-­‐3	   and	   other	   unknown	   death-­‐promoting	   factors.	   Activated	   CED-­‐
3/caspase	  provides	  feedback	  inhibition	  of	  CED-­‐4,	  perhaps	  through	  proteolytic	  cleavage/inactivation.	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activated	  by	  axotomy.	   In	  this	  scenario,	  CED-­‐4	  could	  function	   in	  both	  of	  these	  competing	  pathways	  
(degeneration	  and	  regeneration)	  such	  that	  CoQ-­‐deficient	  GABA	  neurons	  show	  net	  degeneration.	  
To	   test	  whether	  CED-­‐3	   functions	   to	  promote	   regeneration	   in	  parallel	   to	  CED-­‐4	   (Fig.	   4.7A),	  
members	  of	  the	  core	  GABA	  neuron	  regeneration	  pathway	  (e.g.,	  dlk-­‐1)	  could	  be	  knocked	  out	  in	  CoQ	  
mutants	   to	   determine	   if	   their	   absence	   phenocopies	   the	   enhanced	   degeneration	   seen	   in	   ced-­‐3	  
mutants.	   Overexpression	   of	   regeneration	   proteins	   such	   as	   DLK-­‐1/MAPKKK	   in	   GABA	   neurons	  
accelerates	  axonal	  regeneration	  (Hammarlund	  et	  al.	  2009)	  and	  it	  would	  be	  interesting	  to	  determine	  
whether	   overexpression	   of	   this	  MAP	   kinase	   signaling	   cascade	  was	   neuroprotective	   following	   CoQ	  
depletion.	  
The	   idea	   that	   CED-­‐3	   and	   CED-­‐4	   could	   function	   in	   parallel	   pathways	   as	   noted	   above	   is	  
consistent	  with	  our	  genetic	  epistasis	  results	  (i.e.,	  ced-­‐4	  is	  epistatic	  to	  ced-­‐3).	  This	  genetic	  interaction	  
could	  also	  be	  explained	  by	  an	  alternative	  mechanism	  in	  which	  CED-­‐4	  functions	  downstream	  of	  CED-­‐3	  
(Fig.	   4.7B).	   However,	   the	   order	   of	   action	   of	   these	   gene	   products	   is	   reversed	   in	   the	   canonical	  
apoptotic	   pathway	   (where	   CED-­‐4	   functions	   upstream	   of	   CED-­‐3).	   In	   this	   instance	   (under	   CoQ-­‐
deficient	  conditions),	  CED-­‐4	  is	  downstream	  of	  CED-­‐3.	  Recent	  evidence	  from	  other	  organisms	  points	  
to	  a	  potential	  mechanism	  whereby	  CED-­‐3	  could	  function	  to	  inactivate	  CED-­‐4.	  
	  
Mechanisms	  of	  caspase-­‐dependent	  proteolysis	  of	  Apaf-­‐1	  are	  conserved	  
Apaf-­‐1	   is	   proteolytically	   cleaved	   and	   inactivated	   by	   caspase-­‐3	   following	   apoptotic	  
stimulation	   in	   human	   cell	   culture	   and	   in	   vitro	   (Bratton	   et	   al.	   2001;	   Lauber	   2001).	   Similarly,	  
Drosophila	   homologue	   of	   CED-­‐4	   (Dark)	   is	   also	   cleaved	   by	   caspases	   (Akdemir	   2006).	   Apaf-­‐1	   is	  
inactivated	  by	  cleavage	  at	  a	  site	  near	  the	  N-­‐terminus	  that	  removes	  the	  CARD	  domain	  (Bratton	  et	  al.	  
2001;	  Lauber	  2001).	  In	  considering	  this	  mechanism,	  I	  have	  identified	  a	  putative	  CED-­‐3	  cleavage	  site	  
(89-­‐DYID-­‐92)	   between	   the	  N-­‐terminal	   CARD	   domain	   and	   the	   C-­‐terminal	  NB-­‐ARC	   domain	   of	   CED-­‐4	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(Fig.	  4.5A).	  This	  DYID	  site	  matches	  the	  CED-­‐3	  consensus	  cleavage	  site	  of	  DXXD	  and	  is	  the	  only	  such	  
site	  in	  the	  CED-­‐4	  protein	  sequence.	  The	  existence	  of	  this	  candidate	  CED-­‐3	  cleavage	  site	  is	  consistent	  
with	   a	   model	   in	   which	   CED-­‐3	   antagonizes	   CED-­‐4-­‐dependent	   neurodegeneration	   by	   proteolytic	  
inactivation	  of	  CED-­‐4	  function	  (Fig.	  4.7B).	  
One	  curious	  feature	  of	  a	  model	  in	  which	  CED-­‐3	  functions	  upstream	  of	  CED-­‐4	  is	  that	  it	  does	  
not	  explain	  how	  CED-­‐3	  becomes	  activated.	  The	  developmental	  apoptotic	  pathway	  relies	  on	  CED-­‐4	  to	  
activate	  CED-­‐3	  (Shaham	  &	  Horvitz	  1996b;	  Shaham	  &	  Horvitz	  1996a).	  A	  more	  complex	  model	  of	  how	  
CED-­‐4	   functions	   downstream	   of	   CED-­‐3	   could	   involve	   CED-­‐4	   (promotes	   death)	   activating	   CED-­‐3	  
(prevents	   death)	   through	   a	   canonical	  mechanism	   (similar	   to	   CED-­‐3	   activation	  during	   programmed	  
cell	  death)	   (Fig.	  4.7C).	  Unlike	  apoptosis,	  however,	  activated	  CED-­‐3	  does	  not	  promote	  an	  apoptotic	  
response	  but	  could	  instead	  inactivate	  CED-­‐4.	  Under	  this	  paradigm,	  CED-­‐3	  activation	  elicits	  a	  negative	  
feedback	  perhaps	  by	  directly	  cleaving	  and	  inactivating	  CED-­‐4.	  This	  model	  would	  explain	  how	  loss	  of	  
CED-­‐3	  enhances	  degeneration	  due	  to	  the	  absence	  of	  CED-­‐4	  inhibition,	  and	  without	  CED-­‐4	  there	  is	  no	  
degeneration	  which	   aligns	  with	  our	   ced-­‐4	  and	   ced-­‐4;	   ced-­‐3	  double	  mutant	   analysis.	   Currently,	  we	  
have	   a	   basic	   understanding	   of	   the	   interplay	   between	   CED-­‐3	   and	   CED-­‐4,	   where	   CED-­‐4	   is	   either	   in	  
parallel	   or	   downstream	  of	   CED-­‐3.	   Future	   experiments	   should	   be	   designed	   to	   distinguish	   between	  
these	  models	  and	   to	  provide	  a	  clearer	  understanding	  of	  how	  these	  canonical	  apoptotic	   regulators	  
function	  antagonistically	  in	  adult	  GABA	  neurons.	  	  
To	   investigate	   the	  possibility	   that	  CED-­‐3	   cleaves	  CED-­‐4,	  biochemical	   experiments	   could	  be	  
used	   to	   determine	   if	   CED-­‐3	   cleaves	   CED-­‐4	   at	   the	   proposed	   DYID	   site.	   Furthermore,	   mutagenesis	  
strategies	  could	  also	  be	  used	  to	  disrupt	  the	  putative	  DYID	  sequence	  of	  CED-­‐4;	  aspartate-­‐to-­‐alanine	  
mutations	   in	  caspase-­‐recognition	  sites	  abrogate	  caspase-­‐dependent	  cleavage	  (Ditzel	  et	  al.	  2003).	   If	  
CED-­‐3	   cleaves	   at	   this	   site	   to	   inhibit	   CED-­‐4	   in	   vivo,	   then	   expression	   of	   this	  mutant	   form	   of	   CED-­‐4	  
(DYIA)	   could	   potentially	   enhance	   degeneration	   with	   CoQ	   deficiency	   due	   to	   elimination	   of	   the	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damping	  effect	  of	  CED-­‐3-­‐dependent	  cleavage	  of	  CED-­‐4.	  In	  fact,	  transgenic	  expression	  of	  CED-­‐4(DYIA)	  
in	  the	  GABA	  neurons	   is	  predicted	  to	  phenocopy	  the	  enhanced	  neurodegenerative	  effects	  of	  CED-­‐3	  
since	   CED-­‐4	   is	   not	   cleaved	   by	   CED-­‐3.	   These	   experiments	   will	   begin	   to	   distinguish	   between	   our	  
proposed	  models	  (Fig.	  4.7)	  and	  provide	  insight	  into	  the	  antagonistic	  relationship	  between	  CED-­‐3	  and	  
CED-­‐4	  during	  CoQ	  deficiency-­‐induced	  death.	  
	  
A	  novel	  mechanism	  for	  CED-­‐4	  activation	  and	  execution	  of	  necrotic-­‐like	  death	  
Based	  on	  our	  analysis,	  CED-­‐4	  promotes	  GABA	  neuron	  death	  without	  requiring	  its	  canonical	  
downstream	   caspase	   CED-­‐3.	   Another	   CED-­‐4-­‐dependent/CED-­‐3-­‐independent	   apoptotic	   mechanism	  
has	   been	   reported	   (Bloss	   et	   al.	   2003),	   but	   currently	   no	   downstream	   components	   of	   this	   pathway	  
have	  been	   identified.	   In	  addition	  to	  the	  novelty	  of	  CED-­‐4	  regulating	  a	  necrotic-­‐like	  death	  pathway,	  
our	   results	   also	   introduce	   the	   intriguing	   question	   of	   how	   CED-­‐4	   could	   promote	   cell	   death	   in	   the	  
absence	   of	   a	   downstream	   “killing”	   role	   for	   CED-­‐3.	   An	   additional	   caspase	   CSP-­‐1	   has	   recently	   been	  
assigned	   to	  a	  death-­‐promoting	   role	   in	  C.	  elegans	   (Denning	  et	  al.	  2013).	   In	   this	  pathway,	  however,	  
CSP-­‐1	  is	  maternally	  provided	  to	  kill	  a	  subset	  of	  embryonic	  cells	   in	  a	  pathway	  that	  does	  not	  require	  
CED-­‐4	  for	  activation.	  Perhaps	  CoQ	  depletion	  induces	  CSP-­‐1	  expression	  in	  GABA	  neurons	  where	  it	  is	  
activated	  by	  CED-­‐4.	   Future	  experiments	   to	   investigate	  whether	   this	   additional	   caspase	   is	   required	  
for	   GABA	   neurodegeneration	   in	   coq-­‐1	   mutants	   using	   a	   csp-­‐1	   loss-­‐of-­‐function	   background	   will	  
determine	  whether	  CED-­‐4	  potentially	  activates	  another	  caspase	  or	  whether	  novel	  death	  proteins	  are	  
employed.	  Denning	  et	  al.	  (2013)	  also	  identify	  examples	  of	  apoptosis	  that	  are	  independent	  of	  caspase	  
function	   which	   suggests	   that	   cell	   death	   can	   be	   executed	   by	   alternative	   downstream	   effectors	  
(Denning	  et	  al.	  2013).	  
Our	  work	   in	  Chapter	   2	  used	  coq-­‐1	  RNAi	   to	  demonstrate	   that	  ced-­‐4	   is	  activated	  by	  a	  novel	  
mechanism.	   In	   these	  experiments,	  mutations	   in	   the	  canonical	  upstream	  regulators	  of	  ced-­‐4	   (ced-­‐9	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and	  egl-­‐1)	  did	  not	  perturb	  degeneration	  of	  CoQ-­‐deficient	  GABA	  neurons	  (Fig.	  2.7).	  However,	  given	  
my	   recent	  discovery	   that	  RNAi	  efficacy	  varies	  with	  genotype	   (see	  Appendix	  A),	  more	  experiments	  
should	   be	   replicated	   in	   a	   genetic	   model	   of	   CoQ	   deficiency	   (e.g.,	   coq-­‐1	   mutant).	   Since	   all	   CoQ	  
depletion-­‐induced	  GABA	  neuron	  deaths	  (apoptotic	  or	  necrotic)	  are	  promoted	  by	  CED-­‐4	  and	  inhibited	  
by	   CED-­‐3	   it	   seems	   likely	   that	   our	   experiments	   with	   a	   coq-­‐1	  mutant	   will	   confirm	   earlier	   results	  
obtained	  with	  coq-­‐1	  RNAi.	  In	  that	  event,	  future	  experiments	  could	  pursue	  the	  important	  question	  of	  
how	  CED-­‐4	  is	  activated	  in	  this	  neurodegeneration	  pathway.	  
CED-­‐9-­‐independent	   activation	   of	   CED-­‐4	   has	   been	   observed	   with	   neuronal	   regeneration	  
(Pinan-­‐Lucarre	   et	   al.	   2011)	   and	   hypoxic	   conditioning	   (Dasgupta	   et	   al.	   2007);	   however	   neither	   of	  
these	   studies	   identified	   upstream	   regulators	   of	   CED-­‐4.	   Recently,	   a	   member	   of	   the	   Adenine	  
Nucleotide	  Translocator	   (ANT)	   family	  of	  mitochondrial	  proteins	   (wan-­‐1)	  was	  reported	  to	  physically	  
interact	  with	  CED-­‐4	  and	  promote	  apoptosis	   in	  C.	  elegans	  (Q.	  Shen	  et	  al.	  2009).	  ANT	  is	  a	  conserved	  
mitochondrial	  protein	  that	  exchanges	  cytosolic	  ADP	  with	  mitochondrial	  ATP.	  As	  discussed	  in	  Chapter	  
1,	  ANT	  is	  also	  a	  key	  component	  of	  the	  mitochondrial	  permeability	  transition	  pore	  (PTP)	  complex	  that	  
releases	  death-­‐inducing	  factors	  from	  the	  mitochondria	  to	  promote	  cell	  death	  in	  mammals	  (Galluzzi	  
et	  al.	  2010).	  It	  is	  therefore	  reasonable	  to	  speculate	  that	  ANT	  is	  also	  required	  for	  CED-­‐4	  activation	  in	  
CoQ-­‐deficient	  GABA	   neurons.	   Knockout	   of	   ANT	   family	  members	   (wan-­‐1,	  wan-­‐2,	  wan-­‐3,	  wan-­‐4)	   in	  
CoQ	  mutant	  backgrounds	  would	  provide	  a	  genetic	  way	  to	  test	  this	  hypothesis	  (further	  discussed	  in	  
Chapter	  6).	  	  
	  
Apoptotic	  and	  necrotic	  death	  of	  CoQ-­‐deficient	  GABA	  neurons	  occurs	  independently	  of	  CED-­‐3	  	  
Our	   studies	   in	  Chapter	   3	   are	   suggestive	   of	   a	  model	   in	   which	   GABA	   neuron	   degeneration	  
requires	  a	  minimum	  threshold	  of	  CoQ	  function	  that	  is	  sufficient	  to	  maintain	  overall	  animal	  viability	  
but	  which	  is	  not	  adequate	  to	  prevent	  GABA	  neuron	  death	  (Fig.	  3.9).	  We	  have	  also	  observed	  that	  CoQ	  
	   137	  
deficiency	   can	   result	   in	   GABA	   neurons	   adopting	   the	   characteristic	   features	   of	   either	   apoptotic	   or	  
necrotic	  cells	  (Fig.	  4.6).	  Although	  the	  exact	  mechanisms	  that	  distinguish	  between	  these	  alternative	  
outcomes	  are	  not	  known,	   this	  observation	   that	  both	  do	  occur	   suggest	   that	   stress	   signals	   resulting	  
from	  CoQ	  deficiency	  can	  activate	  either	  necrotic	  or	  apoptotic	  killing	  pathways.	  
It	   was	   recently	   discovered	   that	   expression	   of	   HBx	   (Hepatitis	   B	   virus	   protein	   X)	   triggers	  
apoptotic	   and	   necrotic	   death	   in	  C.	   elegans	  and	   that	   CED-­‐9/Bcl-­‐2	   is	   an	   essential	   regulator	   of	   both	  
death	   pathways	   (Geng	   et	   al.	   2012).	   Interestingly,	   the	   mechanism	   by	   which	   CED-­‐9	   promotes	  
apoptosis	  (canonical	  release	  of	  CED-­‐4	  and	  CED-­‐3	  activation)	  is	  distinct	  from	  its	  activation	  of	  necrosis,	  
which	  occurs	  through	  mitochondrial	  permeability	  transition	  (MPT)-­‐dependent	  calcium	  increase.	  Our	  
data	   indicate	   that	   CoQ	   deficiency	   can	   also	   stimulate	   two	   morphologically	   distinct	   modes	   of	   cell	  
death	   in	   GABA	   neurons	   that	   are	   both	   promoted	   by	   CED-­‐4/Apaf-­‐1	   and	   antagonized	   by	   CED-­‐
3/caspase.	   Thus,	   our	   findings	   place	   CED-­‐4	   at	   a	   key	   nexus	   where	   it	   responds	   to	   cellular	   injury	   to	  
promote	  alternative	  cell	  death	  mechanisms.	  
	   	  
	   138	  
CHAPTER	  V	  
GENETIC	  AND	  ULTRASTRUCTURAL	  ANALYSIS	  OF	  A	  NECROTIC	  DEATH	  PATHWAY	  	  
ACTIVATED	  IN	  COENZYME	  Q-­‐DEFICIENT	  MOTOR	  NEURONS	  
	  
INTRODUCTION	  
Coenzyme	  Q	  is	  an	  essential	  component	  of	  the	  mitochondrial	  electron	  transport	  chain	  (ETC)	  
(Fig.	  1.2)	  and	  ETC	  dysfunction	  is	  linked	  to	  cellular	  stresses	  such	  as	  increased	  reactive	  oxygen	  species	  
(ROS)	  and	  depletion	  of	  cellular	  ATP	  levels	  (Petrozzi	  et	  al.	  2007).	  Both	  of	  these	  insults	  are	  known	  to	  
trigger	  apoptotic	  (Kasahara	  et	  al.	  1997)	  and	  necrotic	  cell	  death	  pathways	  (Zong	  &	  Thompson	  2006).	  
As	  discussed	  in	  Chapter	  1,	  neurodegenerative	  disease	  is	  correlated	  with	  impaired	  electron	  transport	  
chain	   function	   (Fig.	   1.1);	   additionally,	  we	   have	   shown	   that	   global	   ATP	   levels	   are	   reduced	   in	   CoQ-­‐
deficient	  animals	  (Fig.	  2.10).	  However,	  Coenzyme	  Q	  may	  also	  exercise	  roles	  that	  are	  independent	  of	  
ETC	   function	   (discussed	   in	   Chapter	   1)	   and	   thus	   could	   support	   GABA	   neuron	   viability	   through	  
mechanisms	  that	  do	  not	  involve	  the	  electron	  transport	  chain.	  
My	  work	  is	  focused	  on	  understanding	  the	  mechanism	  whereby	  CoQ	  depletion	  triggers	  GABA	  
neuron	  degeneration.	  My	  findings	   indicate	  that	  GABA	  neuron	  death	   in	  this	  experimental	  paradigm	  
depends	   on	   the	   canonical	   apoptotic	   genes	   that	   appear	   to	   act	   through	   novel	   mechanisms	   (see	  
Chapter	   4).	   Coenzyme	   Q	   deficiency	   models	   in	   Drosophila	   and	   zebrafish	   detect	   elevated	   caspase	  
activity	   in	  animals	  with	  reduced	  Coenzyme	  Q	  production	   (Heeringa	  et	  al.	  2011;	  Grant	  et	  al.	  2010).	  
Other	   studies	   have	   presented	   evidence	   that	   Coenzyme	   Q	   prevents	   apoptosis	   by	   inhibiting	  
mitochondrial	   permeability	   pore	   opening	   (Papucci	   et	   al.	   2003).	   Although	   my	   results	   have	   also	  
detected	   roles	   for	   apoptotic	   genes	   in	   our	  C.	   elegans	  model	   of	   CoQ	  deficiency,	   the	   affected	  GABA	  
neurons	  show	  the	  swollen	  morphology	  of	  necrotic	  cell	  death	  (Fig.	  2.2,	  Fig.	  3.2).	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It	   is	   currently	  unclear	  whether	  CED-­‐4/Apaf-­‐1	   regulates	   a	   strictly	  necrotic	  death	  or	   if	   dying	  
neurons	   share	   features	   of	   both	   apoptosis	   and	   necrosis.	   Ultrastructural	   analysis	   is	   often	   used	   to	  
distinguish	  between	  these	  two	  cell	  death	  pathways	  (Table	  5.5)	  (Zong	  &	  Thompson	  2006;	  Kerr	  et	  al.	  
1972)	   and	   transmission	   electron	  microscopy	   (TEM)	   has	   also	   identified	   cells	   that	   share	   features	   of	  
both	  pathways	   (Formigli	  et	  al.	  2000).	   I	   therefore	  examined	  ultrastructural	   features	  of	  dying	  motor	  
neurons	  to	  better	  understand	  how	  apoptotic	  proteins	  regulate	  necrotic-­‐like	  death.	  
Like	   apoptosis,	   necrosis	   also	   activates	   distinct	   proteases	   that	   are	   responsible	   for	   cellular	  
demise.	   The	   most	   well-­‐studied	   necrosis	   paradigm	   in	   C.	   elegans	   results	   from	   overactivation	   of	  
neuronal	  ion	  channels	  where	  an	  influx	  of	  cations	  causes	  cell	  swelling	  and	  ultimately	  necrotic	  death	  
(Syntichaki	  et	  al.	  2002).	  Necrosis	  depends	  on	  multiple	  proteases	  including	  two	  calpains	  TRA-­‐3	  &	  CLP-­‐
1	   that	   act	   in	   parallel	   and	   also	   upstream	   of	   two	   aspartyl	   proteases	   ASP-­‐3	   and	   ASP-­‐4	   (Fig.	   1.4).	  
Canonical	   apoptotic	   regulators	   (CED-­‐3,	  CED-­‐4,	   etc)	   (Fig.	   1.3)	   are	  not	   required	   for	   this	   necrotic-­‐like	  
death,	   indicating	   that	   this	   pathway	   is	  molecularly	   distinct	   from	  programmed	   cell	   death.	   Based	  on	  
our	   observation	   that	   GABA	   neurons	   swell	   under	   CoQ-­‐deficient	   conditions,	   I	   hypothesized	   that	  
components	   of	   the	   necrotic	   pathway	   (Fig.	   1.4)	   were	   also	   likely	   components	   of	   this	   cell	   killing	  
machinery.	   Here,	   I	   report	   that	   additional	   proteases	   adopt	   both	   predicted	   and	   novel	   roles	   in	   the	  
GABA	  neurodegeneration	  pathway.	  	  
Work	   in	   this	   chapter	   seeks	   to	   better	   understand	   how	   Coenzyme	   Q	   deficiency	   kills	   GABA	  
neurons	  by	  addressing	  key	  questions:	  How	  is	  cell	  death	  triggered?	  What	  proteases	  are	  required	  to	  
kill	  CoQ-­‐deficient	  neurons?	  What	  type	  of	  death	  occurs	  in	  GABA	  neurons?	  What	  might	  prevent	  other	  
cells	  from	  degenerating?	  My	  studies	  reveal	  that	  initiation	  of	  the	  GABA	  neurodegeneration	  pathway	  
by	   CoQ	   depletion	   is	   not	   solely	   a	   result	   of	   ETC	   dysfunction.	   This	   work	   also	   identifies	   necrotic	  
proteases	  that	  regulate	  GABA	  neuron	  death.	  Finally,	  ultrastructural	  analysis	  of	  CoQ-­‐deficient	  motor	  
neurons	  reveals	  physical	  traits	  that	  are	  characteristic	  of	  necrosis.	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MATERIALS	  AND	  METHODS	  
Nematode	  Strains	  and	  Genetics	  
Nematodes	   were	   maintained	   as	   previously	   described	   (Brenner	   1974).	   Mutant	   alleles	   and	  
genotyping	  primers	  are	  listed	  in	  Table	  5.1.	  Strains	  used	  in	  this	  study	  are	  in	  Table	  5.2.	  
	  
Molecular	  biology	  
cDNA	  and	  unc-­‐25	  RNAi	  generation	  were	  previously	  described	  in	  Chapter	  3.	  
	  
Verifying	  RNAi	  clones	  
RNAi	  clones	  (all	  derived	  from	  the	  pL4440	  vector)	  were	  sequenced	  using	  M13F21.	  The	  asp-­‐
3/H22K11.1	  RNAi	  clone	  in	  the	  Ahringer	   library	   is	   listed	  under	  X-­‐3H21;	  however	  the	  sequence	  of	   its	  
bacterial	  clone	  aligns	  with	  a	  neighboring	  gene	  H22K11.2.	  The	  nuo-­‐2	  RNAi	  clone	  from	  I-­‐3M05	  is	  also	  
mislabeled,	   as	   it	   corresponds	   to	   a	   neighboring	   gene	   T0E9.6.	   The	   following	   Ahringer	   library	   RNAi	  
clones	  are	  correctly	  annotated	  were	  verified	  by	  sequencing:	  D2030.4,	  cyc-­‐1,	  F26E4.6,	  atp-­‐3,	  mev-­‐1,	  
gas-­‐1,	  tra-­‐3.	  	  
	  
RNAi	  
Feeding	  RNAi	  plates	  were	  made	  as	  described	  in	  Chapter	  2	  –	  Materials	  and	  Methods.	  
	  
Movement	  assay	  
Adult	  animals	  on	  Day	  6	  of	  the	  RNAi	  experiment	  were	  tapped	  once	  or	  twice	  on	  the	  head	  and	  
backward	  movement	  was	   scored	   as	   follows:	   “WT”	   (wild-­‐type)	   =	  moves	   2+	   body	   bends	   backward,	  
“Unc”	   =	   only	   moves	   1	   body	   bend	   backward,	   “Very	   Unc”	   =	   cannot	   move	   backward	   but	   does	   not	  
shrink,	  “Shrinker”	  =	  shrinks	  when	  touched	  on	  the	  head.	  n>50	  unless	  there	  were	  not	  enough	  adults	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Table	  5.1.	  Mutant	  alleles	  and	  transgenes	  used	  in	  this	  chapter.	  
	  
Allele	   Source	   Genotyping	  Primers	   Reference	  
asp-­‐4(ok2693)	   CGC	   GCAACCAGTGAACCAGGAAT	   (Geng	  et	  al.	  2012)	  
ATCTGTTGCTTAGTGGCGCT	  
clp-­‐1(tm858)	   NBRP	   AAAAAAGGAAACGAGACATGGCG	   (Bano	  et	  al.	  2009)	  
ATGCATATAGAGAAGCTCGCCG	  
eri-­‐1(mg366)	  IV	   CGC	   CATGCAATTTCAATGCCTTTTA	   (Kennedy	  et	  al.	  
2004)	  TGCATCATCCAATCCACTATGT	  
gas-­‐1(fc21)	  X	   CGC	   TTTTTCTGGATGTTCGAGGG	   (Kayser	  et	  al.	  
1999)	  TCTTGTTGAGGCACTGATGC	  
mev-­‐1(kn1)	  III	   CGC	   CACTCGCCAAGGATAAAAGG	   (Ishii	  et	  al.	  1998)	  
ATGGCGAGAGCAAGAATAGC	  




Transgene	   Source	   Array	   Reference	  
hT2	  (I;III)	   CGC	   bli-­‐4(e937)	  let(q782)	  qIs48	   (McKim	  et	  al.	  
1993)	  
juIs76	  II	   CGC	   punc-­‐25::GFP,	  lin-­‐15(+)	   (Jin	  et	  al.	  1999)	  




wpIs36	  I	   Marc	  
Hammarlund	  
punc-­‐47::mCherry	   Unpublished	  





wpIs39	  X	   Marc	  
Hammarlund	  
punc-­‐47::mCherry	   Unpublished	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Table	  5.2.	  Strains	  generated	  for	  use	  in	  this	  study.	  
Strain	  	   Genotype	  
NC1140	   juIs76	  [punc-­‐25::GFP,	  lin-­‐15(+)]	  II;	  
NC1405	   juIs76	  [punc-­‐25::GFP,	  lin-­‐15(+)]	  II;	  eri-­‐1	  (mg366)	  IV	  
NC1798	   juIs76	  [punc-­‐25::GFP,	  lin-­‐15(+)]	  II;	  tra-­‐3	  (ok2207)	  eri-­‐1(mg366)IV	  
NC1799	   juIs76	  [punc-­‐25::GFP,	  lin-­‐15(+)]	  II;	  clp-­‐1(tm858)	  III;	  eri-­‐1(mg366)IV	  
NC1834	   juIs76	  [punc-­‐25::GFP,	  lin-­‐15(+)]	  II;	  clp-­‐1(tm858)	  III;	  tra-­‐3	  (ok2207)	  eri-­‐1(mg366)IV	  
NC2811	   juIs76	  [punc-­‐25::GFP,	  lin-­‐15(+)]	  II;	  coq-­‐2(ok1066)/hT2	  (I;	  III);	  tra-­‐3	  (ok2207)	  IV	  
NC1959	   juIs76	  [punc-­‐25::GFP,	  lin-­‐15(+)]	  II;	  coq-­‐2(ok1066)/hT2	  (I;	  III)	  
XE1375	   lin-­‐15(n744)	   X	   ;	   eri-­‐1(mg366)	   IV	   ;	   rde-­‐1(ne219)	   V	   ;	   wpSi1[Punc-­‐47::rde-­‐1:SL2:sid-­‐1,	  
Cbunc-­‐119(+)]	  II	  ;	  wpIs36[Punc-­‐47::mCherry]	  I	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on	   the	   plate	   (*).	   For	   all	   movement	   and	   degeneration	   assays,	   the	   experimenter	   was	   blinded	   to	  
genotype	  to	  avoid	  bias.	  
	  
GABA	  neurodegeneration	  assays	  	  
ETC	  RNAi	  
At	   least	  15	  adults	  were	  examined	  for	  breaks	   in	  VNC	  GABAergic	  processes.	  Apoptotic	  GABA	  
neurons	  were	  photographed	  at	  63x	  on	  a	  Zeiss	  Axioplan	  compound	  microscope.	  
	  
RME	  Degeneration	  Assay	  
RME	  degeneration	  was	   scored	  on	  a	  Zeiss	  Axioplan	  compound	  microscope	  by	  counting	   the	  
number	  of	  punc-­‐25::GFP-­‐positive	  neurons	   in	  the	  head	  of	  the	  synchronized	  animals	  at	  Day	  7	  (i.e.,	  7	  
days	  after	  hatching).	  Wild-­‐type	  (WT)	  animals	  have	  four	  RME	  neurons	  (Fig.	  1.7).	  	  
	  
D-­‐Type	  Neuron	  Degeneration	  Assay	  
Degeneration	  of	  the	  D-­‐Type	  GABA	  neurons	  was	  quantified	  by	  counting	  the	  number	  of	  punc-­‐
25::GFP-­‐positive	  neurons	  along	  the	  ventral	  nerve	  cord	  (VNC)	  of	  synchronized	  animals	  at	  Day	  7.	  WT	  
animals	  have	  19	  D-­‐Type	  GABA	  neurons	  (Fig.	  1.7).	  	  
	  
Microscopy	  
A	   Zeiss	   Axioplan	   compound	   microscope	   with	   a	   100x	   objective	   was	   used	   to	   capture	   the	  
images	   in	   Figure	   5.1.	   The	   representative	   images	   collected	   for	   Figure	   5.2	   and	   Figure	   5.3	   were	  
obtained	  on	  a	   Leica	  TCS-­‐SP5	  confocal	  microscope	  with	  a	  40x	  objective	  using	   the	  Leica	  Application	  
Suite	  Advanced	  Fluorescence	  (LAS-­‐AF)	  software.	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Transmission	  Electron	  Microscopy	  (TEM)	  
The	  RNAi	  experiment	  was	  initiated	  at	  Vanderbilt	  University	  and	  samples	  were	  sent	  to	  Albert	  
Einstein	  College	  of	  Medicine	  (AECOM)	  for	  TEM	  preparation	  (fixation,	  sectioning	  and	  staining).	  juIs76	  
[punc-­‐25::GFP,	   lin-­‐15(+)];	   eri-­‐1	   (mg366)	   animals	  were	   treated	  with	  EV	   (control)	  or	  coq-­‐1	   RNAi	   and	  
collected	  for	  fixation	  on	  Day	  5	  of	  the	  RNAi	  experiment.	  Because	  of	  the	  variability	  of	  RNAi	  among	  a	  
population	  (Fraser	  et	  al.	  2000;	  Simmer	  et	  al.	  2003),	  I	  used	  a	  stereomicroscope	  to	  select	  adult	  animals	  
with	  clear	  indications	  of	  multiple	  necrotic	  GABA	  neurons	  (i.e.,	  enlarged	  GFP-­‐positive	  cells).	  Selected	  
animals	   were	   fixed	   by	   high-­‐pressure	   freezing	   (HPF)	   in	   a	   BalTec	   HM	   010	   High-­‐Pressure	   Freezer.	  
Freeze	   substitution	   was	   performed	   using	   a	   BalTec	   Freeze	   Substitution	   device.	   The	   sample	   blocks	  
were	  sectioned	  using	  a	  RMC	  Powertome	  at	  50	  nm	  and	  stained	  with	  uranyl	  acetate	  and	  lead	  citrate.	  
Images	  were	  collected	  on	  a	  Philips	  CM-­‐10	  transmission	  electron	  microscope	   (TEM)	  with	  a	  Morada	  
digital	  camera	  system.	  
	  
Experimental	  contributions	  
Meg	  Mitchell	  built	  the	  pMBM009	  vector	  and	  the	  NC2811	  strain.	  She	  also	  collected	  the	  data	  
for	   Figure	   5.3C-­‐D.	   David	   Hall	   (Albert	   Einstein	   College	   of	   Medicine,	   AECOM)	   prepared	   the	   TEM	  
samples	   (fixation,	   sectioning,	   and	   staining)	   and	   provided	   training	   and	   use	   of	   his	   transmission	  
electron	  microscope	  at	  AECOM.	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RESULTS	  
Global	  electron	  transport	  chain	  knockdown	  results	  in	  developmental	  arrest	  but	  not	  GABA	  neuron	  
degeneration	  
GABA	  neurons	  in	  hypomorphic	  mutants	  of	  ETC	  Complex	  I	  and	  Complex	  II	  do	  not	  degenerate	  	  
	   To	   test	   the	   hypothesis	   that	   ETC	   dysfunction	   underlies	   the	   neurodegeneration	   pathway	  
initiated	  by	  Coenzyme	  Q	  depletion,	   I	  examined	  GABA	  neurons	   in	  hypomorphic	  mutants	  of	  protein	  
subunits	  of	  ETC	  Complexes	   I	  and	   II,	  gas-­‐1(fc21)	  and	  mev-­‐1(kn1),	   respectively.	  These	  mutants	  show	  
significantly	  decreased	  ETC	  activity	  (reduced	  by	  80-­‐90%	  versus	  wild-­‐type)	  (Kayser	  et	  al.	  2001;	  Ishii	  et	  
al.	   1998),	   increased	   oxidative	   stress	   (Hartman	   et	   al.	   2001)	   and	   ced-­‐3/ced-­‐4-­‐dependent	  
supernumerary	  apoptosis	  (Senoo-­‐Matsuda	  2003).	  However,	  neither	  hypomorphic	  mutant	  displayed	  
noticeable	   signs	   of	   GABA	   neuron	   degeneration	   at	   any	   developmental	   age	   (data	   not	   shown).	  
Interpretation	  of	  this	  negative	  result	  is	  difficult	  since	  these	  alleles	  do	  not	  completely	  eliminate	  gene	  
function.	   Unfortunately,	   animals	   with	   more	   severe	   ETC	   mutations	   (i.e.,	   atp-­‐2/Complex	   V,	   nuo-­‐
1/Complex	  I,	  isp-­‐1/Complex	  III	  (Tsang	  &	  Lemire	  2003;	  Ndegwa	  &	  Lemire	  2004;	  Ventura	  &	  Rea	  2007))	  
do	  not	  reach	  adulthood	  and	  therefore	  cannot	  be	  examined	  for	  GABA	  neurodegeneration.	  
	  
Global	  RNAi	  of	  ETC	  genes	  induces	  developmental	  arrest	  
Because	   it	  was	   not	   possible	   to	   test	   null	   alleles	   ETC	   genes	   for	   GABA	   neuron	   degeneration	  
defects,	   I	   instead	   used	   RNAi	   to	   knock	   down	   ETC	   components	   to	   determine	   if	   this	   impairment	  
phenocopies	   the	   GABA	   neurodegeneration	   observed	   with	   Coenzyme	   Q	   deficiency.	   For	   this	  
experiment,	   I	   used	   the	   same	  RNAi-­‐sensitized	   genetic	   background	   (juIs76;	   eri-­‐1)	   that	   shows	   robust	  
GABA	  neurodegeneration	  with	  coq-­‐1	  RNAi	   (Fig.	  2.2).	  Global	  RNAi	  knockdown	  of	  ETC	  genes	   (gas-­‐1,	  
nuo-­‐1,	  cyc-­‐1,	  cco-­‐1,	  F26E4.6,	  atp-­‐3)	  delayed	  or	  arrested	  the	  first	  generation	  progeny	  (Table	  5.3)	  and	  
therefore	  prevented	  analysis	  of	  adult	  neurons.	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  We	  next	  decreased	  overall	  sensitivity	  to	  ETC	  knockdown	  by	  examining	  animals	  without	  the	  
neuronal	  RNAi-­‐enhancing	  mutation	  eri-­‐1(mg366)	   (Kennedy	  et	  al.	  2004);	  however,	  many	  of	  the	  ETC	  
RNAi	  populations	  (gas-­‐1,	  D2030.4,	  cyc-­‐1,	  atp-­‐3)	  still	  arrested	  during	  larval	  development	  with	  global	  
RNAi	   treatment	   (Table	   5.4).	   Knockdown	   of	   two	   ETC	   genes	   (mev-­‐1	   and	   F26E4.6)	   in	   this	   genetic	  
background	  allowed	  the	  first	  generation	  progeny	  to	  reach	  adulthood	  but	  we	  did	  not	  observe	  GABA	  
degeneration	   in	   these	   adults	   (data	   not	   shown).	   Thus,	   these	   findings	   indicate	   that	   the	   severity	   of	  
global	   RNAi	   knockdown	   of	   ETC	   genes	   hinder	   our	   effort	   to	   assess	   potential	   degeneration	   of	   adult	  
GABA	  neurons.	  
	  
GABA	  neuron-­‐specific	  knockdown	  of	  ETC	  genes	  does	  not	  induce	  their	  degeneration	  
Given	  the	  developmental	  delay	  caused	  by	  global	  knockdown	  of	  ETC	  genes,	  I	  decided	  to	  use	  a	  
GABA	   neuron-­‐specific	   RNAi	   strain	   (XE1375)	   generously	   provided	   by	   Marc	   Hammarlund	   (Yale	  
University).	  Mutations	  in	  lin-­‐15b	  (Wang	  et	  al.	  2005)	  and	  eri-­‐1/RNase	  (Kennedy	  et	  al.	  2004)	  enhance	  
sensitivity	   to	   RNAi,	   and	   the	   rde-­‐1/Argonaut	   (Tabara	   et	   al.	   1999)	   is	   required	   to	   process	   dsRNA	   for	  
gene	   interference.	   The	   wpSi1	   [punc-­‐47::rde-­‐1::SL2::sid-­‐1]	   transgene	   drives	   GABA	   neuron-­‐specific	  
expression	   of	  wild-­‐type	   RDE-­‐1/Argonaut	   as	  well	   as	   SID-­‐1,	   a	   dsRNA	   gated	   channel	   protein	   (Shih	  &	  
Hunter	   2011)	   that	   enhances	   RNAi	   in	   cells	   where	   it	   is	   overexpressed	   and	   decreases	   RNAi	   of	   non-­‐
transgenic	  cells	   (Calixto	  et	  al.	  2010).	  Together,	   this	  combination	  of	  RNAi-­‐enhancing	  mutations	  and	  
transgenic	  rescue	  of	  key	  components	  of	  the	  RNAi	  pathway	  in	  GABA	  neurons	  allows	  the	  function	  of	  
otherwise	  lethal	  genes	  to	  be	  assessed	  exclusively	  in	  these	  neurons.	  I	  inspected	  GABA	  neurons	  of	  ETC	  
knockdown	   animals	   in	   the	   GABA	   neuron-­‐specific	   RNAi	   background.	  With	   the	   exception	   of	   a	   rare	  
button-­‐like	  (i.e.,	  apoptotic)	  GABA	  neuron	  in	  a	  single	  gas-­‐1	  RNAi-­‐treated	  animal	  (Fig.	  5.1B-­‐C),	  I	  did	  not	  
detect	  signs	  of	  GABA	  neuron	  death	  (data	  not	  shown).	  To	  verify	  RNAi	  efficacy	  in	  GABA	  neurons	  of	  this	  
genetic	  background,	  I	  used	  RNAi	  to	  knock	  down	  unc-­‐25/Glutamic	  Acid	  Decarboxylase	  and	  quantified	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Table	   5.3:	   Knockdown	   of	   electron	   transport	   chain	   (ETC)	   components	   results	   in	   developmental	  
arrest.	   Global	   RNAi	   of	   eri-­‐1(mg366);	   juIs96	   was	   used	   to	   knock	   down	   genes	   encoding	   ETC	  











EV	   n/a	   many	   Adults	  
gas-­‐1	   I	   very	  few	   L1	  -­‐	  L2	  
nuo-­‐1	   I	   very	  few,	  many	  dead	  eggs	   L1	  
cyc-­‐1	   III	   very	  few	   L1-­‐L2	  
cco-­‐1	   IV	   very	  few	   L1-­‐L2	  
F26E4.6	   IV	   very	  few	   L1-­‐L2	  








Table	  5.4:	  ETC	  RNAi	  treatment	  of	  animals	  without	  eri-­‐1(mg366)	  progress	  to	   later	  developmental	  
stages	   but	   do	   not	   display	   GABA	   neuron	   degeneration.	   Removal	   of	   the	   RNAi-­‐sensitizing	   eri-­‐
1(mg366)	  mutation	  allows	  ETC	  knockdown	  populations	  to	  develop	  to	  later	  stages.	  F1	  adults	  of	  mev-­‐
1	  or	  F26E4.6	  do	  not	  have	  GABA	  neuron	  degeneration	  while	  coq-­‐1	   knockdown	  animals	  show	  dying	  







Quantity	   Stage	   GABA	  neuron	  
Degeneration	  
EV	   n/a	   many	   adults	   0%	  
gas-­‐1	   I	   many	   L3/L4	   0%	  
D2030.4	   I	   few	   L3	   0%	  
mev-­‐1	   II	   many	   small	  adults	   0%	  
cyc-­‐1	   III	   very	  few	   L2	   0%	  
F26E4.6	   IV	   many	   adults	   0%	  
atp-­‐3	   V	   very	  few	   L2/L3	   0%	  
coq-­‐1	   (CoQ)	   many	   adults	   13%	  






Figure	   5.1:	   GABA	   neuron-­‐specific	   knockdown	   of	   electron	   transport	   chain	   (ETC)	   genes	   does	   not	  
phenocopy	  the	  robust	  degeneration	  defect	  of	  Coenzyme	  Q-­‐depleted	  animals.	  A.	  Movement	  (WT,	  
Unc,	  Very	  Unc,	  Shrinker)	  was	  scored	  in	  XE1375	  animals	  treated	  with	  RNAi	  that	  targeted	  components	  
of	  the	  ETC	  as	  well	  as	  controls	  (empty	  vector	  and	  unc-­‐25/GAD).	  Scale	  bar	  =	  5µM,	  n	  >	  50	  except	  atp-­‐3	  
which	  did	  not	  have	  enough	  F1	  progeny	  to	  score	  (*),	   in	  which	  case	  n	  =	  20.	  B.	  DIC	  image	  of	  a	  single	  
apoptotic	  GABA	  neuron	  (yellow	  arrowhead)	  in	  an	  adult	  XE1375	  animal	  with	  gas-­‐1	  RNAi.	  This	  image	  
is	  not	  representative	  of	  overall	  GABA	  neuron	  morphology	  and	  notes	  the	  rare	  presence	  of	  apoptotic	  
features.	  C.	  GABAergic	  identity	  is	  confirmed	  by	  expression	  of	  punc-­‐25::GFP	  in	  the	  dying	  neuron.	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movement	   defects	   caused	   by	   reduction	   of	   this	   GABA	   biosynthetic	   enzyme.	   The	   XE1375	   strain	  
showed	   a	   robust	   Unc	   phenotype	   with	   unc-­‐25	   knockdown,	   showing	   the	   characteristic	   “shrinker”	  
defect	  observed	  in	  nematodes	  without	  functional	  GABA	  neurons	  (McIntire,	  Jorgensen,	  Kaplan,	  et	  al.	  
1993b)	   (Fig.	   5.1A).	   This	   result	   confirmed	   that	  GABA	  neurons	  are	   sensitized	   to	   feeding	  RNAi	   in	   the	  
XE1375	  sensitized	  background.	  The	  GABA	  neuron	  specific	  “shrinker”	  phenotype	  was	  also	  visible	   in	  
~20%	   of	   the	   populations	   targeted	   for	   RNAi	   of	   gas-­‐1/Complex	   I	   and	   F26E4.6/Complex	   IV.	   The	  
“shrinker”	  phenotype	  induced	  by	  the	  RNAi	  treatment	  suggests	  that	  the	  function	  of	  these	  ETC	  genes	  
was	   reduced	   specifically	   in	   GABA	   neurons	   and	   yet	   we	   did	   not	   induce	   GABA	   neurodegeneration.	  
These	  data	   suggest	   that	   ETC	   impairment	   alone	  does	  not	   explain	   the	   cell	   death	  observed	   in	  GABA	  
neurons	  of	  CoQ-­‐deficient	  animals.	  
	  
Specific	   calpain	   and	   cathepsin	   proteases	   are	   differentially	   required	   in	   the	   GABA	  
neurodegeneration	  pathway	  
Despite	   the	   involvement	   of	   key	   apoptotic	   genes	   to	   in	   the	   CoQ	   depletion-­‐induced	  
neurodegeneration	   pathway	   (see	   Chapter	   4),	   the	   swollen	   morphology	   of	   dying	   GABA	   neurons	   is	  
characteristic	  of	  necrotic	  death	   (Fig.	  2.2,	  Fig.	  3.2).	  Studies	   in	  C.	  elegans	  have	   identified	  mutants	   in	  
which	  specific	  hyperactive	  cation	  channels	  induce	  necrotic	  death	  in	  the	  affected	  neurons	  (Syntichaki	  
et	  al.	  2002).	  Mutations	   that	  disable	  either	  of	   two	  classes	  of	  proteases,	   calpains	   (CLP-­‐1	  and	  TRA-­‐3)	  
and	   cathepsins	   (ASP-­‐3	   and	   ASP-­‐4)	   (Fig.	   1.4),	   block	   the	   necrosis	   pathway	   in	   this	   experimental	  
paradigm	  (Syntichaki	  et	  al.	  2002).	  To	  determine	  if	  these	  necrotic	  proteases	  are	  also	  required	  for	  CoQ	  
depletion-­‐induced	  GABA	  neurodegeneration,	  I	  examined	  genetic	  mutants	  of	  clp-­‐1,	  tra-­‐3	  and	  asp-­‐4	  in	  
a	   coq-­‐1	   RNAi	   assay.	   At	   the	   time	   of	   analysis,	   it	   was	   not	   possible	   to	   test	   the	   cathepsin/aspartyl	  
protease	   asp-­‐3	   due	   to	   the	   lack	   of	   a	   genetic	   mutant.	   Recently,	   two	   asp-­‐3	   mutant	   alleles	   were	  
generated	  (tm4450	  and	  tm4559)	  that	  could	  be	  used	  in	  future	  experiments	  to	  investigate	  the	  role	  of	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this	   cathepsin.	   In	   comparison	   to	  wild-­‐type	   animals	   treated	  with	   coq-­‐1	   RNAi,	   there	  was	   significant	  
reduction	   in	   GABA	   neuron	   degeneration	   in	   asp-­‐4(ok2693)	   mutants	   (Fig.	   5.2A).	   This	   result	   is	  
consistent	  with	  the	  death-­‐promoting	  role	  of	  ASP-­‐4	  in	  other	  C.	  elegans	  necrotic	  pathways	  (Syntichaki	  
et	   al.	   2002;	   Geng	   et	   al.	   2012).	   However,	   these	   experiments	   also	   revealed	   that	   GABA	  
neurodegeneration	   did	   not	   depend	   on	   CLP-­‐1	   and	   was	   significantly	   enhanced	   by	   loss	   of	   TRA-­‐3	  
function	  (Fig.	  5.2A-­‐B).	  These	  results	  indicate	  that	  the	  GABA	  neurodegeneration	  pathway	  shares	  the	  
aspartyl	  protease	  ASP-­‐4	  with	  other	  necrotic	  mechanisms	  but	  also	  shows	  important	  differences:	  CLP-­‐
1	  is	  not	  required	  and	  TRA-­‐3/calpain	  appears	  to	  function	  in	  a	  neuroprotective	  role.	  
	  
RME	  GABA	  neurons	  are	  severely	  affected	  by	  CoQ	  depletion	  in	  tra-­‐3	  mutants	  	  
To	   confirm	   enhanced	   GABA	   neuron	   degeneration	   of	   tra-­‐3(ok2207)	   mutants	   with	   CoQ	  
depletion,	  GABA	  neuron	  death	  was	   also	  examined	   in	   the	  coq-­‐2(ok1066)	  mutants.	   For	   this	   assay,	   I	  
examined	  two	  distinct	  populations	  of	  GABA	  neurons:	  the	  four	  RME	  neurons	  in	  the	  head	  and	  the	  19	  
D-­‐Type	  GABA	  neurons	   in	   the	  ventral	  nerve	   cord	   (VNC)	   (Fig.	   1.7).	   Significant	  enhancement	  of	  both	  
RME	   (Fig.	   5.3A-­‐C)	   and	  D-­‐type	  GABA	  neuron	   (Fig.	   5.3D)	  degeneration	  was	  observed	   in	  coq-­‐2;	   tra-­‐3	  
double	  mutants	  compared	   to	  coq-­‐2	   single	  mutants.	  These	  data	  strongly	  support	  a	  model	   in	  which	  
Coenzyme	  Q	  deficiency	  activates	  a	  GABA	  neuron	  degeneration	  pathway	  that	  is	  antagonized	  by	  TRA-­‐
3/calpain	  (Fig.	  5.3E).	  	  
	  
Transmission	  electron	  microscopy	  reveals	  ultrastructural	  features	  of	  Coenzyme	  Q-­‐deficient	  motor	  
neurons	  
Genetic	  data	   from	  my	  studies	   indicate	   that	  both	  apoptotic	   (see	  Chapter	   2	  and	  Chapter	   4)	  
and	   necrotic	   (Fig.	   5.2,	   Fig.	   5.3)	   regulators	   are	   involved	   in	   the	   GABA	   neurodegeneration	   pathway	  
induced	  by	  CoQ	  depletion.	  Additionally,	  light	  microscopy	  reveals	  that	  dying	  GABA	  neurons	  adopt	  a	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Figure	   5.2:	   Specific	   proteases	   from	   the	   necrotic	   death	   pathway	   are	   differentially	   required	   for	  
GABA	  neurodegeneration	  induced	  by	  Coenzyme	  Q	  depletion.	  A.	  coq-­‐1	  RNAi	  induces	  GABA	  neuron	  
degeneration	   that	   is	   enhanced	   by	   the	   tra-­‐3(ok2207)	  mutation	   and	   suppressed	   in	   asp-­‐4(ok1653)	  
mutants.	  n	  >60	  except	  for	  clp-­‐1;	  tra-­‐3	  (n=20),	  **	  p<0.0001	  vs	  wild-­‐type	  (WT).	  Degeneration	  levels	  in	  
clp-­‐1;	  tra-­‐3	  does	  not	  differ	  statistically	  from	  WT	  (data	  not	  shown).	  B.	  Confocal	  image	  showing	  severe	  
GABA	   neuron	   degeneration	   (i.e.,	   neuronal	   process	   blebbing	   –	   yellow	   arrowhead	   and	   break	   in	  
neuronal	  process	  –	  white	  arrowhead)	  in	  tra-­‐3	  mutants	  with	  coq-­‐1	  knockdown.	  pGABA::GFP	  =	  punc-­‐
25::GFP,	  scale	  bar	  =	  25µM.	  
	   	  





Figure	  5.3:	  GABA	  neuron	  degeneration	  is	  enhanced	  in	  coq-­‐2;	  tra-­‐3	  double	  mutants.	  A.	  All	  four	  RME	  
neurons	   are	   visible	   in	   a	   Z-­‐axis	   projection	   of	   punc-­‐25::GFP	   and	   DIC	   confocal	   images	   in	   a	   coq-­‐
2(ok1066)	   adult.	   B.	   RME	   neurons	   are	   missing	   (empty	   arrowheads)	   from	   the	   head	   region	   of	   this	  
representative	   coq-­‐2(ok1066);	   tra-­‐3(ok2207)	   animal.	   Scale	   bar	   =	   25µM.	   C.	   An	   average	   of	   ~1	  
GABAergic	   RME	   degenerates	   in	   -­‐2	   adult	   animals	   scored	   at	   Day	   6.	   RME	   degeneration	   at	   Day	   6	   is	  
significantly	   enhanced	   in	   the	   coq-­‐2;	   tra-­‐3	  background	   (~2.5	  missing	   RMEs).	   n>25,	   **	   p<0.0002	   vs	  
WT,	  ##	  p<0.0001	  vs	  coq-­‐2.	  D.	  coq-­‐2;	  tra-­‐3	  double	  mutants	  also	  have	  significantly	  fewer	  VNC	  D-­‐Type	  
GABA	  neurons	  versus	  coq-­‐2.	  n>25,	  **	  p<0.0001	  vs	  WT,	  #	  p<0.06	  vs	  coq-­‐2.	  E.	   Loss	  of	  Coenzyme	  Q	  
activates	  a	  pathway	  that	  requires	  TRA-­‐3	  to	  block	  GABA	  neuron	  degeneration.	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swollen,	   necrotic-­‐like	   morphology	   (Fig.	   2.2,	   Fig.	   3.2).	   Taken	   together,	   these	   results	   suggest	   that	  
either	  apoptotic	  genes	  regulate	  a	  necrotic	  death	  pathway	  or	  that	  a	  hybrid	  death	  mechanism,	  with	  
shared	  features	  of	  both	  apoptosis	  and	  necrosis,	   is	  activated	  in	  the	  GABA	  neurons	  of	  CoQ-­‐depleted	  
animals.	  Since	  apoptotic	  and	  necrotic	  features	  are	  distinguishable	  at	  the	  ultrastructural	  level	  (Table	  





Table	   5.5.	   Ultrastructural	   features	   that	   distinguish	   apoptotic	   versus	   necrotic	   cell	   death.	  
Characteristics	   of	   apoptotic	   and	   necrotic	   death	   revealed	   through	   ultrastructural	   analysis	   (Zong	   &	  
Thompson	  2006;	  Kerr	  et	  al.	  1972;	  Hall	  et	  al.	  1997).	  
	  
Apoptosis	   Necrosis	  
Chromatin	  condensation	   Extensive	  cytoplasmic	  vacuolation	  
DNA	  fragmentation	   Mitochondrial	  swelling	  
Overall	  cell	  shrinking	   Dilation	  of	  the	  endoplasmic	  reticulum	  
Plasma	  membrane	  blebbing	   Plasma	  membrane	  rupture	  




Longitudinal	  sectioning	  allows	  ultrastructural	  features	  of	  neighboring	  motor	  neurons	  to	  be	  visualized	  
using	  transmission	  electron	  microscopy	  
	   We	   previously	   demonstrated	   that	   CoQ	   deficiency	   results	   in	   the	   degeneration	   of	   GABA	  
neurons	  but	  not	  nearby	  cholinergic	  neurons	  in	  the	  ventral	  nerve	  cord	  (Fig.	  2.2,	  Fig.	  2.4).	  The	  striking	  
difference	   in	   cellular	   responses	   to	   CoQ	   depletion	   between	   these	   neighboring	   neuron	   classes	  
motivated	  us	  to	  examine	  motor	  neurons	  side-­‐by-­‐side	  using	  transmission	  electron	  microscopy	  (TEM).	  
This	  goal	  was	  achieved	  by	  generating	  longitudinal	  sections	  of	  the	  ventral	  nerve	  cord	  (VNC).	  Analysis	  
of	  control	  animals	  confirmed	  the	  utility	  of	  this	  sectioning	  strategy,	  which	  produced	  an	  ultrastructural	  
representation	  of	  adjacent	  motor	  neurons	  cell	  bodies	  in	  the	  ventral	  nerve	  cord	  (Fig.	  5.4).	  	  








Figure	  5.4:	  Transmission	  electron	  micrograph	  shows	  ultrastructural	   features	  of	  wild-­‐type	  ventral	  
nerve	   cord	   (VNC)	   motor	   neurons.	  A.	   Two	   neighboring	   motor	   neuron	   cell	   bodies	   in	   control	   (EV)	  
RNAi-­‐treated	   samples.	   B.	   Pseudocolored	   micrograph	   of	   motor	   neurons	   (green).	   C.	   Pseudocolor	  
schematic	  highlights	   features	  of	  wild-­‐type	  motor	  neuron	  cell	  bodies	  on	  the	  dorsal	  side	  of	   the	  VNC	  
(blue).	   Nucleus	   (N),	   neuronal	   mitochondria	   (M),	   Golgi	   (G),	   ventral	   nerve	   cord	   (VNC),	   muscle	  
mitochondria	  (MM).	  Scale	  bar	  =	  2µM.	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Transmission	  electron	  micrographs	  of	  these	  motor	  neurons	  clearly	  delineated	  prominent	  subcellular	  
structures	  such	  as	  mitochondria,	  Golgi	  and	  the	  cell	  nucleus.	  These	  images	  of	  normal	  motor	  neurons	  
provide	   a	   wild-­‐type	   control	   for	   comparison	   to	   potential	   intracellular	   changes	   in	   CoQ-­‐depleted	  
neurons.	  
	  
Ultrastructural	  analysis	  of	  coq-­‐1	  knockdown	  animals	  reveals	  necrotic	  characteristics	  of	  dying	  motor	  
neurons	  
Next,	   I	   examined	   transmission	   electron	   micrographs	   of	   motor	   neurons	   in	   adult	   animals	  
treated	   with	   coq-­‐1	   RNAi.	   A	   dying	   motor	   neuron	   near	   the	   vulva	   (Fig.	   5.5),	   displayed	   several	  
characteristics	   suggestive	  of	   necrotic	   cell	   death.	   These	   features	   include:	   (1)	   extensive	   intracellular	  
proteolysis	  (i.e.,	  lack	  of	  cytoplasmic	  electron	  density),	  (2)	  a	  large	  cytoplasmic	  vacuole,	  (3)	  rupture	  of	  
the	   plasma	   membrane,	   (4)	   a	   membranous	   whorl,	   and	   (5)	   mitochondrial	   swelling	   (see	   Fig.	   5.5	  
legend).	  Each	  of	  these	  features	  has	  been	  previously	  identified	  in	  necrotic	  C.	  elegans	  neurons	  (Hall	  et	  
al.	   1997).	   Mitochondrial	   distortion	   and	   electron-­‐dense	   membranous	   whorls	   are	   also	   observed	   in	  
cytotoxic	  death	   induced	  by	  dominant	  mutations	   in	   lin-­‐24	   (homology	  to	  bacterial	   toxins)	  and	   lin-­‐33	  
(unknown	   gene	   function)	   (Galvin	   et	   al.	   2008),	   but	   other	   features	   of	   cytotoxic	   death	   (i.e.,	  nuclear	  
envelope	   dilation,	   electron-­‐dense	   nuclear	   punctae)	   were	   not	   observed	   in	   CoQ-­‐deficient	   motor	  
neurons.	  The	  neuron	  depicted	  in	  Figure	  5.5A	  is	  likely	  to	  be	  GABAergic	  motor	  neuron	  VD7	  based	  on	  
its	  position	  next	   to	   the	  vulva	  and	   frequent	  swollen	  VD7	  neurons	   in	   the	   light	  microscope	   (Fig.	  3.2).	  
Similar	  features	  were	  observed	  in	  TEM	  images	  from	  a	  second	  coq-­‐1	  knockdown	  animal	  that	  showed	  
an	   elongated	   swollen	   neuron	   (Fig.	   5.5E)	   with	   a	   striking	   resemblance	   to	   the	   appearance	   of	   CoQ-­‐
depleted	  GABA	  neurons	  in	  the	  light	  microscope	  (Fig.	  2.2C).	  Based	  on	  our	  light	  microscopy	  studies	  in	  
which	  GABA	  neurons	  are	  the	  predominant,	  if	  not	  exclusive,	  type	  of	  VNC	  motor	  neuron	  to	  swell	  with	  
coq-­‐1	  knockdown,	  we	  infer	  that	  the	  cells	  depicted	  in	  Figure	  5.5	  are	  also	  GABAergic	  neurons.	  





Figure	  5.5:	  Ultrastructural	  analysis	  of	  coq-­‐1	  knockdown	  animals	  reveals	  necrotic	  features	  of	  dying	  
motor	  neurons.	  A.	  A	  dying	  motor	  neuron	  (red	  arrow)	  near	  the	  vulva	  (yellow	  bracket)	  of	  coq-­‐1	  RNAi	  
treated	   animal	   #1.	  Anterior	   left,	   ventral	   down.	   Scale	   bar	   =	   5µM.	  B.	   TEM	   image	  of	   the	  neuron	   in	  
Panel	  A.	  C.	  Pseudocolor	  overlay	  distinguishes	  various	   features	  of	   the	  cell:	  M	  =	  ruptured	  neuronal	  
mitochondrion,	   N	   =	   nucleus,	   V	   =	   intracellular	   vacuole,	   W	   =	   electron-­‐dense	   membranous	   whorl,	  
dotted	  line	  =	  plasma	  membrane	  rupture.	  D.	  Pseudocolor.	  Scale	  bar	  =	  1µM.	  E.	  Large	  vacuoles	  (red	  
arrowheads)	  flank	  the	  nucleus	  (yellow	  arrowhead)	  of	  a	  dying	  cell	  in	  coq-­‐1	  RNAi-­‐treated	  animal	  #2.	  
Scale	  bar	  =	  2µM.	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Autophagic	  characteristics	  are	  observed	  in	  coq-­‐1	  depleted	  neurons	  
Interestingly,	   I	   also	   identified	   VNC	   neurons	   with	   features	   consistent	   with	   autophagy.	  
Autophagy	   is	   a	   self-­‐digestion	  mechanism	   that	   is	   associated	   both	  with	   cell	   survival	   and	   cell	   death	  
pathways	   (Kourtis	   &	   Tavernarakis	   2009).	   During	   autophagy,	   double-­‐membrane	   vesicles	   engulf	  
cytoplasmic	   material,	   and	   these	   vesicles	   (i.e.,	   autophagosomes)	   fuse	   with	   lysosomal	   machinery,	  
where	  its	  contents	  are	  degraded.	   In	  a	  CoQ-­‐deficient	  animal,	  we	  noted	  a	  neuron	  containing	  several	  
membrane-­‐enclosed	  structures	  (Fig.	  5.6)	   (Sigmond	  et	  al.	  2008).	   It	   is	  currently	  unclear	  whether	  this	  
neuron	  is	  GABAergic	  or	  cholinergic,	  and	  additional	  experiments	  are	  required	  to	  definitively	  test	  for	  a	  
role	   for	   autophagy	   in	   GABA	   neurodegeneration.	   Perhaps	   GABA	   neuron	   necrosis	   is	   preceded	   by	  
activation	   of	   autophagic	   mechanisms.	   Alternatively,	   other	   cell	   types	   in	   the	   VNC	   may	   activate	  
autophagy	  instead	  of	  necrosis	   in	  response	  to	  CoQ	  depletion,	  perhaps	  as	  a	  cell-­‐survival	  mechanism.	  
We	  note	  that	  the	  autophagic	  cell	  depicted	   in	  Figure	  5.6A-­‐B	   is	  adjacent	  to	  a	  vacuolated	  region	  that	  
likely	   corresponds	   to	   the	   position	   of	   a	   necrotic	   GABA	   neuron	   that	   already	   died	   at	   the	   time	   of	  
analysis.	  This	  finding	  is	  interesting	  because	  it	  could	  point	  to	  an	  important	  role	  for	  autophagy	  in	  the	  
survival	   of	   cholinergic	   neurons	   in	   the	   VNC	   of	   CoQ-­‐depleted	   animals.	   In	   addition	   to	   neurons	   with	  
features	   of	   either	   necrotic	   or	   autophagic	   cells,	   these	   electron	   micrographs	   also	   revealed	   VNC	  
neurons	   with	   the	   normal	   morphology	   of	   viable	   cells	   (Fig.	   5.6	   A,	   C).	   Thus,	   this	   TEM	   analysis	   is	  
important	   because	   it	   confirms	   our	   findings	   in	   the	   light	   microscope	   of	   both	   necrotic	   and	   normal	  











Figure	  5.6:	  Diverse	   cellular	   responses	   to	   coq-­‐1	  depletion	  are	   revealed	  by	   transmission	  electron	  
micrographs.	  A.	  Neurons	  along	   the	  ventral	  nerve	   cord	   (white	  arrow)	  display	  a	   range	  of	   features:	  
autophagic	   cell	   (yellow	   pseudocolor),	   large	   vacuolated	   area	   (blue	   arrow)	   and	   a	   normal	   neuron	  
(green	   pseudocolor).	   Scale	   bar	   =	   5µM.	   B.	  Magnified	   image	   of	   the	   autophagic	   cell	   from	   Panel	   A	  
shows	  membrane-­‐bound	  structures	  in	  the	  cytoplasm.	  Scale	  bar	  =	  1µM.	  C.	  Motor	  neurons	  with	  wild-­‐
type	  features	  from	  Panel	  A.	  Note:	  the	  red	  pseudocolored	  cell	  was	  not	  fully	  visible	  in	  Panel	  A.	  Scale	  
bar	  =	  2µM.	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DISCUSSION	  AND	  FUTURE	  DIRECTIONS	  
Summary	  
Impairing	  ETC	  function	  in	  adult	  animals	  is	  technically	  challenging	  due	  to	  the	  essential	  nature	  
of	  the	  proteins	  that	  make	  up	  the	  multisubunit	  complexes.	  However,	  by	  using	  a	  genetic	  background	  
that	  selectively	  sensitizes	  GABA	  neurons	  to	  RNAi,	  I	  was	  able	  to	  reveal	  that	  knockdown	  of	  ETC	  genes	  
does	   not	   elicit	   a	   GABA	   neurodegeneration	   phenotype.	   This	   result	   suggests	   that	   GABA	   neurons	  
degenerate	  due	  to	  the	  disruption	  of	  a	  CoQ	  function	  that	  is	  independent	  of	  its	  role	  in	  the	  ETC.	  I	  also	  
identified	  specific	  necrotic	  proteases	  that	  regulate	  GABA	  neuron	  death.	  These	  experiments	  revealed	  
that	   the	   CoQ	   depletion-­‐induced	   death	   pathway	   is	   controlled	   by	   proteases	   with	   death-­‐promoting	  
(ASP-­‐4/cathepsin)	   or	   death-­‐preventing	   (TRA-­‐3/calpain)	   functions.	   Examination	   of	   dying	   motor	  
neurons	  in	  the	  electron	  microscope	  revealed	  ultrastructural	  hallmarks	  of	  necrosis	  as	  well	  as	  signs	  of	  
autophagy	   in	  CoQ-­‐deficient	  animals.	  Taken	  together,	   these	   findings	  enhance	  our	  understanding	  of	  
how	   GABA	   neurons	   degenerate	   and	   implicate	   an	   ETC-­‐independent	   function	   of	   Coenzyme	   Q	   for	  
neuronal	  viability.	  
	  
Electron	  transport	  chain	  knockdown	  does	  not	  phenocopy	  GABA	  neurodegeneration	  observed	  with	  
Coenzyme	  Q	  depletion	  
	   As	   discussed	   in	   Chapter	   1,	   although	   Coenzyme	   Q	   functions	   as	   critical	   component	   of	   the	  
mitochondrial	   electron	   transport	   chain,	   it	   also	   is	   required	   for	   additional	   cellular	   activities	   such	   as	  
membrane	   oxidative	   stress	   defense	   (Turunen	   et	   al.	   2004)	   and	   energy	   coupling	   at	   plasma	   and	  
lysosomal	   membranes	   (Crane	   2001;	   Gille	   &	   Nohl	   2000).	   GABA	   neuron-­‐specific	   ablation	   of	   ETC	  
components	   did	   not	   phenocopy	   the	   cell	   death	   phenotype	   that	   accompanies	   global	   Coenzyme	   Q	  
depletion.	   This	  negative	   result	   argues	  against	   a	  model	   in	  which	  GABA	  neuron	  degeneration	  arises	  
from	   disruption	   of	   the	   ETC.	   Our	   initial	   hypothesis	   was	   based	   on	   findings	   that	   correlate	   ETC	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dysfunction	   with	   ATP	   depletion	   and	   elevated	   ROS	   that	   then	   initiate	   both	   apoptotic	   and	   necrotic	  
death	  pathways.	  However,	  these	  results	  now	  favor	  ETC-­‐independent	  roles	  of	  Coenzyme	  Q	  such	  as	  its	  
antioxidant	   properties	   (Turunen	   et	   al.	   2004)	   and	   regulation	   of	   the	   mitochondrial	   permeability	  
transition	   pore	   (PTP)	   (Fontaine	   et	   al.	   1998;	   Papucci	   et	   al.	   2003;	   Devun	   et	   al.	   2010;	   Sahach	   et	   al.	  
2007)	   as	   potentially	   involved	   in	   GABA	   neuron	   necrosis.	   Our	   results	   are	   also	   consistent	   with	   the	  
finding	  that	  global	  reduction	  of	  Coenzyme	  Q	  content	  by	  as	  much	  as	  60-­‐70%	  does	  not	  decrease	  ETC	  
activity	   in	   C.	   elegans	   (Asencio	   et	   al.	   2003).	   While	   we	   have	   not	   directly	   measured	   the	   level	   of	  
Coenzyme	   Q	   deficiency	   achieved	   with	   our	   RNAi	   or	   genetic	   approaches,	   it	   is	   possible	   that	   CoQ	  
depletion	   is	  not	   sufficient	   to	   impair	   ETC	   function.	   In	   any	   case,	  our	   results	   suggest	   that	  CoQ	   levels	  
that	   are	   sufficient	   to	   support	   overall	   animal	   viability	   are	   not	   adequate	   to	   prevent	   GABA	   neuron	  
degeneration	  (Fig.	  3.10).	  
In	  addition	  to	  its	  electron	  transfer	  function	  during	  oxidative	  phosphorylation,	  Coenzyme	  Q	  is	  
also	  a	  potent	  antioxidant	  in	  lipid	  membranes.	  I	  hypothesize	  that	  depletion	  of	  Coenzyme	  Q	  results	  in	  
increased	  oxidative	  stress,	  which	   in	   turn	  could	   trigger	  GABA	  neurodegeneration.	  Future	  studies	   to	  
address	   question	   could	   utilize	   genetic	   knockouts	   of	   enzymes	   with	   antioxidant	   function	   such	   as	  
superoxide	  dismutases	  (sod-­‐1,	  sod-­‐2)	  or	  catalases	  (ctl-­‐1,	  ctl-­‐2,	  ctl-­‐3).	  If	  increased	  ROS	  is	  responsible	  
for	  the	  death	  of	  GABA	  neurons	  in	  CoQ-­‐depleted	  animals,	  then	  GABA	  neuron	  degeneration	  should	  be	  
enhanced	   in	   these	   genetic	   backgrounds.	   Conversely,	   if	   elevated	   oxidative	   stress	   of	   CoQ-­‐depleted	  
animals	  causes	  GABA	  neuron,	  then	  overexpression	  of	  antioxidant	  enzymes	  (e.g.,	  sod-­‐1,	  ctl-­‐1)	  could	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Necrotic	  proteases	  adopt	  opposing	  roles	  in	  the	  CoQ	  deficiency-­‐induced	  GABA	  cell	  death	  pathway	  
TRA-­‐3/calpain	  antagonizes	  GABA	  neurodegeneration	  
	   TRA-­‐3	  is	  an	  atypical	  calpain	  that	  has	  been	  shown	  to	  be	  necessary	  for	  the	  necrotic-­‐like	  death	  
of	   neurons	   induced	   by	   hyper-­‐activation	   of	  DEG/ENac	   cation	   channels	   (Syntichaki	   et	   al.	   2002).	  My	  
results	   offer	   the	   unexpected	   finding	   of	   the	   opposite	   role	   for	   TRA-­‐3	   of	   protecting	   neurons	   from	   a	  
necrotic	  pathway	  induced	  by	  CoQ	  depletion	  (Fig.	  5.2,	  Fig.	  5.3).	  This	  finding	  indicates	  that	  Coenzyme	  
Q	   deficiency-­‐induces	   a	   necrotic	   pathway	   that	   differs	   from	   the	   necrotic	   mechanism	   induced	   by	  
DEG/ENac	   channel	   hyperactivity.	   Additionally,	   TRA-­‐3-­‐dependent	   necrotic	   death	   occurs	   in	   touch	  
receptor	  neurons	  (Syntichaki	  et	  al.	  2002),	  and	  it	  is	  possible	  that	  different	  types	  of	  neurons	  activate	  
distinct	  necrotic	  responses.	  	  
	   Data	   from	   another	   study	   are	   consistent	   with	   our	   finding	   that	   TRA-­‐3	   antagonizes	   a	  
neurodegeneration	   pathway.	   Knockdown	   of	   tra-­‐3	   sensitizes	   animals	   to	   necrosis	   stimulated	   by	  
treatment	  with	   a	   pharmacological	   ETC	   Complex	   IV	   inhibitor	   sodium	   azide	   (Luke	   et	   al.	   2007).	   This	  
independent	  observation	  coupled	  with	  our	  discovery	  that	  TRA-­‐3	  protects	  GABA	  neurons	  from	  CoQ	  
depletion-­‐induced	  death	  suggests	  that	  this	  calpain	  functions	  downstream	  of	  mitochondrial	  stress	  to	  
prevent	   cell	   death.	   A	   similar	   phenomenon	   has	   been	   reported	   for	   human	   Calpain	   10	   for	   which	  
knockdown	   induces	   apoptosis	   (Smith	  &	   Schnellmann	  2012).	   In	   addition,	   Calpain	   10	  proteolytically	  
cleaves	  components	  of	  the	  ETC	  after	  calcium	  overload	  and	  that	  this	  role	  could	  prevent	  a	  buildup	  of	  
damaged	  substrates	  that	  may	  contribute	  to	  both	  mitochondrial	  and	  cellular	  injury	  that	  induces	  cell	  
death.	  A	   similar	  mechanism	  may	   also	   explain	  why	   loss	   of	   TRA-­‐3	   enhances	  CoQ	  depletion-­‐induced	  
GABA	  neuron	  degeneration.	  
	   In	  addition	  to	  calpain	  10	  protecting	  against	  apoptosis	  (Smith	  &	  Schnellmann	  2012),	  calpain-­‐
dependent	   cleavage	   of	   apoptotic	   regulators	   has	   been	   reported.	   For	   example,	   calcium-­‐induced	  
activation	   of	   calpain	   enzymes	   leads	   to	   cleavage	   of	   Bax	   (Bcl-­‐2	   family	  member)	   and	   Apaf-­‐1	   (CED-­‐4	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homologue)	   (Wood	   et	   al.	   1998;	   Reimertz	   et	   al.	   2001).	   Therefore,	   perhaps	   TRA-­‐3	   inhibits	   GABA	  
neurodegeneration	  by	  degrading	  pro-­‐death	  machinery	  (i.e.,	  CED-­‐4/Apaf-­‐1).	  Epistasis	  analysis	  of	  tra-­‐3	  
and	  the	  death-­‐promoting	  genes	  we	  have	  identified	  (i.e.,	  ced-­‐4,	  drp-­‐1,	  crt-­‐1,	  asp-­‐4)	  will	  begin	  to	  shed	  
light	  onto	  the	  relationship	  between	  this	  protective	  protease	  and	  the	  neurodegeneration	  pathway.	  	  
Interestingly,	   TRA-­‐3	   expression	   is	   reportedly	   excluded	   from	   GABA	   neurons	   (Joyce	   et	   al.	  
2012);	  therefore,	  analysis	  of	  potential	  non	  cell-­‐autonomous	  roles	  for	  TRA-­‐3	  could	  also	  be	  insightful	  
for	   delineating	   the	  mechanism	   by	   which	   this	   protease	   protects	   against	   GABA	   neuron	   death.	   Our	  
studies	   also	   do	   not	   indicate	   whether	   the	   protease	   activity	   of	   TRA-­‐3	   is	   required	   for	   its	   protective	  
function	  and	  mutagenesis	  of	  its	  active	  site	  (C83S,	  (Moldoveanu	  et	  al.	  2002;	  Sokol	  &	  Kuwabara	  2000))	  
could	  be	  used	  to	  address	  this	  question.	  
	  
ASP-­‐4/cathepsin	  promotes	  GABA	  neurodegeneration	   	  
	   Results	   in	   this	   chapter	   show	   that	   aspartyl	   protease	   ASP-­‐4	   is	   required	   for	   GABA	   neuron	  
degeneration	   with	   CoQ	   depletion.	   Due	   to	   inconsistencies	   of	   RNAi	   efficacy	   between	   genetic	  
backgrounds	   (see	  Appendix	   A),	   this	   result	   should	   next	   be	   confirmed	   in	   a	   CoQ	   synthetic	   pathway	  
mutant	   background.	   Once	   its	   death-­‐promoting	   role	   is	   validated	   in	   an	   RNAi-­‐independent	   assay,	  
future	  studies	   to	  understand	  how	  this	  protease	  promotes	  degeneration	  could	   focus	  on	  addressing	  
whether	  ASP-­‐4	  promotes	  GABA	  neuron	  death	   cell	   autonomously.	  During	  hyperactive	   ion-­‐channel-­‐
induced	   necrotic	   death,	   ASP-­‐4	   is	   downstream	   of	   TRA-­‐3,	   and	   both	   proteases	   promote	   cell	   death	  
(Syntichaki	   et	   al.	   2002);	   however,	  we	   discovered	   that	   TRA-­‐3	   antagonizes	   a	   death	   pathway	   that	   is	  
promoted	  by	  ASP-­‐4.	  Genetic	   epistasis	   analysis	  of	   the	   tra-­‐3;	   asp-­‐4	  double	  mutant	   could	  determine	  
whether	  these	  proteases	  act	  in	  the	  same	  or	  parallel	  pathways	  in	  response	  to	  CoQ	  depletion.	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Ultrastructural	   studies	   reveal	   canonical	   necrotic	   features	   in	   dying	  motor	   neurons	   and	   implicate	  
autophagy	  as	  a	  mechanism	  of	  neuroprotection	  
	   Our	   transmission	   electron	  microscopy	   analysis	   strongly	   suggests	   that	   CoQ-­‐deficient	   GABA	  
neurons	  die	   through	  a	  necrotic	  pathway.	  The	  ultrastructural	   resolution	  afforded	  by	   this	   technique	  
allowed	   us	   to	   compare	   intracellular	   features	   of	   motor	   neurons	   to	   distinguish	   between	   various	  
modes	   of	   cell	   death.	   Based	   on	   their	   location	   (adjacent	   to	   the	   ventral	   nerve	   cord)	   and	   our	  
reproducible	  observation	   in	  the	   light	  microscope	  that	  GABA	  neurons	  are	  preferentially	  affected	  by	  
CoQ	   depletion,	   we	   have	   tentatively	   identified	   these	   cells	   as	   GABAergic	   neurons.	   I	   performed	  
preliminary	  analysis	  on	  four	  coq-­‐1	  knockdown	  TEM	  samples	  and	  identified	  the	  regions	  in	  each	  that	  
contain	   the	   ventral	   nerve	   cord.	   Further	   examination	   of	   these	   TEM	   samples	   could	   be	   pursued	   to	  
confirm	  the	  findings	  of	  this	  pilot	  study.	  
Because	  we	  chose	  to	  section	   longitudinally,	  we	  were	  able	  to	  observe	  neurons	  with	  normal	  
ultrastructural	  features	  adjacent	  to	  others	  with	  clear	  signs	  of	  distress	  (Fig.	  5.6A).	  Most	  notably,	  we	  
detected	   signs	  of	  autophagy	   (e.g.,	  multiple	  membrane-­‐bound	   structures	   contained	   inside	   the	  cell)	  
(Fig.	  5.6B).	  Autophagy	  refers	  to	  a	  cellular	  self-­‐degradation	  pathway	  that	  has	  been	  tied	  to	  both	  cell	  
survival	  and	  cell	  death	  (Kourtis	  &	  Tavernarakis	  2009).	  Until	  acquiring	  these	  high-­‐resolution	  images,	  
only	   necrosis	   was	   observed	   in	   CoQ-­‐deficient	   animals	   (Fig.	   2.2,	   Fig.	   3.2),	   with	   rare	   instances	   of	  
apoptosis	  (Fig.	  3.3,	  Fig.	  4.6).	  Interestingly,	  primary	  Coenzyme	  Q	  deficiency	  models	  in	  other	  systems	  
have	   reported	   signs	  of	   autophagy	   (Rodriguez-­‐Hernandez	  et	   al.	   2009;	  Peng	  et	   al.	   2004;	  Peng	  et	   al.	  
2008),	   suggesting	   that	   an	   adaptive	   response	   to	   Coenzyme	   Q	   depletion	   is	   conserved	   across	  
phylogeny.	  	  
A	   long-­‐standing	   point	   of	   intrigue	   regarding	   CoQ	   deficiency	   in	   C.	   elegans	   is	   why	   GABA	  
neurons	  die	  and	  neighboring	  cholinergic	  neurons	  are	  spared.	  In	  C.	  elegans,	  autophagy	  is	  required	  for	  
protection	  against	  hypoxic	   injury	  (Samokhvalov	  et	  al.	  2008).	  We	  speculate	  that	  the	  autophagic	  cell	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identified	  in	  our	  TEM	  study	  (Fig.	  5.6)	   is	  a	  non-­‐GABAergic	  neuron	  that	  has	  activated	  autophagy	  as	  a	  
cell-­‐survival	   mechanism	   to	   overcome	   deprivation	   of	   CoQ.	   Alternatively,	   autophagy	   has	   also	   been	  
recognized	   as	   an	   independent	   cell	   death	   pathway	   (i.e.,	   Type	   II	   death),	   and	   it	   is	   also	   upregulated	  
upon	  induction	  of	  necrosis	  in	  C.	  elegans	  neurons	  (Samara	  et	  al.	  2008;	  Samokhvalov	  et	  al.	  2008).	  It	  is	  
therefore	  possible	  that	  the	  autophagic	  cell	  is	  a	  GABA	  neuron	  during	  a	  stage	  of	  necrotic	  degeneration	  
without	   soma	   swelling.	   Future	   studies	   can	   distinguish	   between	   these	   models	   by	   knocking	   down	  
autophagy	  regulators	  (i.e.,	  unc-­‐51/Atg1,	  bec-­‐1/Atg6,	  lgg-­‐1/Atg8)	  and	  examining	  both	  GABAergic	  and	  
cholinergic	  neurons	  in	  animals	  with	  CoQ	  depletion.	  If	  autophagy	  were	  a	  neuroprotective	  mechanism	  
in	   cholinergic	   neurons,	   loss	   of	   autophagic	   regulators	   would	   then	   induce	   cholinergic	  
neurodegeneration	  with	  CoQ	  deficiency.	  Alternatively,	  if	  autophagy	  were	  essential	  for	  GABA	  neuron	  
necrotic	   death,	   its	   inhibition	   would	   suppress	   degeneration.	   The	   outcome	   of	   this	   analysis	   could	  
provide	  insight	  into	  why	  GABA	  neurons	  preferentially	  degenerate	  versus	  cholinergic	  neurons.	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CHAPTER	  VI	  
	  
GENERAL	  DISCUSSION	  AND	  FUTURE	  DIRECTIONS	  
The	  work	  in	  this	  dissertation	  explores	  the	  mechanism	  of	  GABA	  neuron	  degeneration	  in	  a	  C.	  
elegans	  model	  of	  Coenzyme	  Q	  deficiency.	  This	  model	   shares	  key	   features	  with	  neurodegenerative	  
diseases,	   including	   selective	   neuronal	   vulnerability,	   age-­‐related	   onset,	   and	   mitochondrial	  
dysfunction.	   Thus,	  my	   studies	   of	   this	   phenomenon	   in	  C.	   elegans	   have	   the	   potential	   to	   reveal	   key	  
determinants	   of	   neuropathogenic	   disease	   in	   humans.	   The	   molecular	   pathway	   activated	   in	   CoQ-­‐
deficient	   GABA	   neurons	   is	   regulated	   by	   a	   novel	   combination	   of	   elements	   including	   canonical	  
components	  of	  both	  apoptotic	   (Chapter	  2	  and	  Chapter	  4)	  and	  necrotic	   (Chapter	  2	  and	  Chapter	  5)	  
mechanisms.	   	   My	   work	   has	   also	   uncovered	   evidence	   of	   robust	   mechanisms	   for	   intercellular	  
trafficking	   of	   CoQ	   that	   is	   sufficient	   to	   protect	   otherwise	   CoQ-­‐deficient	   GABA	   neurons	   from	  
degeneration	  (Chapter	  3).	  These	  studies	  emphasize	  the	  power	  of	  using	  a	  simple,	  genetic	  organism	  to	  
investigate	   complex	   cellular	   responses	   to	   mitochondrial	   dysfunction.	   The	   strong	   conservation	   of	  
core	   biological	   processes	   between	   nematodes	   and	   mammals	   suggests	   that	   these	   findings	   in	   C.	  
elegans	   could	   contribute	   to	   our	   understanding	   of	   how	   mitochondrial	   impairment	   leads	   to	  
neurodegenerative	  disease.	  Here,	   I	  discuss	  key	  findings	  and	  future	  directions	  to	  further	   investigate	  
the	  effects	  of	  Coenzyme	  Q	  deficiency	  in	  C.	  elegans.	  
	  
Specific	  proteases	  antagonize	  CoQ	  deficiency-­‐induced	  GABA	  neurodegeneration	  
CED-­‐3/caspase	  
	   Our	  studies	  in	  Chapter	  4	   introduced	  a	  novel	  role	  for	  CED-­‐3/caspase	  in	  CoQ-­‐deficient	  GABA	  
neurons;	   in	   this	   context	   CED-­‐3	   antagonizes	   a	   CED-­‐4-­‐dependent	   killing	   pathway.	   Whereas	   the	  
mechanism	  of	  this	  neuroprotective	  role	  of	  CED-­‐3	  is	  unclear,	  another	  recently	  discovered	  function	  for	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CED-­‐3	   could	   explain	   how	   an	   executioner	   caspase	   antagonizes	   GABA	   neuron	   degeneration.	   In	   this	  
finding,	   laser	   axotomy	   of	   GABA	   neurons	   triggers	   a	   regeneration	   pathway	   that	   depends	   on	   CED-­‐3	  
function.	   This	  mechanism	   is	   also	   calcium	  dependent	   and	   requires	   the	   ER	   calcium	  binding	  protein,	  
CRT-­‐1/calreticulin	   (Pinan-­‐Lucarre	   et	   al.	   2011).	   Notably,	   we	   previously	   demonstrated	   that	   CoQ	  
depletion-­‐induced	  GABA	  neuron	  death	  also	  requires	  CRT-­‐1/calreticulin-­‐dependent	  calcium	  signaling	  
(Chapter	  2).	  As	  described	  in	  Chapter	  4,	  we	  favor	  a	  hypothesis	  in	  which	  CoQ	  deficiency	  and	  axotomy	  
induce	  similar	  stress	  responses.	  This	  model	  predicts	  that	  these	  signals	  activate	  a	  common	  pathway	  
to	  neutralize	  the	  cellular	  damage	  in	  GABA	  motor	  neurons.	  In	  this	  paradigm,	  CoQ	  deficiency	  triggers	  a	  
CED-­‐4-­‐dependent	   degeneration	   pathway	   that	   is	   antagonized	   by	   a	   CED-­‐3-­‐requiring	   regeneration	  
mechanism	  (Fig.	  4.7A).	  Studies	  in	  C.	  elegans	  have	  identified	  conserved	  signaling	  pathways	  (i.e.,	  DLK-­‐
1,	   MAP	   kinase-­‐dependent)	   that	   are	   required	   for	   efficient	   neuron	   regeneration	   (Bejjani	   &	  
Hammarlund	   2011).	   Thus,	   future	   experiments	   to	   test	   this	   model	   could	   examine	   regeneration-­‐
deficient	  mutants	   (i.e.,	   dlk-­‐1)	   under	   CoQ-­‐depletion	   conditions.	   If	   DLK-­‐1-­‐dependent	   regeneration	  
pathways	   are	   activated	   in	   response	   to	   CoQ	   deficiency,	   then	   animals	   lacking	   dlk-­‐1	   function	   are	  
predicted	  to	  display	  the	  enhanced	  neurodegeneration	  phenotype	  of	  ced-­‐3	  mutants.	  	  
The	  robust	  degeneration	  of	  GABA	  neurons	  that	  occurs	  with	  CoQ	  deficiency	  suggests	  that	  the	  
CED-­‐4-­‐dependent	   cell-­‐killing	   pathway	   ultimately	   overpowers	   the	   neuroprotective	   effects	   of	   CED-­‐3	  
function.	  This	  observation	  raises	  the	  question	  of	  whether	  a	  stronger	  regenerative	  response	  to	  CoQ	  
deficiency	   could	   also	   offer	   more	   neuroprotection.	   For	   instance,	   neuronal	   regeneration	   in	  
axotomized	   GABA	   neurons	   is	   accelerated	   by	   overexpression	   of	   DLK-­‐1	   (Hammarlund	   et	   al.	   2009).	  
Therefore,	   if	   it	   is	   discovered	   that	   dlk-­‐1	  mutants	   phenocopy	   ced-­‐3	   loss-­‐of-­‐function	   (as	   suggested	  
above),	   it	   would	   be	   interesting	   to	   determine	   if	   overexpression	   of	   DLK-­‐1	   in	   CoQ-­‐deficient	   GABA	  
neurons	  is	  sufficient	  to	  inhibit	  neuron	  death.	  This	  result	  would	  suggest	  that	  the	  balance	  between	  cell	  
protection	  and	  cell	  death	  could	  be	  manipulated	  to	  sustain	  neuron	  viability.	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   Neuroprotective	  roles	   for	  active	  caspases	  have	  also	  been	  detected	   in	  cellular	   responses	  to	  
ischemia	  (McLaughlin	  et	  al.	  2003).	  The	  term	  “preconditioning”	  refers	  to	  a	  process	  in	  which	  sub-­‐toxic	  
challenges	   confer	   tolerance	   to	   subsequent	   insults.	   For	   example,	   exposure	   to	   acute	   stressors	   (i.e.,	  
disrupted	  ROS	  or	  ATP	  levels)	  induces	  up-­‐regulation	  of	  pro-­‐survival	  genes	  that	  in	  turn	  protect	  against	  
future	   injury.	   Sublethal	   ischemic	   conditions	   activate	   caspase-­‐3,	   such	   that	   the	   affected	   cells	   are	  
relatively	  protected	  against	  subsequent	  ischemic	  insults.	  In	  this	  paradigm,	  the	  application	  of	  caspase	  
inhibitors	   abrogated	   the	   neuroprotective	   response,	   and	   therefore	   supports	   the	   hypothesis	   that	  
caspase-­‐3	   is	   required	   for	  neuronal	  preconditioning.	  For	  animals	   that	  are	  exposed	   to	  CoQ-­‐deficient	  
conditions	   throughout	   life,	   damage	   to	   GABA	   neurons	   could	   accumulate	   over	   time	   to	   eventually	  
activate	  cell	  death	  at	  the	  adult	  stage.	  Perhaps	  young	  CoQ-­‐deficient	  animals	  activate	  CED-­‐3	  acutely	  in	  
a	  response	  similar	  to	  caspase-­‐3	  activation	  during	  ischemic	  preconditioning	  (McLaughlin	  et	  al.	  2003).	  
CED-­‐3	  activity	  could	  provide	  cytoprotective	  effects	  that	  prevent	  activation	  of	  a	  neurodegeneration	  
pathway.	   However,	   as	   animals	   age,	   two	   potential	   mechanisms	   could	   explain	   how	   this	  
neuroprotection	   is	   overridden.	   First,	   as	   mentioned	   above,	   the	   cumulative	   intracellular	   damage	  
inflicted	   by	   CoQ-­‐deficiency	   could	   reach	   a	   level	   of	   severity	   in	   adulthood	   that	   can	   no	   longer	   be	  
inhibited	  by	  neuroprotective	  mechanisms.	  Alternatively,	  development	  from	  L3	  to	  adulthood	  is	  a	  very	  
energetically	  demanding	  process	  (due	  to	  a	  large	  expansion	  in	  mitochondria	  DNA	  (mtDNA)	  (Tsang	  &	  
Lemire	  2002)).	  As	  the	  animal	  transitions	  from	  larval	  to	  adult	  stages,	  the	  reduced	  levels	  of	  ATP	  that	  
results	   from	   CoQ	   depletion	   coupled	   with	   this	   robust	   energy	   requirement	   could	   trigger	  
neurodegeneration,	  despite	  early	  CED-­‐3	  neuroprotection.	  	  
Although	   the	   exact	   mechanism	   of	   caspase-­‐3-­‐dependent	   ischemic	   neuroprotection	   is	   not	  
well-­‐understood,	   caspase-­‐3	   activation	   is	   required	   for	   induction	   of	   neuroprotective	   heat-­‐shock	  
proteins	   (HSPs)	  which	  function	  as	  molecular	  chaperones	  under	  conditions	  of	  stress	   (McLaughlin	  et	  
al.	   2003).	   HSPs	   and	   hypoxia	   inducible	   factor	   (HIF)	   are	   up-­‐regulated	   as	   a	   result	   of	   preconditioning	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stresses	  (Albers	  et	  al.	  2010).	  HIF	   is	  a	  conserved	  transcription	  factor	  that	  mediates	  the	   induction	  of	  
hundreds	  of	  genes	  in	  response	  to	  hypoxia.	  In	  C.	  elegans,	  hif-­‐1	  is	  also	  required	  for	  survival	  of	  hypoxic	  
conditions	   (C.	   Shen	   &	   Powell-­‐Coffman	   2003),	   induced	   by	   mitochondrial	   ETC	   inhibitors	   (i.e.,	  
rotenone/Complex	   I,	   antimycin/Complex	   III).	  Although	  our	   studies	   showed	   that	  ETC	  dysfunction	   is	  
not	   sufficient	   to	   account	   for	   degeneration	   of	   CoQ-­‐deficient	   GABA	   neurons	   (Chapter	   5),	   it	   is	  
reasonable	  to	  hypothesize	  that	  CoQ	  deficiency	  likely	  reduces	  ETC	  function	  and	  therefore	  simulates	  
hypoxic	  conditions.	  The	  role	  of	  hypoxic	  response	  genes	   in	  this	  pathway	  has	  not	  been	   investigated,	  
but	   the	   association	   of	   caspases	  with	   the	   preconditioning	   effect	   (McLaughlin	   et	   al.	   2003)	   suggests	  
that	   CED-­‐3	   could	   functions	   through	   a	   similar	   mechanism	   in	   response	   to	   CoQ	   depletion.	   In	   this	  
model,	  the	  neuroprotective	  mechanism	  fails	  in	  ced-­‐3	  mutants,	  which	  thus	  show	  more	  robust	  GABA	  
neuron	  death.	  This	  model	  predicts	  that	  hif-­‐1	  mutants	  could	  phenocopy	  the	  enhanced	  GABA	  neuron	  
degeneration	  defect	  of	  ced-­‐3	   loss-­‐of-­‐function	  mutants.	  The	  precise	  mechanism	  of	  CED-­‐3-­‐mediated	  
neuroprotection	   is	  unclear	  but	   future	   studies	  of	  neuronal	   regeneration	  or	   cellular	  preconditioning	  
could	  be	  informative.	  
	  
Investigating	  the	  role	  of	  autophagy	  under	  CoQ-­‐deficient	  conditions	  
If	  additional	  studies	  confirm	  that	  HIF-­‐1	  is	  required	  for	  GABA	  neuroprotection,	  then	  a	  role	  for	  
hypoxic	   response	   pathways	   in	   CoQ-­‐deficient	   animals	   could	   be	   further	   investigated.	   For	   instance,	  
autophagy	   protects	   against	   hypoxia	   in	   C.	   elegans,	   and	   we	   identified	   ultrastructural	   features	  
consistent	   with	   autophagy	   in	   the	   ventral	   nerve	   cord	   (VNC)	   of	   CoQ-­‐deficient	   animals	   (Chapter	   5)	  
Perhaps,	   in	   this	   instance,	  a	  GABA	  neuron	  has	  activated	  autophagy	  as	  a	   cell-­‐survival	  mechanism	   in	  
response	  to	  CoQ-­‐deficient	  conditions.	  As	  described	  in	  Chapter	  5,	  future	  studies	  could	  use	  mutants	  of	  
known	  autophagy	  genes	  to	  investigate	  the	  role	  of	  autophagy	  in	  the	  CoQ-­‐deficient	  neurons.	  Because	  
autophagy	   can	   contribute	   to	   both	   cell	   survival	   and	   cell	   death	   pathways	   (Kourtis	   &	   Tavernarakis	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2009),	   alternative	   mechanisms	   could	   account	   for	   the	   autophagic	   neuron	   observed	   in	   our	   TEM	  
studies.	  The	  following	  models	  (Fig.	  6.1)	  and	  potential	  outcomes	  are	  considered	  for	  this	  analysis:	  (1)	  
Autophagy	  is	  activated	  in	  GABA	  neurons	  to	  protect	  against	  degeneration.	  Over	  time,	  however,	  these	  
neurons	   succumb	   to	  necrosis.	   In	   this	  model,	  mutations	   in	   autophagy	   genes	  would	   enhance	  GABA	  
neuron	  death.	  (2)	  GABA	  neurons	  activate	  a	  necrotic	  pathway	  that	  requires	  autophagy	  (as	  discussed	  
in	  Chapter	  5);	  therefore,	  inhibiting	  autophagy	  in	  this	  case	  should	  block	  GABA	  neurodegeneration.	  (3)	  
Cholinergic	   neurons	   survive	   CoQ	   deficiency	   by	   activating	   autophagy	   as	   a	   cell-­‐survival	  mechanism.	  
Therefore,	   inhibiting	   autophagy	   could	   result	   in	   degeneration	   of	   cholinergic	   neurons.	   The	   third	  
outcome	   would	   be	   particularly	   interesting,	   as	   it	   would	   suggest	   a	   rationale	   for	   why	   cholinergic	  
neurons	  fail	  to	  degenerate	  with	  CoQ	  deficiency.	  
	  
TRA-­‐3/calpain	  
	   My	   work	   identified	   another	   protease	   TRA-­‐3/calpain	   as	   a	   negative	   regulator	   of	   the	   CoQ	  
depletion-­‐induced	   GABA	   neuron	   death	   pathway	   (Chapter	   5).	   TRA-­‐3	   has	   been	   shown	   to	   promote	  
death	  in	  other	  models	  of	  necrosis	  (Syntichaki	  et	  al.	  2002).	  However,	  in	  the	  context	  of	  CoQ-­‐deficient	  
GABA	  neurons,	  my	  evidence	  suggests	  that	  TRA-­‐3	  exerts	  the	  opposite	  role,	  antagonizing	  cell	  death.	  
tra-­‐3	  mutants	   show	   enhanced	   neurodegeneration	   (Chapter	   5)	   resembling	   that	   of	   ced-­‐3	   loss-­‐of-­‐
function	  animals	   (Chapter	   4).	  The	   identification	  of	   two	  different	  proteases,	  CED-­‐3	  and	  TRA-­‐3,	   that	  
antagonize	   GABA	   neuron	   death	   strengthens	   the	   hypothesis	   that	   both	   cell-­‐killing	   and	   cell-­‐survival	  
mechanisms	  are	  activated	  in	  CoQ-­‐deficient	  GABA	  neurons.	  	  
Calpain-­‐dependent	  antagonism	  of	  death	  pathways	  has	  also	  been	  observed	  in	  mammals.	  For	  
example,	   mitochondrial	   calpain	   10	   protects	   against	   apoptotic	   cell	   death	   (Covington	   et	   al.	   2008).	  
Calpain-­‐dependent	   degradation	   of	   pro-­‐apoptotic	   proteins	   (i.e.,	   Bax	   and	   Apaf-­‐1)	   has	   also	   been	  
reported	  (Wood	  et	  al.	  1998;	  Reimertz	  et	  al.	  2001).	  These	  examples	  are	  consistent	  with	  a	  model	  in	  	  








Figure	  6.1:	  Models	  of	  how	  autophagy	  could	  prevent	  or	  promote	  neurodegeneration.	  	  
A.	  Model	   1:	  Autophagy	   is	   activated	   in	   response	   to	  CoQ	  deficiency	   to	  protect	  GABA	  neurons	   from	  
death.	  However,	  over	   time,	   injuries	   accumulate	  and	  necrosis	   is	   activated	   to	   kill	  GABA	  neurons.	  B.	  
Model	  2:	  CoQ	  deficiency	  triggers	  a	  necrotic	  pathway	  that	  requires	  autophagy.	  C.	  Model	  3:	  Activation	  
of	  the	  autophagy	  pathway	  protects	  cholinergic	  neurons	  from	  degeneration	  with	  CoQ	  deficiency.	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which	  TRA-­‐3	  inhibits	  the	  GABA	  neuron	  death	  pathway	  through	  proteolysis	  of	  the	  killing	  machinery.	  
Future	   studies	   could	   test	   this	  model	   by	   genetic	   epistasis	   experiments	   (see	   below)	   or	   biochemical	  
assays	  to	  determine	  if	  TRA-­‐3	  cleaves	  proteins	  that	  promote	  GABA	  neuron	  degeneration	  (i.e.,	  CED-­‐4).	  	  
	   To	   better	   understand	   how	   CED-­‐3	   and	   TRA-­‐3	   antagonize	   neurodegeneration,	   epistatic	  
relationships	   between	   these	   proteases	   and	   positive	   regulators	   of	   the	   pathway	   (e.g.,	   ced-­‐4,	   asp-­‐4,	  
crt-­‐1,	   drp-­‐1)	   could	   be	   investigated.	   Our	   studies	   of	   ced-­‐3	   and	   ced-­‐4	   uncovered	   a	   novel	   epistatic	  
interaction	  that	  places	  ced-­‐4	  either	  downstream	  or	  in	  parallel	  to	  ced-­‐3	  (Chapter	  4).	  This	  finding	  led	  
to	   testable	  models	   that	   could	   be	   explored	   in	   future	   studies	   (see	  Chapter	   4).	   The	   idea	   that	   TRA-­‐3	  
inhibits	   degeneration	   through	   direct	   cleavage	   of	   death-­‐promoting	   proteins	   could	   be	   tested	   with	  
these	   epistasis	   experiments.	   For	   example,	   if	   TRA-­‐3	   functions	   similarly	   to	   mammalian	   calpain	   to	  
cleave	  CED-­‐4,	  then	  this	  TRA-­‐3-­‐dependent	  activity	  would	  effectively	  reduce	  the	  executioner	  function	  
of	  CED-­‐4	  in	  the	  mechanism	  of	  GABA	  neuron	  death.	  It	  follows	  then	  that	  this	  inhibition	  of	  CED-­‐4	  would	  
be	  relieved	  in	  a	  tra-­‐3	  mutant	  and	  thus	  result	  in	  enhanced	  neurodegeneration.	  In	  this	  model,	  the	  tra-­‐
3;	  ced-­‐4	  double	  mutant	   is	  predicted	  to	  phenocopy	  ced-­‐4	  single	  mutants	  (i.e.,	  ced-­‐4	   is	  epistatic	  and	  
degeneration	  is	  suppressed).	  Similar	  genetic	  epistasis	  experiments	  should	  be	  highly	  useful	  for	  future	  
studies	  that	  seek	  to	  place	  these	  genes	  in	  the	  pathway	  that	  controls	  GABA	  neuron	  death.	  
	  
CED-­‐4/Apaf-­‐1	  promotes	  necrosis	  in	  CoQ-­‐deficient	  GABA	  neurons	  
	   In	   this	   work,	   morphological	   features	   of	   dying	   GABA	   neurons	   were	   examined	   using	   light	  
microscopy	  (Chapter	  2	  and	  Chapter	  3)	  and	  transmission	  electron	  microscopy	  (Chapter	  5).	  Based	  on	  
the	   appearance	   of	   canonical	   necrotic	   features	   of	   GABA	   motor	   neurons	   (e.g.,	   swollen	   cell	   soma,	  
extensive	  proteolysis,	  and	  mitochondrial	  rupture),	  we	  concluded	  that	  CoQ-­‐deficient	  GABA	  neurons	  
activate	  a	  necrotic	  death	  pathway.	  Evidence	  of	  necrosis	  is	  further	  supported	  by	  the	  requirement	  of	  
necrotic	  genes	  (asp-­‐4/cathepsin	  and	  crt-­‐1/calreticulin)	  for	  GABA	  neurodegeneration.	  (Chapter	  5).	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Intriguingly,	  we	  also	  showed	  that	  a	  core	  member	  of	  the	  canonical	  apoptotic	  pathway,	  CED-­‐4,	  
functions	  as	  a	  key	  regulator	  of	  GABA	  neuron	  necrotic	  death	  (Chapter	  2).	  In	  addition,	  we	  discovered	  
that	   CED-­‐4	   does	   not	   promote	   neurodegeneration	   through	   its	   canonical	   apoptotic	   caspase	   CED-­‐3	  
(Chapter	  4).	  Although	  the	  most	  well-­‐documented	  function	  of	  CED-­‐4	  is	  to	  promote	  programmed	  cell	  
death	  (Shaham	  &	  Horvitz	  1996a),	  alternative	  roles	  for	  CED-­‐4	  have	  been	  identified	  in	  other	  biological	  
processes.	   For	  example,	  CED-­‐4	  and	  Apaf-­‐1	   share	  a	   conserved	   function	  of	  mediating	  DNA-­‐damage-­‐
induced	   cell-­‐cycle	   arrest	   (Zermati	   et	   al.	   2007;	   Mouhamad	   et	   al.	   2007).	   Additionally,	   hypoxic	  
preconditioning	  and	  cell-­‐size-­‐regulation	  are	  also	  controlled	  by	  CED-­‐4	  (Dasgupta	  et	  al.	  2007;	  L.	  Chen	  
et	   al.	   2008).	   Notably,	   all	   of	   these	   non-­‐apoptotic	   functions	   of	   CED-­‐4	   occur	   independently	   of	   its	  
downstream	  caspase	  CED-­‐3	  (Zermati	  et	  al.	  2007;	  Dasgupta	  et	  al.	  2007;	  L.	  Chen	  et	  al.	  2008).	  Some	  of	  
these	   non-­‐apoptotic	   roles	   for	   CED-­‐4	   are	   also	   induced	   by	   cellular	   stresses	   (i.e.,	  DNA-­‐damage	   and	  
hypoxia).	   Therefore,	   the	   activation	   of	   a	   CED-­‐4-­‐dependent	   function	   in	   CoQ-­‐deficient	   neurons	   that	  
does	  not	  require	  other	  members	  of	  the	  canonical	  apoptotic	  pathway	  may	  involve	  mechanisms	  that	  
also	   occur	   under	   other	   conditions	   of	   cell	   stress.	   Together,	   these	   findings	   suggest	   that	   CED-­‐4	  
functions	   as	   a	   critical	   stress-­‐sensing	   protein	   that	   can	   be	   activated	   by	   a	   range	   of	   different	  
environmental	  conditions.	  
	  
Potential	  mechanisms	  of	  CED-­‐4	  activation	  
A	   worm	   adenine	   nucleotide	   translocase	   (WAN-­‐1/ANT)	   was	   recently	   identified	   as	   a	   core	  
component	   of	   the	   C.	   elegans	   programmed	   cell	   death	   machinery	   (Q.	   Shen	   et	   al.	   2009).	   Adenine	  
nucleotide	   translocases	   regulate	   the	   mitochondrial	   permeability	   transition	   pore	   (PTP)	   complex	  
(Galluzzi	   et	   al.	   2010).	   As	   discussed	   in	   Chapter	   1,	   mitochondrial	   PTP	   opening	   (i.e.,	  mitochondrial	  
permeability	  transition	  or	  MPT)	  can	  be	  induced	  by	  ROS	  or	  calcium,	  and	  prolonged	  pore	  opening	  can	  
lead	  to	  cell	  death	  (Vaseva	  et	  al.	  2012;	  Geng	  et	  al.	  2012).	  Overexpression	  of	  ANT	  (Bauer	  et	  al.	  1999)	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or	  WAN-­‐1	  (Q.	  Shen	  et	  al.	  2009)	  induces	  apoptosis,	  whereas	  ANT	  inhibition	  blocks	  cell	  death	  (Marzo	  
et	  al.	  1998;	  Q.	  Shen	  et	  al.	  2009).	  Because	  ANT	  is	  a	  critical	  regulator	  of	  PTP	  opening,	  mechanisms	  that	  
control	  ANT	  activity	  are	  likely	  to	  limit	  inappropriate	  cell	  death.	  
Interestingly,	   Coenzyme	   Q	   may	   inhibit	   apoptosis	   by	   physically	   interacting	   with	   the	   PTP,	  
although	  a	  specific	  CoQ-­‐binding	  protein	  in	  this	  complex	  has	  yet	  to	  be	  identified	  (Papucci	  et	  al.	  2003;	  
Devun	   et	   al.	   2010;	   Sahach	   et	   al.	   2007).	   Loss	   of	   Coenzyme	  Q	   could	   stimulate	   pore	   opening	   either	  
directly	   (i.e.,	   by	   removal	   of	   inhibition	   of	   PTP	   opening)	   or	   indirectly	   (i.e.,	   by	   increasing	   ROS	  
production,	   which	   induces	   PTP	   opening).	   In	   considering	   this	   evidence,	   I	   hypothesize	   that	   the	  
mitochondrial	  PTP	  opens	  through	  a	  WAN-­‐1/ANT-­‐dependent	  manner	  in	  CoQ-­‐deficient	  GABA	  neurons	  
to	  promote	  CED-­‐4-­‐dependent	  necrosis.	  	  
Future	   studies	   could	   test	   this	   model	   by	   examining	   CoQ	   depletion-­‐induced	   GABA	  
neurodegeneration	   in	   ANT-­‐deficient	   genetic	   backgrounds.	   If	   ANT	   promotes	   GABA	   neuron	   death,	  
then	   genetic	   ablation	   of	   ANT	   function	   is	   predicted	   to	   block	   neurodegeneration	   (similar	   to	   loss	   of	  
ced-­‐4).	   This	   requirement	   for	  ANT	  during	  GABA	  degeneration	  would	   raise	   the	  question	  of	  whether	  
MTP	  is	   involved	  (as	   in	  HBx-­‐induced	  necrosis	  (Geng	  et	  al.	  2012),	  described	  below)	  or	   if	  ANT	  directly	  
activates	   CED-­‐4	  without	   PTP	   opening	   (as	   in	   apoptosis	   (Q.	   Shen	   et	   al.	   2009),	   described	   above).	   In	  
addition	   to	   ANT,	   the	   PTP	   complex	   also	   contains	   VDAC	   (voltage-­‐dependent	   anion	   channel)	   and	  
cyclophilin	  D	  (discussed	  in	  Chapter	  1)	  (Galluzzi	  et	  al.	  2010).	  A	  recent	  study	  in	  C.	  elegans	  described	  a	  
necrotic	  pathway	  initiated	  by	  ectopic	  expression	  of	  Hepatitis	  B	  virus	  protein	  X	  (HBx)	  that	  functions	  
through	   the	   MPT	   (Geng	   et	   al.	   2012).	   Inhibition	   of	   MPT	   was	   achieved	   using	   cyn-­‐1/Cyclophilin	   D	  
mutants	   that	  prevented	   necrotic	   cell	   death.	   Similar	   genetic	   experiments	   (i.e.,	   cyn-­‐1/Cyclophilin	   D	  
mutants)	   could	   be	   performed	   in	   CoQ-­‐deficient	   animals	   to	   determine	   if	  MPT	   is	   required	   for	  GABA	  
neurodegeneration.	   If	   inactivation	   of	   the	   PTP	   (independent	   of	   ANT/WAN-­‐1)	   does	   not	   suppress	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degeneration,	   this	   result	   would	   suggest	   that	  WAN-­‐1	   functions	   independently	   of	   PTP	   to	   promote	  
CED-­‐4-­‐dependent	  necrosis.	  
Shen	  et	  al.	  report	  that	  overexpression	  of	  WAN-­‐1	  induces	  ectopic	  apoptotic	  death	  (Q.	  Shen	  et	  
al.	  2009).	   In	   the	  case	  of	  CoQ-­‐deficient	  GABA	  neurons,	  however,	  we	  are	  considering	   the	  possibility	  
that	   WAN-­‐1	   would	   promote	   necrosis.	   Cellular	   ATP	   concentration	   can	   determine	   whether	   a	   cell	  
undergoes	  apoptosis	  or	  necrosis	  (Yakovlev	  &	  Faden	  2004)	  (Fig.	  1.5),	  with	  high	  levels	  of	  ATP	  required	  
for	  apoptosis	  and	  low	  ATP	  levels	  resulting	  in	  necrosis.	  We	  have	  shown	  that	  CoQ	  deficiency	  reduces	  
ATP	   levels	   (Fig.	   2.10).	   Therefore,	   the	   decreased	   ATP	   production	   and	   likely	   increased	   ROS	   that	  
accompany	  CoQ	  deficiency	  could	  shift	  WAN-­‐1/ANT-­‐dependent	  cell	  death	  from	  apoptosis	  (Q.	  Shen	  et	  
al.	  2009)	  (wild-­‐type	  CoQ	  levels)	  to	  necrosis	  (reduced	  CoQ	  levels).	  Therefore,	   if	  ANT	  were	  identified	  
as	   a	   component	   of	   the	   GABA	   neurodegeneration	   pathway,	   it	   would	   be	   interesting	   to	   investigate	  
whether	  ectopic	  WAN-­‐1	  expression	  in	  CoQ-­‐deficient	  backgrounds	  enhances	  the	  necrotic	  phenotype.	  
	  
Intercellular	  Coenzyme	  Q	  transport	  in	  C.	  elegans	  
	   Initially,	  I	  considered	  the	  hypothesis	  that	  GABA	  neuron	  degeneration	  results	  from	  decreased	  
synthesis	  of	  Coenzyme	  Q	  in	  the	  affected	  GABA	  neurons.	  However,	  selective	  knockdown	  of	  coq-­‐1	  in	  
GABA	   neurons	   did	   not	   trigger	   neurodegeneration	   (Chapter	   3).	   Because	   global	   reduction	   of	   CoQ	  
results	  in	  GABA	  neuron	  degeneration,	  I	  reasoned	  that	  the	  necrotic	  phenotype	  must	  result	  from	  low	  
CoQ	   levels	   but	   that	  GABA	  neurons	   fail	   to	   degenerate	  with	   cell	   specific	   coq-­‐1	   knockdown	  because	  
other	   cells	   compensate	   for	   the	   lack	   of	  de	   novo	  CoQ	   synthesis	   in	   GABA	   neurons	   (Fig.	   3.9).	   In	   this	  
paradigm,	   CoQ	   provided	   from	   Q-­‐replete	   cells	   is	   capable	   of	   rescuing	   Q-­‐deficient	   tissues.	   This	  
hypothesis	  is	  reinforced	  by	  our	  discovery	  that	  restoration	  of	  CoQ	  production	  in	  muscle	  is	  sufficient	  
to	  overcome	  growth	  and	  fertility	  defects	  of	  coq-­‐1	  mutants	  (Chapter	  3).	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Studies	   of	   uptake	   of	   exogenous	   CoQ	   and	   intracellular	   trafficking	   have	   implicated	   the	  
endomembrane	  system	  but	  the	  molecular	  mechanisms	  that	  govern	  these	  key	  processes	  are	  largely	  
unknown	   (Padilla-­‐López	   et	   al.	   2009;	   Fernández-­‐Ayala	   et	   al.	   2005).	   As	   described	   in	  Chapter	   3,	   this	  
deficit	  could	  be	  addressed	  by	  forward	  genetic	  screens	   in	  C.	  elegans.	  For	  example,	   in	  coq-­‐1	  mutant	  
animals	  that	  are	  viable	  with	  muscle-­‐only	  COQ-­‐1	  expression	  (see	  Chapter	  3),	  genetic	  mutations	  that	  
inhibit	   CoQ	   transport	   would	   result	   in	   lethality.	   Alternatively,	   mutations	   that	   enhance	   CoQ	  
intercellular	   transport	   should	   result	   in	   improved	   viability	   (i.e.,	   increased	   brood	   size,	   Fig.	   3.5).	  
Mutations	  in	  known	  endocytic	  components	  could	  validate	  the	  screen	  and	  potentially	  new	  regulators	  
(i.e.,	   CoQ-­‐binding	   chaperones)	   may	   also	   be	   discovered.	   The	   impact	   of	   these	   studies	   could	   have	  
important	  therapeutic	  implications,	  as	  the	  effectiveness	  of	  CoQ	  supplementation	  is	  currently	  limited	  
by	  its	  inefficient	  uptake	  from	  exogenous	  sources.	  
	  
Model	  of	  CoQ	  deficiency-­‐induced	  GABA	  neurodegeneration	  
	   My	   studies	   have	   identified	   a	   range	  of	   proteins	   that	   adopt	   either	   canonical	   or	   unexpected	  
roles	  in	  the	  neurodegenerative	  response	  to	  CoQ	  deficiency.	  Here,	  I	  describe	  a	  model	  (Fig.	  6.2)	  that	  
incorporates	   my	   current	   knowledge	   of	   this	   pathway.	   Based	   on	   hypotheses	   introduced	   in	   this	  
Discussion,	  I	  speculate	  on	  the	  interactions	  between	  these	  components	  that	  ultimately	  lead	  to	  GABA	  
neuron	   death.	   Confirmation	   of	   this	   model	   will	   depend	   on	   future	   studies	   to	   delineate	   the	   exact	  
sequence	  of	  events	  that	  trigger	  degeneration	  of	  CoQ-­‐deficient	  GABA	  neurons.	  
	  
Events	  that	  lead	  to	  GABA	  neuron	  death	  under	  CoQ	  deficient-­‐conditions	  
Global	   CoQ	   deficiency	   ultimately	   results	   in	   a	   broad	   array	   of	   defects	   in	   many	   tissues	   but	  
GABA	   neurons	   are	   preferentially	   sensitive	   to	   a	   degenerative	   response	   (Chapter	   2).	   Despite	   the	  
prominent	  role	  of	  CoQ	  in	  the	  electron	  transport	  chain	  (ETC),	  our	  studies	  suggest	  that	  ETC-­‐	  	  





Figure	   6.2:	   Model	   of	   CoQ	   deficiency-­‐induced	   GABA	   neurodegeneration.	   Reduced	   Coenzyme	   Q	  
levels	   in	  GABA	  neurons	   increases	  ROS	  production,	  which	   in	   turn	   triggers	  a	  necrotic	  pathway.	  CED-­‐
4/Apaf-­‐1,	  DRP-­‐1/Dynamin-­‐Related	  Protein,	  ASP-­‐4/aspartyl	  protease,	  and	  CRT-­‐1-­‐dependent	  calcium	  
release	   promote	   GABA	   neurodegeneration.	   Conversely,	   GABA	   neuron	   death	   is	   antagonized	   by	  
proteases	   (CED-­‐3/caspase	   and	   TRA-­‐3/calpain).	   GABA	   neurons	   that	   cannot	   synthesize	   CoQ	   can	  
import	  CoQ	  from	  external	  sources	  and	  to	  prevent	  activation	  of	   the	  necrotic	  pathway.	  Solid	   lines	  =	  
experimentally	  supported,	  dashed	  lines	  =	  hypothesized.	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independent	  CoQ	  functions	  (e.g.,	  antioxidant	  defense)	  antagonize	  this	  death	  pathway	  (Chapter	  5).	  I	  
hypothesize	  that	  the	  loss	  of	  Coenzyme	  Q	  reduces	  its	  robust	  antioxidant	  function	  and	  thus	  results	  in	  
increased	   ROS	   production.	   This	   oxidative	   stress	   (i.e.,	   damage	   to	   proteins,	   lipids,	   nucleotides)	  
accumulates	  throughout	  the	  lifetime	  of	  the	  animal	  and	  manifests	  as	  a	  degenerative	  response	  during	  
adulthood	  (Chapter	  2).	  In	  this	  model,	  increased	  oxidative	  stress	  results	  in	  elevated	  cytosolic	  calcium	  
through	  CRT-­‐1-­‐dependent	   release	   from	   the	   endoplasmic	   reticulum	   (ER)	   (Chapter	   2).	   High	   calcium	  
concentrations	   coupled	   with	   elevated	   ROS	   could	   trigger	   ANT/WAN-­‐1-­‐dependent	   mitochondrial	  
permeability	  transition	  (MPT).	  Additionally,	  Coenzyme	  Q	  deficiency	  may	  disrupt	  the	  CoQ-­‐dependent	  
inhibition	  of	  MPT	  and	  thus	  sensitize	  the	  permeability	  transition	  pore	  for	  opening	  by	  elevated	  ROS	  or	  
calcium.	  ANT/WAN-­‐1	  could	   then	  release	  CED-­‐4	   (Chapter	   2	   and	  Chapter	   4),	  allowing	   it	   to	  promote	  
necrosis	   through	   unidentified	   downstream	   effectors.	   In	   parallel	   to	   elevating	   cytoplasmic	   calcium,	  
ROS	   also	   promotes	   DRP-­‐1-­‐dependent	   mitochondrial	   fragmentation	   (Chapter	   2).	   Mitochondrial	  
fragmentation	   and	   PTP	   opening	   would	   then	   release	   unknown	   death-­‐promoting	   factors	   from	   the	  
mitochondria	   into	   the	   cytosol.	   Additionally,	   mitochondrial	   fragmentation	   acidifies	   the	   cell	   (D.	  
Johnson	  &	  Nehrke	  2010)	  and	  activates	  cathepsin	  proteases	  (i.e.,	  ASP-­‐4,	  Chapter	  5)	  that	  require	  low	  
pH	   for	   optimal	   enzymatic	   activity	   (Syntichaki	   et	   al.	   2002).	   These	   cellular	   stresses	   and	   proteolytic	  
events	  culminate	  in	  necrotic	  cell	  death	  of	  GABA	  motor	  neurons.	  
	  
Mechanisms	  that	  antagonize	  GABA	  neurodegeneration	  
	   The	   cascade	   of	   events	   described	   above	   is	   based	   on	   our	   current	   understanding	   of	   the	  
molecular	   components	   that	   promote	   GABA	   neurodegeneration.	   Our	   studies	   have	   also	   revealed	  
mechanisms	   that	   antagonize	  GABA	  neuron	   death	   (Fig.	   6.2).	   For	   example,	  with	   tissue-­‐specific	   CoQ	  
depletion,	   GABA	   neurons	   that	   are	   blocked	   for	  de	   novo	   CoQ	   synthesis	  may	   incorporate	   CoQ	   from	  
other	   cells,	   thus	   preventing	   the	   cell	   death	   response	   (Chapter	   3).	   When	   the	   death-­‐promoting	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mechanism	   is	   triggered	   by	   global	   CoQ	   reduction,	   specific	   proteases	   (CED-­‐3/Chapter	   4	   and	   TRA-­‐
3/Chapter	  5)	  function	  to	  antagonize	  this	  pathway.	  I	  hypothesize	  that	  increased	  intracellular	  calcium	  
levels	   (described	   above)	   activates	   the	   calcium-­‐dependent	   protease	   TRA-­‐3.	   TRA-­‐3/calpain	   could	  
antagonize	  neuron	  death	  by	  degrading	  pro-­‐death	  proteins,	  thus	  dampening	  their	  neurodegenerative	  
effects.	   Additionally,	   the	   neuronal	   stresses	   caused	   by	   CoQ	   depletion	   activate	   CED-­‐3	   (through	   an	  
unknown	  mechanism),	  which	   could	   perhaps	   cleave	   substrates	   required	   for	   neuronal	   regeneration	  
(Chapter	   4).	   Ultimately,	   however,	   the	   degenerative	   pathway	   overrides	   these	   proteolytic	  
neuroprotective	  events	  and	  the	  neuron	  dies.	  
CONCLUSIONS	  
	   My	   studies	  have	  begun	   to	  elucidate	   the	   complex	  molecular	   response	   to	   injury	   induced	  by	  
CoQ	  deficiency.	  This	  chapter	  emphasized	  important	  aspects	  of	  CoQ	  deficiency	  that	  could	  be	  pursued	  
in	  future	  studies:	  (1)	  The	  neuronal	  protection	  offered	  by	  proteolysis;	  (2)	  The	  activation	  mechanism	  
of	   CED-­‐4	   to	   promote	   necrotic	   cell	   death;	   (3)	   Intercellular	   Coenzyme	  Q	   transport	   and	   uptake.	   The	  
outcome	  of	  these	  future	  studies	  could	  have	  translational	  implications	  for	  neurodegenerative	  disease	  
by	   enhancing	   our	   understanding	   of	   neuronal	   protection	   mechanisms,	   mitochondria	   cell	   death	  
activation,	  and	  potential	  therapeutic	  avenues	  for	  enhanced	  CoQ	  treatment.	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APPENDIX	  A	  
	  
LIMITATIONS	  OF	  USING	  RNA	  INTERFERENCE	  AS	  A	  BIOASSAY	  TO	  IDENTIFY	  	  
COMPONENTS	  OF	  A	  MOLECULAR	  PATHWAY	  
	  
SUMMARY	  
Many	   of	   the	   initial	   experiments	   to	   investigate	   the	   mechanism	   Coenzyme	   Q	   deficiency-­‐
induced	   GABA	   neuron	   degeneration	   were	   performed	   using	   coq-­‐1	   RNAi.	   Unlike	   CoQ	   biosynthetic	  
pathway	   mutants	   that	   either	   developmentally	   arrest	   before	   degeneration	   is	   observed	   or	   have	   a	  
weak	  neurodegenerative	  phenotype,	  knockdown	  of	  coq-­‐1	  provided	  a	  large	  number	  of	  adult	  animals	  
with	  robust	  GABA	  neuron	  cell	  death.	  However,	  use	  of	  RNAi	  as	  the	  means	  of	  perturbing	  CoQ	  levels	  in	  
order	   to	   study	   GABA	   neurodegeneration	   presented	   many	   experimental	   challenges	   that	   are	  
highlighted	  in	  this	  appendix.	  
	  
	  
MATERIALS	  AND	  METHODS	  
Nematode	  strains	  and	  genetics	  
Nematodes	  used	  for	  this	  study	  were	  maintained	  as	  previously	  described	  (Brenner	  1974).	  The	  
CGC	  was	   the	   source	  of	  all	  of	   the	  mutants	   [eri-­‐1(mg366),	   ced-­‐3(n718),	   ced-­‐3(n1040),	   ced-­‐3(n1949),	  
ced-­‐3(n2888),	  ced-­‐3(ok2734),	  csp-­‐1(ok2570)]	  and	   integrated	  transgenes	   [juIs76,	   trIs10]	  used	   in	  this	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Molecular	  Biology	  
See	  Materials	  and	  Methods	  sections	  of	  Chapter	  2	  for	  a	  description	  of	  the	  unc-­‐25	  promoter	  
used	  and	  Chapter	   5	   for	  construction	  of	   the	  unc-­‐25	  RNAi	   clone.	  Plasmids	  used	   in	   this	  appendix	  are	  
listed	  in	  Table	  A.2.	  
	  
TOM20::mRFP	  and	  TOM20::GFP	  (Outer	  Mitochondrial	  Membrane	  Localization)	  
See	  Chapter	  3	  –	  Materials	  and	  Methods	  for	  a	  description	  of	  TOM20::mRFP.	  pMLH161	  was	  
made	  by	  replacing	  mRFP	  from	  pMLH035	  with	  GFP	  from	  pMLH084	  with	  5’KpnI/3’ApaI.	  	  
	  
acr-­‐2	  Promoter	  (Cholinergic	  neurons)	  
The	  3.2kb	  acr-­‐2	  promoter	  was	  amplified	  (GoTaq,	  Promega)	  from	  pG2M63	  with	  primers	  that	  
added	  5’SphI/3’AscI	  and	  inserted	  into	  a	  pCR8/GW/TOPO	  vector	  by	  TOPO	  TA	  Cloning	  (Invitrogen)	  to	  
make	   pMLH074.	   pMLH127	   was	   created	   by	   inserting	   the	   acr-­‐2	   promoter	   from	   pMLH074	   into	  




Images	   for	   Figure	   A.1	   were	   obtained	   on	   a	   Leica	   TCS-­‐SP5	   confocal	  microscope	  with	   a	   63x	  
objective	  using	  the	  Leica	  Application	  Suite	  Advanced	  Fluorescence	  (LAS-­‐AF)	  software.	  GABA	  neuron	  
degeneration	  was	  scored	  on	  a	  Zeiss	  Axioplan	  microscope	  with	  a	  100x	  objective.	  
	  
Additional	  Methods	  
Additional	  experimental	  methods	  are	  described	   in	   the	  Materials	   and	  Methods	   sections	  of	  
Chapter	  2	  (RNAi)	  and	  Chapter	  5	  	  (unc-­‐25	  RNAi	  movement	  assay).	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Table	  A.1:	  C.	  elegans	  strains	  used	  in	  this	  appendix.	  
Strain	  	   Genotype	  
NC1405	   juIs76	  [punc-­‐25::GFP,	  lin-­‐15(+)]	  II;	  eri-­‐1	  (mg366)	  IV	  
NC2236	   wdEx707	  [punc-­‐25::TOM20mRFP+elt-­‐2::GFP+pha-­‐1(+)];	  pha-­‐1(e2123);	  lon-­‐2(e678)X	  
NC2479	   wdEx783	  [punc-­‐25::TOM20::GFP,	  pacr-­‐2::TOM20::mRFP,	  pceh-­‐22::GFP]	  
NC2617	   trIs10	  [pmyo-­‐3::MB::YFP,	  pmyo-­‐2::YFP,	  pceh-­‐23::HcRed,	  punc-­‐25::DsRed,	  
unc-­‐129nsp::CFP]	  I;	  eri-­‐1	  (mg366)	  IV	  
NC2627	   trIs10	  [pmyo-­‐3::MB::YFP,	  pmyo-­‐2::YFP,	  pceh-­‐23::HcRed,	  punc-­‐25::DsRed,	  unc-­‐129nsp::CFP]	  I;	  ced-­‐3	  (ok2734)	  eri-­‐1	  (mg366)	  IV	  
NC2628	   trIs10	  [pmyo-­‐3::MB::YFP,	  pmyo-­‐2::YFP,	  pceh-­‐23::HcRed,	  punc-­‐25::DsRed,	  unc-­‐129nsp::CFP]	  I;	  csp-­‐1	  (ok2570)	  II;	  ced-­‐3	  (ok2734)	  eri-­‐1	  (mg366)	  IV	  
NC2626	   trIs10	  [pmyo-­‐3::MB::YFP,	  pmyo-­‐2::YFP,	  pceh-­‐23::HcRed,	  punc-­‐25::DsRed,	  unc-­‐129nsp::CFP]	  I;	  csp-­‐1	  (ok2570)	  II;	  eri-­‐1	  (mg366)	  IV	  
NC2660	   juIs76	  [punc-­‐25::GFP,	  lin-­‐15(+)]	  II;	  ced-­‐3(n1949)	  eri-­‐1(mg366)	  IV	  
NC2676	   juIs76	  [punc-­‐25::GFP,	  lin-­‐15(+)]	  II;	  ced-­‐3(n1040)	  eri-­‐1(mg366)	  IV	  
NC2675	   juIs76	  [punc-­‐25::GFP,	  lin-­‐15(+)]	  II;	  ced-­‐3(n2888)	  eri-­‐1(mg366)	  IV	  




Table	  A.2:	  Plasmids	  used	  in	  this	  work.	  
Vector	   DNA	   Additional	  Information	  
pMBM09	   unc-­‐25	  RNAi	  in	  pL4440	  (HT115	  E.	  coli)	   made	  by	  Meg	  Mitchell	  
pMLH001	   punc-­‐25	  (5’SphI/3’AscI)	  FWD	  in	  pENTR	  D-­‐TOPO	   	  
pMLH035	   punc-­‐25::TOM20::mRFP::unc-­‐10	  3’UTR	   	  
pMLH074	   pacr-­‐2	  (5’SphI/3’AscI)	  in	  pCR8/GW/TOPO	   	  
pMLH084	   punc-­‐25::GFP::unc-­‐10	  3’UTR	   	  
pMLH127	   pacr-­‐2::TOM20::mRFP::unc-­‐10	  3’UTR	   	  
pMLH161	   punc-­‐25::TOM20::GFP::unc-­‐10	  3’UTR	   	  
pG2M02	   pmyo-­‐3::TOM20::mRFP	   a	  gift	  from	  Toshihiko	  Oka	  
pG2M17	   pelt-­‐2::NLS::GFP	   a	  gift	  from	  Oliver	  Hobert	  
pG2M19	   pceh-­‐22::GFP	  (pCW2.1)	   a	  gift	  from	  Oliver	  Hobert	  
pG2M30	   pBlueScript	  II	   	  
pG2M63	   pacr-­‐2::YFP	  (pSC391)	   a	  gift	  from	  Yishi	  Jin	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Table	  A.3:	  Plasmid	  concentrations	  used	  to	  make	  transgenic	  arrays	  used	  for	  this	  study.	  
	  






pMLH035	   25	  ng/μL	  
pG2M17	   25	  ng/μL	  
pG2M30	   25	  ng/μL	  





N2	   pMLH127	   25	  ng/μL	  
pMLH161	   25	  ng/μL	  





Mislabeled	  clones	  in	  the	  Ahringer	  RNAi	  library	  
The	  Ahringer	  RNAi	  library	  is	  a	  useful	  source	  of	  bacterial	  clones	  that	  target	  more	  than	  85%	  of	  
the	  C.	  elegans	  genome	  (Kamath	  &	  Ahringer	  2003;	  Kamath	  et	  al.	  2003;	  Fraser	  et	  al.	  2000).	  However,	  
as	  indicated	  in	  Chapter	  5,	  some	  of	  the	  RNAi	  clones	  selected	  for	  analysis	  were	  incorrectly	  annotated	  
in	  the	  Ahringer	  RNAi	  library.	  Additionally,	  the	  coq-­‐1	  RNAi	  bacterial	  strain	  was	  initially	  discovered	  in	  a	  
location	  designated,	  and	  also	  containing,	  a	  bacterial	  clone	  targeted	  toward	  another	  gene	  (arl-­‐1).	  An	  
estimated	   clone	   error	   rate	   of	   7%	   is	   acknowledged	   by	   the	   Ahringer	   lab	   and	   other	   groups	   have	  
performed	  more	  detailed	  analysis	  on	  the	  Ahringer	  RNAi	  library	  reliability	  (Qu	  et	  al.	  2011).	  Therefore,	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Transgene	  silencing	  by	  the	  RNAi	  pathway	  limits	  use	  of	  extrachromosomal	  transgenic	  arrays	  
RNAi-­‐induced	  Transcriptional	  Gene	  Silencing	  (RNAi-­‐TGS)	  is	  a	  phenomenon	  in	  which	  somatic	  
transgenes	  are	  silenced	  by	  a	  mechanism	   induced	  by	  feeding	  RNAi.	  The	  effect	   is	  suggested	  to	  arise	  
from	  promiscuous	  transcription	  of	  dsRNAs	  from	  sequences	  that	  are	  shared	  between	  the	  RNAi	  vector	  
backbone	   and	   the	   transgenic	   array	   (Grishok	   2005).	   Induction	   of	   this	   silencing	   pathway	   presents	  
experimental	  challenges	  for	  assays	  that	  rely	  on	  RNAi-­‐induced	  phenotypes.	  
We	  also	  observed	  muted	  transgenic	  array	  expression	  in	  genetic	  backgrounds	  containing	  eri-­‐
1(mg366),	   an	   RNAi-­‐sensitizing	   mutation	   (Kennedy	   et	   al.	   2004)	   that	   is	   required	   to	   achieve	   robust	  
GABA	  neurodegeneration	  with	  coq-­‐1	  knockdown.	  This	  combination	  of	  potential	  transgene	  silencing	  
by	   RNAi	   treatment	   and	   the	   need	   to	   use	   a	   genetic	   background	   that	   also	   reduces	   transgene	  
expression	  complicated	  experiments	  that	  relied	  on	  the	  use	  of	  extrachromosomal	  arrays.	  	  
One	  example	  of	  an	  experiment	  that	  could	  not	  be	  performed	  due	  to	  RNAi-­‐TGS	  was	  designed	  
to	   address	   the	   potential	   role	   of	   the	   mitochondrial	   fission	   and	   fusion	   machinery	   in	   the	   GABA	  
neurodegeneration	  pathway	  (see	  Chapter	  2)	  (Earls	  et	  al.	  2010).	  The	  idea	  for	  this	  experiment	  was	  to	  
use	   a	   transgenically-­‐expressed	   fluorescent	  marker	   to	  monitor	   changes	   in	  mitochondria	   (i.e.,	   size,	  
distribution,	   number)	   as	   a	   result	   of	   coq-­‐1	   knockdown.	   	   The	  mitochondrial	  membrane	   localization	  
sequence	  (TOM20)	  was	   fused	  to	  mRFP	  (Ichishita	  et	  al.	  2008)	  and	  expressed	   in	  GABA	  neurons;	   this	  
reporter	  labeled	  mitochondria	  in	  both	  the	  cell	  soma	  and	  neuronal	  processes	  (Fig.	  A.1).	  However,	  the	  
TOM20::RFP	  marker	   was	   too	   dim	   after	   RNAi-­‐induced	   coq-­‐1	   knockdown	   to	   investigate	   changes	   in	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Figure	   A.1:	   Neuronal	   mitochondria	   are	   visualized	   by	   outer-­‐mitochondrial	   membrane	   tagged	  
(TOM20)	  fluorophores.	  A.	  TOM20::mRFP	  labels	  mitochondria	  in	  GABA	  neurons.	  The	  TOM20::mRFP	  
mitochondrial	   signal	   accumulates	   in	   the	   cell	   soma	   (white	   arrowhead)	   and	   labels	   individual	  
mitochondria	   in	   GABAergic	   processes	   (white	   arrows).	   B.	   Mitochondria	   from	   GABA	   (white	  
arrows/arrowhead)	   and	   cholinergic	   (yellow	   arrows/arrowhead)	   neurons	   are	   labeled	   with	  
TOM20::mRFP	  and	  TOM20::GFP,	  respectively.	  Anterior	  left,	  ventral	  down.	  Scale	  bar	  =	  5µM.	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Interpretation	   of	   GABA	   neurodegeneration	   levels	   induced	   by	   coq-­‐1	   knockdown	   is	   difficult	   due	   to	  
varying	  sensitivities	  of	  genetic	  backgrounds	  to	  RNAi	  treatment	  
	   To	   investigate	  the	  mechanism	  of	  GABA	  neuron	  degeneration	  arising	   from	  CoQ	  depletion,	   I	  
generated	  multiple	   strains	  with	   loss	   of	   function	  mutations	   in	   candidate	  death-­‐related	   genes	   (e.g.,	  
ced-­‐4).	  These	  strains	  also	  contained	   the	  RNAi-­‐sensitizing	  mutation	  eri-­‐1(mg366)	  and	  GABA	  neuron	  
reporter	  punc-­‐25::GFP	  (juIs76).	  coq-­‐1	  RNAi	  knockdown	  was	  used	  to	  induce	  GABA	  neuron	  cell	  death	  
and	  levels	  of	  degeneration	  in	  these	  mutants	  were	  compared	  to	  control	  (eri-­‐1;	  juIs76	  alone).	  	  
	   With	   the	   goal	   of	   confirming	   that	   RNAi	   sensitivity	   was	   equivalent	   across	   these	   different	  
genetic	   backgrounds,	   I	   performed	   a	   control	   RNAi	   experiment	   targeting	   unc-­‐25/Glutamic	   Acid	  
Decarboxylase	  (GAD),	  a	  gene	  selectively	  required	  in	  GABA	  neurons	  for	  GABA	  biosynthesis	  (McIntire	  
et	  al.	  1993).	  RNAi	  knockdown	  of	  unc-­‐25	  results	  in	  a	  characteristic	  “shrinker”	  movement	  defect	  due	  
to	   excessive	   muscle	   contraction	   (McIntire	   et	   al.	   1993).	   I	   reasoned	   that	   strains	   with	   equal	   RNAi	  
sensitivity	   would	   show	   comparable	   Unc-­‐25	   shrinker	   phenotypes.	   The	   results	   of	   this	   control	  
experiment,	   however,	   detected	   variable	   levels	   of	   impaired	   movement	   in	   different	   genetic	  
backgrounds	  (Fig.	  A.2).	  For	  example,	  two	  independently-­‐generated	  “wild-­‐type”	  (eri-­‐1;	  juIs76)	  strains	  
showed	   significantly	   different	   sensitivities	   to	  unc-­‐25	   RNAi.	   Additionally,	   transgenic	   lines	   built	  with	  
different	  ced-­‐3	  alleles	  also	  displayed	  variable	   levels	  of	  penetrance	   for	   the	  unc-­‐25	  RNAi	  movement	  
defect.	  These	  results	  suggested	  that	  apparent	  differences	  in	  GABA	  neurodegeneration	  could	  be	  due	  
to	  variable,	  strain-­‐specific	  sensitivity	  to	  RNAi	  and	  rather	  an	  indication	  of	  an	  effect	  of	  tested	  genetic	  
mutant	  on	  the	  degeneration	  pathway.	  
The	  unexpected	  range	  of	  sensitivities	  to	  unc-­‐25	  RNAi	  prompted	  us	  to	  examine	  this	  effect	  in	  
concert	  with	  GABA	  neuron	  degeneration	  induced	  by	  coq-­‐1	  RNAi	  knockdown.	  For	  this	  experiment,	  I	  
used	  a	  second	  transgenic	  GABAergic	  reporter	  (trIs10)	  in	  combination	  with	  the	  RNAi-­‐sensitizing	  eri-­‐1	  
mutation,	  and	  treated	  WT,	  ced-­‐3	  (ok2734),	  csp-­‐1(ok2570),	  and	  the	  ced-­‐3;	  csp-­‐1	  double	  mutant	  with	  	  







Figure	   A.2:	  Sensitivity	   to	   feeding	   RNAi	   is	   variable	   between	   controls	   strains	   and	   among	   animals	  
with	   different	   ced-­‐3	   mutant	   backgrounds.	   RNAi	   knockdown	   of	   unc-­‐25/GAD	   presents	   a	   range	   of	  
Uncoordinated	   (Unc)	  phenotypes	   in	   two	  groups	  of	  animals	  sharing	  the	  eri-­‐1(mg366);	   juIs76	   [punc-­‐
25::GFP,	  lin-­‐15(+)]	  genetic	  background	  (WT	  #1	  vs	  WT	  #2).	  Among	  the	  ced-­‐3	  mutants,	  the	  n718	  allele	  
is	  significantly	  more	  sensitive	  than	  the	  others.	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RNAi	  against	  both	  coq-­‐1	  and	  unc-­‐25.	  The	  extent	  of	  GABA	  neurodegeneration	   in	  these	  experiments	  
indicated	   that	   ced-­‐3(ok2734)	   enhanced	   degeneration,	   csp-­‐1(ok2570)	   suppressed	   it,	   and	   animals	  
mutant	   for	   both	   ced-­‐3	   and	   csp-­‐1	   showed	   significantly	   enhanced	   GABA	   neuron	   degeneration	   (Fig.	  
A.3A).	   The	  wild-­‐type	   control	   for	   this	  experiment	  did	  not	  display	   signs	  of	  GABA	  neuron	  death	  with	  
coq-­‐1	  knockdown.	  Unc-­‐25	  movement	   defects	   paralleled	   these	   results	  with	   ced-­‐3	  and	   ced-­‐3;	   csp-­‐1	  
mutants	  showing	  a	  strong	  Unc-­‐25	  phenotype	  whereas	  most	  of	  the	  csp-­‐1	  mutant	  animals	  displayed	  
wild-­‐type	  movement	  (Fig.	  A.3B).	  I	  therefore	  concluded	  that	  differences	  in	  RNAi	  sensitivity	  are	  likely	  
to	  account	   for	   the	  varying	   levels	  of	  GABA	  neuron	  degeneration	  among	  these	  mutant	  strain	   rather	  
than	   specific	   effects	   of	   cell	   death	   pathway	   mutants	   (e.g.,	   ced-­‐3	   and	   csp-­‐1)	   on	   the	   degeneration	  
pathway.	   In	  addition	  to	  noting	  varying	   levels	  of	  RNAi	  sensitivity	   for	  different	  genetic	  backgrounds,	  
these	  experiments	  were	  also	  plagued	  by	  highly	  variable	  levels	  of	  coq-­‐1	  RNAi-­‐induced	  GABA	  neuron	  
degeneration	   in	   the	  wild	   type	  reference	  strain	   (Fig	  A.2).	  On	  the	  basis	  of	   these	  results,	   I	   concluded	  
that	   the	  use	  of	  RNAi	   to	  knockdown	  coq-­‐1	   could	   result	   in	  misleading	  conclusions.	  The	  mechanisms	  
that	  accounts	  for	  variability	  in	  RNAi	  penetrance	  between	  different	  genetic	  strains	  and	  experimental	  
replicates	  are	  unknown.	  
	  
	  
DISCUSSION	  AND	  FUTURE	  DIRECTIONS	  
	   The	   finding	   that	   GABA	   neurons	   preferentially	   degenerate	   under	   conditions	   of	   CoQ	  
deficiency	   was	   initially	   recognized	   in	   coq-­‐1	   RNAi	   knockdown	   animals	   (Chapter	   2).	   Because	   coq-­‐1	  
mutants	   arrest	   before	   the	   onset	   of	   GABA	   neurodegeneration	   in	   the	   adult	   stage	   (Chapter	   3),	   it	   is	  
fortuitous	   that	   these	   first	   experiments	   were	   conducted	   with	   coq-­‐1	   RNAi-­‐treated	   animals,	   which	  
survive	  to	  adulthood.	  It	  is	  now	  clear,	  however,	  that	  the	  RNAi	  effect	  is	  highly	  variable	  and	  sensitive	  to	  
genetic	  backgrounds	  and	  thus	  must	  be	  interpreted	  with	  caution.	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Figure	   A.3:	   Knockdown	   of	  unc-­‐25/GAD	   reveals	   differential	   sensitivity	   to	   RNAi	   in	   GABA	   neurons	  
among	  mutants	   used	   for	   CoQ	   neurodegeneration	   assays.	   A.	  Global	   coq-­‐1	  RNAi	   produces	   a	  wide	  
range	   of	   neurodegeneration	   levels	   between	   the	   four	   genotypes	   tested.	   The	   csp-­‐1;	   ced-­‐3	   double	  
mutant	  has	   significantly	  enhanced	  GABA	  VNC	  degeneration	  compared	   to	  both	  wild-­‐type	   (WT)	  and	  
csp-­‐1	  single	  mutants.	  #	  p<0.04	  *p<0.08	  **p<0.0001.	  n>15.	  	  B.	  Movement	  defects	  induced	  by	  unc-­‐25	  
RNAi	  treatment	  mirrors	  the	  GABA	  neuron	  degeneration	  levels	  observed	  in	  Panel	  A.	  n>30.	  All	  strains	  
share	   the	   eri-­‐1(mg366);	   trIs10	   [pmyo-­‐3::MB::YFP,	   pmyo-­‐2::YFP,	   pceh-­‐23::HcRed,	   punc-­‐25::DsRed,	  
unc-­‐129nsp::CFP]	  background.	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We	  optimized	  experimental	   conditions	  using	  CoQ	  biosynthetic	  pathway	  mutants	   that	  now	  
allow	   us	   to	   reproducibly	   observe	   GABA	   neurodegeneration	   	   (see	   Chapter	   3).	   We	   have	   used	   this	  
technique	   to	   validate	   components	   of	   the	  GABA	   cell	   death	  pathway	   that	  were	  originally	   identified	  
using	   coq-­‐1	  RNAi.	   This	   RNAi-­‐independent	   system	  has	   confirmed	   that	   ced-­‐4	   is	   necessary	   for	  GABA	  
neuron	   death	   (see	  Chapter	   4)	   and	   two	   proteases	   (ced-­‐3	   and	   tra-­‐3)	   antagonize	   this	   pathway	   (see	  
Chapters	  4	  and	  5).	  Our	  analysis	  of	  components	  of	  this	  pathway	  by	  both	  RNAi	  and	  genetic	  knockout	  
of	   CoQ	   biosynthetic	   genes	   provides	   convincing	   evidence	   supporting	   their	   involvement	   in	   this	  
degenerative	  process.	  	  
	  
Future	  Directions	  
Despite	   technical	   hurdles	   with	   RNAi-­‐induced	   Transcriptional	   Gene	   Silencing,	   efforts	   to	  
examine	  GABAergic	  mitochondria	   in	   CoQ-­‐depleted	   animals	  warrant	   further	   pursuit.	  Differences	   in	  
mitochondrial	   number,	   size,	   and	   distribution	   (Labrousse	   et	   al.	   1999)	   between	  wild-­‐type	   and	   CoQ	  
deficient	  animals	  are	  predicted	  based	  on	  our	  genetic	  and	  RNAi	  studies	  with	  the	  mitochondrial	  fission	  
(drp-­‐1)	  and	  fusion	  (fzo-­‐1)	  genes	  (see	  Chapter	  2,	  (Earls	  et	  al.	  2010)).	  Additionally,	  two-­‐color	  labeling	  
of	  mitochondria	   in	  GABAergic	  and	  cholinergic	  neurons	  can	  be	  used	  to	  detect	  potential	  differential	  
sensitivity	   of	   mitochondria	   to	   CoQ	   depletion	   in	   neighboring	   GABAergic	   versus	   cholinergic	   motor	  
neurons.	   (Fig.	   A.1B).	   With	   our	   discovery	   of	   experimental	   conditions	   for	   detecting	   robust	   GABA	  
neuron	   degeneration	   in	   CoQ	   pathway	  mutants	   (see	   Chapter	   3),	   it	   should	   be	   possible	   to	   analyze	  
mitochondria	  in	  these	  distinct	  neuronal	  populations	  independent	  of	  the	  transgene	  silencing	  effects	  
associated	  with	  the	  RNAi	  pathway.	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APPENDIX	  B	  
MODIFICATION	  OF	  AN	  IN	  VIVO	  CASPASE	  REPORTER	  TO	  DETECT	  	  
CED-­‐3	  PROTEOLYTIC	  ACTIVITY	  IN	  C.	  ELEGANS	  
	  
SUMMARY	  
	   We	  have	  shown	  that	  CED-­‐3/caspase	  antagonizes	  a	  death	  pathway	  in	  GABA	  neurons	  caused	  
by	   CoQ	  deficiency	   (see	  Chapter	   4).	   Genetic	   and	   transgenic	   experiments	   indicate	   that	   the	   caspase	  
activity	  of	  CED-­‐3	  is	  required	  for	   its	  neuroprotection.	  We	  wanted	  to	  characterize	  this	  non-­‐canonical	  
function	  of	  CED-­‐3	  and	  pursued	  a	  methodology	  that	  would	  allow	  us	  to	  detect	  caspase	  activation	   in	  
vivo.	  For	  this,	  we	  modified	  a	  caspase	  biosensor	  (Apoliner)	  originally	  introduced	  in	  Drosophila	  (Bardet	  
et	   al.	   2008)	   for	   use	   in	   C.	   elegans.	   Our	   adapted	   caspase	   reporter	   (Apoworm)	   has	   enhanced	  
expression	   and	   can	   detect	   apoptotic	   events	   in	   live	   animals.	   However,	   experimental	   outcomes	  
described	   in	   this	   appendix	   bring	   the	   fidelity	   of	   this	   reporter	   into	   question.	   Apoworm	   therefore	  
requires	  further	  optimization	  before	  it	  can	  be	  used	  as	  a	  reliable	  indicator	  of	  caspase	  activity.	  Despite	  
current	  technical	  hurdles,	  this	  biosensor	  has	  immense	  potential	  to	  detect	  in	  vivo	  caspase-­‐dependent	  
events	  in	  C.	  elegans.	  
	  
MATERIALS	  AND	  METHODS	  
Nematode	  Strains	  and	  Genetics	  
Nematodes	   were	   cultured	   as	   described	   previously	   (Brenner	   1974).	   The	   following	   strains	  
were	  obtained	   from	  the	  CGC:	  opIs56	   [pegl-­‐1::2X::NLS::GFP]	   (Hofmann	  et	  al.	  2002),	   ced-­‐1(e1735)	   I;	  
ced-­‐5(n1812)	   IV	   (Reddien	  &	  Horvitz	   2004),	   ced-­‐3(ok2734)	   IV,	   sid-­‐1(pk3321)	  V	   (Calixto	  et	   al.	   2010);	  
uIs69	   [pmyo-­‐2::mCherry	   +	   punc-­‐119::sid-­‐1]	   V.	   JR100	   [ced-­‐1(e1735);	   wEx15(hs::p35	   +	   pRF4)]	  
(Abraham	  et	  al.	  2007)	  was	  a	  gift	  from	  Shai	  Shaham.	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Molecular	  Biology	  	  
Table	   B.1	   contains	   primers	   used	   for	   molecular	   cloning,	   and	   plasmids	   generated/used	   are	  
listed	  in	  Table	  B.2.	  Plasmids	  were	  injected	  at	  concentrations	  listed	  in	  Table	  B.3.	  
	  
Apoliner	  
The	  caspase	  reporter	  Apoliner	  was	  amplified	  (GoTaq,	  Promega)	  from	  pG2M03	  with	  primers	  
that	  added	  5’AscI/3’KpnI	  and	  TA	  TOPO	  cloned	  into	  pCR2.1/TOPO	  to	  make	  pMLH024.	  	  
	  
Apoliner(DEVD)	  
The	  caspase	  cleavage	  sequence	  was	  changed	  from	  DQVD	  to	  DEVD	  by	   introducing	  a	  G-­‐to-­‐A	  
change	  at	  nucleotide	  1390	  into	  a	  primer	  that	  also	  contained	  the	  AgeI	  restriction	  site	  within	  Apoliner	  
(between	  mCD8	  and	  mRFP,	  Fig.	  B.1A).	  pG2M03	  was	  used	  as	  template	  for	  the	  PCR	  reaction	  (GoTaq,	  
Promega)	   and	   the	   amplicon	   (5’AgeI-­‐[BIR1-­‐NLS-­‐GFP]-­‐KpnI-­‐3’)	  was	   inserted	   into	   pCR8/GW/TOPO	  by	  
TA	  TOPO	  cloning	  (Invitrogen)	  to	  make	  pMLH075.	  Due	  to	  a	  missense	  mutation	  in	  the	  mRFP	  domain	  of	  
pMLH024	   introduced	   by	   PCR,	   an	   intermediate	   vector	   (pMLH120)	   was	   made	   to	   create	   a	   multiple	  
cloning	  site	  (MCS)	  containing	  restriction	  sites	  necessary	  for	  piecing	  together	  the	  full	  Apoliner(DEVD).	  
This	  was	   done	   by	   amplifying	   an	   unrelated	   sequence	   (from	  pCJS03)	  with	   primers	   that	   added	  AscI-­‐
XhoI-­‐SacII	   and	   AgeI-­‐BamHI-­‐KpnI	   to	   the	   pMLH116	   vector	   using	   5’AscI/3’KpnI	   to	   make	   pMLH120.	  
pMLH137	   was	   made	   by	   assembling	   pieces	   of	   Apoliner-­‐DEVD	   from	   the	   following	   sources	   into	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Apoliner-­‐CED-­‐9	  
A	   region	  of	   ced-­‐9	   cDNA	   containing	   two	   in	   vitro	   CED-­‐3	   cleavage	   sites	   (DAQD,	   ESID)	   (Xue	  &	  Horvitz	  
1997;	  Taylor	  et	  al.	  2007)	  was	  selected	  to	  replace	  the	  BIR1	  domain	  of	  Apoliner	  (Fig.	  B.1A).	  The	  size	  of	  
the	   region	   (~450bp)	   is	   comparable	   to	   that	   of	   the	   BIR1	   domain	   (Fig.	   B.5B).	   pMLH158	  was	   used	   as	  
template	   to	   amplify	   (GoTaq,	   Promega)	   this	   region	   of	   ced-­‐9	   and	   insert	   it	   into	   pMLH142	  
(5’AgeI/3’BamHI)	  to	  make	  pMLH204.	  
	  
Apoworm	  
The	  mCD8	  domain	  of	  Apoliner-­‐DEVD	  was	   replaced	  with	   the	  pat-­‐3	   transmembrane	  domain	  
(Mb)	  to	  make	  Apoworm.	  Lysate	  from	  trIs10	  	  [pmyo-­‐3::Mb::YFP,	  pmyo-­‐2::YFP,	  pceh-­‐23::HcRed,	  punc-­‐
25::DsRed,	   unc-­‐129nsp::CFP]	   (Dixon	   2006)	   animals	   was	   used	   as	   template	   to	   amplify	   (GoTaq,	  
Promega)	   pat-­‐3	  Mb	   (from	   pPD133.58	   contained	   the	   trIs10	   array).	   The	   amplicon	   was	   cloned	   into	  
pMLH103	  (5’BamHI/3’AgeI)	  to	  make	  pMLH221.	  pat-­‐3	  Mb	  was	  subsequently	  inserted	  into	  pMLH142	  
with	  5’AscI/3’SacII	  to	  create	  pMLH237.	  
	  
egl-­‐1	  Promoter	  
The	   2.7kb	   egl-­‐1	   promoter	   (Neukomm	   et	   al.	   2011)	   was	   amplified	   (Phusion	   High-­‐Fidelity	  
Polymerase,	   New	   England	   Biolabs)	   from	   DNA	   lysate	   collected	   from	   opIs56	   [pegl-­‐1::2xNLS::GFP]	  
transgenic	  animals	  (Hofmann	  et	  al.	  2002).	  pMLH157	  was	  generated	  by	  inserting	  the	  egl-­‐1	  promoter	  
PCR	  product	  into	  pMLH137	  with	  5’SphI/3’AscI	  (added	  to	  the	  primers).	  	  
	  
ced-­‐9	  RNAi	  
The	  Miller	  ced-­‐9	  RNAi	  clone	  targets	  most	  of	  ced-­‐9	  cDNA	  sequence	  (Figure	  B.5B).	  ced-­‐9	  was	  
amplified	  from	  N2	  cDNA	  (GoTaq,	  Promega)	  with	  primers	  that	  flanked	  it	  with	  PmeI	  sites	  and	  inserted	  
	   212	  
into	  pCR8/GW/TOPO	  by	  a	  TOPO	  TA	  reaction	  (Invitrogen)	  to	  make	  pMLH152.	  pMLH158	  was	  made	  by	  
using	  a	  PmeI	  digest	  to	  add	  ced-­‐9	  from	  pMLH152	  to	  the	  pL4440	  vector	  in	  pMLH128.	  
	  
p35	  	  
The	   p35	   gene	   was	   PCR	   amplified	   from	   JR100	   [ced-­‐1(e1735);	   wEx15(hs::p35	   +	   pRF4)]	  




Caspase	  cleavage	   is	  abrogated	  by	  mutating	   the	  aspartate	   in	   the	  P1	  position	   (DXXD)	  of	   the	  
caspase	   consensus	   sequence	   to	   alanine	   (DXXA)	   (Ditzel	   et	   al.	   2003).	   The	   5’AgeI-­‐3’KpnI	   region	   of	  
pG2M04	   (DQVA)	   was	   amplified	   (Phusion	   High-­‐Fidelity	   Polymerase,	   New	   England	   Biolabs)	   and	  
inserted	  into	  pMLH240	  to	  make	  pMLH241.	  The	  same	  primer	  that	  introduced	  the	  Q-­‐to-­‐E	  mutation	  to	  
make	   Apoliner-­‐DEVD	   was	   used	   to	   make	   pMLH243;	   pMLH241	   was	   used	   as	   a	   template	   and	   the	  
amplicon	  was	  inserted	  into	  pMLH237	  (5’AgeI/3’KpnI).	  
	  
Additional	  Molecular	  Biology	  
See	  Materials	   and	  Methods	   of	   the	   following	   chapters	   for	   previously	   described	  molecular	  
biology:	   Chapter	   2	   –	   unc-­‐25/GABA	   promoter,	   Chapter	   3	   –	   ttr-­‐39/GABA	   promoter,	   F25B3.3/Pan-­‐
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Table	   B.1.	  Molecular	   cloning	   primers	   used	   to	   generate	   the	   plasmids	   (see	   Table	   B.2)	   used	   in	   this	  
study.	  
	  
Gene/Amplicon	   Primer	  Name	   Primer	  Sequence	  
Apoliner	   Apo_5p_AscI	   AAGGCGCGCCATGGCCTCACCGTTGACCCG	  






Apo_3p_KpnI	   AAGGTACCTTATTTGTATAGTTCATCCA	  
Apoliner	  MCS	   Apo_MCS_5p	   AAGGCGCGCCCTCGAGCCGCGGAAAAAGCAGGAGGAAT
CTAC	  
Apo_MCS_3p	   AAGGTACCGGATCCACCGGTCCAGATAAAGCATTTTCTCT	  












egl-­‐1	  promoter	   pegl-­‐
1_5p_SphI_MLH	   AAGCATGCTCGATTCTTATGGTTAAAACGAGCCTTG	  
pegl-­‐
1_3p_AscI_MLH	   AAGGCGCGCCTTGGTAGAAGATCCGAA	  
p35	   p35_5p_AscI	   GGGGCGCGCCCTTTACCATAGCAAAATGTGTGTA	  




Mb_5p_AscI	   AAGGCGCGCCTCTAGAGGATCCC	  
Mb_3p_SacII	   AACCGCGGACCTCGGATCTATCATGAAG	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Table	  B.2.	  A	  list	  of	  plasmids	  used	  and/or	  generated	  in	  this	  work.	  
	  
Vector	   DNA	   Additional	  Information	  
pMLH007	   punc-­‐25::mCherry::gateway::unc-­‐54	  3’UTR	   	  
pMLH024	   Apoliner	  in	  pCR2.1/TOPO	   	  
pMLH075	   DEVD-­‐BIR1-­‐nls-­‐GFP	  (Apoliner	  piece)	  in	  pCR8	   	  
pMLH103	   pttr-­‐39::mCherry::unc-­‐54	  3’UTR	   	  
pMLH116	   pF25B3.3(minus	  106bp)::Apoliner-­‐DEVD	  (mutations)	   	  
pMLH120	   pF25B3.3(minus	  106bp)::Apoliner	  MCS	   	  
pMLH128	   coq-­‐1	  RNAi	  (flanked	  PmeI)	  in	  pL4440	   	  
pMLH137	   punc-­‐25::Apoliner-­‐DEVD::unc-­‐54	  3’UTR	   	  
pMLH142	   pF25B3.3::Apoliner-­‐DEVD::unc-­‐54	  3’UTR	   	  
pMLH152	   ced-­‐9	  cDNA	  in	  pCR8/GW/TOPO	   	  
pMLH157	   pegl-­‐1::Apoliner-­‐DEVD::unc-­‐54	  3’UTR	   	  
pMLH158	   ced-­‐9	  RNAi	  (Miller)	  in	  HT115	  E.	  coli	   	  
pMLH204	   pF25B3.3::Apoliner-­‐ced-­‐9::unc-­‐54	  3’UTR	   	  
pMLH207	   punc-­‐25::ced-­‐3(p15)-­‐nz	   	  
pMLH210	   punc-­‐25::cz-­‐ced-­‐3(p17)	   	  
pMLH212	   psur-­‐5::Apoliner-­‐ced-­‐9::unc-­‐54	  3’UTR	   	  
pMLH213	   punc-­‐25::Apoliner-­‐ced-­‐9::unc-­‐54	  3’UTR	   	  
pMLH221	   pttr-­‐39::Mb-­‐mCherry	   	  
pMLH222	   punc-­‐25::NLS::GFP	   	  
pMLH237	   pF25B3.3::Apoworm::unc-­‐54	  3’UTR	   	  
pMLH240	   pegl-­‐1::Apoworm::unc-­‐54	  3’UTR	   	  
pMLH241	   pegl-­‐1::Apoworm-­‐DQVA::unc-­‐54	  3’UTR	   	  
pMLH243	   pF25B3.3::Apoworm-­‐DEVA::unc-­‐54	  3’UTR	   	  
pMLH247	   punc-­‐25::p35::unc-­‐10	  3’UTR	   	  
	  
pCJS03	   pF49H12.4::intron2::unc-­‐5	   made	  by	  Cody	  Smith	  
pG2M03	   pC2::Apoliner	  (DQVD)	   a	  gift	  from	  Pierre-­‐Luc	  Bardet	  
pG2M04	   pC2::Apomut	  (DQVA)	   a	  gift	  from	  Pierre-­‐Luc	  Bardet	  
pG2M17	   pelt-­‐2::NLS::GFP	   a	  gift	  from	  Oliver	  Hobert	  
pG2M20	   pcoel:GFP	   a	  gift	  from	  Daniel	  Colon-­‐Ramoz	  
pG2M30	   pBluescript	  II	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Table	  B.3:	  Plasmid	  concentrations	  of	  transgenic	  arrays	  generated	  for	  this	  study.	  
Transgene	   Genotype	  Injected	   Plasmid	  Name	   Concentration	  
wdEx907	  
[pF25B3.3::Apoworm,	  pcoel::GFP]	  
N2	   pMLH237	   80	  ng/μL	  




N2	   pMLH157	   20	  ng/μL	  
pG2M17	   25	  ng/μL	  




N2	   pMLH207	   5.8	  ng/μL	  
pMLH210	   5	  ng/μL	  






Apoliner	  is	  an	  in	  vivo	  caspase	  sensor	  that	  contains	  a	  mRFP-­‐GFP	  fusion	  protein	  that	  normally	  
localizes	   to	   the	   plasma	   membrane	   (Fig.	   B.1E)	   (Bardet,	   Kolahgar,	   Mynett,	   Miguel-­‐Aliaga,	   Briscoe,	  
Meier	  &	  Vincent	  2008a).	  These	  fluorescent	  proteins	  are	  separated	  by	  a	  sequence	  that	  is	  specifically	  
cleaved	  by	  Drosophila	  effector	   caspases	   and	   this	   proteolysis	   separates	  mRFP	   (remains	  membrane	  
localized)	  from	  GFP	  (translocates	  to	  the	  nucleus	  after	  caspase	  cleavage).	  The	  differential	  localization	  
of	   these	   fluorophores	   indicates	   that	   active	   caspases	   are	   present	   within	   the	   cell	   (Fig.	   B.1F).	   A	  
biosensor	   to	   detect	   caspase	   activation	   in	   vivo	  has	   not	   been	   reported	   in	  C.	   elegans.	  We	   therefore	  
modified	  this	  reporter	  to	  enhance	  expression	  and	  CED-­‐3/caspase	  recognition	  in	  the	  nematode.	  
	   	  
Optimizing	  reporter	  expression	  and	  caspase	  recognition	  
Modifying	  the	  caspase	  consensus	  sequence	  
The	  caspase	  recognition	  domain	   in	  Apoliner	   is	  derived	   from	  DIAP1	   (Drosophila	   inhibitor	  of	  
apoptosis	  protein	  1)	  and	  contains	  the	  minimal	  effector	  caspase	  consensus	  site	  (DQVD)	  as	  well	  as	  a	  	  






Figure	  B.1:	  Modifications	  to	  the	  Drosophila	  caspase	  biosensor	  (Apoliner)	  for	  enhanced	  expression	  
and	   caspase	   recognition	   in	  C.	   elegans	   (Apoworm)	  A.	  Diagram	  of	   the	  Drosophila	   caspase	  reporter	  
Apoliner.	  Restriction	  sites	  used	  for	  molecular	  cloning	  (see	  Materials	  and	  Methods)	  are	  indicated.	  B.	  
Apoliner-­‐CED-­‐9:	  The	  Drosophila	  BIR1	  domain	  is	  replaced	  by	  a	  sequence	  from	  ced-­‐9	  with	  two	  CED-­‐3	  
cleavage	  sites.	  C.	  Apoliner(DEVD):	  a	  single	  mutation	  in	  the	  caspase	  recognition	  sequence	  (DQVD	  to	  
DEVD)	  is	  introduced	  to	  enhance	  CED-­‐3	  recognition.	  D.	  Apoworm:	  Mouse	  CD8	  (mCD8)	  is	  replaced	  by	  
the	  transmembrane	  domain	  of	  C.	  elegans	  pat-­‐3	  for	  enhanced	  protein	  expression.	  Mb	  =	  membrane	  
localization	  sequence.	  	  E-­‐F.	  Schematic	  of	  fluorescent	  protein	  signals	  (GFP	  and	  mRFP)	  with	  inactive	  (E)	  
and	  active	  (F)	  caspases	  in	  the	  cell.	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BIR1	   domain	   that	   enhances	   its	   recognition	   by	   caspases	   (Fig.	   B.1A)	   (Bardet,	   Kolahgar,	   Mynett,	  
Miguel-­‐Aliaga,	   Briscoe,	  Meier	  &	  Vincent	   2008a).	   The	   preferred	   substrate	   sequence	   for	  Drosophila	  
effector	  caspases	  (DQVD)	  is	  similar	  to	  that	  of	  CED-­‐3	  (DEVD)	  (Taylor	  et	  al.	  2007);	  we	  mutated	  the	  P3	  
(Crawford	  &	  Wells	  2011)	  glutamine	  (Q)	  in	  Apoliner	  to	  glutamic	  acid	  (E)	  to	  make	  Apoliner	  (DEVD)	  (Fig.	  
B.1C).	  
For	  one	  version	  of	  the	  reporter,	  we	  replaced	  the	  BIR1	  domain	  of	  Apoliner	  (DEVD)	  with	  a	  sequence	  
from	   ced-­‐9,	   an	   in	   vitro	   CED-­‐3	   substrate	   that	   contains	   two	  CED-­‐3	   cleavage	   sites	   (Fig.	   B.1B)	   (Xue	  &	  
Horvitz	  1997;	   Taylor	  et	   al.	   2007).	  We	  were	  unable	   to	  detect	  Apoliner-­‐CED-­‐9	  expression	  under	   the	  
robust	  pan-­‐neural/F25B3.3	  promoter	   (data	  not	  shown);	  we	  therefore	  reverted	  back	  to	  the	  version	  
with	  the	  BIR1	  domain,	  which	  has	  confirmed	  expression	  in	  C.	  elegans	  (Fig.	  B.2).	  
	  
The	  egl-­‐1	  promoter-­‐driven	  Apoliner	  (DEVD)	  is	  dimly	  expressed	  in	  cells	  undergoing	  PCD	  
To	   test	  whether	  Apoliner	   (DEVD)	   detects	   CED-­‐3	   activation	  during	   programmed	   cell	   death,	  
we	  expressed	   it	  using	   the	  egl-­‐1	  promoter,	  which	   is	   transcriptionally	  activated	  during	  programmed	  
apoptosis	   (Fig.	   B.5A)	   (Conradt	   &	   Horvitz	   1998).	   We	   were	   unable	   to	   detect	   Apoliner(DEVD)	  	  
expression	  under	  the	  egl-­‐1	  promoter	  in	  a	  wild-­‐type	  background	  (data	  not	  shown),	  likely	  due	  to	  the	  
swift	   execution	   and	   removal	   of	   dead	   cells	   (Sulston	   &	   Horvitz	   1977;	   Robertson	   &	   Thomson	   1982;	  
Sulston	  et	  al.	  1983;	  Ellis	  et	  al.	  1991).	  Next,	  we	  expressed	  pegl-­‐1::Apoliner(DEVD)	   in	  a	  strong	  corpse	  
engulfment-­‐deficient	   genetic	   background,	   ced-­‐1(e1735);	   ced-­‐5(n1812)	   (Reddien	   &	   Horvitz	   2004).	  
Because	   cell	   corpses	  persist	   in	   this	  background,	  we	  observed	  both	  GFP	  and	  mRFP	   fluroescence	   in	  
dying	   cells	   (Fig.	   B.2).	   However,	   these	   events	   were	   both	   rare	   and	   difficult	   to	   detect	   due	   to	   dim	  
fluorescent	  signal.	  Nevertheless,	  this	  analysis	  confirmed	  the	  egl-­‐1	  promoter	  is	  capable	  of	  expressing	  
Apoliner(DEVD)	  in	  cells	  that	  undergo	  programmed	  cell	  death.	  
	  







Figure	   B.2:	   The	   egl-­‐1	   promoter-­‐driven	   Apoliner(DEVD)	   is	   dimly	   expressed	   in	   cells	   undergoing	  
programmed	   cell	   death.	   A.	   GFP	   signal	   in	   an	   apoptotic	   cell	   in	   the	   head	   of	   the	   animal	   under	   the	  
control	  of	  the	  egl-­‐1	  promoter	  (yellow	  arrowhead).	  B.	  Faint	  mRFP	  signal	  is	  also	  detected	  in	  the	  same	  
cell.	   C.	   	   DIC	   shows	   two	   neighboring	   button-­‐like,	   dying	   cells:	   one	   with	   Apoliner(DEVD)	   expressed	  
(yellow	  arrowhead),	  one	  without	  (white	  arrow).	  D.	  Merged	  image.	  Anterior	  right,	  ventral	  down.	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Modifying	  the	  membrane	  localization	  sequence	  
Preliminary	   data	   using	   multiple	   promoters	   (egl-­‐1/programmed	   cell	   deaths,	   unc-­‐25/GABA	  
neurons,	   and	   F25B3.3/all	   neurons)	   to	   express	   Apoliner(DEVD)	   produced	   very	   weak	   fluorescence	  
intensity	   compared	   to	   other	   fluorescent	   proteins	   (i.e.	   GFP	   alone)	   microinjected	   at	   similar	  
concentrations	  (data	  not	  shown).	  Faint	  expression	  of	  vectors	  without	  introns	  has	  been	  documented	  
(Hutter	  2012),	  and	  the	  lack	  of	  introns	  in	  Apoliner(DEVD)	  may	  explain	  its	  diminished	  fluorescence.	  
To	   enhance	   the	   intensity	   of	   the	   fluorophore	   signal,	   we	   exchanged	   the	   mouse	   CD8	  
membrane	   localization	   sequence	   with	   a	   segment	   from	   the	   pat-­‐3	   integrin	   that	   robustly	   localizes	  
proteins	  to	  the	  plasma	  membrane	  in	  C.	  elegans	  (Gettner	  et	  al.	  1995).	  This	  modification	  significantly	  
enhanced	   of	   the	   fluorescent	   signal,	   and	   this	   version	   of	   the	   biosensor	   (Apoworm)	   was	   used	   for	  
subsequent	  analyses.	  
	  
Apoworm	  detects	  forced	  CED-­‐3	  activation	  in	  GABA	  neurons	  
Without	  robust	  expression	  using	  the	  egl-­‐1	  promoter	   (Fig.	  B.2),	  we	  were	  unable	   to	  address	  
whether	  Apoworm	   is	   cleaved	   in	   cells	   that	   normally	   undergo	  programmed	   cell	   death	   (PCD)	   during	  
development.	  We	  also	  could	  not	  detect	  expression	  of	   the	   reporter	   in	  dying	  cells	  using	  either	  pan-­‐
neural/F25B3.3	   or	   ubiquitous/sur-­‐5	   promoters	   (data	   not	   shown);	   we	   hypothesize	   this	   is	   because	  
apoptotic	  cells	  do	  not	  activate	  these	  promoter	  regions	  before	  their	  death,	  which	  occurs	  shortly	  after	  
their	  birth	  (Sulston	  et	  al.	  1983).	  	  
	   We	   therefore	   took	   advantage	   of	   a	   reconstituted	   caspase	   system	   (described	   in	  Chapter	   4	  
(Chelur	   &	   Chalfie	   2007))	   to	   force	   CED-­‐3	   activation	   in	   a	   subset	   of	   cells	   also	   expressing	   Apoworm.	  
Previous	   experiments	   demonstrated	   that	   expression	   of	   reconstituted	   CED-­‐3	   (rec-­‐CED-­‐3)	   in	   GABA	  
neurons	   was	   sufficient	   to	   induce	   their	   apoptotic	   death	   (see	   Chapter	   4).	   We	   used	   the	   F25B3.3	  
promoter	  to	  express	  Apoworm	  throughout	  the	  nervous	  system	  and	  also	  reconstituted	  CED-­‐3	  in	  	  





Figure	  B.3:	  Apoworm	  detects	  forced	  CED-­‐3	  activation	  in	  GABA	  neurons.	  A.	  Diagram	  illustrating	  the	  
expression	   of	   Pan-­‐Neural	   Apoworm	   (gray)	   and	   reconstituted	   CED-­‐3	   (rec-­‐CED-­‐3)	   in	   GABA	   neurons	  
(green).	  B.	  Nuclear	   localization	  of	  GFP	   indicates	  Apoworm	   cleavage	   in	   an	   apoptotic	  GABA	  neuron	  
(yellow	  arrowhead).	  C.	   In	  contrast,	  non-­‐apoptotic	  neurons	  have	  both	  GFP	  and	  mRFP	  signals	  at	  the	  
membrane	  (white	  arrow).	  D.	  DIC	   image	  shows	  button-­‐like	  morphology	  of	  the	  apoptotic	  neuron.	  E.	  
Merged	  (GFP/mRFP/DIC)	  image.	  Anterior	  left,	  ventral	  down.	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GABA	  neurons	  (Fig.	  B.3A).	  Forced	  CED-­‐3	  activation	  allowed	  us	  to	  detect	  nuclear	  GFP	  (i.e.	  Apoworm	  
cleavage)	   in	  button-­‐like	  GABA	  neurons	   in	   the	  head	  of	   transgenic	  animals	   (Fig.	  B.3B-­‐E).	  This	   finding	  
indicates	  that	  Apoworm	  can	  be	  cleaved	  by	  activated	  CED-­‐3/caspase.	  
	  
Apoworm	  is	  cleaved	  independent	  of	  CED-­‐3	  in	  select	  neurons	  that	  do	  not	  die	  
	   After	   discovering	   that	   Apoworm	   can	   identify	   apoptotic	   events	   when	   CED-­‐3	   activation	   is	  
transgenically	   induced	   (Fig.	   B.3),	   we	   wanted	   to	   know	   whether	   this	   reporter	   could	   also	   detect	  
endogenous	  caspase	  activity.	  Because	  105	  of	  the	  131	  cells	  that	  undergo	  PCD	  are	  neurons	  (Putcha	  &	  
Johnson	  2004),	  we	  chose	  to	  focus	  on	  the	  nervous	  system.	  Using	  pan-­‐neurally	  driven	  Apoworm,	  we	  
examined	  neurons	  that	  express	  the	  caspase	  biosensor	  throughout	  development	  in	  hopes	  of	  catching	  
an	  apoptotic	  event.	  Unfortunately,	  we	  did	  not	  see	  apoptotic	  neurons	  at	  any	  developmental	  stage	  in	  
transgenic	   animals	   expressing	   this	   pan-­‐neural	   caspase	   reporter	   (data	   not	   shown).	   Through	   this	  
analysis,	  we	  noticed	  two	  neurons	  that	  had	  nuclear	  GFP	  and	  membrane-­‐localized	  mRFP	  but	  did	  not	  
display	  morphological	  features	  of	  apoptosis	  (Fig.	  B.4A-­‐D).	  Both	  of	  these	  neurons	  are	  located	  in	  the	  
head	  of	  the	  animal:	  one	  in	  the	  anterior	  bulb	  of	  the	  pharynx	  (cell	  identity	  unknown)	  and	  a	  second	  in	  
the	  posterior	  bulb	  of	   the	  pharynx	   (believed	  to	  be	  either	   the	  M1	  or	   I6	  neuron).	  We	  noted	  a	  higher	  
frequency	  of	  nuclear	  GFP	  for	  the	  neuron	  in	  the	  posterior	  bulb	  of	  the	  pharynx,	  and	  our	  quantification	  
of	   this	   revealed	   that	   this	   neuron	   exhibits	   Apoworm	   cleavage	   throughout	   development	   (data	   not	  
shown)	   and	   in	   almost	   half	   of	   the	   population	   (Fig.	   B.4E).	   Neither	   of	   these	   neurons	   died	   at	   any	  
developmental	  stage	  (data	  not	  shown).	  
In	  addition	  to	  their	  role	  in	  cell	  death	  pathways,	  caspases	  participate	  in	  many	  other	  biological	  
processes	  (see	  Chapter	  4).	  We	  reasoned	  that	  the	  cleavage	  of	  Apoworm	  in	  these	  non-­‐dying	  neurons	  
was	  due	  to	  an	  uncharacterized,	  non-­‐apoptotic	  role	  of	  CED-­‐3.	  To	  test	  this	  hypothesis,	  we	  examined	  	  
	  
	  









Figure	  B.4:	  Apoworm	  is	  cleaved	  in	  select	  neurons	  that	  do	  not	  die,	   independent	  of	  CED-­‐3.	  A.	  Pan-­‐
neurally	  expressed	  Apoworm	  is	  uncleaved	  in	  head	  neurons	  (white	  arrow)	  except	  for	  one	  cell	  in	  the	  
terminal	  bulb	  of	  the	  pharynx	  (yellow	  arrowhead).	  B.	  mRFP	  remains	  at	  the	  plasma	  membrane.	  C.	  DIC	  
shows	  the	  neuron	  with	  cleaved	  Apoworm	  does	  not	  have	  apoptotic	  morphology.	  D.	  Merged	  image.	  
Anterior	  up,	  ventral	  left.	  E.	  Percent	  of	  population	  with	  nuclear	  GFP	  signal	  (i.e.	  Apoworm	  cleavage)	  is	  
not	  significantly	  (n.s.)	  reduced	  in	  ced-­‐3(ok2734)	  versus	  wild-­‐type	  (WT).	  n	  ≥	  25.	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the	  frequency	  of	  Apoworm	  cleavage	  in	  the	  posterior	  pharyngeal	  bulb	  neuron	  in	  both	  wild-­‐type	  (WT)	  
and	   ced-­‐3(ok2734).	   Surprisingly,	   there	  was	   no	   significant	   difference	   in	   the	   frequency	   nuclear	   GFP	  
between	   WT	   and	   ced-­‐3	   mutants,	   which	   suggests	   that	   Apoworm	   cleavage	   in	   some	   cells	   occurs	  
independent	  of	  CED-­‐3.	  
	  
Apoworm	  does	  not	  detect	  all	  apoptotic	  events	  
	   As	   previously	   described,	   pan-­‐neurally	   driven	   Apoworm	   is	   not	   detected	   in	   cells	   that	   die	  
during	  development.	  To	  address	  whether	  Apoworm	  could	  identify	  endogenous	  CED-­‐3	  activation,	  we	  
used	  RNAi	  to	  knockdown	  ced-­‐9,	  a	  negative	  regulator	  of	  apoptosis	  that	  functions	  upstream	  of	  ced-­‐3	  
(Fig.	  B.5A).	  Because	  global	   loss	  of	  ced-­‐9	   is	   lethal	   (Hengartner	  &	  Horvitz	  1994),	  we	  used	  a	  neuron-­‐
specific	  RNAi	  background	  [sid-­‐1;	  punc-­‐119::sid-­‐1]	  (Calixto	  et	  al.	  2010)	  to	  reduce	  ced-­‐9	  function	  only	  
in	   neurons.	   Knockdown	   of	   ced-­‐9	   resulted	   in	   the	   rare	   apoptotic	   death	   of	   neurons	   that	   normally	  
survive	   larval	   development	   (Fig.	   B.5C),	   but	  we	  were	   unable	   to	   see	   nuclear-­‐localized	  GFP	   in	   these	  
button-­‐like	   cells.	   Furthermore,	   neighboring	   neurons	   that	   did	   not	   die	   had	   Apoworm	   cleavage	   (Fig.	  
B.5C-­‐E).	  Taken	  together,	  these	  results	  indicate	  that	  Apoworm	  is	  not	  cleaved	  in	  all	  apoptotic	  cells.	  
	  
	  
DISCUSSION	  AND	  FUTURE	  DIRECTIONS	  
In	   this	   appendix,	   we	   describe	   modifications	   to	   the	   Drosophila	   caspase	   sensor	   Apoliner	  
(Bardet,	   Kolahgar,	  Mynett,	  Miguel-­‐Aliaga,	  Briscoe,	  Meier	  &	  Vincent	   2008a)	   to	   enhance	  expression	  
and	  detection	  of	  CED-­‐3	  activation	  in	  C.	  elegans.	  By	  altering	  the	  membrane	  localization	  domain	  and	  
including	  a	  substrate	  recognition	  sequence	  that	   is	  highly	  preferred	  by	  CED-­‐3,	  we	  have	  generated	  a	  
reporter	  that	  can	  detect	  CED-­‐3	  activation	   in	  cells	  undergoing	  apoptosis.	  With	  further	  optimization,	  
this	   reporter	   may	   become	   a	   useful	   tool	   to	   uncover	   novel	   roles	   for	   CED-­‐3	   and	   other	   C.	   elegans	  
proteases.	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Figure	   B.5:	   Apoworm	  does	   not	   detect	   all	   CED-­‐3-­‐dependent	   apoptotic	   events	   induced	   by	   loss	   of	  
CED-­‐9	  function.	  A.	  Diagram	  of	  the	  apoptotic	  pathway	  in	  C.	  elegans.	  B.	  ced-­‐9	  genomic	  and	  cDNA	  are	  
illustrated.	  The	  region	  of	  ced-­‐9	  cDNA	  used	  to	  make	  Apoliner-­‐CED-­‐9	  is	  orange	  –	  with	  the	  location	  of	  
CED-­‐3	   cleavage	   sites	   (DAQD	   and	   ESID)	   annotated.	   The	   ced-­‐9	   RNAi	   clone	   generated	   for	   this	   study	  
covers	  most	   of	   the	   ced-­‐9	   cDNA	   sequence.	  C.	  DIC	   image	   of	   a	   button-­‐like	   apoptotic	   neuron	   (white	  
arrow)	   caused	   by	   ced-­‐9	   RNAi	   treatment	   of	   a	   sid-­‐1	   (pk3321)	   uIs60	   (pPan-­‐Neural::sid-­‐1);	   wdEx907	  
(pPan-­‐Neural::Apoworm)	  L1	  animal.	  A	  neuron	  that	  does	  not	  have	  morphological	  characteristics	  of	  an	  
apoptotic	   cell	   is	   also	   indicated	   (yellow	   arrowhead).	   D.	   The	   dying	   neuron	   (white	   arrow)	   has	  
membrane-­‐localized	   GFP	   (Apoworm	   not	   cleaved),	   while	   the	   non-­‐apoptotic	   neuron	   (yellow	  
arrowhead)	  has	  a	  pronounced	  nuclear	  GFP	  signal	  (Apoworm	  cleaved).	  Scale	  bar	  =	  10	  μm.	  	  E.	  Merged	  
image.	  Anterior	  right,	  ventral	  down.	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However,	  despite	  the	  progress	  made	  to	  optimize	  this	  sensor,	   there	  are	  specific	   issues	  that	  
should	  be	  addressed	  for	  future	  use.	  First,	  we	  were	  unable	  to	  identify	  reporter	  cleavage	  in	  cells	  that	  
normally	   undergo	   programmed	   cell	   death	   (PCD)	   during	   development.	   Attempts	   to	   express	   the	  
sensor	  under	  the	  egl-­‐1	  promoter	  (transcriptionally	  activated	  to	  begin	  apoptosis)	  were	  unsuccessful	  
due	   to	  both	  dim	  reporter	  expression	  and	   rare	  apoptotic	   cells	  also	  expressing	  Apoliner(DEVD).	  The	  
rapid	  execution	  and	  removal	  of	  apoptotic	  cells	  after	  egl-­‐1	  induction	  (Maurer	  et	  al.	  2007)	  may	  explain	  
why	  we	  did	  not	  detect	  PCD	  events	  with	  this	  reporter.	  
Secondly,	  Apoworm	  is	  cleaved	   in	  a	  CED-­‐3-­‐independent	  manner	   in	  distinct	  neurons	  that	  do	  
not	   undergo	   apoptosis	   (Figure	   B.4).	   This	   suggests	   that	   an	   additional	   protease	   is	   active	   and	  
recognizes	  a	  region	  of	  the	  biosensor	  between	  the	  membrane-­‐tagged	  mRFP	  and	  the	  NLS-­‐GFP	  (Figure	  
B.1D)	  in	  these	  neurons.	  It	  is	  unclear	  whether	  the	  DEVD	  sequence	  (i.e.	  CED-­‐3	  “specific”)	  is	  recognized	  
by	  this	  unidentified	  protease	  or	  another	  sequence	  within	  that	  region	  is	  cleaved.	  Finally,	  we	  detected	  
an	  event	  where	  Apoworm	  failed	  to	  report	  CED-­‐3	  activity	  in	  a	  neuron	  with	  clear	  morphological	  signs	  
of	   apoptosis	   (Figure	   B.5).	   Based	   on	   these	   preliminary	   analyses,	   we	   conclude	   that	   further	  
optimization	  of	  Apoworm	  is	  required	  before	  it	  can	  be	  fully	  utilized	  as	  a	  reliable	   indicator	  of	   in	  vivo	  
CED-­‐3	  activity.	  	  
	  
Future	  Directions	  
	   Despite	   the	   aforementioned	   caveats	   of	   Apoworm,	   our	   work	   provides	   the	   foundation	   for	  
further	   optimization	   that	   may	   lead	   to	   the	   creation	   of	   a	   reliable	   in	   vivo	   caspase	   reporter	   for	   C.	  
elegans.	  Apoworm	  also	  has	   the	  potential	   to	  uncover	  novel,	  apoptotic-­‐independent	   roles	  of	  CED-­‐3.	  
For	  example,	  CED-­‐3	  activity	  is	  required	  for	  neuron	  regeneration	  following	  axotomy	  (Pinan-­‐Lucarre	  et	  
al.	  2011)	  and	  our	  work	  reveals	  a	  neuroprotective	  role	  for	  CED-­‐3	  that	  requires	  its	  caspase	  activity	  (see	  
Chapter	   4).	   Both	  of	   these	  non-­‐apoptotic	   CED-­‐3	   roles	   are	   largely	   unstudied	   and	   require	   a	   detailed	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mechanistic	   characterization.	   An	   in	   vivo	   CED-­‐3	   activity	   sensor	   could	   address	   many	   unanswered	  
questions	  regarding	  caspase	  involvement	  in	  both	  regeneration	  and	  neuroprotection.	  However,	   it	   is	  
worth	   noting	   that	   localized	   caspase	   activity	   is	   currently	   the	   favored	   model	   for	   CED-­‐3-­‐dependent	  
neuronal	   regeneration	   (Pinan-­‐Lucarre	   et	   al.	   2011),	   and	   this	   reporter	   is	   designed	   to	   detect	   robust	  
CED-­‐3	  activation	  (Figure	  B.1F).	   	   It	  will	  be	  difficult	  to	  detect	  minor	  or	   localized	  caspase	  activity	  with	  
the	   sensor	   described	   here.	   Alternative	   approaches	   of	   detecting	   localized	   caspase	   activation	  
currently	  include	  FRET-­‐based	  systems	  (Figueroa	  et	  al.	  2011)	  and	  these	  methods	  may	  be	  the	  desired	  
technique	  to	  uncover	  subtle	  or	  localized	  caspase	  activity.	  
Additionally,	  CSP-­‐1,	  another	  C.	  elegans	  caspase,	  was	  recently	  assigned	  an	  in	  vivo	  role,	  where	  
it	   promotes	   programmed	   cell	   death	   through	   a	   mechanism	   independent	   of	   the	   core	   apoptotic	  
machinery	   (Fig.	   5A)	   (Denning	   et	   al.	   2013).	   Work	   by	   Shai	   Shaham	   revealed	   that	   the	   preferential	  
substrate	   sequence	   for	   CSP-­‐1	   (YVAD)	   is	   very	   distinct	   from	   that	   of	   CED-­‐3	   (DEVD)	   (Neukomm	  et	   al.	  
2011;	  Shaham	  1998).	  By	  modifying	  the	  protease	  recognition	  sequence,	  this	  sensor	  could	  be	  used	  to	  
assess	   properties	   of	   CSP-­‐1-­‐dependent	   apoptotic	   events.	   Furthermore,	   for	   proteases	   with	   unique	  
substrate	   recognition	  sequences,	   this	   reporter	  could	  be	  extremely	  useful	   to	   investigate	   the	   timing	  
and	  consequences	  of	  proteolytic	  activation	  in	  a	  variety	  of	  biological	  contexts.	  
We	  have	   also	   generated	   additional	   reagents	   that	  will	   be	   useful	   for	   future	   optimization	   of	  
Apoworm.	  One	  such	  vector	  contains	  the	  pan-­‐caspase	  inhibitor	  p35	  and	  could	  be	  used	  to	  verify	  the	  
caspase-­‐dependence	  of	  the	  biosensor.	  We	  have	  also	  mutated	  the	  caspase	  recognition	  sequence	  (an	  
aspartate	  essential	   for	   caspase	  cleavage	   is	  mutated	   to	  alanine)	  and	   this	   reagent	   (Apoworm-­‐DEVA)	  
would	  provide	  a	  control	  to	  validate	  caspase	  substrate	  specificity.	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Appendix	  C:	  List	  of	  plasmids	  (pMLH	  #1-­‐303,	  pMBM	  #1-­‐9)	  
	  
Plasmid	  Name	   Description	   From	  
pMLH001	   punc-­‐25	  FWD	  in	  pENTR	  5’	  TOPO	  SphI/AscI	   kanamycin	  
pMLH002	   punc-­‐25	  REV	  in	  pENTR	  5’	  TOPO	  SphI/AscI	   kanamycin	  
pMLH003	   yk1514f03	  FWD	  in	  pCR8/GW	  TOPO	   spectinomycin	  
pMLH004	   pC04G2.1	  FWD	  in	  pENTR	  5’	  TOPO	  SphI/AscI	   kanamycin	  
pMLH005	   pC04G2.1	  REV	  in	  pENTR	  5’	  TOPO	  SphI/AscI	   kanamycin	  
pMLH006	   yk1514f03	  REV	  in	  pCR8/GW	  TOPO	   spectinomycin	  
pMLH007	   punc-­‐25:mcherry:gateway:unc-­‐54	  3’UTR	   ampicillin	  
pMLH008	   punc-­‐25:gateway:YFP	   ampicillin	  
pMLH009	   punc-­‐25:gateway:mcherry	   ampicillin	  
pMLH010	   punc-­‐25:mcherry:yk1514f03:unc-­‐54	  3’UTR	   ampicillin	  
pMLH011	   punc-­‐25	  REV	  in	  pENTR	  5’	  TOPO	  SacI/KpnI	   kanamycin	  
pMLH012	   punc-­‐25:yk1514f03:mcherry	  (93A)	   ampicillin	  
pMLH013	   punc-­‐25:yk1514f03	  RC:mcherry	  (961)	   ampicillin	  
pMLH014	   coq-­‐1	  cDNA	  REV	  in	  pCR8/GW	  TOPO	   spectinomycin	  
pMLH015	   punc-­‐25:rde-­‐1	  cDNA:mcherry:unc-­‐10	  3’UTR	   ampicillin	  
pMLH016*	   pwpro:unc-­‐119:yk1514f03	  IR:unc-­‐54	  3’UTR	   ampicillin	  
pMLH017	   pwpro:unc-­‐119:yk1514f03	   ampicillin	  
pMLH018	   yk1749d10	  in	  L4440	  in	  HT115	  cells	   ampicillin	  
pMLH019	   punc-­‐25:mcherry:csp-­‐3	  genomic	  NO	  STOP	   ampicillin	  
pMLH020	   punc-­‐25	  in	  pCR2.1	  TOPO	  AscI/PmeI	   kanamycin	  
pMLH021	   pcoq-­‐1:gateway:mcherry	   ampicillin	  
pMLH022	   punc-­‐25	  in	  pCR2.1	  TOPO	  SphI/SmaI	  	   kanamycin	  
pMLH023	   yk1479d10	  FWD	  in	  pCR8/GW	  TOPO	   spectinomycin	  
pMLH024	   Apoliner	  in	  pCR2.1	  TOPO	  AscI/KpnI	   kanamycin	  
pMLH025	   punc-­‐25:csp-­‐3	  cDNA:mcherry	   ampicillin	  
pMLH026	   punc-­‐25:luc+:GFP	   ampicillin	  
pMLH027	   punc-­‐25:HyPer:unc-­‐10	  3’UTR	   ampicillin	  
pMLH028	   punc-­‐25:gateway:SL2:mcherry	   ampicillin	  
pMLH029	   coq-­‐1	  cDNA	  Ahringer	  (5p)	  in	  pCR8/GW	  TOPO	   spectinomycin	  
pMLH030	   coq-­‐1	  cDNA	  3prime	  end	  in	  pCR8/GW	  TOPO	   spectinomycin	  
pMLH031	   punc-­‐4:HyPer:unc-­‐10	  3’	  UTR	   ampicillin	  
pMLH032	   coq-­‐1	  cDNA	  Ahringer	  (5p)	  in	  L4440	   ampicillin	  
pMLH032	  	   coq-­‐1	  cDNA	  Ahringer	  (5p)	  RNAi	  (in	  L4440)	   ampicillin	  
pMLH033	   punc-­‐25::yk1479d10::SL2::mcherry::unc-­‐10	  3’UTR	   ampicillin	  
pMLH034	   pcoq-­‐1:yk1479d10:SL2:mcherry:unc-­‐10	  3’UTR	   ampicillin	  
pMLH035	   punc-­‐25:TOM20:mRFP:unc-­‐10	  3’UTR	   ampicillin	  
pMLH036	   punc-­‐4:TOM20:mRFP	   ampicillin	  
pMLH037	   punc-­‐25:rde-­‐1:mcherry:unc-­‐10	  3’UTR	  +	  unc-­‐119	  mini	  gene	   ampicillin	  
pMLH038	   punc-­‐25:HyPer:unc-­‐10	  3’UTR	  +	  unc-­‐119	  mini	  gene	   ampicillin	  
pMLH039	   punc-­‐4:HyPer:unc-­‐10	  3’UTR	  +	  unc-­‐119	  mini	  gene	   ampicillin	  
pMLH040	   punc-­‐25:TOM20:mRFP:unc-­‐10	  3’UTR	  +	  unc-­‐119	  mini	  gene	   ampicillin	  
pMLH041	   punc-­‐25:mcherry:unc-­‐54	  3’UTR	  +	  unc-­‐119	  mini	  gene	   ampicillin	  
pMLH042	   pdes-­‐2:mcherry:unc-­‐54	  3’UTR	  +	  unc-­‐119	  mini	  gene	   ampicillin	  
pMLH043	   punc-­‐25:rde-­‐1:mRFP:unc-­‐10	  3’UTR	  +	  unc-­‐119	  mini	  gene	   ampicillin	  
pMLH044	   punc-­‐25:coq-­‐1	  (yk1479d10):SL2:mcherry	  +	  unc-­‐119	  mini	  gene	   ampicillin	  
pMLH045	   punc-­‐25	  in	  pCR8	  ApaI/NcoI	   spectinomycin	  
pMLH046	   pttr-­‐39::mcherry::unc-­‐54	  3’UTR	  +	  unc-­‐119	  mini	  gene	   ampicillin	  
pMLH047	   punc-­‐25::yk1479d10::RC	  punc-­‐25	   ampicillin	  
pMLH048	   punc-­‐25::gateway::mRFP::unc-­‐10	  3’UTR	   ampicillin	  
pMLH049	   punc-­‐25::gateway::GFP::unc-­‐10	  3’UTR	   ampicillin	  
pMLH050	   punc-­‐25::gateway::SL2::GFP::unc-­‐10	  3’UTR	   ampicillin	  
pMLH051	   punc-­‐25::gateway::SL2::mRFP::unc-­‐10	  3’UTR	   ampcilin	  
pMLH052	   punc-­‐25::gateway::SL2::YFP::unc-­‐54	  3’UTR	   ampicillin	  
pMLH053	   punc-­‐25::yk1479d10::SL2::mRFP::unc-­‐10	  3’UTR	   ampicillin	  
pMLH054	   punc-­‐25::gateway::SL2::CFP::unc	  54	  3’UTR	   ampicillin	  
pMLH055	   pttr-­‐39::egl-­‐36(gf)::unc-­‐54	  3’UTR	  +	  unc-­‐119	  mini	  gene	  (same	  strand)	   ampicillin	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pMLH056	   pttr-­‐39::egl-­‐36(gf)::unc-­‐54	  3’UTR	  +	  unc-­‐119	  mini	  gene	  (opp	  strand)	   ampicillin	  
pMLH057	   pttr-­‐39::egl-­‐36(lf)::unc-­‐54	  UTR	  +	  unc-­‐119	  mini	  gene	  (same	  strand)	   ampicillin	  
pMLH058	   pttr-­‐39::egl-­‐36(lf)::unc-­‐54	  3’UTR	  +	  unc-­‐119	  mini	  gene	  (opp	  strand)	   ampicillin	  
pMLH059	   yk1479d10	  FWD	  (5’	  SacII-­‐	  3’	  AscI)	  in	  pCR8/GW	  TOPO	   spectinomycin	  
pMLH059	   yk1479d10	  FWD	  in	  pCR8/GW	  TOPO	  (5'SacII-­‐3'AscI)	   spectinomycin	  
pMLH060	   yk1479d10	  REV	  in	  pCR8/GW	  TOPO	  (5'SacII-­‐3'AscI)	   spectinomycin	  
pMLH061	   Gateway	  R1R2	  cassette	  (5’	  AscI	  -­‐	  3’	  SacII)	  in	  pCR8/GW	  TOPO	   spec	  +	  CAM	  
pMLH061	   R1R2	  Gateway	  in	  pCR8	  GW/TOPO	  (5'	  AscI-­‐3'	  SacII)	   spectinomycin	  
pMLH062	   punc-­‐25::CFP	  +	  unc-­‐119	  minigene	   ampicillin	  
pMLH063	   pttr-­‐39::coq-­‐1	  cDNA	  REV	  +	  unc-­‐119	  minigene	   ampicillin	  
pMLH064	   unc-­‐30	  cDNA	  minus	  TTAG	  FWD	  in	  pCR8/GW	  TOPO	   spectinomycin	  
pMLH065	   unc-­‐30	  cDNA	  minus	  TTAG	  REV	  in	  pCR8/GW	  TOPO	   spectinomycin	  
pMLH066	   yk1479d10	  REV	  in	  pCR8/GW	  TOPO	  (5'AscI-­‐3'SacII)	   spectinomycin	  
pMLH067	   yk1479d10	  FWD	  in	  pCR8/GW	  TOPO	  (5'AscI-­‐3'SacII)	   spectinomycin	  
pMLH068	   punc-­‐25::gateway::SL2::mRFP	  +	  unc-­‐119	  minigene	   ampicillin	  
pMLH069	   mito::GFP	  PCR'd	  from	  bcEx620	  FWD	  in	  pCR8/GW	  TOPO	   spectinomycin	  
pMLH070	   mito::GFP	  PCR'd	  from	  bcEx620	  REV	  in	  pCR8/GW	  TOPO	   spectinomycin	  
pMLH071	   punc-­‐25::unc-­‐30	  minus	  A	  in	  start::SL2::mRFP	   ampicillin	  
pMLH072	   punc-­‐25::unc-­‐30	  minus	  TTAG	  in	  stop::SL2::mRFP	  +	  unc-­‐119	  minigene	   ampicillin	  
pMLH073	   pttr-­‐39::coq-­‐1	  cDNA	  FOR::punc-­‐25	  RC	  +	  unc-­‐119	  minigene	   ampicillin	  
pMLH074	   pacr-­‐2	  5'SphI	  3'AscI	  in	  pCR8	  (REV)	   spectinomycin	  
pMLH075	   Apoliner	  DEVD	  piece	  in	  pCR8	  FWD	   spectinomycin	  
pMLH076	   pttr-­‐39::coq-­‐1	  cDNA	  FOR	  +	  unc-­‐119	  minigene	   ampicillin	  
pMLH077	   pttr-­‐39::coq-­‐1	  FOR::punc-­‐25	  RC	  +	  unc-­‐119	  minigene	   ampicillin	  
pMLH078	   punc-­‐25::mRFP	  +	  unc-­‐119	  minigene	   ampicillin	  
pMLH079	   pacr-­‐2	  5'SphI	  3'AscI	  in	  pCR8	  (FOR)	   spectinomycin	  
pMLH080	   psur-­‐5	  5'SphI	  3'Asci	  in	  pCR8	  (FOR)	   spectinomycin	  
pMLH081	   pF25B3.3	  5'SphI	  3'AscI	  in	  pCR8	  (unknown	  direction)	   spectinomycin	  
pMLH082	   mitochondrial	  leader	  sequence	  (MLS)-­‐GFP	  5'AscI	  3'SacII	  in	  pCR2.1	   kanamycin/ampicillin	  
pMLH083	   punc-­‐25::gateway::SL2::mRFP	  5'ApaI	  3'ApaI	  in	  pCR8	   chloramphenicol/spectinomycin	  
pMLH084	   punc-­‐25::GFP::unc-­‐10	  UTR	   ampicillin	  
pMLH085	   N/A	   	  
pMLH086	   punc-­‐25::GFP::unc-­‐10	  UTR	  +	  unc-­‐119	  minigene	   ampicillin	  
pMLH087	   psur-­‐5::mRFP	  +	  unc-­‐119	  minigene	   ampicillin	  
pMLH088	   pacr-­‐2::TOM20::mRFP	  +	  unc-­‐119	  minigene	   ampicillin	  
pMLH089	   punc-­‐25::mRFP	  in	  pENTR	  TOPO	   kanamycin	  
pMLH090	   psur-­‐5::yk1479d10	  +	  unc-­‐119	  minigene	   ampicillin	  
pMLH091	   pttr-­‐39-­‐yk1514f03-­‐pu25reverse+unc119minigene	  and	  pdat-­‐1mcherry	   spectinomycin+ampicillin	  
pMLH092	   pmyo-­‐3::dsRed::unc-­‐54	  UTR	  FWD	  in	  pCR8	   spectinomycin	  
pMLH093	   pF25B3.3::GFP	  &	  punc-­‐25::mcherry	   ampicillin	  
pMLH094	   pmyo-­‐3::dsRed::unc-­‐54	  UTR	  REV	  in	  pCR8	   spectinomycin	  
pMLH095	   pttr-­‐39::coq-­‐1	  cDNA	  REV	  +	  punc-­‐25::mcherry	   ampicillin	  
pMLH096	   pttr-­‐39::rde-­‐1	  cDNA	  +	  unc-­‐119	  minigene	   ampicillin	  
pMLH097	   drp-­‐1	  cDNA	  (unknown	  direction)	  in	  pCR8	   spectinomycin	  
pMLH098	   punc-­‐25::drp-­‐1	  cDNA::unc-­‐10	  UTR	   ampicillin	  
pMLH099	   unc-­‐30	  cDNA	  AscI-­‐KpnI	  in	  pCR8	  (unknown	  direction)	   spectinomycin	  
pMLH100	   unc-­‐30	  cDNA	  AscI-­‐KpnI	  in	  pCR8	  (unknown	  direction)	   spectinomycin	  
pMLH101	   punc-­‐25:unc-­‐30::unc-­‐54	  3’UTR	   ampicillin	  
pMLH102	   pacr-­‐2::unc-­‐30::unc-­‐54	  3’UTR	   ampicillin	  
pMLH103	   pttr-­‐39::mcherry::unc-­‐54	  3’UTR	   ampicillin	  
pMLH104	   coq-­‐1	  573bp	  RNAi	  from	  cDNA	  flanked	  PmeI	  in	  pCR8	   spectinomycin	  
pMLH105	   pttr-­‐39::coq-­‐1	  RNAi	  FWD	  +	  unc-­‐119(+)	   ampicillin	  
pMLH106	   pttr-­‐39::(PmeI,	  no	  RNAi	  clone)	  +	  unc-­‐119(+)	   ampicillin	  
pMLH107	   pttr-­‐39::coq-­‐1	  RNAi	  FWD::punc-­‐25::mCherry	   ampicillin	  
pMLH108	   pceh-­‐22::mRFP	   ampicillin	  
pMLH109	   punc-­‐4::TOM20::YFP::unc-­‐54	  3’UTR	   ampicillin	  
pMLH110	   punc-­‐4::TOM20::GFP::unc-­‐10	  3’UTR	   ampicillin	  
pMLH111	   pttr-­‐39::coq-­‐1	  RNAi	  FWD	  +	  unc-­‐119(+)	   ampicillin	  
pMLH112	   pttr-­‐39::coq-­‐1	  RNAi	  REV	  (flanked	  PmeI)	   ampicillin	  
pMLH113	   pF25B3.3(minus	  106bp)::unc-­‐30	  cDNA	   ampicillin	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pMLH114	   pacr-­‐2::ApoDEVD	  missense	  mutations	   ampicillin	  
pMLH115	   pttr-­‐39::coq-­‐1	  RNAi	  FWD	  (flanked	  PmeI)	   ampicillin	  
pMLH116	   pF25B3.3(minus	  106bp)::ApoDEVD	  missense	  mutations	   ampicillin	  
pMLH117	   pttr-­‐39::TOM20::GFP::unc-­‐10	  3’UTR	   ampicillin	  
pMLH117	   pttr-­‐39::TOM20::GFP::unc-­‐10	  3’UTR	   ampicillin	  
pMLH118	   pttr-­‐39::asp-­‐4::GFP	   ampicillin	  
pMLH119	   punc-­‐8	  (FseI-­‐AscI)	  FWD	  in	  pCR8	   spectinomycin	  
pMLH120	   pF25B3.3(minus	  106bp)::Apoliner	  MCS	   ampicillin	  
pMLH121	   pF25B3.3(full)::unc-­‐30	  cDNA	   ampicillin	  
pMLH122	   pttr-­‐39-­‐coq-­‐1	  cDNA-­‐mCherry	   ampicillin	  
pMLH123	   pF25B3.3	  minus106bp::ApoMCS-­‐AscI-­‐SacII	   ampicillin	  
pMLH124	   punc-­‐8::TOM20::GFP::unc-­‐10	  3’UTR	   ampicillin	  
pMLH125	   N/A	   	  
pMLH126	   N/A	   	  
pMLH127	   pacr-­‐2::TOM20::mRFP::unc-­‐10	  3’UTR	   ampicillin	  
pMLH128	   coq-­‐1	  RNAi	  FWD	  in	  L4440	  in	  XL1	  Blues	   ampicillin	  +	  tetracycline	  
pMLH129	   coq-­‐1	  RNAi	  FWD	  in	  L4440	  in	  HT115	   ampicillin	  +	  tetracycline	  
pMLH130	   punc-­‐8::GFP::unc-­‐10	  3’UTR	   ampicillin	  +	  tetracycline	  
pMLH131	   C.	  briggsae	  (#5)	  coq-­‐1	  genomic	  REV	  in	  pCR8	   spectinomycin	  
pMLH132	   punc-­‐25::mcherry::unc-­‐54	  3’UTR	   ampicillin	  
pMLH133	   phsp-­‐16.2::GFP::unc-­‐10	  3’	  UTR	   ampicillin	  
pMLH134	   pF25B3.3	  minus	  106bp::Apoliner	  correct	  DEVD	   ampicillin	  
pMLH135	   N/A	   	  
pMLH136	   phsp-­‐16.2::coq-­‐1	  RNAi	  FWD	   ampicillin	  
pMLH137	   punc-­‐25::Apoliner-­‐DEVD::unc-­‐54	  3’UTR	   ampicillin	  
pMLH138	   coq-­‐1	  &	  asp-­‐3	  RNAi	  clone	  in	  L440	  in	  HT115	   ampicillin	  +	  tetracycline	  
pMLH139	   csp-­‐1B	  cDNA	  no	  stop	  FWD	  AscI-­‐KpnI	  in	  pCR8	   spectinomycin	  
pMLH140	   N/A	   	  
pMLH141	   pttr-­‐39::csp-­‐1B::GFP	   ampicillin	  
pMLH142	   pF25B3.3::Apoliner-­‐DEVD::unc-­‐54	  3’UTR	   ampicillin	  
pMLH143	   punc-­‐25::mcherry::unc-­‐10	  3’UTR	  +	  pmyo-­‐2::mcherry	   ampicillin	  
pMLH144	   punc-­‐25::GFP	  +	  pmyo-­‐2::mcherry	   ampicillin	  
pMLH145	   psur-­‐5::coq-­‐1	  RNAi	  REV	  +	  unc-­‐119(+)	   ampicillin	  
pMLH146	   pacr-­‐2::unc-­‐30	  cDNA	  +	  unc-­‐119(+)	   ampicillin	  
pMLH147	   phsp-­‐16.2::coq-­‐1	  FWD	  RNAi	  +	  pmyo-­‐2::mcherry	   ampicillin	  
pMLH148	   pttr-­‐39::csp-­‐1B::GFP	  +	  unc-­‐119(+)	   ampicillin	  
pMLH149	   pF25B3.3::Apoliner-­‐DEVD	  +	  unc-­‐119(+)	   ampicillin	  
pMLH150	   pacr-­‐2::sod-­‐1	  genomic	  with	  mutation	  +	  unc-­‐119(+)	   ampicillin	  
pMLH151	   C.	  briggsae	  (#2)	  coq-­‐1	  genomic	  FWD	  in	  pCR8	   spectinomycin	  
pMLH152	   ced-­‐9	  RNAi	  FWD	  (flanked	  PmeI)	  in	  pCR8	   spectinomycin	  
pMLH153	   ced-­‐9	  RNAi	  REV	  (flanked	  PmeI)	  in	  pCR8	   spectinomycin	  
pMLH154	   ced-­‐9	  RNAi	  REV	  in	  L4440	  in	  XL1	  Blues	   ampicillin	  
pMLH155	   wan-­‐1	  3’UTR	  (flanked	  PmeI)	  in	  pCR8	   spectinomycin	  
pMLH156	   pttr-­‐39::tra-­‐3	  cDNA::	  unc-­‐10	  3’UTR	   ampicillin	  
pMLH157	   pegl-­‐1::Apoliner-­‐DEVD	   ampicillin	  
pMLH158	   ced-­‐9	  RNAi	  in	  L4440	  in	  HT115	   ampicillin	  +	  tetracycline	  
pMLH159	   wan-­‐1	  3’UTR	  in	  L4440	  in	  HT115	   ampicillin	  +	  tetracycline	  
pMLH160	   pttr-­‐39::asp-­‐4	  cDNA::unc-­‐10	  3’UTR	   ampicillin	  
pMLH161	   punc-­‐25::TOM20::GFP	   ampicillin	  
pMLH162	   pttr-­‐39::ced-­‐3	  cDNA::unc-­‐10	  3’UTR	   ampicillin	  
pMLH163	   pttr-­‐39::ced-­‐3	  (C358S)	  cDNA::unc-­‐10	  3’UTR	   ampicillin	  
pMLH164	   pttr-­‐39::ced-­‐3	  cDNA::unc-­‐10	  3’UTR	  (from	  my	  cDNA)	   ampicillin	  
pMLH165	   pttr-­‐39::C.	  briggsae	  coq-­‐1	  cDNA::unc-­‐10	  3’UTR	   ampicillin	  
pMLH166	   pttr-­‐39::C.	  briggsae	  coq-­‐1	  genomic	  DNA::unc-­‐10	  3’UTR	   ampicillin	  
pMLH167	   punc-­‐25::C.briggsae	  coq-­‐1	  cDNA::unc-­‐10	  3’UTR	   ampicillin	  
pMLH168	   punc-­‐25::C.briggsae	  coq-­‐1	  cDNA::unc-­‐10	  3’UTR	   ampicillin	  
pMLH169	   pttr-­‐39::csp-­‐1	  cDNA::unc-­‐10	  3’UTR	   ampicillin	  
pMLH170	   punc-­‐25::luc+::GFP::unc-­‐10	  3’UTR	   ampicillin	  
pMLH171	   psur-­‐5::C.briggsae	  coq-­‐1	  cDNA::unc-­‐10	  3’UTR	   ampicillin	  
pMLH172	   pacr-­‐2::GFP::unc-­‐10	  3’UTR	   ampicillin	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pMLH173	   pF25B3.3::mcherry::unc-­‐54	  3’UTR	   ampicillin	  
pMLH174	   pttr-­‐39::ced-­‐4	  cDNA::unc-­‐10	  3’UTR	   ampicillin	  
pMLH175	   pF25B3.3::GFP-­‐H2B::unc-­‐54	  3’UTR	   ampicillin	  
pMLH176	   pacr-­‐2::mcherry::unc-­‐54	  3’UTR	   ampicillin	  
pMLH177	   psur-­‐5::C.briggsae	  coq-­‐1	  cDNA	  (STOP)-­‐GFP::unc-­‐54	  3’UTR	   ampicillin	  
pMLH178	   csp-­‐1	  cDNA	  RNAi	  (FWD)	  in	  L4440	  in	  XL1	  Blues	   ampicillin	  
pMLH179	   ced-­‐3	  cDNA	  RNAi	  (FWD)	  in	  L4440	  in	  XL1	  Blues	   ampicillin	  
pMLH180	   pttr-­‐39::csp-­‐1	  cDNA	  RNAi	  REV	   ampicillin	  
pMLH181	   psur-­‐5::sod-­‐2	  gDNA::GFP::unc-­‐54	  3’UTR	   ampicillin	  
pMLH182	   pF25B3.3::C.	  briggsae	  coq-­‐1	  cDNA::unc-­‐10	  3’UTR	   ampicillin	  
pMLH183	   pttr-­‐39::ced-­‐3	  RNAi	  FWD	   ampicillin	  
pMLH184	   punc-­‐25::sod-­‐2	  gDNA::GFP::unc-­‐54	  3’UTR	   ampicillin	  
pMLH185	   pttr-­‐39::csp-­‐1	  cDNA	  RNAi	  FWD	   ampicillin	  
pMLH186	   pttr-­‐39::ced-­‐3	  cDNA	  RNAi	  REV	   ampicillin	  
pMLH187	   punc-­‐25::drp-­‐1	  cDNA	  (STOP)::TAA-­‐unc-­‐54	  3’UTR	   ampicillin	  
pMLH188	   punc-­‐25::ced-­‐3	  cDNA::GFP::unc-­‐54	  3’UTR	   ampicillin	  
pMLH189	   punc-­‐25::ced-­‐4	  cDNA::GFP::unc-­‐54	  3’UTR	   ampicillin	  
pMLH190	   punc-­‐25::csp-­‐1	  cDNA::GFP::unc-­‐54	  3’UTR	   ampicillin	  
pMLH191	   punc-­‐25::sod-­‐2	  gDNA	  (no	  stop)::TAA-­‐unc-­‐54	  3’UTR	   ampicillin	  
pMLH192	   pttr-­‐39::ctl-­‐1	  cDNA	  RNAi	  FWD	   ampicillin	  
pMLH193	   pttr-­‐39-­‐ctl-­‐1_RNAi_FWD_flanked	  PmeI	   ampicillin	  
pMLH194	   pttr-­‐39-­‐ctl-­‐1_RNAi_REV_flanked	  PmeI	   ampicillin	  
pMLH195	   N/A	   	  
pMLH196	   pttr-­‐39_csp-­‐1	  genomic	  DNA-­‐unc-­‐10	  UTR	   ampicillin	  
pMLH197	   punc-­‐25-­‐csp-­‐1B-­‐FLAG-­‐unc-­‐10UTR	   ampicillin	  
pMLH198	   pttr-­‐39_csp-­‐1B_C138S	  BUT	  ALSO	  K131R-­‐	   ampicillin	  
pMLH199	   csp-­‐1A	  cDNA	  FWD	  in	  pCR2.1-­‐TOPO	   ampicillin	  +	  kanamycin	  
pMLH200	   pttr-­‐39_csp-­‐1A_cDNA	  w	  SNPs-­‐unc-­‐10	  	   ampicillin	  
pMLH201	   psur-­‐5_csp-­‐1_gDNA-­‐unc-­‐10	  UTR	   ampicillin	  
pMLH202	   phsp-­‐16-­‐2_csp-­‐1	  gDNA-­‐unc-­‐10	  UTR	   ampicillin	  
pMLH203	   pttr-­‐39_csp-­‐1A_cDNA	  w	  E136	  -­‐unc-­‐10	  	   ampicillin	  
pMLH204	   pF25B3.3_Apoliner_ced-­‐9-­‐unc-­‐54	  3'UTR	   ampicillin	  
pMLH205	   pacr-­‐2-­‐rec-­‐csp-­‐1-­‐large-­‐unc-­‐10-­‐UTR	   ampicillin	  
pMLH206	   pttr-­‐39-­‐ced-­‐3	  (p15)-­‐nz	   ampicillin	  
pMLH207	   punc-­‐25-­‐ced-­‐3	  (p15-­‐SM)-­‐nz	   ampicillin	  
pMLH208	   phsp-­‐16.2-­‐ced-­‐3	  (p15-­‐SM)-­‐nz	   ampicillin	  
pMLH209	   pttr-­‐39-­‐cz-­‐ced-­‐3	  (p17)	   ampicillin	  
pMLH210	   punc-­‐25-­‐cz-­‐ced-­‐3	  (p17-­‐LG)	   ampicillin	  
pMLH211	   phsp-­‐16.2-­‐cz-­‐ced-­‐3	  (p17-­‐LG)	   ampicillin	  
pMLH212	   psur-­‐5_Apoliner_ced-­‐9-­‐unc-­‐54	  3'UTR	   ampicillin	  
pMLH213	   punc-­‐25_Apoliner_ced-­‐9-­‐unc-­‐54	  3'UTR	   ampicillin	  
pMLH214	   phsp_16.2_ced-­‐3	  cDNA-­‐unc-­‐10	  UTR	   ampicillin	  
pMLH215	   pacr-­‐2-­‐csp-­‐1(p10)-­‐unc-­‐10-­‐UTR	   ampicillin	  
pMLH216	   pttr-­‐39-­‐csp-­‐1	  (p10)-­‐nz	   ampicillin	  
pMLH217	   pttr-­‐39-­‐cz-­‐csp-­‐1	  (p20)-­‐unc-­‐10	  3'UTR	   ampicillin	  
pMLH218	   psur-­‐5_Apoliner-­‐DEVD_unc-­‐54-­‐UTR	   ampicillin	  
pMLH219	   psur-­‐5_cz-­‐csp-­‐1(p20)-­‐unc-­‐10	  UTR	   ampicillin	  
pMLH220	   phsp-­‐16.2-­‐csp-­‐1	  (p10)-­‐nz	   ampicillin	  
pMLH221	   pttr-­‐39-­‐Mb-­‐mCherry	   ampicillin	  
pMLH223	   psur-­‐5_coq-­‐1	  RNAi	  FWD	   ampicillin	  
pMLH224	   psur-­‐5-­‐coq-­‐1	  RNAi	  REV	  flanked	  PmeI	   ampicillin	  
pMLH226	   psur-­‐5_Mb-­‐Apoliner-­‐DEVD_unc-­‐54-­‐UTR	   ampicillin	  
pMLH227	   punc-­‐25-­‐Mb-­‐Apoliner-­‐DEVD	   ampicillin	  
pMLH228	   pcsp-­‐1-­‐GFP-­‐unc-­‐10UTR	   ampicillin	  
pMLH229	   pttr-­‐39_ced-­‐3-­‐FLAG-­‐unc-­‐10	  UTR	   ampicillin	  
pMLH230	   pttr-­‐39_ced-­‐3-­‐C358S-­‐FLAG-­‐unc-­‐10	  UTR	   ampicillin	  
pMLH231	   pmec-­‐4_Mb-­‐Apoliner-­‐DEVD_unc-­‐54-­‐UTR	   ampicillin	  
pMLH232	   pcsp-­‐1	  1.3kb	  FWD	  in	  pCR2.1-­‐TOPO	   ampicillin	  +	  kanamycin	  
pMLH233	   pmyo-­‐3-­‐C-­‐briggsae	  coq-­‐1-­‐unc-­‐10	  3'UTR	   ampicillin	  
pMLH234	   pmyo-­‐3-­‐csp-­‐1	  (p10)-­‐nz	  unc-­‐54	  3'UTR	   ampicillin	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pMLH235	   pmyo-­‐3-­‐GFP-­‐unc-­‐10	  3'UTR	   ampicillin	  
pMLH236	   pttr-­‐39_csp-­‐1C_cDNA-­‐unc-­‐10	  UTR	   ampicillin	  
pMLH237	   pF25B3.3-­‐Mb-­‐Apo-­‐DEVD-­‐unc-­‐54	  3'UTR	   ampicillin	  
pMLH238	   N/A	   	  
pMLH239	   N/A	   	  
pMLH240	   pegl-­‐1_Mb-­‐Apo_DEVD-­‐unc-­‐54	  3'UTR	   ampicillin	  
pMLH241	   pegl-­‐1_Mb-­‐Apo_DQVA-­‐unc-­‐54	  3'UTR	   ampicillin	  
pMLH242	   pegl-­‐1_Mb-­‐Apo_DEVA-­‐unc-­‐54	  3'UTR	   ampicillin	  
pMLH243	   pF25B3.3-­‐Mb-­‐Apo-­‐DEVA-­‐unc-­‐54	  3'UTR	   ampicillin	  
pMLH244	   csp-­‐1	  FWD	  RNAi	  in	  L4440	  (HT115)	   ampicillin	  +	  tetracycline	  
pMLH245	   ced-­‐3	  FWD	  RNAi	  in	  L4440	  (HT115)	   ampicillin	  +	  tetracycline	  
pMLH246	   punc-­‐25-­‐WldS-­‐unc-­‐10	  3'UTR	   ampicillin	  
pMLH247	   punc-­‐25-­‐p35-­‐unc-­‐10-­‐3'UTR	   ampicillin	  
pMLH248	   pmec-­‐4-­‐csp-­‐1	  (p10)-­‐nz	   ampicillin	  
pMLH249	   pttr-­‐39_ced-­‐3_NO-­‐CARD_unc-­‐10	  UTR	   ampicillin	  
pMLH250	   pttr-­‐39_csp-­‐3_cDNA_unc-­‐10	  UTR	   ampicillin	  
pMLH251	   pdat-­‐1_TOM20-­‐GFP-­‐unc-­‐10	  UTR	   ampicillin	  
pMLH252	   pdat-­‐1_unc-­‐30cDNA-­‐unc-­‐54	  3'UTR	   ampicillin	  
pMLH253	   N/A	   	  
pMLH254	   punc-­‐25_S-­‐sp-­‐ispB-­‐incomplete_unc10UTR	   ampicillin	  
pMLH255	   psur-­‐5-­‐S	  sp-­‐ispB-­‐incomplete-­‐unc-­‐10	  UTR	   ampicillin	  
pMLH256	   punc-­‐25_coq-­‐1-­‐GFP-­‐unc-­‐54	  3'	  UTR	   ampicillin	  
pMLH257	   psur-­‐5-­‐coq-­‐1-­‐GFP-­‐unc-­‐54	  UTR	   ampicillin	  
pMLH258	   psur-­‐5-­‐coq-­‐1-­‐GFP-­‐unc-­‐54	  UTR	   ampicillin	  
pMLH259	   N/A	   	  
pMLH260	   punc-­‐25_coq-­‐1-­‐GFP-­‐unc-­‐54	  3'	  UTR	   ampicillin	  
pMLH261	   punc-­‐25	  HindIII-­‐SphI-­‐-­‐XbaI-­‐AscI-­‐mCherry	   ampicillin	  
pMLH262	   punc-­‐25	  HindIII-­‐SphI-­‐-­‐XbaI-­‐AscI-­‐TOM20-­‐GFP	   ampicillin	  
pMLH263	   pceh-­‐22	  HindIII-­‐SphI-­‐-­‐XbaI-­‐AscI-­‐TOM20-­‐GFP	   ampicillin	  
pMLH264	   pmyo-­‐3	  HindIII-­‐SphI-­‐-­‐XbaI-­‐AscI-­‐TOM20-­‐GFP	   ampicillin	  
pMLH265	   pF25B3.3-­‐ced-­‐3(p15)-­‐nz-­‐unc-­‐54	  3'UTR	   ampicillin	  
pMLH266	   pF25B3.3-­‐cz-­‐ced-­‐3(p17)-­‐unc-­‐54	  3'UTR	   ampicillin	  
pMLH267	   pmec-­‐4-­‐ced-­‐3	  (p15)-­‐nz	   ampicillin	  
pMLH268	   pmec-­‐4-­‐cz-­‐ced-­‐3	  (p17)	   ampicillin	  
pMLH269	   pceh-­‐22	  COQ-­‐1-­‐GFP	   ampicillin	  
pMLH270	   pmyo-­‐3	  COQ-­‐1-­‐GFP	   ampicillin	  
pMLH271	   pmyo-­‐3-­‐TOM20mRFP-­‐unc-­‐10	  UTR	   ampicillin	  
pMLH272	   pmyo-­‐3	  COQ-­‐1-­‐mCherry	   ampicillin	  
pMLH273	   N/A	   	  
pMLH274	   N/A	   	  
pMLH275	   N/A	   	  
pMLH277	   psur-­‐5_PDSS2_mut-­‐S382L_human_cDNA-­‐unc-­‐10	  UTR	   ampicillin	  
pMLH278	   psur-­‐5::PDSS1-­‐wt	  partial	  (missing	  1st	  500bp)	   ampicillin	  
pMLH279	   psur-­‐5::PDSS1-­‐mut	  partial	  (missing	  1st	  500bp)	   ampicillin	  
pMLH280	   psur-­‐5-­‐mCherry	   ampicillin	  
pMLH281	   psur-­‐5::PDSS2-­‐wt(no	  stop)	   ampicillin	  
pMLH282	   pmyo-­‐3::PDSS2-­‐wt(stop)	   ampicillin	  
pMLH283	   psur-­‐5_PDSS2-­‐wild-­‐type-­‐unc-­‐10	  UTR	   ampicillin	  
pMLH284	   pmyo-­‐3-­‐PDSS2	  wild	  type-­‐GFP	   ampicillin	  
pMLH285	   pttr-­‐39::PDSS1	  full	  pat-­‐3	  out-­‐mcherry	  (intermediate	  vector)	   ampicillin	  
pMLH286	   psur-­‐5::PDSS1	  wild	  type::unc-­‐10	  3’UTR	   ampicillin	  
pMLH287	   psur-­‐5::PDSS1(D308E)::unc-­‐10	  3’UTR	   ampicillin	  
pMLH288	   N/A	   	  
pMLH289	   N/A	   	  
pMLH290	   pdpy-­‐7::COQ-­‐1::GFP::unc-­‐54	  3’UTR	   ampicillin	  
pMLH291	   pelt-­‐2::COQ-­‐1::GFP::unc-­‐54	  3’UTR	   ampicillin	  
pMLH294	   psur-­‐5::PDSS1-­‐wt-­‐stop-­‐GFP::unc-­‐54	  3’UTR	   ampicillin	  
pMLH295	   pmyo-­‐3::end-­‐of-­‐PDSS1::GFP	   ampicillin	  
pMLH298	   punc-­‐25	  (XbaI-­‐KpnI)::COQ-­‐1::GFP	  (intermediate	  vector)	   ampicillin	  
pMLH299	   psur-­‐5::human	  COQ2	  (missing	  stop)::unc-­‐54	  3’UTR	   ampicillin	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pMLH300	   psur-­‐5::PDSS1-­‐mCherry::unc-­‐54	  3’UTR	   ampicillin	  
pMLH301	   psur-­‐5::human	  COQ2	  wild-­‐type::unc-­‐54	  3’UTR	   ampicillin	  
pMLH302	   psur-­‐5::human	  COQ2	  N401fsX415::unc-­‐54	  3’UTR	   ampicillin	  
pMLH303	   psur-­‐5::PDSS2::GFP	   ampicillin	  
pMBM1	   pttr-­‐39::sod-­‐1	  genomic	  DNA	  +	  unc-­‐119	  minigene	   ampicillin	  
pMBM3	   punc-­‐25::sod-­‐1	  genomic	  DNA::unc-­‐10	  3’UTR	   ampicillin	  
pMBM4	   punc-­‐25::sod-­‐2	  genomic	  DNA::unc-­‐10	  3’UTR	   ampicillin	  
pMBM5	   punc-­‐25::ctl-­‐2	  genomic	  DNA::unc-­‐10	  3’UTR	   ampicillin	  
pMBM0	   punc-­‐25::ctl-­‐1	  cDNA::unc-­‐10	  3’UTR	   ampicillin	  
pMBM7	   punc-­‐25::ctl-­‐3	  cDNA::unc-­‐10	  3’UTR	   ampicillin	  
pMBM8	   unc-­‐25	  cDNA	  RNAi	  in	  pCR2.1	   ampicillin	  





Appendix	  D:	  List	  of	  Gifts	  to	  Mal	  plasmids	  (pG2M#1-­‐64)	  
	  
Plasmid	  Name	   Description	   From	   Institution	   Reference	  
pG2M01	   pcsp-­‐3::csp-­‐3::GFP	   Ding	  Xue	   UC	  Boulder	   (Geng	  et	  al.	  2008)	  
pG2M02	   pmyo-­‐
3::TOM20::mRFP	  
Toshihikio	  Oka	   Kyushu	  Universita,	  
Japan	  
(Ichishita	  et	  al.	  2008)	  
pG2M03	   Apoliner	   Jean-­‐Paul	  
Vincent	  /	  Pierre-­‐
Luc	  Bardet	  
MRC	   (Bardet,	  Kolahgar,	  Mynett,	  Miguel-­‐Aliaga,	  
Briscoe,	  Meier	  &	  Vincent	  2008b)	  
pG2M04	   Apomut	   Jean-­‐Paul	  
Vincent	  /	  Pierre-­‐
Luc	  Bardet	  
MRC	   (Bardet,	  Kolahgar,	  Mynett,	  Miguel-­‐Aliaga,	  
Briscoe,	  Meier	  &	  Vincent	  2008b)	  
pG2M05	   odr-­‐1::GFP	   Geraldine	  Maro	   Stanford	   (Maro	  et	  al.	  2009)	  
pG2M06	   odr-­‐1::RFP	   Geraldine	  Maro	   Stanford	   (Maro	  et	  al.	  2009)	  
pG2M07	   odr-­‐1::mcherry	   Cori	  Bargmann	   Rockafeller	   (Lesch	  et	  al.	  2009)	  
pG2M08	   ced-­‐3	  RNAi	  clone	   David	  Eisenman	   University	  of	  Maryland	   (Joshi	  &	  Eisenmann	  2004)	  
pG2M09	   ced-­‐4	  RNAi	  clone	   David	  Eisenman	   University	  of	  Maryland	   (Joshi	  &	  Eisenmann	  2004)	  
pG2M10	   pTG96	  (psur-­‐
5::NLS::GFP)	  
David	  Fay	   University	  of	  Wyoming	   (Kirienko	  et	  al.	  2008)	  
pG2M11	   pwpro::unc-­‐
119::ccdb	  
David	  Sattelle	   Oxford	   (Briese	  et	  al.	  2006)	  
pG2M12	   pwpro::myo-­‐
3::ccdb	  
David	  Sattelle	   Oxford	   (Briese	  et	  al.	  2006)	  
pG2M13	   L4440-­‐Gateway	   Addgene	   	   	  
pG2M14	   punc-­‐8::mec-­‐4(d)	   Nektarios	  
Tavernarakis	  
IMBB	  	   (Syntichaki	  et	  al.	  2002)	  
pG2M15	   pasp-­‐3::asp-­‐3::GFP	   Nektarios	  
Tavernarakis	  
IMBB	   (Syntichaki	  et	  al.	  2002)	  
pG2M16	   pasp-­‐4::asp-­‐4::GFP	   Nektarios	  
Tavernarakis	  
IMBB	   (Syntichaki	  et	  al.	  2002)	  
pG2M17	   pelt-­‐2::GFP	   Oliver	  Hobert	   Columbia	   	  
pG2M18	   pttx-­‐3::GFP	   Oliver	  Hobert	   Columbia	   	  
pG2M19	   pceh-­‐22::GFP	   Oliver	  Hobert	   Columbia	   	  
pG2M20	   coel::GFP	   Daniel	  Colon-­‐
Ramoz	  (Cody)	  
Yale	   	  
pG2M21	   coel::RFP	   Daniel	  Colon-­‐
Ramoz	  (Cody)	  
Yale	   	  
pG2M22	   pET3a-­‐csp-­‐1B-­‐
FLAG	  
Shai	  Shaham	   Rockafeller	   (Shaham	  1998)	  
pG2M23	   pET3a-­‐csp-­‐1B-­‐
C138S-­‐FLAG	  
Shai	  Shaham	   Rockafeller	   (Shaham	  1998)	  
pG2M24	   pET3a-­‐ced-­‐3-­‐FLAG	   Shai	  Shaham	   Rockafeller	   (Shaham	  1998)	  
pG2M25	   pET3a-­‐ced-­‐3-­‐
C358S-­‐FLAG	  
Shai	  Shaham	   Rockafeller	   (Shaham	  1998)	  
pG2M26	   GD1	  (Q-­‐less	  E.coli)	   Cathy	  Clarke	   UCLA	   (Saiki	  et	  al.	  2008)	  
pG2M27	   K0229:pSN18	  
(CoQ-­‐9	  E.	  coli)	  
Cathy	  Clarke	   UCLA	   (Saiki	  et	  al.	  2008)	  
pG2M28	   him-­‐14	  RNAi	   Randy	  Blakely	  
(via	  Andrew	  
Hardaway)	  
Vanderbilt	   	  
pG2M29	   pCFJ90	  (pmyo-­‐
2::mcherry)	  
Addgene	   	   	  
pG2M30	   pBluescript	  II	   unknown	  (old	  lab	  
stocks)	  
	   	  
pG2M31	   pRF4	  (rol-­‐6(d))	   unknown	  (old	  lab	  
stocks)	  
	   	  
pG2M32	   pCM1.151	  
(mCherry::H2B)	  
Addgene	   	   	  
pG2M33	   pCM1.35	  
(GFP::H2B)	  
Addgene	   	   	  
pG2M34	   TU#730	  (psto-­‐ old	  Miller	  lab	   	   	  
	  235	  
6::cz::GFP)	   stocks	  
pG2M35	   pPD95.69	   old	  Miller	  lab	  
stocks	  
	   	  
pG2M36	   pJER1	  (pmyo-­‐
3::dsRed)	  
old	  Miller	  lab	  
stocks	  
	   	  




Shai	  Shaham	   Rockafeller	   (Abraham	  et	  al.	  2007)	  
pG2M38	   coq-­‐2	  fosmid	   	   	   	  
pG2M39	   TU#806	  (pmec-­‐
18::ced-­‐3(p15)-­‐nz)	  
Addgene	   	   (Chelur	  &	  Chalfie	  2007)	  
pG2M40	   TU#807	  (pmec-­‐
18::cz-­‐ced-­‐3(p17))	  
	   	   (Chelur	  &	  Chalfie	  2007)	  
pG2M41	   PDSS2	   	   	   	  
pG2M42	   unc-­‐119	  minigene	  
(MM051)	  
	   	   	  
pG2M43	   PDSS1	  wt	   Agnes	  Rotig	   	   (Mollet	  et	  al.	  2007)	  
pG2M44	   PDSS1	  D308E	   Agnes	  Rotig	   	   (Mollet	  et	  al.	  2007)	  
pG2M45	   PDSS2	  wt	   Agnes	  Rotig	   	   (Mollet	  et	  al.	  2007)	  
pG2M46	   PDSS2	  S382L	   Agnes	  Rotig	   	   (Mollet	  et	  al.	  2007)	  
pG2M47	   COQ2	  wt	   Agnes	  Rotig	   	   (Mollet	  et	  al.	  2007)	  
pG2M48	   COQ2	  N401fsX415	   Agnes	  Rotig	   	   (Mollet	  et	  al.	  2007)	  
pG2M49	   pJM360	  (elt-­‐2	  
promoter)	  
Jim	  McGhee	   	   	  
pG2M50	   pdpy-­‐7::swip-­‐10	   Andrew	  
Hardaway/Blakel
y	  Lab	  
	   	  
pG2M51	   pHyPer-­‐cyto	   	   	   	  
pG2M52	   pSLGCV	   	   	   (Lagido	  et	  al.	  2008)	  
pG2M53	   pBC401	  (drp-­‐1	  WT)	   Barbara	  Conradt	   	   (Jagasia	  et	  al.	  2005)	  
pG2M54	   pBC402	  (drp-­‐1	  WT)	   	   	   (Jagasia	  et	  al.	  2005)	  
pG2M55	   pBC403	  (drp-­‐1	  DN)	   	   	   (Jagasia	  et	  al.	  2005)	  
pG2M56	   pBC404	  (drp-­‐1	  
(DN)	  
	   	   (Jagasia	  et	  al.	  2005)	  
pG2M57	   yk1514f03	   	   	   	  
pG2M58	   yk1479d10	   	   	   	  
pG2M59	   pPD#S006	  
(pF25B3.3::GFP)	  
	   	   	  
pG2M60	   pSC392	  (punc-­‐
25::CFP)	  
	   	   	  
PG2M61	   K0229:pKA3	  (Q8)	   Cathy	  Clarke	   UCLA	   (Saiki	  et	  al.	  2008)	  
pG2M62	   K0229:pLD23	  
(Q10)	  
Cathy	  Clarke	   UCLA	   (Saiki	  et	  al.	  2008)	  
pG2M63	   pSC391	  (pacr-­‐
2::YFP)	  
	   	   	  
pG2M64	   pBX	  (pha-­‐1(+))	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